
<html lang="en"     class="pb-page"  data-request-id="14abde44-da70-462c-9ad5-79e3e69b9883"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-24;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.9b00857"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of a Highly Selective and Potent κ Opioid Receptor Agonist from N-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines with Reduced Central Nervous System (CNS) Side Effects Navigated by the Message–Address Concept" /></meta><meta name="dc.Creator" content="Li  Xiao" /></meta><meta name="dc.Creator" content="Yujun  Wang" /></meta><meta name="dc.Creator" content="Mumei  Zhang" /></meta><meta name="dc.Creator" content="Weiwei  Wu" /></meta><meta name="dc.Creator" content="Linghui  Kong" /></meta><meta name="dc.Creator" content="Yan  Ma" /></meta><meta name="dc.Creator" content="Xuejun  Xu" /></meta><meta name="dc.Creator" content="Xiao  Liu" /></meta><meta name="dc.Creator" content="Qian  He" /></meta><meta name="dc.Creator" content="Yuanyuan  Qian" /></meta><meta name="dc.Creator" content="Huijiao  Sun" /></meta><meta name="dc.Creator" content="Haihao  Wu" /></meta><meta name="dc.Creator" content="Cheng  Lin" /></meta><meta name="dc.Creator" content="Huoming  Huang" /></meta><meta name="dc.Creator" content="Rongrong  Ye" /></meta><meta name="dc.Creator" content="Shuang  Jiang" /></meta><meta name="dc.Creator" content="Ru-Feng  Ye" /></meta><meta name="dc.Creator" content="Congmin  Yuan" /></meta><meta name="dc.Creator" content="Shengyang  Fang" /></meta><meta name="dc.Creator" content="Dengqi  Xue" /></meta><meta name="dc.Creator" content="Xicheng  Yang" /></meta><meta name="dc.Creator" content="Hao  Chen" /></meta><meta name="dc.Creator" content="Yilin  Zheng" /></meta><meta name="dc.Creator" content="Linqian  Yu" /></meta><meta name="dc.Creator" content="Qiong  Xie" /></meta><meta name="dc.Creator" content="Lan  Zheng" /></meta><meta name="dc.Creator" content="Wei  Fu" /></meta><meta name="dc.Creator" content="Wei  Li" /></meta><meta name="dc.Creator" content="Zhuibai  Qiu" /></meta><meta name="dc.Creator" content="Jinggen  Liu" /></meta><meta name="dc.Creator" content="Liming  Shao" /></meta><meta name="dc.Description" content="Effective and safe analgesics represent an unmet medical need for the treatment of acute and chronic pain. A series of N-cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines were desig..." /></meta><meta name="Description" content="Effective and safe analgesics represent an unmet medical need for the treatment of acute and chronic pain. A series of N-cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines were desig..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 18, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00857" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00857" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00857" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00857" /></link>
        
    
    

<title>Discovery of a Highly Selective and Potent κ Opioid Receptor Agonist from N-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines with Reduced Central Nervous System (CNS) Side Effects Navigated by the Message–Address Concept | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00857" /></meta><meta property="og:title" content="Discovery of a Highly Selective and Potent κ Opioid Receptor Agonist from N-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines with Reduced Central Nervous System (CNS) Side Effects Navigated by the Message–Address Concept" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0013.jpeg" /></meta><meta property="og:description" content="Effective and safe analgesics represent an unmet medical need for the treatment of acute and chronic pain. A series of N-cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines were designed, synthesized, and assayed, leading to the discovery of a benzylamine derivative (compound 4, SLL-039) as a highly selective and potent κ opioid agonist (κ, Ki = 0.47 nM, κ/μ = 682, κ/δ = 283), which was confirmed by functional assays in vitro and antinociceptive assays in vivo. The in vivo effect could be blocked by pretreatment with the selective κ antagonist nor-BNI. Moreover, this compound did not induce sedation, a common dose limiting effect of κ opioid receptor agonists, at its analgesic dose compared to U50,488H. The dissociation of sedation/antinociception found in SLL-039 was assumed to be correlated with the occupation of its benzamide motif in a unique subsite involving V1182.63, W124EL1, and E209EL2." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00857"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00857">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00857&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00857&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00857&amp;href=/doi/10.1021/acs.jmedchem.9b00857" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 11054-11070</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00742" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00918" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Highly Selective and Potent κ Opioid Receptor Agonist from <i>N</i>-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines with Reduced Central Nervous System (CNS) Side Effects Navigated by the Message–Address Concept</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Li Xiao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li Xiao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li++Xiao">Li Xiao</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5238-6393" title="Orcid link">http://orcid.org/0000-0002-5238-6393</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yujun Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yujun Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Collaborative Innovation Center for Brain Science, 555 Zuchongzhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yujun++Wang">Yujun Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mumei Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mumei Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mumei++Zhang">Mumei Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Weiwei Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Weiwei Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Collaborative Innovation Center for Brain Science, 555 Zuchongzhi Road, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Weiwei++Wu">Weiwei Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linghui Kong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linghui Kong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linghui++Kong">Linghui Kong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yan Ma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yan Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Collaborative Innovation Center for Brain Science, 555 Zuchongzhi Road, Shanghai 201203, China</div><div class="loa-info-affiliations-info">Shanghai University School of Life Sciences, No. 99 Shangda Road, Shanghai 200444, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Ma">Yan Ma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xuejun Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuejun Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Collaborative Innovation Center for Brain Science, 555 Zuchongzhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuejun++Xu">Xuejun Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiao Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiao Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiao++Liu">Xiao Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qian He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qian He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qian++He">Qian He</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuanyuan Qian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuanyuan Qian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuanyuan++Qian">Yuanyuan Qian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huijiao Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huijiao Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huijiao++Sun">Huijiao Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haihao Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haihao Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haihao++Wu">Haihao Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cheng Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cheng Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cheng++Lin">Cheng Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huoming Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huoming Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huoming++Huang">Huoming Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rongrong Ye</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rongrong Ye</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Institute of Technology, No. 100 Haiquan Road, Shanghai 201418, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rongrong++Ye">Rongrong Ye</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuang Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuang Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Nanjing University of Chinese Medicine, No. 138 Xianlin Avenue, Nanjing 210023, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuang++Jiang">Shuang Jiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ru-Feng Ye</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ru-Feng Ye</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Collaborative Innovation Center for Brain Science, 555 Zuchongzhi Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ru-Feng++Ye">Ru-Feng Ye</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Congmin Yuan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Congmin Yuan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Congmin++Yuan">Congmin Yuan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shengyang Fang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shengyang Fang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shengyang++Fang">Shengyang Fang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dengqi Xue</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dengqi Xue</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dengqi++Xue">Dengqi Xue</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xicheng Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xicheng Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xicheng++Yang">Xicheng Yang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8284-3631" title="Orcid link">http://orcid.org/0000-0001-8284-3631</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hao Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hao Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Chen">Hao Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yilin Zheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yilin Zheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yilin++Zheng">Yilin Zheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linqian Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linqian Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linqian++Yu">Linqian Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qiong Xie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qiong Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qiong++Xie">Qiong Xie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lan Zheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lan Zheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Minhang Hospital, Fudan University, No. 170 Xinsong Road, Shanghai 201199, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lan++Zheng">Lan Zheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Fu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Fu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Fu">Wei Fu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2335-8908" title="Orcid link">http://orcid.org/0000-0002-2335-8908</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><span class="conrtib-corresp"><strong>*</strong>W.L: e-mail, <a href="/cdn-cgi/l/email-protection#d3a4b6bafebfba93b5a6b7b2bdfdb6b7a6fdb0bd"><span class="__cf_email__" data-cfemail="8cfbe9e5a1e0e5cceaf9e8ede2a2e9e8f9a2efe2">[email protected]</span></a>; phone, (+86) 21-51108 0122.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Li">Wei Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhuibai Qiu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhuibai Qiu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhuibai++Qiu">Zhuibai Qiu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jinggen Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jinggen Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Collaborative Innovation Center for Brain Science, 555 Zuchongzhi Road, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</div></div><span class="conrtib-corresp"><strong>*</strong>J.-g.L.: e-mail, <a href="/cdn-cgi/l/email-protection#4c262b2025390c212d2520623f242f222f622d2f622f22"><span class="__cf_email__" data-cfemail="bad0ddd6d3cffad7dbd3d694c9d2d9d4d994dbd994d9d4">[email protected]</span></a>; phone, (+86) 21-50807 588.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jinggen++Liu">Jinggen Liu</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Liming Shao</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liming Shao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</div><div class="loa-info-affiliations-info">State Key Laboratory of Medical Neurobiology, Fudan University, No. 138 Yixueyuan Road, Shanghai 200032, China</div></div><span class="conrtib-corresp"><strong>*</strong>L.-m.S.: e-mail, <a href="/cdn-cgi/l/email-protection#c4a8ada9adaaa3b7aca5ab84a2b1a0a5aaeaa1a0b1eaa7aa"><span class="__cf_email__" data-cfemail="89e5e0e4e0e7eefae1e8e6c9effcede8e7a7ecedfca7eae7">[email protected]</span></a>; phone, (+86) 21- 51108 0201.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liming++Shao">Liming Shao</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0694-7011" title="Orcid link">http://orcid.org/0000-0003-0694-7011</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00857&amp;href=/doi/10.1021%2Facs.jmedchem.9b00857" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 11054–11070</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 18, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 May 2019</li><li><span class="item_label"><b>Published</b> online</span>18 November 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 December 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00857" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00857</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D11054%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLi%2BXiao%252C%2BYujun%2BWang%252C%2BMumei%2BZhang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D24%26contentID%3Dacs.jmedchem.9b00857%26title%3DDiscovery%2Bof%2Ba%2BHighly%2BSelective%2Band%2BPotent%2B%25CE%25BA%2BOpioid%2BReceptor%2BAgonist%2Bfrom%2BN-Cyclopropylmethyl-7%25CE%25B1-phenyl-6%252C14-endoethanotetrahydronorthebaines%2Bwith%2BReduced%2BCentral%2BNervous%2BSystem%2B%2528CNS%2529%2BSide%2BEffects%2BNavigated%2Bby%2Bthe%2BMessage%25E2%2580%2593Address%2BConcept%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D11070%26publicationDate%3DDecember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00857"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1087</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00857" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Highly Selective and Potent κ Opioid Receptor Agonist from N-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines with Reduced Central Nervous System (CNS) Side Effects Navigated by the Message–Address Concept&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Xiao&quot;},{&quot;first_name&quot;:&quot;Yujun&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Mumei&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Weiwei&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Linghui&quot;,&quot;last_name&quot;:&quot;Kong&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Xuejun&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Xiao&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Qian&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Yuanyuan&quot;,&quot;last_name&quot;:&quot;Qian&quot;},{&quot;first_name&quot;:&quot;Huijiao&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Haihao&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Cheng&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Huoming&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Rongrong&quot;,&quot;last_name&quot;:&quot;Ye&quot;},{&quot;first_name&quot;:&quot;Shuang&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Ru-Feng&quot;,&quot;last_name&quot;:&quot;Ye&quot;},{&quot;first_name&quot;:&quot;Congmin&quot;,&quot;last_name&quot;:&quot;Yuan&quot;},{&quot;first_name&quot;:&quot;Shengyang&quot;,&quot;last_name&quot;:&quot;Fang&quot;},{&quot;first_name&quot;:&quot;Dengqi&quot;,&quot;last_name&quot;:&quot;Xue&quot;},{&quot;first_name&quot;:&quot;Xicheng&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Yilin&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Linqian&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Qiong&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Lan&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Fu&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Zhuibai&quot;,&quot;last_name&quot;:&quot;Qiu&quot;},{&quot;first_name&quot;:&quot;Jinggen&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Liming&quot;,&quot;last_name&quot;:&quot;Shao&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;11054-11070&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00857&quot;},&quot;abstract&quot;:&quot;Effective and safe analgesics represent an unmet medical need for the treatment of acute and chronic pain. A series of N-cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines were designed, synthesized, and assayed, leading to the discovery of a benzylamine derivative (compound 4, SLL-039) as a highly selective and potent κ opioid agonist (κ, Ki = 0.47 nM, κ/μ = 682, κ/δ = 283), which was confirmed by functional assays in vitro and antinociceptive assays in vivo. The in vivo effect could be blocked by pretreatment with the selective κ antagonist nor-BNI. Moreover, this compound did not induce sedation, a common dose limiting effect of κ opioid receptor agonists, at its analgesic dose compared to U50,488H. The dissociation of sedation/antinociception found in SLL-039 was assumed to be correlated with the occupation of its benzamide motif in a unique subsite involving V1182.63, W124EL1, and E209EL2.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00857&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00857" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00857&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00857" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00857&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00857" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00857&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00857&amp;href=/doi/10.1021/acs.jmedchem.9b00857" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00857" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00857" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00857%26sid%3Dliteratum%253Aachs%26pmid%3D31738550%26genre%3Darticle%26aulast%3DXiao%26date%3D2019%26atitle%3DDiscovery%2Bof%2Ba%2BHighly%2BSelective%2Band%2BPotent%2B%25CE%25BA%2BOpioid%2BReceptor%2BAgonist%2Bfrom%2BN-Cyclopropylmethyl-7%25CE%25B1-phenyl-6%252C14-endoethanotetrahydronorthebaines%2Bwith%2BReduced%2BCentral%2BNervous%2BSystem%2B%2528CNS%2529%2BSide%2BEffects%2BNavigated%2Bby%2Bthe%2BMessage%25E2%2580%2593Address%2BConcept%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D24%26spage%3D11054%26epage%3D11070%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/jmcmar.2019.62.issue-24/20191226/jmcmar.2019.62.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Effective and safe analgesics represent an unmet medical need for the treatment of acute and chronic pain. A series of <i>N</i>-cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines were designed, synthesized, and assayed, leading to the discovery of a benzylamine derivative (compound <b>4</b>, SLL-039) as a highly selective and potent κ opioid agonist (κ, <i>K</i><sub>i</sub> = 0.47 nM, κ/μ = 682, κ/δ = 283), which was confirmed by functional assays <i>in vitro</i> and antinociceptive assays <i>in vivo</i>. The <i>in vivo</i> effect could be blocked by pretreatment with the selective κ antagonist nor-BNI. Moreover, this compound did not induce sedation, a common dose limiting effect of κ opioid receptor agonists, at its analgesic dose compared to U50,488H. The dissociation of sedation/antinociception found in SLL-039 was assumed to be correlated with the occupation of its benzamide motif in a unique subsite involving V118<sup>2.63</sup>, W124<sup>EL1</sup>, and E209<sup>EL2</sup>.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88644" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88644" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As a response to noxious stimuli or medical conditions, pain is generally considered as a warning signal to the body. However, neuropathic and cancer pain are more likely to be a pathological entity<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> rather than a protective mechanism and produce not only an unpleasant experience but also physical and psychological dysfunction if left untreated. Considering the enormous clinical, economic, and social burden of this condition,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> appropriate and adequate pain management is therefore necessary and important. While nonsteroidal anti-inflammatory drugs (NSAIDs) work well to relieve mild-to-moderate pain, morphine and other narcotics are indispensable for the management of more severe and refractory forms. Unfortunately, common narcotic drugs used in clinical practice are inseparable from their severe side effects including abuse potential, respiratory depression, and constipation.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4−7)</a> These unwanted effects are believed to be mediated through stimulation of the μ opioid receptor, the chief component responsible for potent analgesia effects of opioid analgesics. Substantial efforts have been invested in the separation of their analgesia effects from their liability for notorious effects based on the understanding of the pharmacological action of μ opioids and opioid receptors.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> As a consequence, the discovery of multiple opioid receptor subtypes<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a> and characterization of their pharmacological properties have opened the possibility to alleviate the safety concerns of typical narcotics.</div><div class="NLM_p">The κ opioid receptor is a subtype of opioid receptors with high homology to the μ opioid receptor. Unlike μ opioid agonists, κ opioid agonists can potentially promote potent analgesia without producing typical opioid-like adverse effects, providing a basis for the development of selective κ opioid agonists as potential analgesics.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15">(12−15)</a> Early identified κ opioid agonists from benzomorphans, such as ethylketazocine (EKC, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and bremazocine,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> have been used as pharmacological tools in κ opioid receptor studies, though they were found to be nonselective over other opioid receptors. With the advent of U50,488H,<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> an arylacetamide structurally unrelated to benzomorphans, the 1980s witnessed booming research focused on highly selective and potent κ opioid agonists. This effort put several arylacetamides (e.g., enadoline<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> and spiradoline<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>) in clinical trials as potential analgesics. Unfortunately, despite the demonstration of pain relief similar to that of morphine, these agents failed to survive phase II clinical trials due to their dose-limiting psychoactive effects, including dysphoria, sedation, and hallucinations. These undesirable effects were generally considered to be related to stimulation of the κ opioid receptor, but it remained controversial whether κ opioid agonists other than arylacetamides could also invoke these unwanted reactions. Salvinorin A, one of the most investigated κ opioid agonists derived from naturally occurring diterpenes, could also produce all of the above arylacetamide-like behaviors in rodents and nonhuman primates, as well as in human laboratory studies.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Most of these κ opioid agonists were criticized on the grounds that they could cause dysphoria, sedation, and hallucinations, which made them aversive as medications. In contrast, some mixed agonist–antagonist opioids, including nalbuphine,<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> butorphanol,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and pentazocine,<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> contain a component of κ partial or full agonism in their activities and demonstrate more acceptable safety profiles. These opioids have been used as useful analgesics in clinical practice for several decades. Moreover, nalfurafine (also known as TRK-820),<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29−31)</a> a 4,5-epoxymorphinan derivative identified as a potent and centrally acting κ opioid agonist, was recently approved for clinical use in Japan. Unlike other κ opioid agonists, nalfurafine induces neither aversive nor dysphoric effects, which has been confirmed by both clinical and postmarketing surveillance studies.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32−34)</a> These features were proposed to be consequences of G protein biased signaling,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> since the β-arrestin biased signaling was considered to be responsible for the aversion induced by κ opioid agonists<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and some studies suggested G protein biased signaling may produce analgesic and antipruritic effects with reduced sedation or dysphoria related side effects.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> This hypothesis has been challenged by more recent studies,<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> and the involvement of the mTOR pathway was proposed to be an alternative explanation for the κ opioid aversion.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of typical κ opioid agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The nalfurafine 4,5-epoxymorphinan scaffold provides the possibility to separate the analgesia and psychoactive effects of κ opioid agonists through further innovation of chemical structures. However, there remain some obstacles to overcome. First, it is important to note that nalfurafine was approved in Japan for second-line treatment of uremic pruritus other than pain; however, its marketing authorization application was declined by the European Medicines Agency, which might possibly be due to its unacceptable sedative effects at lower treatment analgesia doses. Second, despite the claim it is a selective κ agonist,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> nalfurafine demonstrated low to moderate subtype selectivity for the κ over μ opioid receptor and was identified as a partial agonist of the μ opioid receptor <i>in vitro.</i><a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> Therefore, if 4,5-epoxymorphinan is chosen as the fundamental structure to design potential κ opioid agonists, the concern of subtype selectivity should be resolved first to avoid any unexpected off-target effects, especially those associated with stimulation of the μ opioid receptor. Therefore, on the basis of the pros and cons of nalfurafine, considerable interest remains in the development of selective and potent κ opioid agonists with reduced psychoactive adverse effects from 4,5-epoxymorphinans as potential analgesics.</div><div class="NLM_p">The message–address concept was first introduced by Portoghese to explain and design selective opioid ligands from the morphinan structure.<a onclick="showRef(event, 'ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46">(44−46)</a> According to this hypothesis, subtype-selective opioid ligands have been proposed to contain two chemical motifs, one for efficacy (message) and the other for subtype selectivity (address).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> While the message motif is very similar or invariant, the address motif is variable.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> This concept has been widely adopted to study opioid ligands and their pharmacology and is also exemplified by the discovery of a highly selective and potent aryltetralin derivative δ opioid receptor agonist in our previous work.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><div class="NLM_p">Thebaine is a natural product isolated from opium. While it is inactive as a pain medication, Diels–Alder reaction of thebaine with an appropriate dienophile followed by subsequent transformations<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> could afford extremely highly active semisynthetic opiates, such as buprenorphine, etorphine, and diprenorphine. Among the extensive research reported in this area,<a onclick="showRef(event, 'ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53">(51−53)</a> Steven Husbands and John Traynor’s work<a onclick="showRef(event, 'ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref54 ref55 ref56">(54−56)</a> has massively expanded our understanding of the diversity and pharmacology of Diels–Alder adducts of thebaine derivatives on opioid receptors. In our ongoing studies, with the 4,5-epoxymorphinan scaffold of thebaine as the message component, we examined potential address components relevant to the κ opioid receptor<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> and chose nepenthones and 7α-phenyl-6,14-endoethanotetrahydrothebaines as fundamental scaffolds for further investigations. For the nepenthone series, extensive activity optimization efforts led to the discovery of SLL-020ACP (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), which has been identified as a highly selective and potent κ opioid agonist.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In contrast, 7α-phenyl-6,14-endoethanotetrahydrothebaines could be considered as nepenthone analogs devoid of the 7α-carbonyl group. Despite its negligible activities on all opioid receptors,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> 7α-phenyl-6,14- endoethenotetrahydrothebaine (<b>2</b>) could be modified by introducing a <i>p</i>-amino substituent to afford SLL-004C (<b>3</b>), which produced moderate κ agonistic effects in the rabbit vas deferens (RVD) and antinociceptive effects in the tail-flick test.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Examples of compounds derived from the Diels–Alder adducts of thebaine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With 7α-phenyl-6,14-endoethenotetrahydrothebaine as the message component, introduction of a <i>p</i>-amino group will guarantee greater synthetic accessibility to compounds with chemical diversity, expand the chemical space to probe any components for subtype selectivity, and provide a unique opportunity to search for potential selective κ opioid agonists. As shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, with SLL-004C as the starting point, the message component was first optimized by <i>N</i>-cyclopropylmethyl substitution and reduction of the 6,14-endoetheno bridge. Thereafter, a series of compounds including secondary and tertiary amines, amides, and an azobenzene were designed, synthesized, and assayed to probe any potential components for κ opioid selectivity, resulting in the discovery of compound <b>4</b> (SLL-039), a highly selective and potent κ opioid receptor agonist with reduced psychoactive effects.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Design Rationale for Novel 4,5-Epoxymorphinan Derivatives as Potential κ Opioid Receptor Ligands Based on the Message–Address Concept</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81605" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81605" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">The synthesis of substituted <i>N</i>-cyclopropylmethyl-7α-phenyl-6,14-endoethano tetrahydronorthebaines was shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Thebaine initially reacted with DIAD and subsequently with pyridine hydrochloride to yield northebaine <b>5</b>, which was first reported by Kim et al.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> and also described in our previous work.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> After alkylation with cyclopropylmethyl bromide, the resultant <i>N</i>-cyclopropylmethylnorthebaine <b>6</b> was refluxed with 4-nitrostyrene in xylene to afford the Diels–Alder adduct <b>7</b>, which was reduced with hydrogen over palladium on carbon leading to the aniline <b>8</b>. With compound <b>8</b> as a key intermediate, a series of compounds were designed and synthesized. The secondary (<b>9a</b>–<b>i</b>) and tertiary (<b>10a</b>–<b>g</b>) amines were prepared by alkylation of compound <b>8</b> with the corresponding alkyl halides. With <b>10c</b> as a key intermediate, the tertiary amines (<b>10d</b>–<b>g</b>) were synthesized with the appropriate acryl reagents. The amides (<b>11a</b>–<b>c</b> and <b>4</b>) were synthesized by condensation of compound <b>8</b> with the appropriate acids or acyl halides. The aniline <b>8</b> was coupled with phenol in sodium nitrite and hydrochloride mixture to afford the azobenzene <b>12</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>N</i>-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DIAD, HCl and CH<sub>3</sub>CN; (b) cyclopropylmethyl bromide, Na<sub>2</sub>CO<sub>3</sub> and DMF at rt; (c) 4-nitrostyrene and xylene under reflux; (d) Pd/C and H<sub>2</sub> at 65 psi and 25 °C; (e) DIPEA, Cbz-Cl, and DCM at 35 °C, followed by LiAlH<sub>4</sub> and THF at 0 °C; (f) haloalkanes, Na<sub>2</sub>CO<sub>3</sub>, and DMF at rt; (g) dibromoalkanes, Na<sub>2</sub>CO<sub>3</sub>, and CH<sub>3</sub>CN at 110 °C under microwave; (h) haloalkanes or acyl chlorides, Et<sub>3</sub>N, and DCM at rt; (i) NaNO<sub>2</sub>, HCl, and H<sub>2</sub>O at −5 to 0 °C; phenol, NaOH, and H<sub>2</sub>O at −5 to 0 °C.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> <i>In Vitro</i> Studies</h3><div class="NLM_p">The saturation binding of [<sup>3</sup>H]DAMGO, [<sup>3</sup>H]DPDPE, and [<sup>3</sup>H]U69593 to the human μ-, rat δ-, and rat κ-opioid receptors was performed, with <i>K</i><sub>d</sub> values of 1.0 ± 0.3 nM, 2.0 ± 0.8 nM, and 0.7 ± 0.2 nM, respectively, and <i>B</i><sub>max</sub> values of 794.5 ± 108.8 fmol/mg protein, 1211.2 ± 273.3 fmol/mg protein, and 871.3 ± 80.4 fmol/mg protein, respectively. The binding affinities of <i>N</i>-cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines for μ, δ, and κ opioid receptors are presented in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Compared with SLL-004C, the aniline <b>8</b> (κ, <i>K</i><sub>i</sub> = 6.4 ± 0.8 nM) showed a substantial increase in binding affinities to all three opioid receptors as a consequence of the structural optimization for the message component. Although its dominant activity on the κ opioid receptor was maintained, its subtype selectivity over other opioid receptors was insignificant, with a selectivity ratio of 7.2 and 5.2 for κ/μ and κ/δ, respectively. For the secondary amines <b>9a</b>–<b>d</b>, alkylation of the amino group resulted in a decrease in the binding affinities for all opioid receptors. Introduction of a benzyl group affected the μ and δ affinities more severely than the κ affinities, yielding a moderately κ-selective benzylamine <b>9e</b> (κ, <i>K</i><sub>i</sub> = 17.2 ± 0.3 nM, κ/μ = 18.6, κ/δ = 36.4). In contrast, alkylation of the terminal position with a polar group was associated with a marginal increase or decrease in μ affinities and reduced κ opioid affinities, resulting in a loss of subtype selectivity for compounds <b>9f</b>–<b>i</b>. Tertiary amines, such as pyrrolidine <b>10a</b>, piperidine <b>10b</b>, and piperazine <b>10c</b> displayed a substantial reduction in κ and δ affinities, while the binding affinities to the μ opioid receptor were less affected, resulting in an inversion of the subtype selectivity. In contrast, the piperazine derivatives (<b>10d</b>–<b>g</b>) excluding <b>10f</b> with a bulky tosyl substitution could preserve δ but not κ binding affinities.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Binding Affinities of <i>N</i>-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines for μ, δ and κ Opioid Receptors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0011.gif" alt="" id="GRAPHIC-d7e1048-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0012.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Values are expressed as the mean ± SEM for three independent experiments performed in triplicate.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Displacement of [<sup>3</sup>H]DAMGO from the CHO cell membrane expressing the μ opioid receptor.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Displacement of [<sup>3</sup>H]DPDPE from the CHO cell membrane expressing the δ opioid receptor.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Displacement of [<sup>3</sup>H]U69593 from the CHO cell membrane expressing the κ opioid receptor.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Not determined.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Not applicable.</p></div></div><div></div></div><div class="NLM_p">Compared with the aniline <b>8</b>, the amides (<b>11a</b>–<b>c</b>, <b>4</b>) consistently demonstrated decreased δ affinities to a similar extent. Their binding profiles to the μ and κ opioid receptors were distinct. As for <b>11a</b>–<b>c</b>, their μ opioid affinities were marginally increased, with κ opioid affinities remaining relatively constant. However, the benzamide <b>4</b> (κ, <i>K</i><sub>i</sub> = 0.47 ± 0.1 nM) displayed a substantial improvement in its κ opioid affinity and a significant loss in μ opioid affinity, resulting in its highly selective and potent affinity for the κ opioid receptor (κ/μ = 683 and κ/δ = 284). Finally, for the azobenzene <b>10</b>, the binding affinities to all three opioid receptors were almost abandoned.</div><div class="NLM_p">Additionally, [<sup>35</sup>S]GTPγS functional assays were conducted to examine the stimulation effects of the aniline <b>8</b>, benzylamine <b>9e</b>, and amides <b>11b</b> and <b>4</b> on opioid receptors, and the results are described in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. As expected, the aniline <b>8</b> demonstrated a significant increase in κ agonistic activities compared with SLL-004C (<b>2</b>) as a result of its structural optimization, but the subtype selectivity for κ over δ opioid receptor was poor (κ/δ = 1.87), which is consistent with that observed in the competitive binding assays. The amides <b>11b</b> and <b>4</b> demonstrated similar stimulation activities as the aniline <b>8</b>, but <b>4</b> displayed the most potent activity in stimulating the κ opioid receptor and was more than 300-fold selective for the κ over the δ opioid receptor. It should be noted the aniline <b>8</b>, as well as the amides <b>11b</b>, <b>4</b>, and <b>11c</b>, did not substantially stimulate the μ opioid receptor even at high concentrations, suggesting the possible existence of partial-agonistic or antagonistic activities based on competitive binding assay results. Moreover, neither compound <b>4</b> (SLL-039) nor <b>11b</b> displayed κ antagonist activity, which was confirmed by their lack of ability to inhibit U50,488H-stiumulated [<sup>35</sup>S]GTPγS binding compared with the full antagonism produced by nor-BNI (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00857/suppl_file/jm9b00857_si_001.pdf" class="ext-link">Figure 1 in Supporting Information</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Functional Activity in Stimulating [<sup>35</sup>S]GTPγS Binding of <i>N</i>-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines for μ, δ, and κ Opioid Receptors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">μ</th><th class="rowsep1 colsep0" colspan="2" align="center">δ</th><th class="rowsep1 colsep0" colspan="2" align="center">κ</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">174.8 ± 19.0</td><td class="colsep0 rowsep0" align="left">189.7 ± 7.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">low stim<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">21.14 ± 7.7</td><td class="colsep0 rowsep0" align="left">267.54 ± 4.6</td><td class="colsep0 rowsep0" align="left">11.32 ± 1.8</td><td class="colsep0 rowsep0" align="left">217.4 ± 4.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9e</b></td><td class="colsep0 rowsep0" align="left">1426 ± 195.2</td><td class="colsep0 rowsep0" align="left">181.4 ± 5.1</td><td class="colsep0 rowsep0" align="left">78.89 ± 20.4</td><td class="colsep0 rowsep0" align="left">250.5 ± 8.6</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">low stim<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">low stim<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">low stim<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">20.7 ± 1.53</td><td class="colsep0 rowsep0" align="left">201.9 ± 4.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b> (SLL-039)</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">low stim<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">794.1 ± 161.4</td><td class="colsep0 rowsep0" align="left">222.3 ± 2.4</td><td class="colsep0 rowsep0" align="left">2.0 ± 0.4</td><td class="colsep0 rowsep0" align="left">191.3 ± 1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">low stim<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">132.4 ± 16.0</td><td class="colsep0 rowsep0" align="left">182.7 ± 1.4</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">low stim<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">morphine</td><td class="colsep0 rowsep0" align="left">123.5 ± 30.5</td><td class="colsep0 rowsep0" align="left">209 ± 15.9</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U50,488H</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">122.1 ± 1.1</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">112.6 ± 2.0</td><td class="colsep0 rowsep0" align="left">1.8 ± 0.6</td><td class="colsep0 rowsep0" align="left">262.0 ± 0.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Potency and efficacy in stimulating [<sup>35</sup>S]GTPγS binding to CHO cell membranes stably expressing opioid receptors. Data are expressed as the mean ± SEM of independent experiments performed in triplicate.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Not determined.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Not applicable.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Low stimulation of [<sup>35</sup>S]GTPγS binding at both 1 μM and 10 μM.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Molecular Modeling</h3><div class="NLM_p">The binding models of compound <b>4</b> (SLL-039) and relevant compounds with the μ and κ opioid receptors were further examined by molecular modeling. A putative binding model of SLL-039 in the μ opioid receptor binding site of and its overlays with compounds <b>8</b>, <b>11b</b>, and <b>11c</b> are shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. As for SLL-039, the morphinan scaffold could maintain most residue contacts observed in the morphinan-μ opioid receptor complex from the crystal structure,<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> including the salt bridge between the tertiary amine and D147<sup>3.32</sup>, the hydrophobic interactions of the cyclopropylmethyl group packed with W293<sup>6.48</sup> and Y326<sup>7.43</sup>, and the hydrogen bond between Y148<sup>3.33</sup> and the morphinan backbone, as shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a. Moreover, the 7α-phenyl linker formed a loose hydrophobic contact with I144<sup>3.29</sup> while the relatively rigid benzamide was oriented to a subpocket involving D216<sup>EL2</sup>, W133<sup>EL1</sup>, and N127<sup>2.63</sup>. Compounds <b>8</b>, <b>11b</b>, and <b>11c</b> shared almost the same poses in the μ opioid receptor binding site, but there was a minor deviation for SLL-039 particular to its morphinan substructure, as shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b. Additionally, it should be noted that the terminal phenylacetamide of compound <b>11c</b> assumed a semifolded conformation and extended to an adjacent subsite that included N127<sup>2.63</sup>, Q124<sup>2.60</sup>, and Y128<sup>2.64</sup>.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Putative binding mode of SLL-039 (in green) in the μ opioid receptor binding site and (b) overlays with compounds <b>8</b> (in magenta), <b>11b</b> (in yellow), and <b>11c</b> (in cyan). All these models were developed based on the crystal structure of the μ opioid receptor (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DKL">4DKL</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Furthermore, SLL-039 could maintain the identical conserved contacts with the κ opioid receptor in its morphinan structure, as shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a. D138<sup>3.32</sup>, W287<sup>6.48</sup>, Y320<sup>7.43</sup>, I294<sup>6.43</sup>, and Y139<sup>3.33</sup> were identified as the key residues responsible for these contacts. A loose hydrophobic interaction was also detected for the 7α-phenyl linker with L135<sup>3.29</sup> of the κ opioid receptor, which is consistent with I144<sup>3.29</sup> found in the modeled SLL-039-μ opioid receptor complex. There were significant interactions between the benzamide terminal of SLL-039 and the κ opioid receptor binding site, which were not observed in the modeled complex of SLL-039 and the μ opioid receptor. The benzamide amide proton could form a hydrogen bond with the C210<sup>EL2</sup> main-chain amide group. The benzamide phenyl group fit into a tight hydrophobic subpocket seated at the top of the TM2 domain and surrounded by the EL1 and EL2 domains, making hydrophobic interactions with V118<sup>2.63</sup>, W124<sup>EL1</sup>, and E209<sup>EL2</sup>. Compounds <b>8</b> and <b>11b</b> were also docked individually to the κ opioid receptor, and the results of the overlays suggest they assume an almost equivalent position to that of SLL-039 in the binding site, as shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b. Moreover, the complexes of other morphinan-based κ opioid agonists (e.g., nalfurafine in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and SLL-020ACP<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) with the κ opioid receptor were also established for further comparison. As expected, the morphinan motif of these κ opioid agonists overlapped well with one another in the binding site, as is shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>c. The nalfurafine furan ring and the SLL-020ACP phenyl group maintained the hydrophobic interactions with L135<sup>3.29</sup>, V118<sup>2.63</sup>, and W124<sup>EL1</sup>, and these contacts were also observed in the modeled complex of SLL-039 with the κ opioid receptor. However, nalfurafine and SLL-020ACP failed to touch the tight subpocket at the top of the EL1 and EL2 regions. Moreover, the E209<sup>EL2</sup> residue did not contribute to the binding of these κ opioid agonists, which was not true for SLL-039, as is shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>d.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Putative binding mode of SLL-039 (in green) in the κ opioid receptor binding site. (b) Overlays with compounds <b>8</b> (in magenta) and <b>11b</b> (in yellow). (c) Overlays with nalfurafine (in indigo) and SLL-020ACP (in orange). (d) Electrostatic potential surfaces generated by residues around SLL-039. All these models were developed based on the crystal structure of κ opioid receptor (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B73">6B73</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> <i>In Vivo</i> Studies</h3><div class="NLM_p">The preliminary pharmacological characteristics of SLL-039 were further investigated <i>in vivo</i> in male Kunming mice. The antinociceptive effects of SLL-039 were examined by both hot-plate and abdominal constriction assays. Compared with U50,488H, SLL-039 was much more potent in producing analgesia in both antinociception assays, as is shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Moreover, SLL-039 displayed a relatively long-term action in the hot-plate assay, as is shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. Additionally, it was noted that the antinociceptive effects of SLL-039 could be dismissed by pretreatment with the κ antagonist nor-BNI but not the μ antagonist β-FNA, suggesting a mechanism of selective stimulation of the κ rather than the μ opioid receptor <i>in vivo</i>, as is shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. ED<sub>50</sub> Values of the Antinociception Produced by Intraperitoneal Injection of SLL-039 Evaluated with the Hot-Plate and Abdominal Constriction Tests</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">antinociception ED<sub>50</sub> (mg/kg, ip)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">hot plate test</th><th class="colsep0 rowsep0" align="center">abdominal constriction test</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SLL-039</td><td class="colsep0 rowsep0" align="left">0.20 (0.10–0.60)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.10 (0.10–0.10)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U50,488H</td><td class="colsep0 rowsep0" align="left">4.42 (2.51–7.75)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.89 (0.54–1.45)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">morphine</td><td class="colsep0 rowsep0" align="left">6.95 (5.68–8.50)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.84 (0.56–1.27)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The antinociceptive ED<sub>50</sub> value of SLL-039 was calculated from data obtained at 2 h after drug administration. Data are presented from 8 to 10 mice/data point.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">The U50,488H and morphine data were cited from our previous data.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> The 95% confidence limits are in parentheses.</p></div></div></div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Time course for the antinociceptive effects of compound SLL-039 in the hot plate test. Mice were injected with SLL-039 (0.8 mg/kg) intraperitoneally. At varying times, antinociception was measured in the hot plate test. Data are the mean ± SEM from 8 to 10 mice/data point.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. The κ opioid receptor mediated SLL-039-induced antinociception. Mice were pretreated with the κ-opioid receptor antagonist nor-BNI (10 mg/kg, sc, −24 h) or μ-opioid receptor antagonist β-FNA (20 mg/kg, sc, −24 h). Then the antinociceptive effects of the compound SLL-039 (0.2 mg/kg, sc) were assessed 2 h after administration in the abdominal constriction test. Data are presented as the mean ± SEM from 8 mice/data point: ***<i>p</i> < 0.001 compared with SLL-039 alone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inhibition of locomotor activity was used as an indicator for sedation. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, at the doses with antinociceptive ED<sub>50</sub> values, U50,488H (5 mg/kg) significantly induced inhibition, while SLL-039 (0.3 mg/kg) did not. Moreover, at doses up to 2.7 mg/kg (9 × ED<sub>50</sub> values in the antinociceptive test), SLL-039 still did not cause sedation.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effects of U50,488H and SLL-039 on novelty-induced locomotor activity. Mice were treated with U50,488H (5 mg/kg) for 30 min or various doses of SLL-039 (0.3, 0.9, or 2.7 mg/kg) for 2 h, Then the total locomotor activities were monitored for 30 min. Data are presented as the mean ± SEM from 8 mice/data point: *<i>p</i> < 0.05 compared with the saline group by one-way ANOVA followed by Bonferroni test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Discussion and Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24128" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24128" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">During the campaign to combat the opioid-like side effects associated with the use of narcotics, κ opioid agonists have been considered as promising candidates as ideal analgesics at some time in the past. Unfortunately, unexpected CNS side effects such as dysphoria and hallucinogenic effects prohibited early identified arylacetamide-derived κ opioid agonists from becoming clinically useful agents. In contrast, nalfurafine, a 4,5-epoxymorphinan derivative, was claimed to be a potent κ opioid agonist free of these psychoactive side effects, which was supported by both clinical and postmarketing evidence.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32−34)</a> However, nalfurafine could produce an unacceptable sedative effect at lower treatment doses of analgesia, which made it inappropriate for the intended indication of analgesia. Moreover, nalfurafine displayed an apparent nonselectivity between κ and μ opioid activities <i>in vitro</i>, which is generally considered as a potential risk factor for patients demanding long-term use of analgesics. Therefore, the existing challenges in subtype selectivity and unwanted psychoactive effects should be tackled carefully before suggesting further κ opioid agonists derived from 4,5-epoxymorphinan derivatives for use in clinical practice.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Molecular Basis for the Interaction between SLL-039 and Opioid Receptors</h3><div class="NLM_p">According to the SAR (structure–activity relationship) analysis and molecular mechanism elucidated by modeling, the following three components were considered to contribute to the high selectivity and activity of SLL-039 on the κ opioid receptor: First, the polar proton from the benzamide motif could form a hydrogen bond with the C210<sup>EL2</sup> main-chain amide group, which was not observed in the SLL-039 complex with the μ opioid receptor. This was consistent with the result of our prior work, which showed that compound <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) with a <i>p</i>-amino substitution could confer RVD activities that were reversible by treatment with nor-BNI <i>ex vivo</i>, while analogs with <i>o-</i> or <i>m-</i>amino substitution were inactive. The tertiary amines (<b>10a</b>–<b>g</b>) displayed complete loss of κ/μ selectivity as a consequence of the deletion of this polar proton.</div><div class="NLM_p">Second, the benzamide phenyl group was fit into a tight hydrophobic subpocket seated at the top of TM2 domain and surrounded by the EL1 and EL2 domains. Among the three residues in this subpocket involved in hydrophobic contacts with the κ opioid receptor, two residues V118<sup>2.63</sup> and E209<sup>EL2</sup> but not W124<sup>EL1</sup> were nonconserved among the three opioid receptors, as is shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a. In particular, the residue at 2.63 on the extracellular surface of TM2 domain is valine for κ, asparagine for μ, and lysine for δ, which display distinctly different physiochemical properties. As for the EL2 residue, the μ and κ opioid receptors both contain an acidic residue. The longer chain of E209<sup>EL2</sup> for κ could confer an additional hydrophobic contact with SLL-039, but this was not the case with the shorter chain of D216<sup>EL2</sup> for the μ opioid receptor. On the basis of these favorable contacts, SLL-039 became the most potent κ opioid agonist and was also the only compound with low nanomolar affinities for the κ opioid receptor among all the series of compounds synthesized in this study. In contrast, when SLL-039 is bound to the μ opioid receptor, it was presumed that the SLL-039 benzamide phenyl group was oriented to the similar subpocket corresponding to D216<sup>EL2</sup>, W133<sup>EL1</sup>, and N126<sup>2.63</sup>. Unfortunately, noncompliance in the physicochemical properties between these residues and the SLL-039 benzamide phenyl group might result in unfavorable contacts. Although there was a distant hydrophobic contact with W133<sup>EL1</sup> at the bottom of this subpocket, this might not promote additional binding affinities. As a consequence, SLL-039 suffers an enormous loss in affinities to the μ opioid receptor. Moreover, consistent with this finding, the secondary amines <b>9a</b>–<b>e</b> with a hydrophobic terminus also showed a significant decrease in binding affinities to the μ opioid receptor compared to the aniline <b>9a</b>.</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (a) Residue triad in the κ opioid receptor involved in binding with SLL-039 (in green) and the corresponding residues in the μ and δ receptors. (b) Top view of overlays from the modeled structure of the SLL-039 (in green)−κ opioid receptor complex based on the crystal structure of the κ opioid receptor (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B73">6B73</a>) and the crystal structure of the naltrindole (in white)−δ opioid receptor complex (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EJ4">4EJ4</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Third, the benzamide carbonyl linker was also considered as a key component in determining the high selectivity and activity of SLL-039 for the κ opioid receptor. This linker was not substantially involved in binding to the κ opioid receptor, but its relative structural rigidity could produce conformational constraints to fix the SLL-039 benzamide motif into a preferred conformation to fit into the unique subpocket in the κ opioid receptor and prevent the formation of an inducible conformation of SLL-039 compliant with the corresponding sites in other receptor subtypes. In contrast, replacement with a flexible methylene linker was associated with an enormous loss of κ opioid affinity for compound <b>9f</b>, while substitution with an acetyl linker contributed to significant increase of μ opioid affinity by compound <b>11c</b>. Moreover, as shown from the molecular modeling, the phenylacetyl terminus of <b>11c</b> could assume a semifolded conformation to avoid the unfavorable noncompliance in physiochemical properties for the binding subpocket in the μ opioid receptor, resulting in preservation of most of the μ opioid affinity and complete loss of κ opioid selectivity.</div><div class="NLM_p last">The concept of message and address was first introduced by Portoghese to the field of non-peptide opioid studies approximately 30 years ago and was well exemplified by the discovery of naltrindole, a highly selective and potent δ opioid antagonist.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> To date, we believe the essence of this concept still works to navigate us toward identifying highly selective and potent κ opioids from 4,5-expoxymorphinans with suboptimal selectivity and activity. Thus, the conformational restriction through the introduction of structural rigidity could confer binding to the address subsite of the κ opioid receptor and generate noncompliant physicochemical properties for the address subsite of other opioid receptors, resulting in optimal selectivity and activity. This recognition could be further exemplified by our recent identification of SLL-020ACP as a highly selective and potent κ opioid agonist from nepenthone analogs, which contains a rigid benzoyl substitution at the 7α position of 4,5-expoxymorphinans.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> However, it should be noted that introduction of a 7β-methyl substitution was associated with an enormous reduction in selectivity and activity, which was observed in the corresponding analog,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> indicating the complicated nature of the structural components for determining the subtype selectivity of 4,5-expoxymorphinans. Furthermore, this concept was challenged by emerging structural biology evidence that indicated that the subtype selectivity of κ opioid agonists was a result of interactions with both conserved and nonconserved residues rather than single address components with the receptor.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> As for SLL-039, besides the conservative contacts of the scaffold 4,5-expoxymorphinan, interactions with identical (C210<sup>EL2</sup> and W124<sup>EL1</sup>), similar (L135<sup>3.29</sup> and E209<sup>EL2</sup>), and variable (V118<sup>2.</sup><a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a>) residues, as well as the structural rigidity maintained by the carbonyl linker, were all considered to contribute to the high selectivity and activity of this compound. Additionally, the subpocket seated at the top of TM2 domain was definitely different from the one occupied by the naltrindole address component in the δ opioid receptor, as is shown by <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>b.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Potential Biological Relevance and Insights for the Design and Discovery of Novel κ Opioid Agonists from 4,5-Expoxymorphinans</h3><div class="NLM_p">In addition to its highly selective and potent κ opioid agonistic activities both <i>in vitro</i> and <i>in vivo</i>, SLL-039 also displayed a relatively unique pharmacological profile compared to nalfurafine, which is derived from 4,5-epoxymorphinans. Nalfurafine could produce significant sedative effects under low analgesia doses. Due to this dose-limiting effect, it was given up as a useful analgesic in clinical trials.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In contrast, SLL-039 did not cause sedation at the effective analgesia dose. Since nalfurafine displayed an antinociception/sedation ED<sub>50</sub> ratio very similar to that of U50,488H,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> SLL-039 was presumed to have a defined separation between antinociception and sedation compared with nalfurafine, thus apparently expanding the therapeutic window for the indication of analgesia, although there were no head-to-head comparisons available between SLL-039 and nalfurafine. In particular, from a perspective of molecular modeling, SLL-039 benzamide terminus could occupy a subpocket composed of TM3, EL1, and EL2 on the extracellular surface of the κ opioid receptor, while the structure of nalfurafine was too short in its structure to touch this subsite, as is demonstrated in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. Considering that SLL-039 and nalfurafine are both 4,5-epoxymorphinans and their binding poses with the κ opioid receptor were almost the same, it was assumed that the interaction with this subpocket involving V118<sup>2.</sup>,<sup>63</sup> W124<sup>EL1</sup>, and E209<sup>EL2</sup> might be of relevance to separate the antinociception effects from the sedation effects for κ opioid agonists.</div><div class="NLM_p last">In conclusion, despite the early failure of arylacetamides and the discontinuation of nalfurafine as a potential analgesic in clinical trials, the preliminary results for SLL-039 were encouraging and demonstrate its potential to become an effective and safe analgesic.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06857" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06857" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry</h3><div class="NLM_p last">Reagents and solvents were purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China), Acros, or other suppliers, which were used as received. Tetrahydrofuran was refluxed with sodium/benzopheneone and distilled before use. Uncorrected melting points were measured using capillary technique on a SGW X-4A melting-point apparatus with microscope (Shanghai INESA Physico-Optical Instrument Co., Ltd., Shanghai, China). NMR data were recorded with a Mercury plus 400 MHz (Varian, Inc., Palo Alto, CA, USA) or Bruker ASCEND 600 MHz NMR system. Chemical shifts (δ) are expressed in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard. The exchangeable protons of hydroxy or amino groups were examined by the addition of D<sub>2</sub>O. Mass spectra were measured on an Agilent 1100 series LC/MSD 1946D spectrometer (Agilent Technologies, Inc., Santa Clara, CA, USA). High-resolution mass spectra (HRMS) were obtained on an AB SCIEX TripleTOF 5600+ mass spectrometer (AB SCIEX, LLC., Redwood City, CA, USA). Specific rotation values were recorded on an AUTOPOL IV (Rudolph Research Analytical, Hackettstown, NJ, USA) (λ = 589 nm, 100 mm cell, 25 °C). The contents of compounds for biological evaluation were examined with a WATERS Breeze 2 HPLC system (Waters Corporation, Milford, MA, USA) with methanol/water (80:20 or 85:15) as the eluent. Unless specified, the purity of target compounds was >95%, which was considered to be pure enough for biological assays.</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Procedure for the Synthesis of Intermediates. <i>N</i>-Cyclopropylmethyl-7α-4′-(<i>N</i>′-benzoyl)aminophenyl-6,14-endoethan-tetrahydronorthebaine, Compound <b>4</b></h3><div class="NLM_p">To a solution of <b>8</b> (41 mg, 0.087 mmol) in dichloromethane (1 mL) was added triethylamine (26 mg, 0.261 mmol), then benzoyl chloride (24 mg, 0.174 mmol) was added dropwise at 0 °C. The mixture was stirred for 2 h and washed with water and saturated sodium chloride solution successively, dried over sodium sulfate, filtered, and concentrated. The residue was purified by prep TLC (DCM: MeOH = 10: 1). Compound <b>4</b> was obtained as a white solid (18 mg, yield 10.7%); mp 201–202 °C; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.06 (s, 1H), 7.87–7.83 (m, 2H), 7.60 (d, <i>J</i> = 8.3 Hz, 2H), 7.54 (t, <i>J</i> = 7.3 Hz, 1H), 7.48 (t, <i>J</i> = 7.5 Hz, 2H), 7.34 (d, <i>J</i> = 8.4 Hz, 2H), 6.73 (d, <i>J</i> = 8.1 Hz, 1H), 6.60 (d, <i>J</i> = 8.1 Hz, 1H), 4.62 (s, 1H), 3.88 (s, 3H), 3.27 (t, <i>J</i> = 25.6 Hz, 1H), 3.20 (s, 3H), 3.18–3.08 (m, 2H), 3.04 (d, <i>J</i> = 18.4 Hz, 1H), 2.75 (s, 1H), 2.33 (t, <i>J</i> = 29.0 Hz, 4H), 2.21 (s, 1H), 1.82–1.72 (m, 1H), 1.72–1.61 (m, 2H), 1.48 (td, <i>J</i> = 12.3, 4.9 Hz, 1H), 1.42–1.32 (m, 1H), 0.95–0.88 (m, 1H), 0.81 (s, 1H), 0.49 (dt, <i>J</i> = 17.1, 8.7 Hz, 2H), 0.12 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 165.64, 147.04, 141.90, 138.41, 136.22, 135.09, 132.92, 132.71, 131.75, 130.10, 128.77, 126.98, 119.87, 119.01, 113.86, 93.29, 59.74, 58.56, 56.66, 51.10, 45.94, 43.94, 43.27, 36.17, 36.13, 35.41, 29.67, 22.96, 18.56, 9.20, 4.18, 3.38. [α]<sub>D</sub><sup>25</sup> −92.8° (<i>c</i> 0.10, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>37</sub>H<sub>40</sub>N<sub>2</sub>O<sub>4</sub> + H<sup>+</sup>, 577.3061 [M + H]<sup>+</sup>; found, 577.3064.</div><div class="NLM_p last">Northebaine hydrochloride (compound <b>5</b>) and <i>N</i>-cyclopropylmethyl-northebaine (compound <b>6</b>) were prepared according to the procedure described in our previous work.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>N</i>-Cyclopropylmethyl-7α-4′-nitrophenyl-6,14-endoethenotetrahydronorthebaine, Compound <b>7</b></h3><div class="NLM_p last">In a three-neck flask fitted with a reflux condenser, <b>6</b> (3.8 g, 2.27 mmol) was dissolved in xylene (60 mL). 4-Nitrostyrene (1.01 g, 6.81 mmol) was added, and the mixture was heated to reflux for 24 h. The reaction was allowed to cool to room temperature, and the solvent was removed under reduced pressure. The reaction residue was purified by silica gel flash chromatography (PE–EA 10:1 as eluent). <b>7</b> was obtained as a yellow solid (4.2 g, yield 78%). Mp 200–201 °C. ESI-MS (M + H)<sup>+</sup>: 501.2.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>N</i>-Cyclopropylmethyl-7α-4′-aminophenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>8</b></h3><div class="NLM_p last"><b>7</b> (2.63 g, 5.25 mmol), ethanol (60 mL), and palladium on charcoal (5%, 0.67 g) were added to an autoclave. The reaction was performed under a hydogen atmosphere at a pressure of approximately 65 psi and heated to 50 °C for 36 h. The mixture was filtered and the filtrate was evaporated to give <b>8</b> as a white solid (2.1 g, yield 84.6%). Mp 94–95 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.12 (d, <i>J</i> = 8.3 Hz, 2H), 6.72 (d, <i>J</i> = 8.1 Hz, 1H), 6.65 (d, <i>J</i> = 8.3 Hz, 2H), 6.58 (d, <i>J</i> = 8.1 Hz, 1H), 5.29 (s, 2H), 4.60 (s, 1H), 3.87 (s, 3H), 3.21 (t, <i>J</i> = 12.7 Hz, 1H), 3.18 (s, 3H), 3.10 (d, <i>J</i> = 6.1 Hz, 1H), 3.00 (dd, <i>J</i> = 20.8, 12.8 Hz, 2H), 2.71 (dd, <i>J</i> = 11.6, 4.9 Hz, 1H), 2.34 (tdd, <i>J</i> = 19.7, 13.6, 6.3 Hz, 4H), 2.18 (td, <i>J</i> = 12.7, 5.5 Hz, 1H), 1.74 (dd, <i>J</i> = 12.9, 2.4 Hz, 1H), 1.68–1.59 (m, 2H), 1.42 (td, <i>J</i> = 12.2, 6.1 Hz, 1H), 1.31 (td, <i>J</i> = 12.7, 6.1 Hz, 1H), 0.90–0.83 (m, 1H), 0.82–0.75 (m, 1H), 0.51–0.42 (m, 2H), 0.10 (d, <i>J</i> = 4.1 Hz, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 147.04, 144.65, 141.81, 132.86, 131.96, 130.21, 128.48, 118.85, 115.06, 113.71, 93.16, 76.88, 59.72, 58.59, 56.62, 50.88, 45.85, 43.91, 42.78, 36.25 (d, <i>J</i> = 36.8 Hz), 35.45, 29.65, 22.86, 18.66, 9.26, 4.10, 3.32. [α]<sub>D</sub><sup>25</sup> −128.7° (<i>c</i> 0.15, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>36</sub>N<sub>2</sub>O<sub>3</sub> + H<sup>+</sup>, 473.2799 [M + H]<sup>+</sup>; found, 473.2799.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>N</i>-Cyclopropylmethyl-7α-4′-methylaminophenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>9a</b></h3><div class="NLM_p last"><i>N</i>,<i>N</i>-Diisopropyl-ethylamine (34 mg, 0.26 mmol was added to a solution of <b>8</b> (100 mg, 0.21 mmol) in DCM (1 mL), after which benzyl chloroformate (39 mg, 0.23 mmol) was added dropwise at 0 °C. The mixture was heated to 35 °C for 6 h, washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The mixture residue was dissolved with dry THF (1 mL), and LiAlH<sub>4</sub> (0.32 mmol) was added dropwise at 0 °C; the temperature was adjusted to 35 °C and maintained for 2 h. The mixture was quenched with ice water and NaOH solution (4 N, 0.5 mL). The white solid was separated out and removed by filtering. The organic phase of the filtrate was removed under reduced pressure; the aqueous residue was extracted with DCM (2 mL × 3). The combined extracts were washed with saturated sodium chloride solution, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by reversed-phase flash chromatography (MeOH–H<sub>2</sub>O 10%–100% as eluent) to afford <b>9a</b> as a yellow solid (19 mg, yield 19%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.16 (d, <i>J</i> = 8.3 Hz, 2H), 6.72 (d, <i>J</i> = 8.1 Hz, 1H), 6.63–6.55 (m, 3H), 5.29 (s, 1H), 4.61 (s, 1H), 3.87 (s, 3H), 3.28–3.20 (m, 1H), 3.18 (s, 3H), 3.09 (s, 1H), 3.01 (t, <i>J</i> = 14.5 Hz, 2H), 2.82 (s, 3H, <i>N</i>-CH3), 2.68 (s, 1H), 2.33 (d, <i>J</i> = 26.7 Hz, 4H), 2.18 (s, 1H), 1.74 (d, <i>J</i> = 12.2 Hz, 1H), 1.71–1.59 (m, 2H), 1.42 (td, <i>J</i> = 12.3, 5.3 Hz, 1H), 1.37–1.28 (m, 1H), 0.87 (dd, <i>J</i> = 16.0, 9.2 Hz, 1H), 0.78 (s, 1H), 0.53–0.40 (m, 2H), 0.10 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 147.81, 147.09, 143.61, 141.86, 132.95, 130.61, 130.15, 128.63, 118.86, 113.72, 112.32, 93.19, 59.73, 58.60, 56.64, 50.89, 45.87, 43.96, 42.72, 36.47, 36.17, 35.54, 30.86, 29.70, 22.87, 22.67, 18.73, 9.38, 4.12, 3.30. [α]<sub>D</sub><sup>25</sup> −80.5° (<i>c</i> 0.12, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>38</sub>N<sub>2</sub>O<sub>3</sub> + H<sup>+</sup>, 487.2955 [M + H]<sup>+</sup>; found, 487.2960.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> <i>N</i>-Cyclopropylmethyl-7α-4′-ethylaminophenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>9b</b></h3><div class="NLM_p last">Sodium carbonate (67 mg, 0.63 mmol) and bromoethane (35 mg, 0.32 mmol) were added to a solution of 8 (100 mg, 0.21 mmol) in DMF (2 mL). The mixture was heated to 30 °C for 4 h and then cooled down to room temperature before the addition of water. The aqueous phase was extracted with EtOAc (2 mL × 3). The combined extract was washed with brine, dried over sodium sulfate, and evaporated to dryness. The residue was purified by prep TLC (DCM:MeOH = 20:1) to afford title compound <b>9b</b> as a yellow oil (21 mg, yield 23.5%). <sup><b>1</b></sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.14 (d, <i>J</i> = 8.4 Hz, 2H), 6.72 (d, <i>J</i> = 8.1 Hz, 1H), 6.58 (d, <i>J</i> = 8.4 Hz, 3H), 5.30 (s, 1H), 4.60 (s, 1H), 3.87 (s, 3H), 3.20 (s, 1H), 3.17 (s, 3H), 3.14 (q, <i>J</i> = 7.1 Hz, 2H), 3.07 (s, 1H), 3.00 (dd, <i>J</i> = 21.9, 14.6 Hz, 2H), 2.67 (s, 1H), 2.32 (d, <i>J</i> = 21.6 Hz, 4H), 2.17 (s, 1H), 1.74 (d, <i>J</i> = 12.0 Hz, 1H), 1.67 (d, <i>J</i> = 13.0 Hz, 1H), 1.62 (dd, <i>J</i> = 13.5, 7.0 Hz, 1H), 1.42 (dd, <i>J</i> = 16.1, 10.3 Hz, 1H), 1.35–1.29 (m, 1H), 1.26–1.19 (m, 3H), 0.88–0.82 (m, 1H), 0.77 (s, 1H), 0.51–0.41 (m, 2H), 0.10 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 147.10, 146.95, 141.83, 133.01, 130.56, 130.18, 118.85, 113.69, 112.60, 93.27, 59.76, 58.63, 56.65, 50.84, 45.89, 43.97, 42.79, 38.60, 36.50, 36.17, 35.60, 29.70, 22.85, 18.70, 14.97, 9.42, 4.11, 3.31. [α]<sub>D</sub><sup>25</sup> −26.2° (<i>c</i> 0.10, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>40</sub>N<sub>2</sub>O<sub>3</sub> + H<sup>+</sup>, 501.3112 [M + H]<sup>+</sup>; found, 501.3116.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>N</i>-Cyclopropylmethyl-7α-4′-propylaminophenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>9c</b></h3><div class="NLM_p last">A solution of palladium on carbon (5%, 46 mg) in isopropyl alcohol was added to a solution of ammonium formate (200 mg, 3.2 mmol) in H<sub>2</sub>O (1 mL). The mixture was stirred at room temperature for 10 min. Compound <b>8</b> (100 mg, 0.21 mmol) and propionaldehyde (36 mg, 0.63 mmol) were added to the mixture and stirred at room temperature for 16 h before removal of the isopropanol <i>in vacuo</i>. The aqueous phase was extracted with DCM (3×), and the combined extract was washed with brine and dried over sodium sulfate before evaporation to dryness. The residue was purified by prep TLC (DCM:MeOH = 15:1) to afford title compound <b>9c</b> as a colorless oil (17 mg, yield 15.6%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.13 (d, <i>J</i> = 8.4 Hz, 2H), 6.74 (d, <i>J</i> = 7.4 Hz, 1H), 6.59 (dd, <i>J</i> = 19.8, 7.9 Hz, 4H), 5.41 (s, 1H), 4.63 (s, 1H), 3.88 (s, 4H), 3.22 (d, <i>J</i> = 11.2 Hz, 1H), 3.18 (s, 3H), 3.12–3.00 (m, 5H), 2.37 (s, 5H), 2.00–1.79 (m, 3H), 1.63 (dt, <i>J</i> = 14.8, 7.5 Hz, 4H), 0.99 (t, <i>J</i> = 7.4 Hz, 3H), 0.96 (d, <i>J</i> = 6.7 Hz, 1H), 0.94–0.90 (m, 1H), 0.52 (s, 2H), 0.16 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 147.11, 143.22, 140.86, 133.10, 132.00, 130.11, 121.43, 119.05, 114.42, 112.57, 94.34, 59.66, 58.64, 50.88, 45.94, 36.21, 35.31, 29.73, 28.42, 28.16, 25.21, 22.94, 22.78, 22.48, 18.67, 11.65, 9.08, 3.96, 3.17. [α]<sub>D</sub><sup>25</sup> −51.6° (<i>c</i> 0.1, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>33</sub>H<sub>42</sub>N<sub>2</sub>O<sub>3</sub> + H<sup>+</sup>, 515.3268 [M + H]<sup>+</sup>; found, 515.3269.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N</i>-Cyclopropylmethyl-7α-4′-cyclophenylmethylaminophenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>9d</b></h3><div class="NLM_p last">Sodium carbonate (67 mg, 0.63 mmol) and (bromomethyl)cyclopropane (43 mg, 0.32 mmol) were added to a solution of 8 (100 mg, 0.21 mmol) in DMF (2 mL). The mixture was heated to 30 °C for 4 h. The reaction mixture was then cooled to room temperature before the addition of water. The aqueous phase was extracted with EtOAc (3×), and the combined organic phase was washed with brine and dried over sodium sulfate before evaporation to dryness. The residue was purified by prep TLC (DCM:MeOH = 20:1) to afford title compound <b>9d</b> as a yellow oil (37 mg, yield 33.5%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.14 (d, <i>J</i> = 8.4 Hz, 2H), 6.71 (d, <i>J</i> = 8.1 Hz, 1H), 6.58 (d, <i>J</i> = 8.4 Hz, 3H), 5.30 (s, 1H), 4.60 (s, 1H), 3.87 (s, 3H), 3.20 (d, <i>J</i> = 7.5 Hz, 1H), 3.17 (s, 3H), 3.06 (d, <i>J</i> = 5.1 Hz, 1H), 3.00 (dd, <i>J</i> = 23.9, 14.8 Hz, 2H), 2.94 (d, <i>J</i> = 6.9 Hz, 2H), 2.65 (d, <i>J</i> = 6.7 Hz, 1H), 2.31 (dd, <i>J</i> = 27.0, 7.9 Hz, 4H), 2.21–2.11 (m, 1H), 1.73 (d, <i>J</i> = 12.1 Hz, 1H), 1.69–1.57 (m, 2H), 1.42 (td, <i>J</i> = 12.1, 5.9 Hz, 1H), 1.32 (d, <i>J</i> = 15.9 Hz, 1H), 1.12–1.05 (m, 1H), 0.88–0.82 (m, 1H), 0.76 (s, 1H), 0.54 (q, <i>J</i> = 5.6 Hz, 2H), 0.51–0.40 (m, 2H), 0.22 (q, <i>J</i> = 4.9 Hz, 2H), 0.09 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 147.08, 146.98, 141.79, 133.04, 130.66, 130.18, 128.75, 118.83, 113.65, 112.63, 99.96, 93.29, 62.27, 59.80, 58.65, 56.65, 50.91, 49.23, 45.93, 43.93, 42.82, 36.53, 36.17, 35.66, 29.69, 22.81, 18.72, 14.40, 10.95, 9.48, 4.07, 3.82, 3.42, 3.32. [α]<sub>D</sub><sup>25</sup> −124.0° (<i>c</i> 0.13, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>34</sub>H<sub>42</sub>N<sub>2</sub>O<sub>3</sub> + H<sup>+</sup>, 527.3268 [M + H]<sup>+</sup>; found, 527.3272.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N</i>-Cyclopropylmethyl-7α-4′-benylaminophenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>9e</b></h3><div class="NLM_p last">Sodium carbonate (67 mg, 0.63 mmol) and benzyl chloride (40 mg, 0.32 mmol) were added to a solution of compound <b>8</b> (100 mg, 0.21 mmol) in DMF (2 mL). The mixture was heated to 30 °C for 4 h. The reaction mixture was then cooled to room temperature and supplemented with water before the aqueous phase was extracted with EtOAc (3×). The combined extract was washed with brine and dried over sodium sulfate before evaporation to dryness. The residue was purified by prep TLC (DCM:MeOH = 20:1) to afford title compound <b>9e</b> as a colorless oil (36 mg, yield 30.2%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.45–7.30 (m, 4H), 7.27 (d, <i>J</i> = 7.2 Hz, 1H), 7.14 (d, <i>J</i> = 8.4 Hz, 2H), 6.71 (d, <i>J</i> = 8.1 Hz, 1H), 6.61 (d, <i>J</i> = 8.4 Hz, 2H), 6.57 (d, <i>J</i> = 8.1 Hz, 1H), 5.29 (s, 1H), 4.60 (s, 1H), 4.31 (s, 2H), 3.87 (s, 3H), 3.24–3.14 (m, 4H), 3.06 (d, <i>J</i> = 5.3 Hz, 1H), 3.00 (t, <i>J</i> = 15.7 Hz, 2H), 2.65 (d, <i>J</i> = 6.8 Hz, 1H), 2.31 (dt, <i>J</i> = 18.3, 12.8 Hz, 4H), 2.16 (dd, <i>J</i> = 11.5, 7.2 Hz, 1H), 1.73 (d, <i>J</i> = 11.5 Hz, 1H), 1.68–1.56 (m, 2H), 1.46–1.36 (m, 1H), 1.33–1.29 (m, 1H), 0.87 (dd, <i>J</i> = 23.5, 9.6 Hz, 1H), 0.76 (s, 1H), 0.51–0.39 (m, 2H), 0.09 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 147.05, 146.67, 141.78, 139.56, 133.00, 130.96, 130.19, 128.72, 128.57, 127.56, 127.16, 118.84, 113.63, 112.69, 93.15, 62.22, 59.76, 58.60, 56.62, 50.87, 48.55, 45.91, 43.91, 42.73, 36.51, 36.14, 35.63, 29.66, 22.79, 18.75, 14.39, 9.45, 4.08, 3.29. [α]<sub>D</sub><sup>25</sup> −76.7° (<i>c</i> 0.17, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>37</sub>H<sub>42</sub>N<sub>2</sub>O<sub>3</sub> + H<sup>+</sup>, 563.3268 [M + H]<sup>+</sup>; found, 563.3264.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-Cyclopropylmethyl-7α-4′-(<i>N</i>′,<i>N</i>′-dimethylaminoethyl)aminophenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>9f</b></h3><div class="NLM_p last">Potassium carbonate (88 mg, 0.63 mmol) and potassium iodide (72 mg, 0.42 mmol) were added to a solution of compound <b>8</b> (100 mg, 0.21 mmol) in EtOH (2 mL). Then, 2-bromoethyl(dimethyl)azanium bromide (97 mg, 0.42 mmol) was added and refluxed for 9 h. The reaction mixture was cooled to room temperature, filtered, and evaporated to dryness <i>in vacuo</i>. The residue was purified by prep TLC (DCM:MeOH = 10:1) to afford title compound <b>9f</b> as a colorless oil (19 mg, yield 16.5%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.14 (d, <i>J</i> = 8.2 Hz, 2H), 6.74 (d, <i>J</i> = 8.1 Hz, 1H), 6.65 (d, <i>J</i> = 8.3 Hz, 2H), 6.60 (d, <i>J</i> = 8.0 Hz, 1H), 5.30 (s, 1H), 4.62 (s, 1H), 3.88 (s, 3H), 3.54–3.23 (m, 3H), 3.19 (d, <i>J</i> = 12.7 Hz, 3H), 3.09 (t, <i>J</i> = 24.4 Hz, 1H), 3.06–2.93 (m, 4H), 2.85 (s, 1H), 2.62 (s, 6H), 2.47 (s, 4H), 2.30 (s, 1H), 1.78 (d, <i>J</i> = 12.4 Hz, 1H), 1.65 (t, <i>J</i> = 12.9 Hz, 2H), 1.50–1.28 (m, 2H), 0.88 (s, 2H), 0.54 (d, <i>J</i> = 25.6 Hz, 2H), 0.28–019 (m, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 147.08, 145.85, 142.08, 132.28, 130.62, 130.25, 119.07, 114.52 (d, <i>J</i> = 155.4 Hz), 112.81, 92.61, 59.48, 58.45, 57.22, 56.61, 50.84, 45.51, 44.20 (d, <i>J</i> = 67.6 Hz), 42.34, 39.67, 36.19, 34.63, 29.64, 23.34, 18.69, 8.52, 4.60, 3.30. [α]<sub>D</sub><sup>25</sup> −97.0° (<i>c</i> 0.15, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>34</sub>H<sub>45</sub>N<sub>3</sub>O<sub>3</sub> + H<sup>+</sup>, 544.3534 [M + H]<sup>+</sup>; found, 544.3539.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>N</i>-Cyclopropylmethyl-7α-4′-(<i>N</i>″,<i>N</i>″-dimethylaminopropyl)aminophenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>9g</b></h3><div class="NLM_p last">Potassium carbonate (88 mg, 0.63 mmol) and potassium iodide (72 mg, 0.42 mmol) were added to a solution of <b>8</b> (100 mg, 0.21 mmol) in EtOH (2 mL). Then, 3-chloro-<i>N</i>,<i>N</i>-dimethylpropan-1-amine (51 mg, 0.42 mmol) was added and refluxed for 9 h. The reaction mixture was cooled to room temperature, filtered, and evaporated to dryness <i>in vacuo</i>. The residue was purified by prep TLC (DCM:MeOH = 10:1) to afford title compound <b>9g</b> as a yellow oil (15 mg, yield 12.7%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.14 (d, <i>J</i> = 8.4 Hz, 2H), 6.73 (d, <i>J</i> = 8.1 Hz, 1H), 6.60 (d, <i>J</i> = 8.3 Hz, 3H), 5.30 (s, 1H), 4.62 (s, 1H), 3.88 (s, 3H), 3.31 (t, <i>J</i> = 6.1 Hz, 2H), 3.19 (s, 4H), 3.03 (d, <i>J</i> = 18.6 Hz, 3H), 3.01–2.94 (m, 3H), 2.67 (s, 6H), 2.41 (t, <i>J</i> = 34.7 Hz, 4H), 2.24 (s, 1H), 1.77 (d, <i>J</i> = 12.8 Hz, 1H), 1.66 (d, <i>J</i> = 12.2 Hz, 2H), 1.59 (dd, J = 27.0, 16.2 Hz, 2H), 1.47–1.38 (m, 2H), 0.83 (d, <i>J</i> = 7.5 Hz, 2H), 0.51 (d, <i>J</i> = 15.2 Hz, 2H), 0.15 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 147.38, 143.19, 131.49, 130.60, 130.49, 129.95, 128.21, 124.85, 124.45, 123.24, 119.85, 115.53, 92.26, 58.95, 56.85, 55.94, 51.49, 46.15, 44.99, 42.77, 42.14, 36.28, 32.00, 31.92, 29.78, 29.33, 27.23, 25.23, 22.69, 17.94, 14.11, 9.86, 4.04, 3.37. [α]<sub>D</sub><sup>25</sup> −39.7° (<i>c</i> 0.11, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>35</sub>H<sub>47</sub>N<sub>3</sub>O<sub>3</sub> + H<sup>+</sup>, 558.3690 [M + H]<sup>+</sup>; found, 558.3682.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N</i>-Cyclopropylmethyl-7α-4′-(2″-acetamido)aminophenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>9h</b></h3><div class="NLM_p last">Potassium carbonate (88 mg, 0.63 mmol) and potassium iodide (72 mg, 0.42 mmol) were added to a solution of <b>8</b> (100 mg, 0.21 mmol) in EtOH (2 mL). Then, 2-bromoacetamide (58 mg, 0.42 mmol) was added and refluxed for 9 h. The reaction mixture was cooled to room temperature, filtered, and evaporated to dryness <i>in vacuo</i>. The residue was purified by prep TLC (DCM:MeOH = 10:1) to afford title compound <b>9h</b> as a colorless oil (20 mg, yield 17.8%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.02 (s, 1H), 7.17 (d, <i>J</i> = 7.9 Hz, 2H), 6.74 (d, <i>J</i> = 7.6 Hz, 1H), 6.67 (s, 1H), 6.59 (d, <i>J</i> = 8.1 Hz, 3H), 5.30 (s, 1H), 4.64 (s, 1H), 3.88 (s, 3H), 3.77 (s, 2H), 3.30–3.17 (m, 4H), 3.16–3.01 (m, 3H), 2.70 (s, 1H), 2.36 (s, 5H), 1.78 (s, 1H), 1.73–1.55 (m, 2H), 1.42 (ddd, <i>J</i> = 21.2, 13.7, 6.3 Hz, 2H), 0.86 (dd, <i>J</i> = 25.4, 18.4 Hz, 2H), 0.50 (s, 2H), 0.14 (s, 2H).<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 173.90, 147.25, 145.65, 131.30, 130.43, 130.35, 128.73, 119.41, 113.41, 113.01, 91.85, 76.33, 59.01, 58.19, 56.70, 50.89, 48.39, 45.10, 43.69, 42.64, 36.31, 35.78, 35.43, 29.82, 22.72, 18.58, 9.21, 4.11, 3.28. [α]<sub>D</sub><sup>25</sup> −140.5° (<i>c</i> 0.10, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>39</sub>N<sub>3</sub>O<sub>4</sub> + H<sup>+</sup>, 530.3013 [M + H]<sup>+</sup>; found, 530.3012.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-Cyclopropylmethyl-7α-4′-(2″-(ethoxycarbonyl)ethyl)aminophenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>9i</b></h3><div class="NLM_p last">Potassium carbonate (88 mg, 0.63 mmol) and potassium iodide (72 mg, 0.42 mmol) were added to a solution of compound <b>8</b> (100 mg, 0.21 mmol) in EtOH (2 mL). Next, ethyl 3-bromopropionate (76 mg, 0.42 mmol) was added and refluxed for 9 h. The reaction mixture was cooled to room temperature, filtered, and evaporated to dryness <i>in vacuo</i>. The residue was purified by prep TLC (DCM:MeOH = 20:1) to afford title compound <b>9i</b> as a colorless oil (26 mg, yield 21.4%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.13 (d, <i>J</i> = 8.3 Hz, 2H), 6.76 (d, <i>J</i> = 7.9 Hz, 1H), 6.63 (d, <i>J</i> = 7.8 Hz, 1H), 6.58 (d, <i>J</i> = 8.4 Hz, 2H), 5.38–5.30 (m, 1H), 4.65 (s, 1H), 4.18–4.14 (m, 2H), 3.88 (s, 3H), 3.43 (t, <i>J</i> = 6.4 Hz, 2H), 3.23–3.16 (m, 4H), 3.08 (d, <i>J</i> = 17.2 Hz, 3H), 2.81–2.41 (m, 7H), 1.83 (s, 1H), 1.69 (t, <i>J</i> = 11.7 Hz, 2H), 1.47–1.38 (m, 2H), 1.30 (d, <i>J</i> = 13.3 Hz, 1H), 1.27 (s, 3H), 0.92 (dd, <i>J</i> = 20.0, 10.7 Hz, 2H), 0.58 (s, 2H), 0.28 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 172.42, 147.21, 146.16, 130.71, 130.23, 119.05, 112.98 (d, <i>J</i> = 15.9 Hz), 92.81, 60.57, 59.65, 58.39, 56.69, 50.87, 45.80, 43.93, 42.82, 39.61, 36.24, 35.90, 35.62, 34.02, 29.64, 18.59, 14.16, 9.46, 4.07, 3.26. [α]<sub>D</sub><sup>25</sup> −83.8° (<i>c</i> 0.15, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>35</sub>H<sub>44</sub>N<sub>2</sub>O<sub>5</sub> + H<sup>+</sup>, 573.3323 [M + H]<sup>+</sup>; found, 573.3326.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> General Procedure for the Synthesis of <b>10a</b>–<b>c</b></h3><div class="NLM_p last">Compound <b>6</b> (75 mg, 0.16 mmol) in acetonitrile (2 mL) was supplemented with the corresponding dibromoalkanes (0.3 mmol) before the mixture was stirred at 110 °C under microwave irradiation for 1 h. Next, the reaction was monitored for completion by TLC. The reaction was allowed to cool to room temperature, and the solvent was removed under reduced pressure. The residue was purified by silica gel flash chromatography with PE–EA as the eluent to afford <b>10a</b>–<b>c</b>.</div></div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i>-Cyclopropylmethyl-7α-4′-tetrahydropyrrolylphenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>10a</b></h3><div class="NLM_p last">Compound <b>10a</b> was obtained as a white solid (24.7 mg, yield 28.6%). Mp 103–104 °C; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.18 (d, <i>J</i> = 7.7 Hz, 2H), 6.73 (s, 1H), 6.59 (s, 1H), 6.53 (d, <i>J</i> = 8.3 Hz, 2H), 4.63 (s, 1H), 3.88 (s, 3H), 3.32–3.23 (m, 4H), 3.19 (s, 4H), 3.03 (d, <i>J</i> = 16.7 Hz, 3H), 2.65 (s, 1H), 2.47–2.11 (m, 4H), 2.01 (s, 1H), 2.00–1.93 (m, 4H), 1.79–1.58 (m, 4H), 1.47–1.38 (m, 1H), 0.77 (s, 2H), 0.46 (s, 2H), 0.10 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 147.20, 146.65, 142.00, 133.03, 130.11, 128.77, 118.89, 113.68, 111.43, 93.25, 60.10–59.78 (m), 59.15 (d, <i>J</i> = 158.8 Hz), 56.69, 50.89, 47.61, 45.92, 44.00, 42.63, 37.51–36.73 (m), 36.40 (d, <i>J</i> = 42.8 Hz), 35.67, 29.70, 25.48, 22.70, 18.76, 9.51, 4.13, 3.29. [α]<sub>D</sub><sup>25</sup> −110.0° (<i>c</i> 0.12, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>34</sub>H<sub>42</sub>N<sub>2</sub>O<sub>3</sub> + H<sup>+</sup>, 527.3268 [M + H]<sup>+</sup>; found, 527.3272.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-Cyclopropylmethyl-7α-4′-piperidinylphenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>10b</b></h3><div class="NLM_p last">Compound <b>10b</b> was obtained as a white solid (41.6 mg, yield 48.4%). Mp 107–108 °C; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.20 (d, J = 8.4 Hz, 2H), 6.89 (d, <i>J</i> = 8.4 Hz, 2H), 6.75 (d, <i>J</i> = 7.1 Hz, 1H), 6.61 (d, <i>J</i> = 6.3 Hz, 1H), 4.64 (s, 1H), 3.88 (s, 3H), 3.22 (d, J = 63.5 Hz, 4H), 3.15–2.97 (m, 7H), 2.68 (s, 1H), 2.36 (s, 4H), 1.80 (s, 2H), 1.70 (t, <i>J</i> = 11.1 Hz, 6H), 1.56 (dt, <i>J</i> = 11.6, 5.9 Hz, 2H), 1.41 (ddd, <i>J</i> = 24.7, 16.8, 5.3 Hz, 2H), 0.90 (s, 2H), 0.52 (s, 2H), 0.16 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 147.21, 142.22, 132.76, 132.42, 129.98, 128.72, 119.12, 116.31, 114.10, 93.05, 59.37, 58.44, 56.71, 50.84 (d, J = 21.0 Hz), 45.73, 44.16, 42.60, 36.16 (d, <i>J</i> = 28.2 Hz), 36.00–35.64 (m), 35.41, 29.80, 25.90, 24.29, 22.69, 18.64, 9.43, 4.53, 3.30. [α]<sub>D</sub><sup>25</sup> −138.9° (<i>c</i> 0.13, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>35</sub>H<sub>44</sub>N<sub>2</sub>O<sub>3</sub> + H<sup>+</sup>, 541.3425 [M + H]<sup>+</sup>; found, 541.3421.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-Cyclopropylmethyl-7α-4′-piperazinylphenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>10c</b></h3><div class="NLM_p last">Compound <b>10c</b> was obtained as a white solid (10 mg, yield 19.4%). Mp 185–186 °C; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.27 (s, 1H), 6.87 (d, <i>J</i> = 8.4 Hz, 2H), 6.74 (d, <i>J</i> = 8.1 Hz, 1H), 6.60 (d, <i>J</i> = 8.1 Hz, 1H), 4.68 (s, 1H), 4.63 (s, 1H), 3.88 (s, 3H), 3.38 (s, 4H), 3.29 (s, 4H), 3.18 (s, 4H), 3.13–3.01 (m, 3H), 2.85 (d, <i>J</i> = 9.4 Hz, 1H), 2.58 (d, <i>J</i> = 5.6 Hz, 1H), 2.46 (d, <i>J</i> = 9.5 Hz, 3H), 2.34–2.24 (m, 1H), 1.80 (d, <i>J</i> = 11.5 Hz, 1H), 1.69–1.60 (m, 2H), 1.58 (t, <i>J</i> = 10.2 Hz, 1H), 1.47 (dd, <i>J</i> = 12.2, 5.8 Hz, 1H), 1.41 (d, J = 10.9 Hz, 1H), 0.83 (dd, J = 14.9, 6.7 Hz, 2H), 0.54 (dd, <i>J</i> = 11.2, 5.5 Hz, 2H), 0.24 (s, 1H), 0.18 (s, 1H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 148.76, 147.14, 142.13, 132.38, 130.39, 127.39, 119.12, 117.09, 114.05, 92.92, 59.70, 58.60, 56.71, 51.04, 50.41, 47.54, 45.67, 44.35, 43.76, 42.65, 36.15 (d, <i>J</i> = 18.1 Hz), 36.09, 29.68, 22.67, 18.58, 8.61, 4.50, 3.46. [α]<sub>D</sub><sup>25</sup> −56.4°(<i>c</i> 0.15, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>34</sub>H<sub>43</sub>N<sub>3</sub>O<sub>3</sub> + H<sup>+</sup>, 542.3377 [M + H]<sup>+</sup>; found, 542.3371.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-Cyclopropylmethyl-7α-4′-(<i>N</i>″-cycloproylmethyl)piperazinylphenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>10d</b></h3><div class="NLM_p last">Potassium carbonate (38 mg, 0.276 mmol) was added to a solution of <b>10c</b> (50 mg, 0.092 mmol) in MeCN (1 mL). Then, (bromomethyl)cyclopropane (19 mg, 0.138 mmol) was added and the mixture was heated to 70 °C for 2 h. The reaction mixture was cooled to room temperature, filtered, and evaporated to dryness <i>in vacuo</i>. The residue was purified by prep TLC (DCM:MeOH = 10:1) to afford title compound <b>10d</b> as a white solid (18 mg, yield 32.7%). Mp 142–143 °C; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.24 (d, <i>J</i> = 8.5 Hz, 2H), 6.88 (d, <i>J</i> = 8.5 Hz, 2H), 6.74 (d, <i>J</i> = 8.1 Hz, 1H), 6.61 (d, <i>J</i> = 8.1 Hz, 1H), 4.63 (s, 1H), 3.88 (s, 3H), 3.48 (s, 4H), 3.31 (dd, <i>J</i> = 62.4, 49.8 Hz, 2H), 3.18 (s, 3H), 3.16–2.94 (m, 6H), 2.86 (s, 1H), 2.71 (d, <i>J</i> = 6.4 Hz, 2H), 2.47 (s, 4H), 2.32 (s, 1H), 1.80 (d, <i>J</i> = 12.2 Hz, 1H), 1.67 (dd, <i>J</i> = 24.1, 12.8 Hz, 2H), 1.45 (td, <i>J</i> = 12.3, 5.4 Hz, 1H), 1.37 (dd, <i>J</i> = 17.5, 12.3 Hz, 1H), 1.19 (s, 1H), 0.90 (dd, <i>J</i> = 26.1, 9.8 Hz, 2H), 0.71 (d, <i>J</i> = 7.7 Hz, 2H), 0.54 (d, <i>J</i> = 24.4 Hz, 2H), 0.34 (d, <i>J</i> = 4.8 Hz, 2H), 0.20 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 148.56, 147.07, 142.11, 133.96, 132.31, 130.25, 119.09, 116.51, 114.08, 92.74, 62.49, 59.49, 58.41, 56.64, 51.98, 50.94, 47.64, 45.55, 44.41, 42.49, 36.15, 36.02, 34.71, 29.70, 23.35, 18.58, 8.45, 6.35, 4.57, 4.47, 3.29. [α]<sub>D</sub><sup>25</sup> −96.8° (<i>c</i> 0.10, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>38</sub>H<sub>49</sub>N<sub>3</sub>O<sub>3</sub> + H<sup>+</sup>, 596.3847 [M + H]<sup>+</sup>; found, 596.3838.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>N</i>-Cyclopropylmethyl-7α-4′-(<i>N</i>″-acetamido)piperazinylphenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>10e</b></h3><div class="NLM_p last">Triethylamine (26 mg, 0.261 mmol) was added to a solution of <b>10c</b> (45 mg, 0.087 mmol) in DCM (1 mL). Then, acetyl chloride (14 mg, 0.173 mmol) was added and the mixture was stirred at room temperature for 2 h. The mixture was washed with water and brine and then dried over sodium sulfate before evaporation to dryness. The residue was purified by prep TLC (DCM:MeOH = 10:1) to afford title compound <b>10e</b> as a white solid (25 mg, yield 51.0%); mp 138–140 °C; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.24 (d, <i>J</i> = 8.2 Hz, 2H), 6.88 (d, <i>J</i> = 8.5 Hz, 2H), 6.75 (d, <i>J</i> = 4.7 Hz, 1H), 6.63 (s, 1H), 4.65 (s, 1H), 3.88 (s, 3H), 3.80–3.70 (m, 2H), 3.68–3.55 (m, 2H), 3.19 (s, 4H), 3.13 (ddd, <i>J</i> = 47.5, 26.2, 11.5 Hz, 7H), 2.70 (s, 2H), 2.35 (s, 3H), 2.18–2.08 (m, 4H), 1.80 (s, 1H), 1.67 (s, 2H), 1.45 (td, <i>J</i> = 12.4, 4.9 Hz, 2H), 0.92 (s, 2H), 0.52 (s, 2H), 0.15 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 168.99, 149.37, 147.12, 142.40, 133.78, 130.69, 130.17, 128.51, 119.13, 116.39, 114.05, 92.90, 59.98–59.58 (m), 58.45, 56.65, 50.90, 49.77, 49.34, 46.25, 45.86, 43.99, 42.47, 41.35, 36.20, 36.03–35.95 (m), 35.32, 29.75, 23.02, 21.30, 18.63, 9.21, 4.28, 3.26 (s). [α]<sub>D</sub><sup>25</sup> −78.9° (<i>c</i> 0.11, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>36</sub>H<sub>46</sub>N<sub>3</sub>O<sub>4</sub> + H<sup>+</sup>, 585.3561 [M + H]<sup>+</sup>; found, 585.3563.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>N</i>-Cyclopropylmethyl-7α-4′-(<i>N</i>″-benzoyl)piperazinyl)phenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>10f</b></h3><div class="NLM_p last">Triethylamine (26 mg, 0.261 mmol) was added to a solution of <b>10c</b> (45 mg, 0.087 mmol) in DCM (1 mL). Then, tosyl chloride (33 mg, 0.173 mmol) was added and the mixture was stirred at room temperature for 2 h. The mixture was washed with water and brine and then dried over sodium sulfate before evaporation to dryness. The residue was purified by prep TLC (DCM:MeOH = 10:1) to afford title compound <b>10f</b> as a white solid (20 mg, yield 34.6%); mp 153–154 °C; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.07 (d, <i>J</i> = 8.2 Hz, 2H), 7.57 (t, <i>J</i> = 7.4 Hz, 1H), 7.46 (d, <i>J</i> = 7.9 Hz, 2H), 7.23 (d, <i>J</i> = 8.0 Hz, 2H), 6.87 (d, <i>J</i> = 8.4 Hz, 2H), 6.75 (s, 1H), 6.63 (s, 1H), 4.65 (s, 1H), 4.48–4.43 (m, 1H), 3.95 (dd, <i>J</i> = 10.8, 6.1 Hz, 3H), 3.88 (s, 3H), 3.58 (s, 2H), 3.24 (s, 2H), 3.19 (s, 4H), 3.10 (s, 4H), 2.34 (s, 2H), 2.17 (s, 3H), 1.82 (s, 1H), 1.68 (s, 2H), 1.45 (td, <i>J</i> = 12.4, 4.4 Hz, 2H), 0.93 (s, 2H), 0.53 (s, 2H), 0.17 (s, 2H).<sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 170.39, 149.40, 147.18, 135.60, 133.12, 130.18, 129.77, 129.65, 128.51, 128.37, 127.07, 119.20, 116.44, 114.01, 92.51, 59.18, 58.34, 56.66, 50.92, 47.68, 45.39, 43.29, 42.10, 36.22, 36.01, 33.91, 29.71 (d, <i>J</i> = 18.1 Hz), 22.65, 18.59, 8.41, 4.22, 3.27. [α]<sub>D</sub><sup>25</sup> −84.8° (<i>c</i> 0.12, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>41</sub>H<sub>49</sub>N<sub>3</sub>O<sub>5</sub>S + H<sup>+</sup>, 696.3466 [M + H]<sup>+</sup>; found, 696.3461.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>N</i>-Cyclopropylmethyl-7α-4′-(<i>N</i>″-<i>p</i>-tosyl)piperazinyl)phenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>10g</b></h3><div class="NLM_p last">Triethylamine (26 mg, 0.261 mmol) was added to a solution of <b>10c</b> (50 mg, 0.092 mmol) in DCM (1 mL). Then, benzoyl chloride (14 mg, 0.11 mmol) was added and the resultant mixture was stirred at room temperature for 2 h. It was then washed with water and brine and dried over sodium sulfate before evaporation to dryness. The residue was purified by prep TLC (DCM:MeOH = 10:1) to afford title compound <b>10g</b> as a white solid (20 mg, yield 33.6%); mp 119–120 °C; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.67 (d, <i>J</i> = 8.1 Hz, 2H), 7.34 (d, <i>J</i> = 8.1 Hz, 2H), 7.20 (d, <i>J</i> = 8.0 Hz, 2H), 6.81 (d, <i>J</i> = 8.4 Hz, 2H), 6.74 (s, 1H), 6.61 (s, 1H), 4.62 (s, 1H), 3.87 (s, 3H), 3.24–3.20 (m, 4H), 3.16 (s, 4H), 3.15 (d, <i>J</i> = 4.8 Hz, 3H), 3.05 (d, <i>J</i> = 14.5 Hz, 3H), 2.64 (d, <i>J</i> = 28.9 Hz, 1H), 2.44 (s, 4H), 2.43–2.08 (m, 4H), 1.78 (s, 3H), 1.63 (s, 2H), 1.43 (td, <i>J</i> = 12.4, 5.2 Hz, 1H), 1.37–1.28 (m, 1H), 0.89 (s, 2H), 0.47 (s, 2H), 0.10 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 149.08, 147.08, 143.81, 142.18, 137.07, 132.33, 131.92, 130.15, 129.70, 127.85, 119.06, 116.57, 113.88, 92.92, 59.75, 58.38, 56.64, 53.40, 50.89, 49.12, 46.06, 43.90, 42.67, 36.29, 36.17, 35.80, 29.66, 22.79, 21.50, 18.65, 9.40, 4.05, 3.27. [α]<sub>D</sub><sup>25</sup> −79.8° (<i>c</i> 0.14, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>41</sub>H<sub>47</sub>N<sub>3</sub>O<sub>4</sub> + H<sup>+</sup>, 646.3639 [M + H]<sup>+</sup>; found, 646.3631.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>-Cyclopropylmethyl-7α-4′-(<i>N</i>′-formyl)aminophenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>11a</b></h3><div class="NLM_p last">Zinc oxide (5.3 mg, 0.065 mmol) was added to a solution of compound <b>8</b> (60 mg, 0.13 mmol) in formic acid (0.39 mmol), and the mixture was heated to 70 °C and stirred for 4 h. The reaction was allowed to cool to room temperature, was supplemented with water, had its pH adjusted to 9–10 with ammonia, and was extracted with dichloromethane (3×). The combined extracts were dried over sodium sulfate, filtered, and concentrated. The residue was purified by prep TLC (DCM:CH<sub>3</sub>OH = 20:1). <b>11a</b> was obtained as a colorless oil (44 mg, yield 69.1%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.36 (s, 1H), 7.49 (d, <i>J</i> = 8.4 Hz, 1H), 7.32 (dd, <i>J</i> = 13.3, 8.4 Hz, 2H), 7.03 (d, <i>J</i> = 8.3 Hz, 1H), 6.73 (dd, <i>J</i> = 8.1, 2.9 Hz, 1H), 6.59 (dd, <i>J</i> = 8.0, 3.3 Hz, 1H), 5.30 (s, 1H), 4.61 (s, 1H), 3.88 (s, 3H), 3.31–3.17 (m, 4H), 3.09 (q, <i>J</i> = 9.4 Hz, 2H), 3.05–2.99 (m, 1H), 2.68 (d, <i>J</i> = 10.2 Hz, 1H), 2.42–2.25 (m, 4H), 2.16 (td, <i>J</i> = 12.7, 5.3 Hz, 1H), 1.76 (d, <i>J</i> = 12.7 Hz, 1H), 1.69–1.54 (m, 2H), 1.54–1.43 (m, 1H), 1.36 (s, 2H), 0.89 (dd, <i>J</i> = 15.4, 8.6 Hz, 2H), 0.77 (s, 1H), 0.53–0.40 (m, 2H), 0.10 (d, <i>J</i> = 3.3 Hz, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 162.25, 146.99, 141.86, 135.07, 134.70, 130.78, 130.11, 128.61, 119.66, 119.03 (d, <i>J</i> = 8.5 Hz), 118.86, 113.77, 93.30, 59.83, 58.63, 56.66, 51.13 (d, <i>J</i> = 11.3 Hz), 46.08 (d, <i>J</i> = 8.1 Hz), 43.86, 43.29 (d, <i>J</i> = 7.0 Hz), 36.28, 36.09, 35.63, 29.66 (d, <i>J</i> = 5.7 Hz), 22.83, 18.63, 9.43, 4.07, 3.38. [α]<sub>D</sub><sup>25</sup> −108.9° (<i>c</i> 0.08, CHCl<sub>3</sub>); HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>36</sub>N<sub>2</sub>O<sub>4</sub> + H<sup>+</sup>, 501.2748 [M + H]<sup>+</sup>; found, 501.2746.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> General Procedure for the Synthesis of <b>11b</b> and <b>11c</b></h3><div class="NLM_p last">Triethylamine (26 mg, 0.261 mmol) was added to a solution of <b>8</b> (0.087 mmol) in dichloromethane (1 mL), after which the corresponding acyl chloride (0.174 mmol) was added dropwise at 0 °C. The mixture was stirred for 2 h, washed with water and saturated sodium chloride solution successively, dried over sodium sulfate, filtered, and concentrated. The residue was purified by prep TLC (DCM–Me 10:1) to give the corresponding products <b>11b</b> and <b>11c</b>.</div></div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-Cyclopropylmethyl-7α-4′-(<i>N</i>′-acetyl)aminophenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>11b</b></h3><div class="NLM_p last">Compound <b>11b</b> was obtained as a colorless oil (30 mg, yield 55.5%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.44 (d, <i>J</i> = 8.3 Hz, 2H), 7.39 (s, 1H), 7.28 (d, <i>J</i> = 8.3 Hz, 2H), 6.72 (d, <i>J</i> = 8.1 Hz, 1H), 6.59 (d, <i>J</i> = 8.1 Hz, 1H), 5.30 (s, 1H), 4.61 (s, 1H), 3.87 (s, 3H), 3.30–3.22 (m, 1H), 3.18 (s, 3H), 3.12–3.05 (m, 2H), 3.03 (d, <i>J</i> = 18.6 Hz, 1H), 2.67 (s, 1H), 2.31 (dd, <i>J</i> = 36.8, 20.5 Hz, 4H), 2.15 (s, 4H), 1.75 (d, <i>J</i> = 12.0 Hz, 1H), 1.63 (d, <i>J</i> = 12.6 Hz, 2H), 1.46 (td, <i>J</i> = 12.5, 5.8 Hz, 1H), 1.32 (dd, <i>J</i> = 11.8, 6.3 Hz, 1H), 0.89 (t, <i>J</i> = 11.4 Hz, 1H), 0.78 (s, 1H), 0.53–0.39 (m, 2H), 0.10 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 168.24, 146.99, 141.84, 138.07, 136.26, 132.81, 129.93, 128.70, 119.58, 119.00, 113.73, 93.19, 59.79, 58.58, 56.63, 50.99, 45.98, 43.87, 43.19, 36.30, 36.09, 35.61, 29.62, 24.53, 22.83, 18.63, 9.44, 4.07, 3.35. [α]<sub>D</sub><sup>25</sup> −130.4° (<i>c</i> 0.15, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>38</sub>N<sub>2</sub>O<sub>4</sub> + H<sup>+</sup>, 515.2904 [M + H]<sup>+</sup>; found, 515.2907.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i>-Cyclopropylmethyl-7α-4′-(<i>N</i>′-phenylacetyl)aminophenyl-6,14-endoethanotetrahydronorthebaine, Compound <b>11c</b></h3><div class="NLM_p last">Compound <b>11c</b> was obtained as a colorless oil (36 mg, yield 57.6%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.42–7.31 (m, 7H), 7.25 (d, <i>J</i> = 8.3 Hz, 2H), 7.08 (s, 1H), 6.71 (d, <i>J</i> = 8.0 Hz, 1H), 6.58 (d, <i>J</i> = 7.9 Hz, 1H), 4.59 (s, 1H), 3.87 (s, 3H), 3.73 (s, 2H), 3.19 (d, <i>J</i> = 15.5 Hz, 1H), 3.15 (s, 3H), 3.09–2.98 (m, 3H), 2.65 (s, 1H), 2.32 (d, <i>J</i> = 38.8 Hz, 4H), 2.14 (s, 1H), 1.74 (d, <i>J</i> = 11.8 Hz, 1H), 1.59 (t, <i>J</i> = 12.4 Hz, 2H), 1.45 (td, <i>J</i> = 12.4, 5.9 Hz, 1H), 1.33 (s, 1H), 0.87 (dd, <i>J</i> = 14.2, 7.4 Hz, 1H), 0.76 (s, 1H), 0.51–0.41 (m, 2H), 0.08 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 168.89, 147.00, 141.82, 138.40, 135.90, 134.49, 132.85, 129.92, 129.51, 129.22, 128.69, 127.64, 119.48, 118.97, 113.73, 93.35, 59.83, 58.60, 56.64, 51.05, 46.03, 44.85, 43.84, 43.28, 36.26, 36.08, 35.64, 29.65 (d, <i>J</i> = 8.5 Hz), 22.78, 18.54, 9.45, 4.03, 3.36. [α]<sub>D</sub><sup>25</sup> −117.7° (<i>c</i> 0.11, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>38</sub>H<sub>42</sub>N<sub>2</sub>O<sub>4</sub> + H<sup>+</sup>, 591.3217 [M + H]<sup>+</sup>; found, 591.3220.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>N</i>-Cyclopropylmethyl-7α-4′-(4″-hydroxyphenylazo)phenyl-6,14-endoethanotetrahydronorthebaine, <b>12</b></h3><div class="NLM_p last">Compound <b>6</b> (50 mg, 0.1 mmol) was added to a solution of hydrochloric acid (0.2 mL) in water, after which the solution of sodium nitrite (8 mg, 0.11 mmol) in water (0.1 mL) was added at −5 to 0 °C for 15 min. The mixture was then added to the solution of phenol (10 mg, 0.10 mmol) in water (0.2 mL) at −5 to 0 °C; the pH value was adjusted to 8–9 with 30% NaOH solution, the mixture was stirred at −5 to 0 °C for 1 h. After adjusting the pH to 9–10 with 30% NaOH solution, the mixture was extracted with ethyl acetate (3×). The combined extracts were dried over sodium sulfate, filtered, and concentrated. The residue was purified by prep TLC (DCM:CH<sub>3</sub>OH = 10:1). <b>12</b> was obtained as an orange solid (10 mg, yield 16.3%). Mp 134–135 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.76 (d, <i>J</i> = 8.3 Hz, 2H), 7.68 (d, <i>J</i> = 8.7 Hz, 2H), 7.43 (d, <i>J</i> = 8.3 Hz, 2H), 6.75 (d, <i>J</i> = 8.2 Hz, 1H), 6.63 (t, <i>J</i> = 8.2 Hz, 3H), 6.23 (s, 1H), 4.70 (s, 1H), 3.89 (s, 3H), 3.43–3.15 (m, 6H), 3.06 (d, <i>J</i> = 18.5 Hz, 1H), 2.88–2.72 (m, 1H), 2.55–2.33 (m, 4H), 2.27 (d, <i>J</i> = 14.9 Hz, 1H), 1.82 (d, <i>J</i> = 13.0 Hz, 1H), 1.80–1.68 (m, 2H), 1.59–1.48 (m, 1H), 1.46–1.38 (m, 1H), 0.93 (dd, J = 23.5, 13.6 Hz, 2H), 0.60–0.42 (m, 2H), 0.15 (s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 159.14, 151.68, 146.90, 146.64, 144.08, 141.96, 132.47, 130.01, 128.55, 124.76, 122.46, 119.30, 115.48, 113.80, 91.80, 78.27, 59.79, 58.53, 56.61, 50.77, 46.09, 43.92, 43.01, 36.29, 36.17, 35.66, 29.62, 22.89, 19.29, 9.40, 4.19, 3.42. [α]<sub>D</sub><sup>25</sup> −136.2° (<i>c</i> 0.12, CHCl<sub>3</sub>). HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>36</sub>H<sub>39</sub>N<sub>3</sub>O<sub>4</sub> + H<sup>+</sup>, 578.3013 [M + H]<sup>+</sup>; found, 578.3008.</div></div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Pharmacology. Cell Membrane Preparation</h3><div class="NLM_p last">The cells were detached by incubation with phosphate buffered saline containing 1 mM EDTA and centrifuged at 1000<i>g</i> for 10 min. The cell pellet was then suspended in homogenized in ice-cold homogenization buffer (50 mM HEPES, pH 7.4, 1 mM MgCl<sub>2</sub> and 1 mMEGTA). After centrifugation at 40 000<i>g</i> for 30 min (4 °C), pellets were resuspended, homogenized, and centrifuged again as described. This procedure was repeated twice more. The final pellets were resuspended in a 50 mM Tris-HCl buffer, pH 7.4. The protein concentration was determined and aliquots were stored at −80 °C.</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Receptor Binding Assay</h3><div class="NLM_p last">Ligand binding experiments were carried out with [<sup>3</sup>H]U69593 (39.1 Ci/mmol) for human κ-opioid receptor, [<sup>3</sup>H]DAMGO (50.1 Ci/mmol) for rat μ-opioid receptor, and [<sup>3</sup>H]DPDPE (52.7 Ci/mmol) for rat δ-opioid receptor. Competition inhibition by compounds showing [<sup>3</sup>H]ligand binding to opioid receptors was performed in the absence or presence of various concentrations of each compound. Binding was carried out in 50 mM Tris-HCl buffer (pH 7.4) at 37 °C for 30 min in triplicate in a final volume of 0.5 mL with 30 μg of membrane protein. U50,488H, DAMGO, or DPDPE at a concentration of 10 μM was used to define nonspecific binding. Bound and free [<sup>3</sup>H]-labeled ligands were separated by filtration under reduced pressure with GF/B filters. The radioactivity on filters was determined by liquid scintillation counting. Binding data and <i>K</i><sub><i>i</i></sub> values were analyzed and determined with the Prism 6.0 program (GraphPad software).</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> [<sup>35</sup>S]GTPγS Binding Assay</h3><div class="NLM_p last">[<sup>35</sup>S]GTPγS binding was conducted as previously described.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Briefly, membranes (15 μg/sample) were incubated with 0.1 nM [<sup>35</sup>S]GTPγS (1030 Ci/mmol, PerkinElmer) in a binding buffer composed of 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 5 mM MgCl<sub>2</sub>, 100 mM NaCl, and 40 μM GDP at 30 °C for 1 h in the presence of increasing concentrations of compounds. Nonspecific binding was determined in the presence of nonradioactive GTPγS (10 μM). Reactions were terminated by rapid filtration, and bound radioactivity was determined by liquid scintillation counting as described above. The percentage of stimulated [<sup>35</sup>S]GTPγS binding was calculated as follows: 100 × (cpm<sub>sample</sub> – cpm<sub>nonspecific</sub>)/(cpm<sub>basal</sub> – cpm<sub>nonspecific</sub>). EC<sub>50</sub> and <i>E</i><sub>max</sub> values were analyzed and determined with the Prism 6.0 program (GraphPad software).</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Animals</h3><div class="NLM_p last">Kunming strain male mice (18–22 g) were obtained from the Laboratory Animal Center, Chinese Academy of Sciences (Shanghai, China). Mice were housed in groups (5 mice/group) and maintained with a 12 h light/dark cycle (lights-on at 8:00 a.m.) in a temperature controlled environment with free access to food and water. All animal experiments were performed under the guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals using an approved animal protocol (2019-01-LJG-41).</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Hot Plate Test</h3><div class="NLM_p last">Hot-plate tests were conducted according to our previously reported procedure.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Mice were placed on the heated smooth surface (55 °C), and the latency to licking of the back paws was measured. Prior to drug administration, the nociceptive response of each mouse was measured twice, and the mean was used as the basal latency. Mice not responding within 30 s were excluded from further studies. A cutoff time of 60 s was used to avoid tissue damage. Antinociception was calculated by the following formula: % antinociception = 100 × (test latency – prebasal latency)/(cutoff time – basal latency). The antinociceptive ED<sub>50</sub> value was obtained as the dose that produced 50% analgesia.</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Abdominal Constriction Test</h3><div class="NLM_p last">Abdominal constriction tests were performed in mice according to the method previously described.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Briefly, an abdominal constriction was defined as a wave of contraction of the abdominal musculature followed by extension of the hind limbs. After receiving graded doses of compounds, an intraperitoneal injection of 0.6% acetic acid (10 mL/kg body weight) was administered to each mouse, and then the number of writhing signs displayed by each mouse was counted for 20 min. Antinociception was calculated by the following formula: % antinociception = 100 × (no. of mean control abdominal constriction – no. of test abdominal constriction)/no. of mean control abdominal constriction. The antinociceptive ED<sub>50</sub> value of each compound was obtained as the dose that produced 50% analgesia.</div></div><div id="sec4_5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Spontaneous Locomotor Activity</h3><div class="NLM_p last">Mouse locomotor activity was measured using a video tracking system (JLBehv-LAG, Shanghai, China). Mice were pretreated with U50,488H (5 mg/kg) or SLL-039 (0.3, 0.9, 2.7 mg/kg) and placed into locomotor chambers (30 cm × 30 cm × 40 cm) right after injection or 2 h after injection, and the total distance traveled was monitored for 30 min.</div></div><div id="sec4_5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Molecular Modeling</h3><div class="NLM_p">With the aim of elucidating the molecular mechanism of SLL-039 and its analogs, we built a complex of the κ opioid receptor with relevant compounds using the recently published crystal structure of κ opioid receptor in complex with an epoxymorphinan.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Moreover, additional binding models for the μ opioid receptor were also developed to elucidate the subtype selectivity of the compounds.</div><div class="NLM_p">The crystal structures of the κ opioid receptor in its agonistic state (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B73">6B73</a>)<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> and the μ opioid receptor in its antagonistic state (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DKL">4DKL</a>)<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> were retrieved from the Protein Data Bank (<a href="http://www.rcsb.org/" class="extLink">http://www.rcsb.org/</a>). The Nb39 domain in the κ opioid receptor and the T4L residues in the μ opioid receptor were deleted from the crystal structures. All hydrogen atoms were added, and charges were loaded using the method of Kollman all atoms.</div><div class="NLM_p">The chemical structures of compounds <b>8</b>, <b>11b</b>, <b>4</b>, <b>11c</b>, nalfurafine, and SLL-020ACP were sketched in SYBYL (Tripos, St Louis, MO, USA) and protonated, if appropriate, before energy minimization using the Tripos force field (Gasteiger–Hückel charges, distance-dependent dielectric constant = 4.0, nonbonded interaction cutoff = 8 Å, and termination criterion = energy gradient <0.05 kcal/(mol × Å) for 10 000 iterations).</div><div class="NLM_p last">The docking program GOLD Suite 5.1 (Cambridge Crystallographic Data Centre, Cambridge, U.K.) with a genetic algorithm was employed to dock ligands to the opioid receptors. The binding site was defined as a sphere with a radius of 15 Å around the Asp147<sup>3.32</sup> C<sup>β</sup> atom in the μ opioid receptor or Asp138<sup>3.32</sup> C<sup>β</sup> atom in the κ opioid receptor. The GoldScore was chosen as the fitness scoring function, and the output results were rescored by the ChemScore function. In addition to conformation cluster analysis and fitness scores, the ligands (β-FNA for the μ opioid receptor and MP1104 for the κ opioid receptor) in the crystal structures were also used to select the final output ligand–receptor complexes, since all these compounds contain the conserved 4,5-expoxymorphinan backbone. The resulting complexes were plotted using the PyMOL (The PyMOL molecular graphics system, version 0.98, DeLano Scientific, Palo Alto, CA) software.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00857" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65223" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65223" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b00857?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00857</a>. <ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Activity of compound <b>4</b>, <sup>1</sup>H and <sup>13</sup>C NMR spectra for all final compounds, and and HPLC spectra for compound <b>4</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00857/suppl_file/jm9b00857_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00857/suppl_file/jm9b00857_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00857/suppl_file/jm9b00857_si_001.pdf">jm9b00857_si_001.pdf (3.65 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00857/suppl_file/jm9b00857_si_002.csv">jm9b00857_si_002.csv (2.4 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00857" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38717" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38717" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f0879599dd9c99b0968594919ede959485de939e"><span class="__cf_email__" data-cfemail="097e6c60246560496f7c6d6867276c6d7c276a67">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinggen Liu</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences and Collaborative
Innovation Center for Brain Science, 555 Zuchongzhi Road, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c9a3aea5a0bc89a4a8a0a5e7baa1aaa7aae7a8aae7aaa7"><span class="__cf_email__" data-cfemail="aac0cdc6c3dfeac7cbc3c684d9c2c9c4c984cbc984c9c4">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liming Shao</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medical Neurobiology, Fudan University, No.
138 Yixueyuan Road, Shanghai 200032, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0694-7011" title="Orcid link">http://orcid.org/0000-0003-0694-7011</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#dab6b3b7b3b4bda9b2bbb59abcafbebbb4f4bfbeaff4b9b4"><span class="__cf_email__" data-cfemail="6d01040004030a1e050c022d0b18090c0343080918430e03">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Xiao</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5238-6393" title="Orcid link">http://orcid.org/0000-0002-5238-6393</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yujun Wang</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences and Collaborative
Innovation Center for Brain Science, 555 Zuchongzhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mumei Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weiwei Wu</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences and Collaborative
Innovation Center for Brain Science, 555 Zuchongzhi Road, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linghui Kong</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Ma</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences and Collaborative
Innovation Center for Brain Science, 555 Zuchongzhi Road, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">Shanghai
University School of Life Sciences, No. 99 Shangda Road, Shanghai 200444, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuejun Xu</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences and Collaborative
Innovation Center for Brain Science, 555 Zuchongzhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiao Liu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qian He</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuanyuan Qian</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huijiao Sun</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haihao Wu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng Lin</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huoming Huang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rongrong Ye</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Institute of Technology, No. 100 Haiquan Road, Shanghai 201418, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuang Jiang</span> - <span class="hlFld-Affiliation affiliation">Nanjing
University of Chinese Medicine, No. 138 Xianlin Avenue, Nanjing 210023, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ru-Feng Ye</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences and Collaborative
Innovation Center for Brain Science, 555 Zuchongzhi Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Congmin Yuan</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shengyang Fang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dengqi Xue</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xicheng Yang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8284-3631" title="Orcid link">http://orcid.org/0000-0001-8284-3631</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Chen</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yilin Zheng</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linqian Yu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiong Xie</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lan Zheng</span> - <span class="hlFld-Affiliation affiliation">Minhang
Hospital, Fudan University, No. 170 Xinsong Road, Shanghai 201199, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Fu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2335-8908" title="Orcid link">http://orcid.org/0000-0002-2335-8908</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhuibai Qiu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai 201203, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>L.X., Y.W., M.Z., and W.W. contributed equally to this work. L.S., W.L., J.L., and Z.Q. conceived the research. L.X., M.Z., and L.K. conducted chemical synthesis and structural characterization under the supervision of W.L. and L.S. In vitro assays were performed by W.W, M.Z. X.X, Y.M., L.K., H.S., H.W, C.L., Y.Q., H.H., X.L., Q.H., R.Y., S.J., and R.Y. under the supervision of Y.W. and J.G.L. In vivo assays were conducted by Y.W, W.W, M.Z., and X.X under the supervision of J.L. Molecular modeling works were conducted by W.L., L.X., M.Z., C.Y, and Y.Q. under the supervision of W.F., M.Z., L.X., L.K., X.L., Q.H., W.L., S.F., D.X., X.Y., H.C., Y.Z., L.Z., L.Y, Q.X., W.F., Y.W., and J.L. were involved in data interpretation and discussion. The manuscript was drafted by L.X., W.L., L.K., and Y.W. and was revised by L.S. and J.L. All authors approved the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66238" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66238" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by CAS Key Laboratory of Receptor Research (Grant SIMM1706YKF-02 to W.L.), the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant XDA12040319, to J.L), the National Natural Foundation of China Grants 81671322 (to J.L.) and 81773710 (to Y.W.), and the Youth Innovation Promotion Association of the Chinese Academy of Sciences Grant 2017334 (to Y.W.).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">Cbz-Cl</td><td class="NLM_def"><p class="first last">benzyl chloroformate</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">EL</td><td class="NLM_def"><p class="first last">extracellular domain</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">nor-BNI</td><td class="NLM_def"><p class="first last">nor-binaltorphimine</p></td></tr><tr><td class="NLM_term">prep TLC</td><td class="NLM_def"><p class="first last">preparative thin layer chromatography</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">transmembrane</p></td></tr><tr><td class="NLM_term">tosyl</td><td class="NLM_def"><p class="first last">toluenesulfonyl</p></td></tr><tr><td class="NLM_term">RVD</td><td class="NLM_def"><p class="first last">rabbit vas deferens.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77150" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77150" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 68 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dinakar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillman, A. M.</span></span> <span> </span><span class="NLM_article-title">Pathogenesis of pain</span>. <i>Semin Pediatr Neurol</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/j.spen.2016.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.spen.2016.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=27989327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FlvFequg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=201-208&author=P.+Dinakarauthor=A.+M.+Stillman&title=Pathogenesis+of+pain&doi=10.1016%2Fj.spen.2016.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis of Pain</span></div><div class="casAuthors">Dinakar Pradeep; Stillman Alexandra Marion</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in pediatric neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">201-208</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The pathogenesis of pain sensation includes mechanisms that result in acute or chronic pain.  Pain itself is described as an unpleasant sensory and emotional experience beginning with a peripheral stimulus that undergoes a physiological process ultimately resulting in the sensation of pain.  Biologists recognize pain to be a common sign of potential tissue damage.  Hence, pain sensation is protective in function.  However, pathologic states of pain exist secondary to disruption of the nociceptive process both peripherally and centrally or secondary to psychological conditions.  It is essential to identify these aberrant states of pain and distinguish them from situations of potential tissue damage.  Chronic pain is defined as pain that exceeds 3 or 6 months duration.  This article is an overview of the essential neuroanatomy and neurophysiology of normal pain nociception, its clinical implications, and the development of persistent and pathological pain conditions following improperly or poorly treated pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAFoyTiUN_4WhHGZei4OW9fW6udTcc2ebcJBlbr7nvCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FlvFequg%253D%253D&md5=e119e44f0ca474ae0de47125abfcf903</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.spen.2016.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.spen.2016.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DDinakar%26aufirst%3DP.%26aulast%3DStillman%26aufirst%3DA.%2BM.%26atitle%3DPathogenesis%2520of%2520pain%26jtitle%3DSemin%2520Pediatr%2520Neurol%26date%3D2016%26volume%3D23%26spage%3D201%26epage%3D208%26doi%3D10.1016%2Fj.spen.2016.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raffaeli, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnaudo, E.</span></span> <span> </span><span class="NLM_article-title">Pain as a disease: an overview</span>. <i>J. Pain Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2003</span>– <span class="NLM_lpage">2008</span>, <span class="refDoi"> DOI: 10.2147/JPR.S138864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.2147%2FJPR.S138864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=28860855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADC%252BC1cbjs1Wrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=2003-2008&author=W.+Raffaeliauthor=E.+Arnaudo&title=Pain+as+a+disease%3A+an+overview&doi=10.2147%2FJPR.S138864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Pain as a disease: an overview</span></div><div class="casAuthors">Raffaeli William; Arnaudo Elisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pain research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2003-2008</span>
        ISSN:<span class="NLM_cas:issn">1178-7090</span>.
    </div><div class="casAbstract">The acknowledgment of pain as a pathologic entity in its own right remains debated.  Notwithstanding the data showing the burden of pain as a disease, an ultimate recognition of the pathologic nature of this condition is lacking.  In this study, we analyze the notion of pain as a disease through an historical overview of its several conceptualizations and report the main evidence supporting this notion.  We believe that a clear definition of pain as a disease is necessary, especially considering the enormous global burden of this condition.  Indeed, the recognition of pain as a definite pathologic state is crucial to raise awareness about this neglected global health problem and to promote the exploration of new specific therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbiAT6YvtYabesJRIHUP1ofW6udTcc2ebcJBlbr7nvCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbjs1Wrsg%253D%253D&md5=223877b7200e08efd88b0726870326fd</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2147%2FJPR.S138864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJPR.S138864%26sid%3Dliteratum%253Aachs%26aulast%3DRaffaeli%26aufirst%3DW.%26aulast%3DArnaudo%26aufirst%3DE.%26atitle%3DPain%2520as%2520a%2520disease%253A%2520an%2520overview%26jtitle%3DJ.%2520Pain%2520Res.%26date%3D2017%26volume%3D10%26spage%3D2003%26epage%3D2008%26doi%3D10.2147%2FJPR.S138864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rice, A. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blyth, F. M.</span></span> <span> </span><span class="NLM_article-title">Pain and the global burden of disease</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">796</span>, <span class="refDoi"> DOI: 10.1097/j.pain.0000000000000454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1097%2Fj.pain.0000000000000454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=26670465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADC%252BC28vpvFynsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2016&pages=791-796&author=A.+S.+C.+Riceauthor=B.+H.+Smithauthor=F.+M.+Blyth&title=Pain+and+the+global+burden+of+disease&doi=10.1097%2Fj.pain.0000000000000454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Pain and the global burden of disease</span></div><div class="casAuthors">Rice Andrew S C; Smith Blair H; Blyth Fiona M</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">791-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKHO5fBRG3WE2yPDyEFiigfW6udTcc2ebcJBlbr7nvCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vpvFynsQ%253D%253D&md5=4b920f9d391385db51b43bea65d9dec7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1097%2Fj.pain.0000000000000454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fj.pain.0000000000000454%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DA.%2BS.%2BC.%26aulast%3DSmith%26aufirst%3DB.%2BH.%26aulast%3DBlyth%26aufirst%3DF.%2BM.%26atitle%3DPain%2520and%2520the%2520global%2520burden%2520of%2520disease%26jtitle%3DPain%26date%3D2016%26volume%3D157%26spage%3D791%26epage%3D796%26doi%3D10.1097%2Fj.pain.0000000000000454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benyamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trescot, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buenaventura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adlaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehgal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallejo, R.</span></span> <span> </span><span class="NLM_article-title">Opioid complications and side effects</span>. <i>Pain Physician</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">S105</span>– <span class="NLM_lpage">S120</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=18443635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADC%252BD1czosVSjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=S105-S120&author=R.+Benyaminauthor=A.+M.+Trescotauthor=S.+Dattaauthor=R.+Buenaventuraauthor=R.+Adlakaauthor=N.+Sehgalauthor=S.+E.+Glaserauthor=R.+Vallejo&title=Opioid+complications+and+side+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid complications and side effects</span></div><div class="casAuthors">Benyamin Ramsin; Trescot Andrea M; Datta Sukdeb; Buenaventura Ricardo; Adlaka Rajive; Sehgal Nalini; Glaser Scott E; Vallejo Ricardo</div><div class="citationInfo"><span class="NLM_cas:title">Pain physician</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2 Suppl</span>),
    <span class="NLM_cas:pages">S105-20</span>
        ISSN:<span class="NLM_cas:issn">1533-3159</span>.
    </div><div class="casAbstract">Medications which bind to opioid receptors are increasingly being prescribed for the treatment of multiple and diverse chronic painful conditions.  Their use for acute pain or terminal pain is well accepted.  Their role in the long-term treatment of chronic noncancer pain is, however, controversial for many reasons.  One of the primary reasons is the well-known phenomenon of psychological addiction that can occur with the use of these medications.  Abuse and diversion of these medications is a growing problem as the availability of these medications increases and this public health issue confounds their clinical utility.  Also, the extent of their efficacy in the treatment of pain when utilized on a chronic basis has not been definitively proven.  Lastly, the role of opioids in the treatment of chronic pain is also influenced by the fact that these potent analgesics are associated with a significant number of side effects and complications.  It is these phenomena that are the focus of this review.  Common side effects of opioid administration include sedation, dizziness, nausea, vomiting, constipation, physical dependence, tolerance, and respiratory depression.  Physical dependence and addiction are clinical concerns that may prevent proper prescribing and in turn inadequate pain management.  Less common side effects may include delayed gastric emptying, hyperalgesia, immunologic and hormonal dysfunction, muscle rigidity, and myoclonus.  The most common side effects of opioid usage are constipation (which has a very high incidence) and nausea.  These 2 side effects can be difficult to manage and frequently tolerance to them does not develop; this is especially true for constipation.  They may be severe enough to require opioid discontinuation, and contribute to under-dosing and inadequate analgesia.  Several clinical trials are underway to identify adjunct therapies that may mitigate these side effects.  Switching opioids and/or routes of administration may also provide benefits for patients.  Proper patient screening, education, and preemptive treatment of potential side effects may aid in maximizing effectiveness while reducing the severity of side effects and adverse events.  Opioids can be considered broad spectrum analgesic agents, affecting a wide number of organ systems and influencing a large number of body functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRS-eBn7Ppy6vx2phytoz6_fW6udTcc2eYAipffyRrRfbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czosVSjsQ%253D%253D&md5=26196f3cc302b1cad86e32477bb52e18</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBenyamin%26aufirst%3DR.%26aulast%3DTrescot%26aufirst%3DA.%2BM.%26aulast%3DDatta%26aufirst%3DS.%26aulast%3DBuenaventura%26aufirst%3DR.%26aulast%3DAdlaka%26aufirst%3DR.%26aulast%3DSehgal%26aufirst%3DN.%26aulast%3DGlaser%26aufirst%3DS.%2BE.%26aulast%3DVallejo%26aufirst%3DR.%26atitle%3DOpioid%2520complications%2520and%2520side%2520effects%26jtitle%3DPain%2520Physician%26date%3D2008%26volume%3D11%26spage%3DS105%26epage%3DS120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kata, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novitch, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anyama, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helander, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, A. D.</span></span> <span> </span><span class="NLM_article-title">Opioid addiction, diversion, and abuse in chronic and cancer pain</span>. <i>Curr. Opin Support Pa</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1097/SPC.0000000000000333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1097%2FSPC.0000000000000333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=29465470" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=124-130&author=V.+Kataauthor=M.+B.+Novitchauthor=M.+R.+Jonesauthor=B.+O.+Anyamaauthor=E.+M.+Helanderauthor=A.+D.+Kaye&title=Opioid+addiction%2C+diversion%2C+and+abuse+in+chronic+and+cancer+pain&doi=10.1097%2FSPC.0000000000000333"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2FSPC.0000000000000333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FSPC.0000000000000333%26sid%3Dliteratum%253Aachs%26aulast%3DKata%26aufirst%3DV.%26aulast%3DNovitch%26aufirst%3DM.%2BB.%26aulast%3DJones%26aufirst%3DM.%2BR.%26aulast%3DAnyama%26aufirst%3DB.%2BO.%26aulast%3DHelander%26aufirst%3DE.%2BM.%26aulast%3DKaye%26aufirst%3DA.%2BD.%26atitle%3DOpioid%2520addiction%252C%2520diversion%252C%2520and%2520abuse%2520in%2520chronic%2520and%2520cancer%2520pain%26jtitle%3DCurr.%2520Opin%2520Support%2520Pa%26date%3D2018%26volume%3D12%26spage%3D124%26epage%3D130%26doi%3D10.1097%2FSPC.0000000000000333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuczynska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzonkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kacprzak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawilska, J. B.</span></span> <span> </span><span class="NLM_article-title">Abuse of fentanyl: An emerging problem to face</span>. <i>Forensic Sci. Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/j.forsciint.2018.05.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.forsciint.2018.05.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=29902699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFSgtrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2018&pages=207-214&author=K.+Kuczynskaauthor=P.+Grzonkowskiauthor=L.+Kacprzakauthor=J.+B.+Zawilska&title=Abuse+of+fentanyl%3A+An+emerging+problem+to+face&doi=10.1016%2Fj.forsciint.2018.05.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Abuse of fentanyl: An emerging problem to face</span></div><div class="casAuthors">Kuczynska, Katarzyna; Grzonkowski, Piotr; Kacprzak, Lukasz; Zawilska, Jolanta B.</div><div class="citationInfo"><span class="NLM_cas:title">Forensic Science International</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207-214</span>CODEN:
                <span class="NLM_cas:coden">FSINDR</span>;
        ISSN:<span class="NLM_cas:issn">0379-0738</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Fentanyl is a potent synthetic opioid used as a narcotic analgesic supplement in general and regional anesthesia as well as in management of persistent, severe chronic pain.  Alarming epidemiol. and forensic medicine reports, accumulated mainly during the last two decades, point to a growing increase in illicit use of fentanyl, mainly in North America and Europe.  Toxicol. data indicates that fentanyl use is inextricably linked with polydrug use.  There are two main sources of fentanyl on the "recreational" drug market.  First, the most common, combines illicitly manufd. fentanyl from clandestine sources.  The drug is often mixed up with heroin ("fake heroin") to increase its potency at a little cost, or included in cocaine products.  It can also be mixed into and sold as oxycodone-, hydrocodone- or alprazolam-contg. tablets.  The other way to gain fentanyl is through the diversion of fentanyl-contg. medicines, esp. transdermal patches (FTPs).  Fentanyl extd. from FTP can be administered i.v., insufflated or inhaled after volatilization.  The drug can also be delivered by oral or transmucosal application of the whole patch, or by rectal insertion.  The most common overdose symptoms are coma, lethargy, respiratory depression and arrest.  Although naloxone, an opioid receptor antagonist, is the std. drug for fentanyl overdose rescue, attempts to revive patients with naloxone could be unsuccessful, due to the rapid onset of fentanyl's action.  As the fentanyl problem is constantly growing, there is an urgent need for new, effective harm-redn. strategies and technologies, as well as overdose maintenance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobGFPK9MCq1bVg90H21EOLACvtfcHk0lj4kKwpxweIGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFSgtrjO&md5=94abe4ec9777382050539428405e01dd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.forsciint.2018.05.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.forsciint.2018.05.042%26sid%3Dliteratum%253Aachs%26aulast%3DKuczynska%26aufirst%3DK.%26aulast%3DGrzonkowski%26aufirst%3DP.%26aulast%3DKacprzak%26aufirst%3DL.%26aulast%3DZawilska%26aufirst%3DJ.%2BB.%26atitle%3DAbuse%2520of%2520fentanyl%253A%2520An%2520emerging%2520problem%2520to%2520face%26jtitle%3DForensic%2520Sci.%2520Int.%26date%3D2018%26volume%3D289%26spage%3D207%26epage%3D214%26doi%3D10.1016%2Fj.forsciint.2018.05.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volkow, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, A. T.</span></span> <span> </span><span class="NLM_article-title">Opioid abuse in chronic pain - misconceptions and mitigation strategies</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1253</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1507771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1056%2FNEJMra1507771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=27028915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1253-1263&author=N.+D.+Volkowauthor=A.+T.+McLellan&title=Opioid+abuse+in+chronic+pain+-+misconceptions+and+mitigation+strategies&doi=10.1056%2FNEJMra1507771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid abuse in chronic pain - misconceptions and mitigation strategies</span></div><div class="casAuthors">Volkow, Nora D.; McLellan, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1253-1263</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Chronic pain not caused by cancer is among the most prevalent and debilitating medical conditions but also among the most controversial and complex to manage.  The urgency of patients' needs, the demonstrated effectiveness of opioid analgesics for the management of acute pain, and the limited therapeutic alternatives for chronic pain have combined to produce an overreliance on opioid medications in the United States, with assocd. alarming increases in diversion, overdose, and addiction.  Given the lack of clin. consensus and research-supported guidance, physicians understandably have questions about whether, when, and how to prescribe opioid analgesics for chronic pain without increasing public health risks.  Here, we draw on recent research to address common misconceptions regarding the abuse-related risks of opioid analgesics and highlight strategies to minimize those risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyMM2U8jPbvbVg90H21EOLACvtfcHk0lj4kKwpxweIGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurrM&md5=9e32c0adcd78ab163267bc7735efb514</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1507771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1507771%26sid%3Dliteratum%253Aachs%26aulast%3DVolkow%26aufirst%3DN.%2BD.%26aulast%3DMcLellan%26aufirst%3DA.%2BT.%26atitle%3DOpioid%2520abuse%2520in%2520chronic%2520pain%2520-%2520misconceptions%2520and%2520mitigation%2520strategies%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1253%26epage%3D1263%26doi%3D10.1056%2FNEJMra1507771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y. X.</span></span> <span> </span><span class="NLM_article-title">Mu opioids and their receptors: evolution of a concept</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1257</span>– <span class="NLM_lpage">1317</span>, <span class="refDoi"> DOI: 10.1124/pr.112.007138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1124%2Fpr.112.007138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=24076545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1257-1317&author=G.+W.+Pasternakauthor=Y.+X.+Pan&title=Mu+opioids+and+their+receptors%3A+evolution+of+a+concept&doi=10.1124%2Fpr.112.007138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mu opioids and their receptors: evolution of a concept</span></div><div class="casAuthors">Pasternak, Gavril W.; Pan, Ying-Xian</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1257-1317</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Opiates arc among the oldest medications available to manage a no. of medical problems.  Although pain is the current focus, early use initially focused upon the treatment of dysentery.  Opium contains high concns. of both morphine and codeine, along with thebaine, which is used in the synthesis of a no. of semisynthetic opioid analgesics.  Thus, it is not surprising that new agents were initially based upon the morphine scaffold.  The concept of multiple opioid receptors was first suggested almost 50 years ago, opening the possibility of new classes of drugs, but the morphine-like agents have remained the mainstay in the medical management of pain.  Termed mu, our understanding of these morphine-like agents and their receptors has undergone an evolution in thinking over the past 35 years.  Early pharmacol. studies identified three major classes of receptors, helped by the discovery of endogenous opioid peptides and receptor subtypes-primarily through the synthesis of novel agents.  These chem. biol. approaches were then eclipsed by the mol. biol. revolution, which now reveals a complexity of the morphine-like agents and their receptors that had not been previously appreciated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodv3eFyO841LVg90H21EOLACvtfcHk0lgVRHge6uyXfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLzJ&md5=49f6dc7f031f9302b72710d42f2a00ea</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1124%2Fpr.112.007138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.112.007138%26sid%3Dliteratum%253Aachs%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26aulast%3DPan%26aufirst%3DY.%2BX.%26atitle%3DMu%2520opioids%2520and%2520their%2520receptors%253A%2520evolution%2520of%2520a%2520concept%26jtitle%3DPharmacol.%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D1257%26epage%3D1317%26doi%3D10.1124%2Fpr.112.007138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhawan, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesselin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghubir, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, M.</span></span> <span> </span><span class="NLM_article-title">International union of pharmacology. XII. Classification of opioid receptors</span>. <i>Pharmacol Rev.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">592</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=8981566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaK2sXlsVGgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1996&pages=567-592&author=B.+N.+Dhawanauthor=F.+Cesselinauthor=R.+Raghubirauthor=T.+Reisineauthor=P.+B.+Bradleyauthor=P.+S.+Portogheseauthor=M.+Hamon&title=International+union+of+pharmacology.+XII.+Classification+of+opioid+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">International union of Pharmacology. XII. Classification of opioid receptors</span></div><div class="casAuthors">Dhawan, B. N.; Cesselin, R. Raghubir; Reisine, T.; Bradley, P. B.; Portoghese, P. S.; Hamon, M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">567-592</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review, with >300 refs.  Topics discussed include: characterization and distribution of opioid receptors, mol. biol. of opioid receptors and transduction mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0spM3ygvAyrVg90H21EOLACvtfcHk0lgVRHge6uyXfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlsVGgtQ%253D%253D&md5=faf0720d736a8cff4fb432755543d705</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDhawan%26aufirst%3DB.%2BN.%26aulast%3DCesselin%26aufirst%3DF.%26aulast%3DRaghubir%26aufirst%3DR.%26aulast%3DReisine%26aufirst%3DT.%26aulast%3DBradley%26aufirst%3DP.%2BB.%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26aulast%3DHamon%26aufirst%3DM.%26atitle%3DInternational%2520union%2520of%2520pharmacology.%2520XII.%2520Classification%2520of%2520opioid%2520receptors%26jtitle%3DPharmacol%2520Rev.%26date%3D1996%26volume%3D48%26spage%3D567%26epage%3D592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janecka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janecki, T.</span></span> <span> </span><span class="NLM_article-title">Opioid receptors and their ligands</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.2174/1568026043451618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.2174%2F1568026043451618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=14754373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitlCgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1-17&author=A.+Janeckaauthor=J.+Fichnaauthor=T.+Janecki&title=Opioid+receptors+and+their+ligands&doi=10.2174%2F1568026043451618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid receptors and their ligands</span></div><div class="casAuthors">Janecka, Anna; Fichna, Jakub; Janecki, Tomasz</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-17</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review which gives an historical perspective, summarizing ∼25 yr of research on opioids.  The typical opioid peptides produced in the brain, atypical opioids encrypted in milk protein or Hb sequences, and extremely potent and selective opioids of amphibian origin are described.  The main focus is on the structure-activity relationship studies of peptide ligands for 3 main opioid receptor types (μ, δ, κ), their selectivities and pharmacol. activities in vitro.  Chem. modifications that led to obtaining potent and selective agonists and antagonists for these receptors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxFiGL3DSyLbVg90H21EOLACvtfcHk0lgVRHge6uyXfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitlCgtg%253D%253D&md5=dddd8e79e184730707b8fa926295dcc2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F1568026043451618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026043451618%26sid%3Dliteratum%253Aachs%26aulast%3DJanecka%26aufirst%3DA.%26aulast%3DFichna%26aufirst%3DJ.%26aulast%3DJanecki%26aufirst%3DT.%26atitle%3DOpioid%2520receptors%2520and%2520their%2520ligands%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D1%26epage%3D17%26doi%3D10.2174%2F1568026043451618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldhoer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whistler, J. L.</span></span> <span> </span><span class="NLM_article-title">Opioid receptors</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">990</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.73.011303.073940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1146%2Fannurev.biochem.73.011303.073940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=15189164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslagsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2004&pages=953-990&author=M.+Waldhoerauthor=S.+E.+Bartlettauthor=J.+L.+Whistler&title=Opioid+receptors&doi=10.1146%2Fannurev.biochem.73.011303.073940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid receptors</span></div><div class="casAuthors">Waldhoer, Maria; Bartlett, Selena E.; Whistler, Jennifer L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">953-990</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Opioid receptors belong to the large superfamily of 7 transmembrane-spanning (7TM) G protein-coupled receptors (GPCRs).  As a class, GPCRs are of fundamental physiol. importance mediating the actions of the majority of known neurotransmitters and hormones.  Opioid receptors are particularly intriguing members of this receptor family.  They are activated both by endogenously produced opioid peptides and by exogenously administered opiate compds., some of which are not only among the most effective analgesics known but also highly addictive drugs of abuse.  A fundamental question in addiction biol. is why exogenous opioid drugs, such as morphine and heroin, have a high liability for inducing tolerance, dependence, and addiction.  This review focuses on many aspects of opioid receptors with the aim of gaining a greater insight into mechanisms of opioid tolerance and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSV3Nl3WDHrVg90H21EOLACvtfcHk0lh3PpFKrHXI_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslagsbs%253D&md5=9f865544116a6dac76c80432587180a3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.73.011303.073940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.73.011303.073940%26sid%3Dliteratum%253Aachs%26aulast%3DWaldhoer%26aufirst%3DM.%26aulast%3DBartlett%26aufirst%3DS.%2BE.%26aulast%3DWhistler%26aufirst%3DJ.%2BL.%26atitle%3DOpioid%2520receptors%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2004%26volume%3D73%26spage%3D953%26epage%3D990%26doi%3D10.1146%2Fannurev.biochem.73.011303.073940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Assana, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fogel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frelka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottfried, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kujawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lautz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ries, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schauer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strandberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strandberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, C.</span></span> <span> </span><span class="NLM_article-title">Kappa opioid receptor-based treatments for pain</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">LB88</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=LB88&author=C.+Assanaauthor=C.+Fellerauthor=M.+Fogelauthor=A.+Frelkaauthor=S.+Gottfriedauthor=R.+Jaberauthor=M.+Keyesauthor=M.+Koehlerauthor=K.+Kujawaauthor=N.+Lautzauthor=S.+Olsonauthor=J.+Penaauthor=L.+Riesauthor=L.+Schauerauthor=C.+Scherrerauthor=C.+Strandbergauthor=S.+Strandbergauthor=C.+Cunningham&title=Kappa+opioid+receptor-based+treatments+for+pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAssana%26aufirst%3DC.%26aulast%3DFeller%26aufirst%3DC.%26aulast%3DFogel%26aufirst%3DM.%26aulast%3DFrelka%26aufirst%3DA.%26aulast%3DGottfried%26aufirst%3DS.%26aulast%3DJaber%26aufirst%3DR.%26aulast%3DKeyes%26aufirst%3DM.%26aulast%3DKoehler%26aufirst%3DM.%26aulast%3DKujawa%26aufirst%3DK.%26aulast%3DLautz%26aufirst%3DN.%26aulast%3DOlson%26aufirst%3DS.%26aulast%3DPena%26aufirst%3DJ.%26aulast%3DRies%26aufirst%3DL.%26aulast%3DSchauer%26aufirst%3DL.%26aulast%3DScherrer%26aufirst%3DC.%26aulast%3DStrandberg%26aufirst%3DC.%26aulast%3DStrandberg%26aufirst%3DS.%26aulast%3DCunningham%26aufirst%3DC.%26atitle%3DKappa%2520opioid%2520receptor-based%2520treatments%2520for%2520pain%26jtitle%3DFASEB%2520J.%26date%3D2014%26volume%3D28%26spage%3DLB88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grechko, O. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spasov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shtareva, D. M.</span></span> <span> </span><span class="NLM_article-title">Opioid kappa receptors as a molecular target for the creation of a new generation of analgesic drugs</span>. <i>Pharm. Chem. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1007/s11094-016-1388-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1007%2Fs11094-016-1388-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsV2lurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2016&pages=1-9&author=O.+Y.+Grechkoauthor=A.+A.+Spasovauthor=D.+M.+Shtareva&title=Opioid+kappa+receptors+as+a+molecular+target+for+the+creation+of+a+new+generation+of+analgesic+drugs&doi=10.1007%2Fs11094-016-1388-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid κ Receptors as a Molecular Target for the Creation of a New Generation of Analgesic Drugs</span></div><div class="casAuthors">Grechko, O. Yu.; Spasov, A. A.; Shtareva, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Chemistry Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">PCJOAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-150X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  This review provides a brief description of the main structural and functional features of the κ opioid receptor, along with the properties of its agonists and the potential for using these in medicine.  Of all the opioid receptor subtypes, κ receptors are the most attractive in terms of creating new drugs with a min. of side effects.  The opioid κ receptor is a member of the superfamily of metabotropic G-protein-coupled receptors.  Opioid κ receptors are widely distributed in the CNS and at the periphery.  They are involved in numerous physiol. processes, including analgesia, regulation of neuroendocrine secretion, water balance, drinking and feeding behavior, autonomic functions, and the mechanisms of learning and memory.  Data have been reported on the existence of three subtypes of κ opioid receptor, though the mol. properties of only subtype 1 (e  1) have been studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBuNcDBDCKWLVg90H21EOLACvtfcHk0lh3PpFKrHXI_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsV2lurk%253D&md5=1501d222bcc5ec998330a3ecad4968a1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs11094-016-1388-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11094-016-1388-z%26sid%3Dliteratum%253Aachs%26aulast%3DGrechko%26aufirst%3DO.%2BY.%26aulast%3DSpasov%26aufirst%3DA.%2BA.%26aulast%3DShtareva%26aufirst%3DD.%2BM.%26atitle%3DOpioid%2520kappa%2520receptors%2520as%2520a%2520molecular%2520target%2520for%2520the%2520creation%2520of%2520a%2520new%2520generation%2520of%2520analgesic%2520drugs%26jtitle%3DPharm.%2520Chem.%2520J.%26date%3D2016%26volume%3D50%26spage%3D1%26epage%3D9%26doi%3D10.1007%2Fs11094-016-1388-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanderah, T. W.</span></span> <span> </span><span class="NLM_article-title">Delta and kappa opioid receptors as suitable drug targets for pain</span>. <i>Clin J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">S10</span>– <span class="NLM_lpage">S15</span>, <span class="refDoi"> DOI: 10.1097/AJP.0b013e3181c49e3a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1097%2FAJP.0b013e3181c49e3a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=20026960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FjtV2lsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2010&pages=S10-S15&author=T.+W.+Vanderah&title=Delta+and+kappa+opioid+receptors+as+suitable+drug+targets+for+pain&doi=10.1097%2FAJP.0b013e3181c49e3a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Delta and kappa opioid receptors as suitable drug targets for pain</span></div><div class="casAuthors">Vanderah Todd W</div><div class="citationInfo"><span class="NLM_cas:title">The Clinical journal of pain</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">26 Suppl 10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">S10-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Similar to mu opioid receptors, kappa and delta opioid receptors reside in the periphery, the dorsal root ganglion, the spinal cord, and in supraspinal regions associated with pain modulation.  Both delta and kappa opioid agonists have been shown to activate pain inhibitory pathways in the central nervous system.  Yet, currently there are only a few pharmacologic agents that target kappa receptors, and none that target delta receptors.  Spurred by the need for an efficacious analgesic without the unwanted side effects associated with the typical clinical profile of mu opioid agonists, new research has provided insight into why the development of effective kappa and delta opioid receptor agonists has remained elusive thus far, and importantly, how these obstacles may be overcome.  For example, for delta opioid agonists to be effective, a state of inflammation may be required as this induces delta opioid receptors to migrate to the surface of neuronal cells and thereby become accessible to delta opioid agonists.  Studies have shown that delta opioid agonists can provide relief of inflammatory pain and malignant bone pain.  Meanwhile, peripherally restricted kappa opioid agonists have been developed to target kappa opioid receptors located on visceral and somatic afferent nerves for relief of inflammatory, visceral, and neuropathic chronic pain.  The recently shown efficacy of these analgesics combined with a possible lower abuse potential and side effect burden than mu opioid receptor agonists makes delta and peripherally restricted kappa opioid receptor agonists promising targets for treating pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwsScs20wGhFZoq0fPSOTvfW6udTcc2ea34GqoeRYXMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FjtV2lsQ%253D%253D&md5=bdde085a4b229f4a12c5b6034e5a1b20</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1097%2FAJP.0b013e3181c49e3a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FAJP.0b013e3181c49e3a%26sid%3Dliteratum%253Aachs%26aulast%3DVanderah%26aufirst%3DT.%2BW.%26atitle%3DDelta%2520and%2520kappa%2520opioid%2520receptors%2520as%2520suitable%2520drug%2520targets%2520for%2520pain%26jtitle%3DClin%2520J.%2520Pain%26date%3D2010%26volume%3D26%26spage%3DS10%26epage%3DS15%26doi%3D10.1097%2FAJP.0b013e3181c49e3a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaitseva, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galan, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlova, L. A.</span></span> <span> </span><span class="NLM_article-title">Prospects of a search for kappa-opioid receptor agonists with analgesic activity (review)</span>. <i>Pharm. Chem. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1007/s11094-018-1703-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1007%2Fs11094-018-1703-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&pages=843-851&author=N.+I.+Zaitsevaauthor=S.+E.+Galanauthor=L.+A.+Pavlova&title=Prospects+of+a+search+for+kappa-opioid+receptor+agonists+with+analgesic+activity+%28review%29&doi=10.1007%2Fs11094-018-1703-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects of a Search for Kappa-Opioid Receptor Agonists with Analgesic Activity (Review)</span></div><div class="casAuthors">Zaitseva, N. I.; Galan, S. E.; Pavlova, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Chemistry Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">843-851</span>CODEN:
                <span class="NLM_cas:coden">PCJOAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-150X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Current approaches to the search for new kappa-opioid receptor (κ-OR) agonists with potential analgesic activity are reviewed.  Agents with peripheral activity and biased agonists are most promising for development.  Signal events initiated by κ-OR activation are considered.  Chem. structures of presently known κ-OR agonists are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMeghxEJcAUbVg90H21EOLACvtfcHk0ljCthJ7U48AhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKltr0%253D&md5=e76be1dd8fbe48432b2997724aeb863b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs11094-018-1703-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11094-018-1703-y%26sid%3Dliteratum%253Aachs%26aulast%3DZaitseva%26aufirst%3DN.%2BI.%26aulast%3DGalan%26aufirst%3DS.%2BE.%26aulast%3DPavlova%26aufirst%3DL.%2BA.%26atitle%3DProspects%2520of%2520a%2520search%2520for%2520kappa-opioid%2520receptor%2520agonists%2520with%2520analgesic%2520activity%2520%2528review%2529%26jtitle%3DPharm.%2520Chem.%2520J.%26date%3D2018%26volume%3D51%26spage%3D843%26epage%3D851%26doi%3D10.1007%2Fs11094-018-1703-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charleson, S.</span></span> <span> </span><span class="NLM_article-title">High-affinity [h-3]-labeled ethylketazocine binding - evidence for specific kappa-receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1016/0028-3908(82)90190-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2F0028-3908%2882%2990190-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=6122185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaL38XksV2hsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1982&pages=215-219&author=P.+L.+Woodauthor=S.+Charleson&title=High-affinity+%5Bh-3%5D-labeled+ethylketazocine+binding+-+evidence+for+specific+kappa-receptors&doi=10.1016%2F0028-3908%2882%2990190-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">High affinity tritium-labeled ethylketazocine binding:  evidence for specific κ receptors</span></div><div class="casAuthors">Wood, P. L.; Charleson, S.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-19</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    </div><div class="casAbstract">κ Opiate receptors (3H-labeled ethylketazocine  [36292-66-7] binding) in rat brain membrane prepns. were resistant to low concns. of N-ethylmaleimide  [128-53-0], whereas μ (3H-labeled dihydromorphine binding) and δ [3H-labeled 2-D-alanine-5-D-leucine-enkephalin (I)] opiate receptors were not.  The κ site was selectively protected from inactivation with 5mM N-ethylmaleimide by the κ agonists, ethylketazocine and (-)-α-(1R,5R,9R)-5,9-dimethyl-2-(L-tetrahydrofurfuryl)-2'-hydroxy-6,7-benzomorphan, but not by morphine or I.  Hence, a unique κ receptor may be present in the rat CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Rc8yuIlGWrVg90H21EOLACvtfcHk0ljCthJ7U48AhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XksV2hsLw%253D&md5=9e851db138d0a7f32c9d23fd7c54cacb</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2F0028-3908%2882%2990190-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0028-3908%252882%252990190-3%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DP.%2BL.%26aulast%3DCharleson%26aufirst%3DS.%26atitle%3DHigh-affinity%2520%255Bh-3%255D-labeled%2520ethylketazocine%2520binding%2520-%2520evidence%2520for%2520specific%2520kappa-receptors%26jtitle%3DNeuropharmacology%26date%3D1982%26volume%3D21%26spage%3D215%26epage%3D219%26doi%3D10.1016%2F0028-3908%2882%2990190-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dortch-Carnes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, D. E.</span></span> <span> </span><span class="NLM_article-title">Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2005.tb00270.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1111%2Fj.1527-3458.2005.tb00270.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=16007240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVOlsbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=195-212&author=J.+Dortch-Carnesauthor=D.+E.+Potter&title=Bremazocine%3A+a+kappa-opioid+agonist+with+potent+analgesic+and+other+pharmacologic+properties&doi=10.1111%2Fj.1527-3458.2005.tb00270.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Bremazocine: A κ-opioid agonist with potent analgesic and other pharmacologic properties</span></div><div class="casAuthors">Dortch-Carnes, Juanita; Potter, David E.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-212</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review.  Bremazocine is a κ-opioid receptor agonist with potent analgesic and diuretic activities.  As an analgesic it is three- to four-times more potent than morphine, as detd. in both hot plate and tail flick tests.  Bremazocine and other benzomorphan analogs were synthesized in an effort to produce opiates with greater κ-opioid receptor selectivity and with minimal morphine-like side effects.  Unlike morphine bremazocine is devoid of phys. and psychol. dependence liability in animal models and produces little or no respiratory depression.  While bremazocine does not produce the characteristic euphoria assocd. with morphine and its abuse, it has been shown to induce dysphoria, a property that limits its clin. usefulness.  Similarly to morphine, repeated administration of bremazocine leads to tolerance to its analgesic effect.  It has been demonstrated that the marked diuretic effect of bremazocine is mediated primarily by the central nervous system.  Because of its psychotomimetic side effects (disturbance in the perception of space and time, abnormal visual experience, disturbance in body image perception, de-personalization, de-realization and loss of self control) bremazocine has limited potential as a clin. analgesic.  However, its possible utility for the therapy of alc. and drug addiction warrants further consideration because of its ability to decrease ethanol and cocaine self-administration in non-human primates.  In addn., the ability of bremazocine-like drugs to lower intraocular pressure and to minimize ischemic damage in animal models suggests their possible use in the therapy of glaucoma and cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6rq4x2jCP0bVg90H21EOLACvtfcHk0ljCthJ7U48AhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVOlsbfM&md5=6ecfd3bdfc3d5969ed4ed5e7afd54d83</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2005.tb00270.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2005.tb00270.x%26sid%3Dliteratum%253Aachs%26aulast%3DDortch-Carnes%26aufirst%3DJ.%26aulast%3DPotter%26aufirst%3DD.%2BE.%26atitle%3DBremazocine%253A%2520a%2520kappa-opioid%2520agonist%2520with%2520potent%2520analgesic%2520and%2520other%2520pharmacologic%2520properties%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2005%26volume%3D11%26spage%3D195%26epage%3D212%26doi%3D10.1111%2Fj.1527-3458.2005.tb00270.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahti, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonvoigtlander, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsuhn, C.</span></span> <span> </span><span class="NLM_article-title">Properties of a selective kappa agonist, u-50,488h</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2257</span>– <span class="NLM_lpage">2260</span>, <span class="refDoi"> DOI: 10.1016/0024-3205(82)90132-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2F0024-3205%2882%2990132-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=6131357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaL3sXhtFemtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1982&pages=2257-2260&author=R.+A.+Lahtiauthor=P.+F.+Vonvoigtlanderauthor=C.+Barsuhn&title=Properties+of+a+selective+kappa+agonist%2C+u-50%2C488h&doi=10.1016%2F0024-3205%2882%2990132-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Properties of a selective kappa agonist, U-50,488H</span></div><div class="casAuthors">Lahti, R. A.; VonVoigtlander, P. F.; Barsuhn, C.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">20-21</span>),
    <span class="NLM_cas:pages">2257-60</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    </div><div class="casAbstract">U-50488H (I)  [83913-06-8] was shown to be a naloxone-antagonizable analgesic in rodents.  However, the dose of naloxone needed for antagonism was higher than it was for morphine.  I did not produce phys. dependence; however it did produce tolerance upon chronic administration.  I was cross tolerant with bremazocine but not with morphine.  Monkeys trained to discriminate ethylketocyclazocine (EKC) from saline showed a complete generalization to I but not to morphine.  The evaluation of I in 3H-EKC site-selective binding indicated that it has a high affinity for the κ receptor and a low affinity for the μ receptor.  I appears to be a selective inhibitor of opioid κ receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTQYm0oFnQYLVg90H21EOLACvtfcHk0li8qPQaJ_fzwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhtFemtw%253D%253D&md5=ea19b1ba054b4b74f8e9f53579666eed</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2882%2990132-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252882%252990132-1%26sid%3Dliteratum%253Aachs%26aulast%3DLahti%26aufirst%3DR.%2BA.%26aulast%3DVonvoigtlander%26aufirst%3DP.%2BF.%26aulast%3DBarsuhn%26aufirst%3DC.%26atitle%3DProperties%2520of%2520a%2520selective%2520kappa%2520agonist%252C%2520u-50%252C488h%26jtitle%3DLife%2520Sci.%26date%3D1982%26volume%3D31%26spage%3D2257%26epage%3D2260%26doi%3D10.1016%2F0024-3205%2882%2990132-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vonvoigtlander, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahti, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludens, J. H.</span></span> <span> </span><span class="NLM_article-title">U-50,488: a selective and structurally novel non-mu-(kappa) opioid agonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>224</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=6129321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaL3sXhtF2ms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=224&publication_year=1983&pages=7-12&author=P.+F.+Vonvoigtlanderauthor=R.+A.+Lahtiauthor=J.+H.+Ludens&title=U-50%2C488%3A+a+selective+and+structurally+novel+non-mu-%28kappa%29+opioid+agonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">U-50,488: a selective and structurally novel non-mu (kappa) opioid agonist</span></div><div class="casAuthors">Vonvoigtlander, P. F.; Lahti, R. A.; Ludens, J. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">224</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-12</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">U-50,488 (I)  [67198-13-4] displays analgesic actions in a variety (thermal, pressure and irritant) of assays in mice and rats.  Naloxone and MR-2266 block this analgesic effect; thus it is mediated by opioid receptors.  However, when compared to morphine analgesia, the naloxone and MR-2266 pA2 values for U-50,488 analgesia were much lower and higher, resp.  Likewise, although tolerance occurs to both morphine and U-50,488 analgesia, there was no cross-tolerance between these drugs, and U-50,488 does not cause morphine-type phys. dependence.  Apparently, different opioid receptors mediate the analgesic effects of morphine and U-50,488.  The effects of U-50,488 appear to be mediated by the so-called κ opioid receptor.  In contrast to U-50,488, other reputed κ opioid agonists displayed varying degrees of μ agonist (ketazocine and ethylketocyclazocine) and narcotic antagonist (bremazocine) activities.  Thus, U-50,488 is a more selective κ agonist.  This conclusion is further supported by binding studies; of all compds. tested, U-50,488 displacement of [3H]ethyllketocyclazocine binding was uniquely not blocked by high concns. of dihydromorphine.  In addn. to analgesia, this selective κ agonist also causes opioid receptor-mediated sedation, diuresis and corticosteroid elevations.  U-50,488 is a useful tool for studying contrasting κ and μ opioid receptor-mediated effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB4gIGB1gYe7Vg90H21EOLACvtfcHk0li8qPQaJ_fzwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhtF2ms7k%253D&md5=b54070c6b374dd8a938ff3dccbfda564</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVonvoigtlander%26aufirst%3DP.%2BF.%26aulast%3DLahti%26aufirst%3DR.%2BA.%26aulast%3DLudens%26aufirst%3DJ.%2BH.%26atitle%3DU-50%252C488%253A%2520a%2520selective%2520and%2520structurally%2520novel%2520non-mu-%2528kappa%2529%2520opioid%2520agonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1983%26volume%3D224%26spage%3D7%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pande, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyke, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wideman, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, M. W.</span></span> <span> </span><span class="NLM_article-title">Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain</span>. <i>Clin. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1097/00002826-199619050-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1097%2F00002826-199619050-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=8889289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaK28Xmtlynu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1996&pages=451-456&author=A.+C.+Pandeauthor=R.+E.+Pykeauthor=M.+Greinerauthor=G.+L.+Widemanauthor=R.+Benjaminauthor=M.+W.+Pierce&title=Analgesic+efficacy+of+enadoline+versus+placebo+or+morphine+in+postsurgical+pain&doi=10.1097%2F00002826-199619050-00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain</span></div><div class="casAuthors">Pande, Atul C.; Pyke, Robert E.; Greiner, Martha; Wideman, Gilder L.; Benjamin, Ronald; Pierce, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Neuropharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">451-456</span>CODEN:
                <span class="NLM_cas:coden">CLNEDB</span>;
        ISSN:<span class="NLM_cas:issn">0362-5664</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">Enadoline, a selective agonist of the κ-opioid receptor, was studied for its analgesic efficacy in patients with pain after obstetric or gynecol. surgery.  An initial study involving a comparison of enadoline (2, 5, 15μg), an acetaminophen-codeine (ACET/COD) combination, and placebo showed all treatments to be ineffective analgesics.  Therefore, a second study with the same design but using higher doses of enadoline (15 and 25μg) and replacing ACET/COD with morphine 10 mg i.m. was conducted.  Enadoline 25μg produced similar pain relief to that of morphine, although of shorter duration, and better than enadoline 15μg or placebo.  However, enadoline was assocd. with dose-limiting neuropsychiatric adverse events, which led to early termination of the study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkWntz_uJvzLVg90H21EOLACvtfcHk0li8qPQaJ_fzwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xmtlynu74%253D&md5=111db0a878ebfed0fdec77f0e936aaf7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1097%2F00002826-199619050-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00002826-199619050-00009%26sid%3Dliteratum%253Aachs%26aulast%3DPande%26aufirst%3DA.%2BC.%26aulast%3DPyke%26aufirst%3DR.%2BE.%26aulast%3DGreiner%26aufirst%3DM.%26aulast%3DWideman%26aufirst%3DG.%2BL.%26aulast%3DBenjamin%26aufirst%3DR.%26aulast%3DPierce%26aufirst%3DM.%2BW.%26atitle%3DAnalgesic%2520efficacy%2520of%2520enadoline%2520versus%2520placebo%2520or%2520morphine%2520in%2520postsurgical%2520pain%26jtitle%3DClin.%2520Neuropharmacol.%26date%3D1996%26volume%3D19%26spage%3D451%26epage%3D456%26doi%3D10.1097%2F00002826-199619050-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strain, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abreu, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigelow, G. E.</span></span> <span> </span><span class="NLM_article-title">Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1007/s002130100788</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1007%2Fs002130100788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=11594439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3MXns1Clt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2001&pages=151-162&author=S.+L.+Walshauthor=E.+C.+Strainauthor=M.+E.+Abreuauthor=G.+E.+Bigelow&title=Enadoline%2C+a+selective+kappa+opioid+agonist%3A+comparison+with+butorphanol+and+hydromorphone+in+humans&doi=10.1007%2Fs002130100788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans</span></div><div class="casAuthors">Walsh, Sharon L.; Strain, Eric C.; Abreu, Mary E.; Bigelow, George E.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-162</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">The availability of the highly selective and specific kappa opioid agonist enadoline provides an opportunity to explore the function of kappa receptors in humans and their potential utility as a target for substance abuse pharmacotherapy development.  The pharmacodynamic effects of enadoline, a selective kappa agonist, were characterized and butorphanol, a mixed mu/kappa agonist, and hydromorphone, a mu agonist, were compared with it in humans.  Pilot evaluation served to establish i.m. doses of enadoline (20, 40, 80, and 160 μg/70 kg), butorphanol (1.5, 3, 6, and 12 mg/70 kg), and hydromorphone (1.5, 3, and 6 mg/70 kg) of comparable activity.  These acute doses were examd. under double-blind, placebo-controlled and constrained randomized conditions with a min. of 72 h between tests in volunteers with polysubstance abuse histories.  Physiol. and subject- and observer-rated measures were collected 30 min before and for 4 h after administration.  Enadoline significantly increased measures of sedation, confusion and dizziness, produced visual distortions and feelings of depersonalization, and increased urinary output.  The highest dose (160 μg/70 kg) was not tolerated and led to psychotomimetic effects.  Hydromorphone produced prototypic mu opioid effects including respiratory depression, miosis, and euphoria.  Butorphanol was most similar to hydromorphone and shared few effects with enadoline.  These results are discussed with respect to the potential use and safety of kappa agonists for clin. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUXIJ-OK2aL7Vg90H21EOLACvtfcHk0li8qPQaJ_fzwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXns1Clt7w%253D&md5=2eec6fc4a78e9fabf79a0508babe5d4e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs002130100788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002130100788%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DS.%2BL.%26aulast%3DStrain%26aufirst%3DE.%2BC.%26aulast%3DAbreu%26aufirst%3DM.%2BE.%26aulast%3DBigelow%26aufirst%3DG.%2BE.%26atitle%3DEnadoline%252C%2520a%2520selective%2520kappa%2520opioid%2520agonist%253A%2520comparison%2520with%2520butorphanol%2520and%2520hydromorphone%2520in%2520humans%26jtitle%3DPsychopharmacology%26date%3D2001%26volume%3D157%26spage%3D151%26epage%3D162%26doi%3D10.1007%2Fs002130100788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wadenberg, M. L. G.</span></span> <span> </span><span class="NLM_article-title">A review of the properties of spiradoline: A potent and selective kappa-opioid receptor agonist</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2003.tb00248.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1111%2Fj.1527-3458.2003.tb00248.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=12847558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsl2qt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=187-198&author=M.+L.+G.+Wadenberg&title=A+review+of+the+properties+of+spiradoline%3A+A+potent+and+selective+kappa-opioid+receptor+agonist&doi=10.1111%2Fj.1527-3458.2003.tb00248.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A review of the properties of spiradoline: a potent and selective .vkappa.-opioid receptor agonist</span></div><div class="casAuthors">Wadenberg, M.-L. G.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-198</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review.  The selective .vkappa.-opioid receptor agonist spiradoline mesylate (U62,066E), an arylacetamide, was synthesized with the intention of creating an analgesic that, while still retaining its analgesic properties, would be devoid of the, mainly μ receptor mediated, side effects such as phys. dependence and respiratory depression assocd. with morphine.  Spiradoline is highly selective for the .vkappa. receptor with Ki of 8.6 nM in guinea pig.  Examn. of the enantiomers of spiradoline, showed the (-)enantiomer to be responsible for the .vkappa. agonist properties.  Spiradoline easily penetrates the blood brain barrier, and does not seem to have any significant active metabolites.  In preclin. studies, spiradoline has a short duration of action with a peak at around 30 min after administration.  The analgesic properties of spiradoline are well documented in mice and rats.  Antitussive properties have also been reported in rats.  Furthermore, spiradoline was reported to display effects suggestive of neuroprotective properties in animal models of ischemia.  In humans, spiradoline is a potent diuretic.  It also produces significant sedation presumably due to its antihistamine properties.  Preclin. studies have shown that spiradoline reduces blood pressure and heart rate, and has possible antiarrhythmic properties.  Clin. studies did not confirm these findings.  .vkappa. Receptors inhibit dopaminergic neurotransmission.  Spiradoline, given systematically to rats, produces a significant and long lasting decrease in dopamine release, and in locomotor activity.  It has also antipsychotic-like effect in animal behavioral tests.  At low doses spiradoline was reported to decrease tics in patients with Tourette's syndrome.  Although spiradoline had promising effects in animal tests of analgesia, and a reasonably good safety profile in preliminary studies, it did not replace morphine as an analgesic.  The available clin. data suggest that spiradoline produces disturbing adverse effects such as diuresis, sedation, and dysphoria at doses lower than those needed for analgesic effects.  Thus, future development of spiradoline-like analgesic compds. should preferably focus on redn. of unwanted effects on the central nervous system.  Spiradoline, which currently is com. available for preclin. research, might prove useful in some psychiatric conditions and possibly as a neuroprotective agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvNIeGyLqL87Vg90H21EOLACvtfcHk0lgGMOCLSuS7gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsl2qt7s%253D&md5=11de5c95875bd8a8f1db5304a1cd2889</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2003.tb00248.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2003.tb00248.x%26sid%3Dliteratum%253Aachs%26aulast%3DWadenberg%26aufirst%3DM.%2BL.%2BG.%26atitle%3DA%2520review%2520of%2520the%2520properties%2520of%2520spiradoline%253A%2520A%2520potent%2520and%2520selective%2520kappa-opioid%2520receptor%2520agonist%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2003%26volume%3D9%26spage%3D187%26epage%3D198%26doi%3D10.1111%2Fj.1527-3458.2003.tb00248.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butelman, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreek, M. J.</span></span> <span> </span><span class="NLM_article-title">Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">190</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.3389%2Ffphar.2015.00190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=26441647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADC%252BC283ps1Sgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=190&author=E.+R.+Butelmanauthor=M.+J.+Kreek&title=Salvinorin+A%2C+a+kappa-opioid+receptor+agonist+hallucinogen%3A+pharmacology+and+potential+template+for+novel+pharmacotherapeutic+agents+in+neuropsychiatric+disorders&doi=10.3389%2Ffphar.2015.00190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders</span></div><div class="casAuthors">Butelman Eduardo R; Kreek Mary Jeanne</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">190</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Salvinorin A is a potent hallucinogen, isolated from the ethnomedical plant Salvia divinorum.  Salvinorin A is a selective high efficacy kappa-opioid receptor (KOPr) agonist, and thus implicates the KOPr system and its endogenous agonist ligands (the dynorphins) in higher functions, including cognition and perceptual effects.  Salvinorin A is the only selective KOPr ligand to be widely available outside research or medical settings, and salvinorin A-containing products have undergone frequent non-medical use.  KOPr/dynorphin systems in the brain are known to be powerful counter-modulatory mechanisms to dopaminergic function, which is important in mood and reward engendered by natural and chemical reinforcers (including drugs of abuse).  KOPr activation (including by salvinorin A) can thus cause aversion and anhedonia in preclinical models.  Salvinorin A is also a completely new scaffold for medicinal chemistry approaches, since it is a non-nitrogenous neoclerodane, unlike other known opioid ligands.  Ongoing efforts have the goal of discovering novel semi-synthetic salvinorin analogs with potential KOPr-mediated pharmacotherapeutic effects (including partial agonist or biased agonist effects), with a reduced burden of undesirable effects associated with salvinorin A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTsuodK6iLMsve_zCu79I8fW6udTcc2eZvyY36Z4grIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ps1Sgsw%253D%253D&md5=5e7d64ca553f082d43c77510a0e14970</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00190%26sid%3Dliteratum%253Aachs%26aulast%3DButelman%26aufirst%3DE.%2BR.%26aulast%3DKreek%26aufirst%3DM.%2BJ.%26atitle%3DSalvinorin%2520A%252C%2520a%2520kappa-opioid%2520receptor%2520agonist%2520hallucinogen%253A%2520pharmacology%2520and%2520potential%2520template%2520for%2520novel%2520pharmacotherapeutic%2520agents%2520in%2520neuropsychiatric%2520disorders%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D190%26doi%3D10.3389%2Ffphar.2015.00190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hameroff, S. R.</span></span> <span> </span><span class="NLM_article-title">Opiate receptor pharmacology: mixed agonist/antagonist narcotics</span>. <i>Contemp. Anesth. Pract</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">43</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=6136392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADyaL3s3os1Kjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1983&pages=27-43&author=S.+R.+Hameroff&title=Opiate+receptor+pharmacology%3A+mixed+agonist%2Fantagonist+narcotics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Opiate receptor pharmacology: mixed agonist/antagonist narcotics</span></div><div class="casAuthors">Hameroff S R</div><div class="citationInfo"><span class="NLM_cas:title">Contemporary anesthesia practice</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-43</span>
        ISSN:<span class="NLM_cas:issn">0191-247X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAAtttRn0ZGNFxYDaSSP8XfW6udTcc2eZ8hIBeHFqyhrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s3os1Kjtg%253D%253D&md5=405d24054d313803505f5c79c404642d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHameroff%26aufirst%3DS.%2BR.%26atitle%3DOpiate%2520receptor%2520pharmacology%253A%2520mixed%2520agonist%252Fantagonist%2520narcotics%26jtitle%3DContemp.%2520Anesth.%2520Pract%26date%3D1983%26volume%3D7%26spage%3D27%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Souza, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhar, M. J.</span></span> <span> </span><span class="NLM_article-title">Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>244</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">402</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=2826773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaL1cXosl2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=1988&pages=391-402&author=E.+B.+De%0ASouzaauthor=W.+K.+Schmidtauthor=M.+J.+Kuhar&title=Nalbuphine%3A+an+autoradiographic+opioid+receptor+binding+profile+in+the+central+nervous+system+of+an+agonist%2Fantagonist+analgesic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Nalbuphine:  an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic</span></div><div class="casAuthors">De Souza, Errol B.; Schmidt, William K.; Kuhar, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">391-402</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The sites of nalbuphine binding to μ, δ, and κ opioid receptors in the central nervous system (CNS) were localized by use of in vitro labeling light-microscopic autoradiog.  Mu, delta and kappa opioid receptors were labeled selectively by [3H]dihydromorphine, D-[3H]Ala2-D-Leu5-enkephalin and (-)-[3H]ethylketocyclazocine, resp.  In displacement studies in rat brain homogenates, nalbuphine had the highest affinity for μ receptors (0.5 nM) with progressively lower affinities for κ (29 nM) and δ (60 nM) opioid receptors.  In autoradiog. studies in slide-mounted sections of guinea pig brain and monkey spinal cord, nalbuphine (300 nM) displaced completely the binding at μ and κ receptors without significantly altering the binding at δ receptors.  The binding of [3H]nalbuphine in slide-mounted sections of guinea pig forebrain was saturable and showed a curvilinear profile, indicating the presence of 2 binding sites with apparent dissocn. const. values of 0.5 and 12 nM.  Morphine and U-50,488H, which have high affinities for μ and κ opioid receptors, resp., inhibited [3H]nalbuphine binding with IC50 values of 0.9 and 10 nM, resp.  In satn. studies, morphine (50 nM) and U-50,488H (100 nM) selectively blocked the high- and low-affinity components of [3H]nalbuphine binding, resp.  The autoradiog. distribution of [3H]nalbuphine binding sites in the CNS corresponds well to the distribution of μ and κ opioid receptors.  In addn., CNS areas (deep layers of the cerebral cortex, laminae I and II of the spinal cord, substantia gelatinosa of the trigeminal nerve, periaqueductal gray and thalamic nuclei) that mediate analgesia contain high concns. of [3H]nalbuphine binding sites.  These data demonstrate that nalbuphine acts on μ and κ opioid receptors and identify anatomical loci in the CNS in which nalbuphine may produce its actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmheQFujG0trVg90H21EOLACvtfcHk0lhAXit3CVt5sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXosl2ruw%253D%253D&md5=3e081fc8a7bd54a10a3c83d38b62a18d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSouza%26aufirst%3DE.%2BB.%26aulast%3DSchmidt%26aufirst%3DW.%2BK.%26aulast%3DKuhar%26aufirst%3DM.%2BJ.%26atitle%3DNalbuphine%253A%2520an%2520autoradiographic%2520opioid%2520receptor%2520binding%2520profile%2520in%2520the%2520central%2520nervous%2520system%2520of%2520an%2520agonist%252Fantagonist%2520analgesic%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1988%26volume%3D244%26spage%3D391%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosow, C. E.</span></span> <span> </span><span class="NLM_article-title">Butorphanol in perspective</span>. <i>Acute Care</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">Suppl. 1</span>),  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">7</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=2830756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADyaL1c7kslehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1988&pages=2-7&issue=Suppl.+1&author=C.+E.+Rosow&title=Butorphanol+in+perspective"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Butorphanol in perspective</span></div><div class="casAuthors">Rosow C E</div><div class="citationInfo"><span class="NLM_cas:title">Acute care</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">12 Suppl 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2-7</span>
        ISSN:<span class="NLM_cas:issn">0254-0819</span>.
    </div><div class="casAbstract">Butorphanol tartrate is a highly effective opioid agonist-antagonist analgesic with qualitative as well as quantitative differences from the pure agonists.  These differences are thought to be due to interaction with a distinct subset of opioid receptors.  Although it relieves severe pain, the drug does not usually elevate mood, and it may occasionally cause dysphoria.  Counterbalancing its disadvantages is a wealth of clinical experience with the drug showing an impressive record of safety.  Butorphanol produces limited respiratory depression and smooth muscle spasm, and both effects are reversible with naloxone.  The most prominent side effect is sedation, a property that is generally quite useful in the perioperative period.  Butorphanol is a weak morphine antagonist, so it may interact with agonists like morphine or fentanyl.  The chief advantages of this agent are its low toxicity and very low potential for abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6VtwAdAXrBhpyrDyM_m9cfW6udTcc2eZ8hIBeHFqyhrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c7kslehug%253D%253D&md5=084e280ae238036875c8f14d66c393c8</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosow%26aufirst%3DC.%2BE.%26atitle%3DButorphanol%2520in%2520perspective%26jtitle%3DAcute%2520Care%26date%3D1988%26volume%3D12%26issue%3DSuppl.%25201%26spage%3D2%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brogden, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speight, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, G. S.</span></span> <span> </span><span class="NLM_article-title">Pentazocine: a review of its pharmacological properties, therapeutic efficacy and dependence liability</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.2165/00003495-197305010-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.2165%2F00003495-197305010-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=4578369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaE3sXktlygt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1973&pages=6-91&author=R.+N.+Brogdenauthor=T.+M.+Speightauthor=G.+S.+Avery&title=Pentazocine%3A+a+review+of+its+pharmacological+properties%2C+therapeutic+efficacy+and+dependence+liability&doi=10.2165%2F00003495-197305010-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pentazocine.  Review of its pharmacological properties, therapeutic efficacy, and dependence liability</span></div><div class="casAuthors">Brogden, R. N.; Speight, T. M.; Avery, G. S.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-91</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    </div><div class="casAbstract">A review with 121 refs.  The analgesic and side effects of pentazocine (I) [359-83-1] are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnJ3bri5VkZ7Vg90H21EOLACvtfcHk0lhAXit3CVt5sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXktlygt78%253D&md5=b7a86c1a0dfc4c122c3d916d5f895b6b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2165%2F00003495-197305010-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-197305010-00002%26sid%3Dliteratum%253Aachs%26aulast%3DBrogden%26aufirst%3DR.%2BN.%26aulast%3DSpeight%26aufirst%3DT.%2BM.%26aulast%3DAvery%26aufirst%3DG.%2BS.%26atitle%3DPentazocine%253A%2520a%2520review%2520of%2520its%2520pharmacological%2520properties%252C%2520therapeutic%2520efficacy%2520and%2520dependence%2520liability%26jtitle%3DDrugs%26date%3D1973%26volume%3D5%26spage%3D6%26epage%3D91%26doi%3D10.2165%2F00003495-197305010-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span> <span> </span><span class="NLM_article-title">Pentazocine-Induced Biphasic Analgesia in Mice</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1827</span>– <span class="NLM_lpage">1835</span>, <span class="refDoi"> DOI: 10.1016/0024-3205(91)90238-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2F0024-3205%2891%2990238-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1645834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaK3MXit1Whtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1991&pages=1827-1835&author=T.+Suzukiauthor=M.+Naritaauthor=M.+Misawaauthor=H.+Nagase&title=Pentazocine-Induced+Biphasic+Analgesia+in+Mice&doi=10.1016%2F0024-3205%2891%2990238-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pentazocine-induced biphasic analgesia in mice</span></div><div class="casAuthors">Suzuki, Tsutomu; Narita, Minoru; Misawa, Miwa; Nagase, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1827-35</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    </div><div class="casAbstract">Pentazocine (PZ) is well known to act as an opioid mixed agonist-antagonist analgesic.  In the present study, mouse warm plate test condition of 51° was selected instead of 55° to det. the analgesic action of PZ.  PZ (intracerebroventricular, i.c.v.) produced a biphasic antinociceptive response, while U-50,488H (U-50) and morphine (MRP) produced a monophasic response.  Pretreatment with i.c.v. β-FNA (μ antagonist) antagonized the initial response, whereas the delayed response was antagonized by pretreatment with nor-BNI (κ antagonist).  In addn., pretreatment with NTI (δ antagonist) significantly attenuated the initial response but not the delayed response.  These results suggest that the initial and delayed responses may be mediated mainly by μ/δ and κ receptors, resp.  With regards to the interaction between MRP and PZ, a low dose of PZ antagonized the analgesic action of MRP, while a high dose PZ plus MRP showed the additive effect.  Furthermore, tolerance developed almost equally to both initial and delayed responses, indicating that tolerance to both the κ and the μ components of action of PZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrpC7oURoIobVg90H21EOLACvtfcHk0lj0yZdnhm3qPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXit1Whtb8%253D&md5=39f108f607d3e736b286b2881d098b2d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2891%2990238-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252891%252990238-7%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DNarita%26aufirst%3DM.%26aulast%3DMisawa%26aufirst%3DM.%26aulast%3DNagase%26aufirst%3DH.%26atitle%3DPentazocine-Induced%2520Biphasic%2520Analgesia%2520in%2520Mice%26jtitle%3DLife%2520Sci.%26date%3D1991%26volume%3D48%26spage%3D1827%26epage%3D1835%26doi%3D10.1016%2F0024-3205%2891%2990238-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Endoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumimoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span> <span> </span><span class="NLM_article-title">TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys</span>. <i>Jpn. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1254/jjp.85.282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1254%2Fjjp.85.282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=11325021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitlSlsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2001&pages=282-290&author=T.+Endohauthor=A.+Tajimaauthor=N.+Izumimotoauthor=T.+Suzukiauthor=A.+Saitohauthor=T.+Suzukiauthor=M.+Naritaauthor=J.+Kameiauthor=L.+F.+Tsengauthor=H.+Mizoguchiauthor=H.+Nagase&title=TRK-820%2C+a+selective+kappa-opioid+agonist%2C+produces+potent+antinociception+in+cynomolgus+monkeys&doi=10.1254%2Fjjp.85.282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">TRK-820, a selective κ-opioid agonist, produces potent antinociception in cynomolgus monkeys</span></div><div class="casAuthors">Endoh, Takashi; Tajima, Atsushi; Izumimoto, Naoki; Suzuki, Tomohiko; Saitoh, Akiyoshi; Suzuki, Tsutomu; Narita, Minoru; Kamei, Junzo; Tseng, Leon F.; Mizoguchi, Hirokazu; Nagase, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">282-290</span>CODEN:
                <span class="NLM_cas:coden">JJPAAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-5198</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">TRK-820 ((-)-17-cyclopropylmethyl-3,14b-dihydroxy-4,5a-epoxy-6b-[N-methyl-trans-3-(3-furyl)acrylamide]morphinan hydrochloride) has been shown to be a potent opioid κ-receptor agonist with pharmacol. properties different from those produced by κ1-opioid receptor agonists in rodents.  To ascertain whether or not these properties of TRK-820 would be extended to primates, the antinociceptive effect of TRK-820 was evaluated in cynomolgus monkeys by the hot-water tail-withdrawal procedure.  TRK-820 given i.m. produced a potent antinociceptive effect that was 295- and 495-fold more potent than morphine with the 50 and 55 hot-water tests, resp., and 40-fold more potent than U-50,488H and 1,000-fold more potent than pentazocine in the 50 hot-water test.  The duration of antinociceptive effects of TRK-820 treatment (0.01 and 0.03 mg/kg, i.m.) lasted more than 6 h, which was much longer than those of U-50,488H.  The antinociception produced by the higher dose (0.03 mg/kg, i.m.) of TRK-820 was not inhibited by nor-binaltorphimine (3.2 and 10 mg/kg, s.c.) or by naloxone (0.1 mg/kg, s.c.), although the antinociception induced by a lower dose of TRK-820 (0.01 mg/kg, i.m.) was inhibited by nor-binaltorphimine (10 mg/kg, s.c.).  The same doses of nor-binaltorphimine and naloxone effectively inhibited the antinociception induced by the higher doses of U-50,488H (1.0 mg/kg, i.m.) and morphine (10 mg/kg, i.m.), resp.  These results indicate that the antinociception induced by TRK-820 is less sensitive to nor-binaltorphimine and suggest that it is mediated by the stimulation of a subtype of κ-opioid receptor different from the κ1-opioid receptor in cynomolgus monkeys.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF6dqs9rxXi7Vg90H21EOLACvtfcHk0lj0yZdnhm3qPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitlSlsL4%253D&md5=f0218796bbb4cab1693fec812c6c5b85</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1254%2Fjjp.85.282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjjp.85.282%26sid%3Dliteratum%253Aachs%26aulast%3DEndoh%26aufirst%3DT.%26aulast%3DTajima%26aufirst%3DA.%26aulast%3DIzumimoto%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DSaitoh%26aufirst%3DA.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DNarita%26aufirst%3DM.%26aulast%3DKamei%26aufirst%3DJ.%26aulast%3DTseng%26aufirst%3DL.%2BF.%26aulast%3DMizoguchi%26aufirst%3DH.%26aulast%3DNagase%26aufirst%3DH.%26atitle%3DTRK-820%252C%2520a%2520selective%2520kappa-opioid%2520agonist%252C%2520produces%2520potent%2520antinociception%2520in%2520cynomolgus%2520monkeys%26jtitle%3DJpn.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D85%26spage%3D282%26epage%3D290%26doi%3D10.1254%2Fjjp.85.282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorbera, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. A.</span></span> <span> </span><span class="NLM_article-title">Nalfurafine hydrochloride. Antipruritic, analgesic, kappa opioid agonist</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1358/dof.2003.028.03.723584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1358%2Fdof.2003.028.03.723584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvVCju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=237-242&author=L.+A.+Sorberaauthor=J.+Castanerauthor=P.+A.+Leeson&title=Nalfurafine+hydrochloride.+Antipruritic%2C+analgesic%2C+kappa+opioid+agonist&doi=10.1358%2Fdof.2003.028.03.723584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Nalfurafine hydrochloride</span></div><div class="casAuthors">Sorbera, L. A.; Castaner, J.; Leeson, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">237-242</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Pruritus is a common symptom seen in 25-90% of uremic patients, esp. those with chronic renal failure requiring hemodialysis.  The cause and mechanism of induction of pruritus are not known.  However, studies comparing hemodialysis patients with healthy subjects provided evidence that an imbalance in the endogenous opioid system may be responsible for pruritus with particular involvement of the kappa opioid system.  Although existing kappa opioid receptor agonists lack morphine-like adverse effects, they are assocd. with dysphoria and psychotomimetic alterations.  Thus, research efforts continue to focus on new kappa opioid agonists with novel structures to circumvent unwanted adverse effects.  Nalfurafine hydrochloride is a novel kappa opioid receptor agonist that emerged using procedures incorporating a modification of the message-address concept.  Nalfurafine was shown to be highly selective for the kappa opioid receptor in vitro and has displayed potent antipruritic activity in vivo.  Moreover, a single dose of an oral formulation was shown to alleviate itch in hemodialysis patients suffering from severe pruritus.  Nalfurafine has also shown potent antinociceptive activity both in vitro and in vivo in various animal models of pain and was also selected for further development as an analgesic for moderate and severe pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooH3rw2_KPFLVg90H21EOLACvtfcHk0lj0yZdnhm3qPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvVCju7w%253D&md5=c49ca8c50d9a670f443f604b39b9753e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1358%2Fdof.2003.028.03.723584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2003.028.03.723584%26sid%3Dliteratum%253Aachs%26aulast%3DSorbera%26aufirst%3DL.%2BA.%26aulast%3DCastaner%26aufirst%3DJ.%26aulast%3DLeeson%26aufirst%3DP.%2BA.%26atitle%3DNalfurafine%2520hydrochloride.%2520Antipruritic%252C%2520analgesic%252C%2520kappa%2520opioid%2520agonist%26jtitle%3DDrugs%2520Future%26date%3D2003%26volume%3D28%26spage%3D237%26epage%3D242%26doi%3D10.1358%2Fdof.2003.028.03.723584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumimoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takezawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endoh, T.</span></span> <span> </span><span class="NLM_article-title">Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>995</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2003.09.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.brainres.2003.09.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=14672806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1Gktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=995&publication_year=2004&pages=167-175&author=T.+Suzukiauthor=N.+Izumimotoauthor=Y.+Takezawaauthor=M.+Fujimuraauthor=Y.+Togashiauthor=H.+Nagaseauthor=T.+Tanakaauthor=T.+Endoh&title=Effect+of+repeated+administration+of+TRK-820%2C+a+kappa-opioid+receptor+agonist%2C+on+tolerance+to+its+antinociceptive+and+sedative+actions&doi=10.1016%2Fj.brainres.2003.09.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of repeated administration of TRK-820, a κ-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions</span></div><div class="casAuthors">Suzuki, Tomohiko; Izumimoto, Naoki; Takezawa, Yuko; Fujimura, Morihiro; Togashi, Yuko; Nagase, Hiroshi; Tanaka, Toshiaki; Endoh, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">995</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-175</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Repeated administration of μ-opioid receptor agonist, morphine induces tolerance not only to the antinociceptive effect but also to other pharmacol. effects, resulting in shortened working duration and decreased efficacy.  But less is known about κ-opioid agonist-induced tolerance.  The tolerance-development potency of κ-opioid receptor agonists with a focus on TRK-820 was characterized.  After five administrations of κ-opioid receptor agonists, TRK-820 (0.1 - 0.8 mg/kg), U-50488H (10 - 80 mg/kg) and ICI-199441 (0.025 - 0.2 mg/kg) s.c. over 3 days, tolerance to the antinociceptive effects, assessed by an acetic acid-induced abdominal constriction test, developed in a repeated dose-dependent manner.  The tolerance-development potency of TRK-820 was the least among these κ-opioid receptor agonists.  Similarly, TRK-820 and U-50488H induced tolerance to their sedative effects as judged by a wheel-running test in mice.  Greater tolerance was developed to the sedative effect than to the antinociceptive effect in both compds.  After repeated administration, the no. of κ-opioid receptors in the mouse brain was reduced by U-50488H (80 mg/kg) but not by TRK-820 (0.4 mg/kg).  There was no change of the affinity by the treatment with both compds.  These results demonstrated that the κ-opioid receptor agonists developed tolerance both to the antinociceptive and the sedative effects, though the tolerance to the sedative effect developed more readily than tolerance to the antinociceptive effect.  The difference in the potency for down-regulating the κ-opioid receptors in the brain may account for the tolerance-development potency of the compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvzd730_cPurVg90H21EOLACvtfcHk0ljdm0pMVqfQiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1Gktrc%253D&md5=7c0c3e01e44ca51bb2ac4972e1b10786</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2003.09.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2003.09.057%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DIzumimoto%26aufirst%3DN.%26aulast%3DTakezawa%26aufirst%3DY.%26aulast%3DFujimura%26aufirst%3DM.%26aulast%3DTogashi%26aufirst%3DY.%26aulast%3DNagase%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DEndoh%26aufirst%3DT.%26atitle%3DEffect%2520of%2520repeated%2520administration%2520of%2520TRK-820%252C%2520a%2520kappa-opioid%2520receptor%2520agonist%252C%2520on%2520tolerance%2520to%2520its%2520antinociceptive%2520and%2520sedative%2520actions%26jtitle%3DBrain%2520Res.%26date%3D2004%26volume%3D995%26spage%3D167%26epage%3D175%26doi%3D10.1016%2Fj.brainres.2003.09.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozono, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshitani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, R.</span></span> <span> </span><span class="NLM_article-title">Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch (R) capsules 2.5 mu g) in 3,762 hemodialysis patients with intractable pruritus</span>. <i>Int. J. Nephrol. Renovasc. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.2147/IJNRD.S145720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.2147%2FIJNRD.S145720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=29391822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Crtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=9-24&author=H.+Kozonoauthor=H.+Yoshitaniauthor=R.+Nakano&title=Post-marketing+surveillance+study+of+the+safety+and+efficacy+of+nalfurafine+hydrochloride+%28Remitch+%28R%29+capsules+2.5+mu+g%29+in+3%2C762+hemodialysis+patients+with+intractable+pruritus&doi=10.2147%2FIJNRD.S145720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch capsules 2.5 μg) in 3,762 hemodialysis patients with intractable pruritus</span></div><div class="casAuthors">Kozono, Hideki; Yoshitani, Hiroshi; Nakano, Ryoko</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nephrology and Renovascular Disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-24</span>CODEN:
                <span class="NLM_cas:coden">IJNRBW</span>;
        ISSN:<span class="NLM_cas:issn">1178-7058</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Intractable pruritus in hemodialysis patients can significantly decrease their quality of life and is also assocd. with poor vital prognosis.  Although combined multiple causes of intractable pruritus in these patients have been identified, no existing treatments are proven to be sufficiently effective.  We conducted a post-marketing surveillance to follow-up and assess the safety and efficacy of nalfurafine, a selective-opioid receptor agonist, for the treatment of intractable pruritus in patients undergoing hemodialysis.  Patients and methods: Hemodialysis patients with intractable pruritus from institutions in Japan who received oral nalfurafine hydrochloride between Jan. 2010 and Dec. 2013 were enrolled in the surveillance.  Surveillance was completed in July 2015.  Safety data during 1 yr after nalfurafine treatment onset, and efficacy data of nalfurafine evaluating the first 12-wk treatment period and the following period until 1 yr after the initial dose of nalfurafine (using global assessment of the itch improvement by the physician, Visual Analog Scale, and the Shiratori's severity scores) were collected and analyzed.  Results: In total, 3,762 patients were analyzed for safety.  Adverse drug reactions were experienced by 402/3,762 (10.69%) patients.  The most frequent adverse drug reactions were insomnia (127/3,762 [3.38%] patients), constipation (34 [0.90%]), somnolence (32 [0.85%]), dizziness (23 [0.61%]), nausea (13 [0.35%]), and malaise (9 [0.24%]).  No patients developed dependence on nalfurafine.  Nalfurafine was effective in 82.50% (2,880/3,491) of patients during the first 12 wk and in 84.95% (2,167/2,551) on treatment during the subsequent period until 1 yr after nalfurafine treatment initiation.  Statistically significant decreases were reported in the Visual Analog Scale and the Shiratori's severity scores (p = 0.001).  Conclusion: Oral nalfurafine hydrochloride (from 2.5 μg/day to a max. of 5.0 μg/day) continues to be safe and effective for the treatment of intractable pruritus in hemodialysis patients in real-world clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpk-a0x0gULrVg90H21EOLACvtfcHk0ljdm0pMVqfQiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Crtb%252FJ&md5=720d3fae7de92bad56e3bc991ee8f473</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2147%2FIJNRD.S145720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJNRD.S145720%26sid%3Dliteratum%253Aachs%26aulast%3DKozono%26aufirst%3DH.%26aulast%3DYoshitani%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DR.%26atitle%3DPost-marketing%2520surveillance%2520study%2520of%2520the%2520safety%2520and%2520efficacy%2520of%2520nalfurafine%2520hydrochloride%2520%2528Remitch%2520%2528R%2529%2520capsules%25202.5%2520mu%2520g%2529%2520in%25203%252C762%2520hemodialysis%2520patients%2520with%2520intractable%2520pruritus%26jtitle%3DInt.%2520J.%2520Nephrol.%2520Renovasc.%2520Dis.%26date%3D2018%26volume%3D11%26spage%3D9%26epage%3D24%26doi%3D10.2147%2FIJNRD.S145720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumagai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients</span>. <i>Am. J. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1159/000341268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1159%2F000341268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=22868684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KmsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=175-183&author=H.+Kumagaiauthor=T.+Ebataauthor=K.+Takamoriauthor=K.+Miyasatoauthor=T.+Muramatsuauthor=H.+Nakamotoauthor=M.+Kuriharaauthor=T.+Yanagitaauthor=H.+Suzuki&title=Efficacy+and+safety+of+a+novel+k-agonist+for+managing+intractable+pruritus+in+dialysis+patients&doi=10.1159%2F000341268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of a Novel κ-Agonist for Managing Intractable Pruritus in Dialysis Patients</span></div><div class="casAuthors">Kumagai, Hiroo; Ebata, Toshiya; Takamori, Kenji; Miyasato, Katsumasa; Muramatsu, Taro; Nakamoto, Hidetomo; Kurihara, Masanao; Yanagita, Tomoji; Suzuki, Hiromichi</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Nephrology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-183</span>CODEN:
                <span class="NLM_cas:coden">AJNED9</span>;
        ISSN:<span class="NLM_cas:issn">0250-8095</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Our previous placebo-controlled, prospective, double-blind study demonstrated that a new opioid κ-receptor agonist, nalfurafine hydrochloride, effectively reduced treatment-resistant pruritus in 337 hemodialysis patients.  Thus, we designed this study to evaluate prospectively the efficacy, safety, addiction liability, and pharmacokinetics of nalfurafine given orally for 1 yr.  Methods: This open-label study examd. the effects and adverse drug reactions (ADRs) of 52-wk oral administration of nalfurafine hydrochloride (5 μg/day) in 211 hemodialysis patients with a treatment-resistant itch.  Results: Of 211 patients, 145 completed the study as scheduled.  The mean pruritus value assessed by the visual analog scale was 75.2 mm during the pre-observation period, which decreased significantly to 50.9 and 30.9 mm in week 2 and 52, resp., indicating a long-lasting efficacy.  ADRs occurred in 103 patients (48.8%).  Frequent ADRs were insomnia (sleep disturbance, 19.4%), constipation (7.1%) and increased blood prolactin (3.3%), similar to previous reports.  Regarding addiction liability, it appeared unlikely that nalfurafine hydrochloride was abused.  After the start of treatment, plasma drug levels reached a steady state in week 2 with no apparent tendency of systemic accumulation.  Conclusions: Nalfurafine hydrochloride, orally administered at 5 μg/day for 52 wk to hemodialysis patients, produced a long-term suppression of pruritus without significant safety problems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0PURKsHap9LVg90H21EOLACvtfcHk0ljdm0pMVqfQiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KmsbvM&md5=7ecde41d3b88711f9130b167fb350c85</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1159%2F000341268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000341268%26sid%3Dliteratum%253Aachs%26aulast%3DKumagai%26aufirst%3DH.%26aulast%3DEbata%26aufirst%3DT.%26aulast%3DTakamori%26aufirst%3DK.%26aulast%3DMiyasato%26aufirst%3DK.%26aulast%3DMuramatsu%26aufirst%3DT.%26aulast%3DNakamoto%26aufirst%3DH.%26aulast%3DKurihara%26aufirst%3DM.%26aulast%3DYanagita%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DH.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520a%2520novel%2520k-agonist%2520for%2520managing%2520intractable%2520pruritus%2520in%2520dialysis%2520patients%26jtitle%3DAm.%2520J.%2520Nephrol.%26date%3D2012%26volume%3D36%26spage%3D175%26epage%3D183%26doi%3D10.1159%2F000341268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrom, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gellert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladefoged, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ide, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span> <span> </span><span class="NLM_article-title">Kappa-opioid system in uremic pruritus: Multicenter, randomized, double-blind, placebo-controlled clinical studies</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3742</span>– <span class="NLM_lpage">3747</span>, <span class="refDoi"> DOI: 10.1681/ASN.2005020152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1681%2FASN.2005020152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=16251241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADC%252BD2MnjtlCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=3742-3747&author=B.+Wikstromauthor=R.+Gellertauthor=S.+D.+Ladefogedauthor=Y.+Dandaauthor=M.+Akaiauthor=K.+Ideauthor=M.+Ogasawaraauthor=Y.+Kawashimaauthor=K.+Uenoauthor=A.+Moriauthor=Y.+Ueno&title=Kappa-opioid+system+in+uremic+pruritus%3A+Multicenter%2C+randomized%2C+double-blind%2C+placebo-controlled+clinical+studies&doi=10.1681%2FASN.2005020152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies</span></div><div class="casAuthors">Wikstrom Bjorn; Gellert Ryszard; Ladefoged Soren D; Danda Yasuaki; Akai Masahiko; Ide Kaoru; Ogasawara Midori; Kawashima Yoshiharu; Ueno Koki; Mori Akio; Ueno Yuji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology : JASN</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3742-7</span>
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    </div><div class="casAbstract">Uremic pruritus is a very common and frustrating condition for both patients and clinicians because no treatment has been demonstrated to be effective in relieving the itch.  In this report, nalfurafine, a new kappa-opioid receptor agonist, was used to treat uremic pruritus in patients who were undergoing routine hemodialysis.  Two multicenter, randomized, double-blind, placebo-controlled studies enrolled 144 patients with uremic pruritus to postdialysis intravenous treatment with either nalfurafine or placebo for 2 to 4 wk.  A meta-analysis approach was used to assess the efficacy of nalfurafine.  Statistically significant reductions in worst itching (P = 0.0212), itching intensity (P = 0.0410), and sleep disturbances (P = 0.0003) were noted in the nalfurafine group as compared with placebo.  Improvements in itching (P = 0.0025) and excoriations (P = 0.0060) were noted for the nalfurafine-treated patients.  Nalfurafine showed similar types and incidences of drug-related adverse events as did placebo.  Nalfurafine was shown to be an effective and safe compound for use in this severely ill patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8PRRh3zI6BxLDWw4HIq2sfW6udTcc2ea1_1KiFp08J7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnjtlCjtQ%253D%253D&md5=e4360617b3c4477bed75b44de0aed872</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1681%2FASN.2005020152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2005020152%26sid%3Dliteratum%253Aachs%26aulast%3DWikstrom%26aufirst%3DB.%26aulast%3DGellert%26aufirst%3DR.%26aulast%3DLadefoged%26aufirst%3DS.%2BD.%26aulast%3DDanda%26aufirst%3DY.%26aulast%3DAkai%26aufirst%3DM.%26aulast%3DIde%26aufirst%3DK.%26aulast%3DOgasawara%26aufirst%3DM.%26aulast%3DKawashima%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DUeno%26aufirst%3DY.%26atitle%3DKappa-opioid%2520system%2520in%2520uremic%2520pruritus%253A%2520Multicenter%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520clinical%2520studies%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2005%26volume%3D16%26spage%3D3742%26epage%3D3747%26doi%3D10.1681%2FASN.2005020152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schattauer, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhar, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavkin, C.</span></span> <span> </span><span class="NLM_article-title">Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2017.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.cellsig.2017.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=28088389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=59-65&author=S.+S.+Schattauerauthor=J.+R.+Kuharauthor=A.+Songauthor=C.+Chavkin&title=Nalfurafine+is+a+G-protein+biased+agonist+having+significantly+greater+bias+at+the+human+than+rodent+form+of+the+kappa+opioid+receptor&doi=10.1016%2Fj.cellsig.2017.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor</span></div><div class="casAuthors">Schattauer, Selena S.; Kuhar, Jamie R.; Song, Allisa; Chavkin, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-65</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Nalfurafine is a moderately selective kappa opioid receptor (KOR) analgesic with low incidence of dysphoric side effects in clin. development for the treatment of uremic pruritis.  The basis for its reduced dysphoric effect compared to other KOR agonists is not clear, but prior studies suggest that the aversive properties of KOR agonists require p38α MAPK activation through an arrestin-dependent mechanism.  To det. whether nalfurafine is a functionally selective KOR agonist, we measured its potency to activate the G protein-dependent early phase of Extracellular Signal-Regulated Kinase (ERK1/2) phosphorylation and the arrestin-dependent late phase of p38 MAPK signaling.  Nalfurafine was approx. 250 fold more potent for ERK1/2 activation as compared to p38 MAPK activation in human KOR (hKOR) expressing HEK293 cells, and approx. 20 fold more potent for ERK1/2 activation than p38 activation in rodent KOR (rKOR) expressing HEK293 cells.  The 10-fold greater G-bias at the hKOR than rKOR was unexpected, however the G protein biased effect of nalfurafine is consistent with its reduced dysphoric effects in human and rodent models.  Although nalfurafine is reported to have low receptor selectivity in radioligand binding assays, its antinociceptive effect was blocked by the selective KOR antagonist norbinaltorphimine.  Nalfurafine pretreatment also resulted in a KOR-dependent and mu opioid receptor-independent redn. in scratching induced by 5'-GNTI.  These findings suggest that nalfurafine is a functionally selective KOR agonist and that KOR agonists able to selectively activate G protein signaling without activating p38α MAPK may have therapeutic potential as non-dysphoric antipruritic analgesics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqJR2Iu_bivbVg90H21EOLACvtfcHk0lhAbxDurws6vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCrtL8%253D&md5=13799707352aa7133e92eff7e6f32b71</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2017.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2017.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DSchattauer%26aufirst%3DS.%2BS.%26aulast%3DKuhar%26aufirst%3DJ.%2BR.%26aulast%3DSong%26aufirst%3DA.%26aulast%3DChavkin%26aufirst%3DC.%26atitle%3DNalfurafine%2520is%2520a%2520G-protein%2520biased%2520agonist%2520having%2520significantly%2520greater%2520bias%2520at%2520the%2520human%2520than%2520rodent%2520form%2520of%2520the%2520kappa%2520opioid%2520receptor%26jtitle%3DCell.%2520Signalling%26date%3D2017%26volume%3D32%26spage%3D59%26epage%3D65%26doi%3D10.1016%2Fj.cellsig.2017.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehrich, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messinger, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knakal, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhar, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schattauer, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchas, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweifel, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, P. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavkin, C.</span></span> <span> </span><span class="NLM_article-title">Kappa opioid receptor-induced aversion requires p38 mapk activation in vta dopamine neurons</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">12917</span>– <span class="NLM_lpage">12931</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.2444-15.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1523%2FJNEUROSCI.2444-15.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=26377476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1yjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=12917-12931&author=J.+M.+Ehrichauthor=D.+I.+Messingerauthor=C.+R.+Knakalauthor=J.+R.+Kuharauthor=S.+S.+Schattauerauthor=M.+R.+Bruchasauthor=L.+S.+Zweifelauthor=B.+L.+Kiefferauthor=P.+E.+M.+Phillipsauthor=C.+Chavkin&title=Kappa+opioid+receptor-induced+aversion+requires+p38+mapk+activation+in+vta+dopamine+neurons&doi=10.1523%2FJNEUROSCI.2444-15.2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Kappa opioid receptor-induced aversion requires p38 MAPK activation in VTA dopamine neurons</span></div><div class="casAuthors">Ehrich, Jonathan M.; Messinger, Daniel I.; Knakal, Cerise R.; Kuhar, Jamie R.; Schattauer, Selena S.; Bruchas, Michael R.; Zweifel, Larry S.; Kieffer, Brigitte L.; Phillips, Paul E. M.; Chavkin, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">12917-12931</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The endogenous dynorphin-κ opioid receptor (KOR) system encodes the dysphoric component of the stress response and controls the risk of depression-like and addiction behaviors; however, the mol. and neural circuit mechanisms are not understood.  In this study, we report that KOR activation of p38α MAPK in ventral tegmental (VTA) dopaminergic neurons was required for conditioned place aversion (CPA) in mice.  Conditional genetic deletion of floxed KOR or floxed p38α MAPK by Cre recombinase expression in dopaminergic neurons blocked place aversion to the KOR agonist U50,488.  Selective viral rescue by wild-type KOR expression in dopaminergic neurons of KOR-/- mice restored U50,488-CPA, whereas expression of a mutated form of KOR that could not initiate p38α MAPK activation did not.  Surprisingly, while p38α MAPK inactivation blocked U50,488-CPA, p38α MAPK was not required for KOR inhibition of evoked dopamine release measured by fast scan cyclic voltammetry in the nucleus accumbens.  In contrast, KOR activation acutely inhibited VTA dopaminergic neuron firing, and repeated exposure attenuated the opioid response.  This adaptation to repeated exposure was blocked by conditional deletion of p38α MAPK, which also blocked KOR-induced tyrosine phosphorylation of the inwardly rectifying potassium channel (GIRK) subunit Kir3.1 in VTA dopaminergic neurons.  Consistent with the reduced response, GIRK phosphorylation at this amino terminal tyrosine residue (Y12) enhances channel deactivation.  Thus, contrary to prevailing expectations, these results suggest that κ opioid-induced aversion requires regulation of VTA dopaminergic neuron somatic excitability through a p38α MAPK effect on GIRK deactivation kinetics rather than by presynaptically inhibiting dopamine release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfHJ_3hcX-grVg90H21EOLACvtfcHk0lhAbxDurws6vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1yjs7c%253D&md5=2df9bcde190fbec2d09aa964de4cd17e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2444-15.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2444-15.2015%26sid%3Dliteratum%253Aachs%26aulast%3DEhrich%26aufirst%3DJ.%2BM.%26aulast%3DMessinger%26aufirst%3DD.%2BI.%26aulast%3DKnakal%26aufirst%3DC.%2BR.%26aulast%3DKuhar%26aufirst%3DJ.%2BR.%26aulast%3DSchattauer%26aufirst%3DS.%2BS.%26aulast%3DBruchas%26aufirst%3DM.%2BR.%26aulast%3DZweifel%26aufirst%3DL.%2BS.%26aulast%3DKieffer%26aufirst%3DB.%2BL.%26aulast%3DPhillips%26aufirst%3DP.%2BE.%2BM.%26aulast%3DChavkin%26aufirst%3DC.%26atitle%3DKappa%2520opioid%2520receptor-induced%2520aversion%2520requires%2520p38%2520mapk%2520activation%2520in%2520vta%2520dopamine%2520neurons%26jtitle%3DJ.%2520Neurosci.%26date%3D2015%26volume%3D35%26spage%3D12917%26epage%3D12931%26doi%3D10.1523%2FJNEUROSCI.2444-15.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brust, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenweck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarry, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aube, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">ra117</span>, <span class="refDoi"> DOI: 10.1126/scisignal.aai8441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1126%2Fscisignal.aai8441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=27899527" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=ra117&author=T.+F.+Brustauthor=J.+Morgenweckauthor=S.+A.+Kimauthor=J.+H.+Roseauthor=J.+L.+Lockeauthor=C.+L.+Schmidauthor=L.+Zhouauthor=E.+L.+Stahlauthor=M.+D.+Cameronauthor=S.+M.+Scarryauthor=J.+Aubeauthor=S.+R.+Jonesauthor=T.+J.+Martinauthor=L.+M.+Bohn&title=Biased+agonists+of+the+kappa+opioid+receptor+suppress+pain+and+itch+without+causing+sedation+or+dysphoria&doi=10.1126%2Fscisignal.aai8441"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aai8441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aai8441%26sid%3Dliteratum%253Aachs%26aulast%3DBrust%26aufirst%3DT.%2BF.%26aulast%3DMorgenweck%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BA.%26aulast%3DRose%26aufirst%3DJ.%2BH.%26aulast%3DLocke%26aufirst%3DJ.%2BL.%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DScarry%26aufirst%3DS.%2BM.%26aulast%3DAube%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DS.%2BR.%26aulast%3DMartin%26aufirst%3DT.%2BJ.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DBiased%2520agonists%2520of%2520the%2520kappa%2520opioid%2520receptor%2520suppress%2520pain%2520and%2520itch%2520without%2520causing%2520sedation%2520or%2520dysphoria%26jtitle%3DSci.%2520Signaling%26date%3D2016%26volume%3D9%26spage%3Dra117%26doi%3D10.1126%2Fscisignal.aai8441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiBerto, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polepally, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zjawiony, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malanga, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">The G protein-biased kappa-opioid receptor agonist rb-64 is analgesic with a unique spectrum of activities in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.216820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1124%2Fjpet.114.216820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=25320048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOlu7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=98-109&author=K.+L.+Whiteauthor=J.+E.+Robinsonauthor=H.+Zhuauthor=J.+F.+DiBertoauthor=P.+R.+Polepallyauthor=J.+K.+Zjawionyauthor=D.+E.+Nicholsauthor=C.+J.+Malangaauthor=B.+L.+Roth&title=The+G+protein-biased+kappa-opioid+receptor+agonist+rb-64+is+analgesic+with+a+unique+spectrum+of+activities+in+vivo&doi=10.1124%2Fjpet.114.216820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo</span></div><div class="casAuthors">White, Kate L.; Robinson, J. Elliott; Zhu, Hu; DiBerto, Jeffrey F.; Polepally, Prabhakar R.; Zjawiony, Jordan K.; Nichols, David E.; Malanga, C. J.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-109, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The hypothesis that functionally selective G protein-coupled receptor (GPCR) agonists may have enhanced therapeutic benefits has revitalized interest for many GPCR targets.  In particular, although κ-opioid receptor (KOR) agonists are analgesic with a low risk of dependence and abuse, their use is limited by a propensity to induce sedation, motor incoordination, hallucinations, and dysphoria-like states.  Several labs. have produced a body of work suggesting that G protein-biased KOR agonists might be analgesic with fewer side effects.  Although that has been an intriguing hypothesis, suitable KOR-selective and G protein-biased agonists have not been available to test this idea.  Here we provide data using a G protein-biased agonist, RB-64 (22-thiocyanatosalvinorin A), which suggests that KOR-mediated G protein signaling induces analgesia and aversion, whereas β-arrestin-2 signaling may be assocd. with motor incoordination.  Addnl., unlike unbiased KOR agonists, the G protein-biased ligand RB-64 does not induce sedation and does not have anhedonia-like actions, suggesting that a mechanism other than G protein signaling mediates these effects.  Our findings provide the first evidence for a highly selective and G protein-biased tool compd. for which many, but not all, of the neg. side effects of KOR agonists can be minimized by creating G protein-biased KOR agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGporsYw3knd37Vg90H21EOLACvtfcHk0lgwboqQi7QONQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOlu7bM&md5=686b5b718e2919aaf08e34855cc39ebf</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.216820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.216820%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DRobinson%26aufirst%3DJ.%2BE.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DDiBerto%26aufirst%3DJ.%2BF.%26aulast%3DPolepally%26aufirst%3DP.%2BR.%26aulast%3DZjawiony%26aufirst%3DJ.%2BK.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DMalanga%26aufirst%3DC.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DThe%2520G%2520protein-biased%2520kappa-opioid%2520receptor%2520agonist%2520rb-64%2520is%2520analgesic%2520with%2520a%2520unique%2520spectrum%2520of%2520activities%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D98%26epage%3D109%26doi%3D10.1124%2Fjpet.114.216820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazenka, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moerke, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span> <span> </span><span class="NLM_article-title">Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>235</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1007/s00213-017-4758-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1007%2Fs00213-017-4758-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=29063139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslShs73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2018&pages=203-213&author=M.+L.+Lazenkaauthor=M.+J.+Moerkeauthor=E.+A.+Townsendauthor=K.+B.+Freemanauthor=F.+I.+Carrollauthor=S.+S.+Negus&title=Dissociable+effects+of+the+kappa+opioid+receptor+agonist+nalfurafine+on+pain%2Fitch-stimulated+and+pain%2Fitch-depressed+behaviors+in+male+rats&doi=10.1007%2Fs00213-017-4758-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats</span></div><div class="casAuthors">Lazenka, Matthew L.; Moerke, Megan J.; Townsend, E. Andrew; Freeman, Kevin B.; Carroll, F. Ivy; Negus, S. Stevens</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">203-213</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Nalfurafine is a G protein signaling-biased kappa opioid receptor (KOR) agonist approved in Japan for second-line treatment of uremic pruritus.  Neither nalfurafine nor any other KOR agonist is currently approved anywhere for treatment of pain, but recent evidence suggests that G protein signaling-biased KOR agonists may have promise as candidate analgesics/antipruritics with reduced side effects compared to nonbiased or ss-arrestin-signaling-biased KOR agonists.  Objectives: This study compared nalfurafine effects in rats using assays of pain-stimulated and pain-depressed behavior used previously to evaluate other candidate analgesics.  Nalfurafine effects were also examd. in complementary assays of itch-stimulated and itch-depressed behavior.  Methods: I.p. lactic acid (IP acid) and intradermal serotonin (ID 5HT) served as noxious and pruritic stimuli, resp., in male Sprague Dawley rats to stimulate stretching (IP acid) or scratching (ID 5HT) or to depress pos. reinforced operant responding in an assay of intracranial self-stimulation (ICSS; both stimuli).  Results: Nalfurafine was equipotent to decrease IP acid-stimulated stretching and ID 5HT-stimulated scratching; however, doses of nalfurafine that decreased these pain/itch-stimulated behaviors also decreased control ICSS performance.  Moreover, nalfurafine failed to alleviate either IP acid- or ID 5HT-induced depression of ICSS.  Conclusions: These results suggest that nalfurafine-induced decreases in pain/itch-stimulated behaviors may reflect nonselective decreases in motivated behavior rather than analgesia or antipruritus against the noxious and pruritic stimuli used here.  This conclusion agrees with the absence of clin. data for nalfurafine analgesia and the weak clin. data for nalfurafine antipruritus.  Nalfurafine bias for G protein signaling may not be sufficient for clin. safe and reliable analgesia or antipruritus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEkm4nAMagerVg90H21EOLACvtfcHk0lgwboqQi7QONQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslShs73K&md5=13f9d2d5f4340b136971eb1bc2bbfc5e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs00213-017-4758-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-017-4758-7%26sid%3Dliteratum%253Aachs%26aulast%3DLazenka%26aufirst%3DM.%2BL.%26aulast%3DMoerke%26aufirst%3DM.%2BJ.%26aulast%3DTownsend%26aufirst%3DE.%2BA.%26aulast%3DFreeman%26aufirst%3DK.%2BB.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DNegus%26aufirst%3DS.%2BS.%26atitle%3DDissociable%2520effects%2520of%2520the%2520kappa%2520opioid%2520receptor%2520agonist%2520nalfurafine%2520on%2520pain%252Fitch-stimulated%2520and%2520pain%252Fitch-depressed%2520behaviors%2520in%2520male%2520rats%26jtitle%3DPsychopharmacology%26date%3D2018%26volume%3D235%26spage%3D203%26epage%3D213%26doi%3D10.1007%2Fs00213-017-4758-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Machelska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celik, M. O.</span></span> <span> </span><span class="NLM_article-title">Advances in achieving opioid analgesia without side effects</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1388</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.3389%2Ffphar.2018.01388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=30555325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGmurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1388&author=H.+Machelskaauthor=M.+O.+Celik&title=Advances+in+achieving+opioid+analgesia+without+side+effects&doi=10.3389%2Ffphar.2018.01388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in achieving opioid analgesia without side effects</span></div><div class="casAuthors">Machelska, Halina; Celik, Melih O.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1388</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Opioids are the most effective drugs for the treatment of severe pain, but they also cause addiction and overdose deaths, which have led to a worldwide opioid crisis.  Therefore, the development of safer opioids is urgently needed.  In this article, we provide a crit. overview of emerging opioid-based strategies aimed at effective pain relief and improved side effect profiles.  These approaches comprise biased agonism, the targeting of (i) opioid receptors in peripheral inflamed tissue (by reducing agonist access to the brain, the use of nanocarriers, or low pH-sensitive agonists); (ii) heteromers or multiple receptors (by monovalent, bivalent, and multifunctional ligands); (iii) receptor splice variants; and (iv) endogenous opioid peptides (by preventing their degrdn. or enhancing their prodn. by gene transfer).  Substantial advancements are underscored by pharmaceutical development of new opioids such as peripheral κ-receptor agonists, and by treatments augmenting the action of endogenous opioids, which have entered clin. trials.  Addnl., there are several promising novel opioids comprehensively examd. in preclin. studies, but also strategies such as biased agonism, which might require careful rethinking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfgv-LX7fUPbVg90H21EOLACvtfcHk0ljOw0g7HB0Vvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGmurjM&md5=fa4937fcdbc17a3590623c4368fded38</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01388%26sid%3Dliteratum%253Aachs%26aulast%3DMachelska%26aufirst%3DH.%26aulast%3DCelik%26aufirst%3DM.%2BO.%26atitle%3DAdvances%2520in%2520achieving%2520opioid%2520analgesia%2520without%2520side%2520effects%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1388%26doi%3D10.3389%2Ffphar.2018.01388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMattio, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muschamp, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Chen, L. Y.</span></span> <span> </span><span class="NLM_article-title">Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in kappa opioid aversion</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0155-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1038%2Fs41386-018-0155-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=30082888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGrs7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=939-949&author=J.+J.+Liuauthor=Y.+T.+Chiuauthor=K.+M.+DiMattioauthor=C.+Chenauthor=P.+Huangauthor=T.+A.+Gentileauthor=J.+W.+Muschampauthor=A.+Cowanauthor=M.+Mannauthor=L.+Y.+Liu-Chen&title=Phosphoproteomic+approach+for+agonist-specific+signaling+in+mouse+brains%3A+mTOR+pathway+is+involved+in+kappa+opioid+aversion&doi=10.1038%2Fs41386-018-0155-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion</span></div><div class="casAuthors">Liu, Jeffrey J.; Chiu, Yi-Ting; DiMattio, Kelly M.; Chen, Chongguang; Huang, Peng; Gentile, Taylor A.; Muschamp, John W.; Cowan, Alan; Mann, Matthias; Liu-Chen, Lee-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">939-949</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Kappa opioid receptor (KOR) agonists produce analgesic and anti-pruritic effects, but their clin. application was limited by dysphoria and hallucinations.  Nalfurafine, a clin. used KOR agonist, does not cause dysphoria or hallucinations at therapeutic doses in humans.  We found that in CD-1 mice nalfurafine produced analgesic and anti-scratch effects dose-dependently, like the prototypic KOR agonist U50,488H.  In contrast, unlike U50,488H, nalfurafine caused no aversion, anhedonia, or sedation or and a low level of motor incoordination at the effective analgesia and anti-scratch doses.  Thus, we established a mouse model that recapitulated important aspects of the clin. observations.  We then employed a phosphoproteomics approach to investigate mechanisms underlying differential KOR-mediated effects.  A large-scale mass spectrometry (MS)-based anal. on brains revealed that nalfurafine perturbed phosphoproteomes differently from U50,488H in a brain-region specific manner after 30-min treatment.  In particular, U50,488H and nalfurafine imparted phosphorylation changes to proteins found in different cellular components or signaling pathways in different brain regions.  Notably, we obsd. that U50,488H, but not nalfurafine, activated the mammalian target of rapamycin (mTOR) pathway in the striatum and cortex.  Inhibition of the mTOR pathway by rapamycin abolished U50,488H-induced aversion, without affecting analgesic, anti-scratch, and sedative effects and motor incoordination.  The results indicate that the mTOR pathway is involved in KOR agonist-induced aversion.  This is the first demonstration that phosphoproteomics can be applied to agonist-specific signaling of G protein-coupled receptors (GPCRs) in mouse brains to unravel pharmacol. important pathways.  Furthermore, this is one of the first two reports that the mTOR pathway mediates aversion caused by KOR activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWThicLA_aOLVg90H21EOLACvtfcHk0ljOw0g7HB0Vvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGrs7fJ&md5=1321e5b38ad0626c6f47291c69eb887d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0155-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0155-0%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DChiu%26aufirst%3DY.%2BT.%26aulast%3DDiMattio%26aufirst%3DK.%2BM.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DGentile%26aufirst%3DT.%2BA.%26aulast%3DMuschamp%26aufirst%3DJ.%2BW.%26aulast%3DCowan%26aufirst%3DA.%26aulast%3DMann%26aufirst%3DM.%26aulast%3DLiu-Chen%26aufirst%3DL.%2BY.%26atitle%3DPhosphoproteomic%2520approach%2520for%2520agonist-specific%2520signaling%2520in%2520mouse%2520brains%253A%2520mTOR%2520pathway%2520is%2520involved%2520in%2520kappa%2520opioid%2520aversion%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D939%26epage%3D949%26doi%3D10.1038%2Fs41386-018-0155-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagumo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of new opioid derivatives with a propellane skeleton and their pharmacologies: Part 5, novel pentacyclic propellane derivatives with a 6-amide side chain</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6271</span>– <span class="NLM_lpage">6279</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.08.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.bmc.2015.08.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=26346669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKgs7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=6271-6279&author=R.+Nakajimaauthor=N.+Yamamotoauthor=S.+Hirayamaauthor=T.+Iwaiauthor=A.+Saitohauthor=Y.+Nagumoauthor=H.+Fujiiauthor=H.+Nagase&title=Synthesis+of+new+opioid+derivatives+with+a+propellane+skeleton+and+their+pharmacologies%3A+Part+5%2C+novel+pentacyclic+propellane+derivatives+with+a+6-amide+side+chain&doi=10.1016%2Fj.bmc.2015.08.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of new opioid derivatives with a propellane skeleton and their pharmacologies: Part 5, novel pentacyclic propellane derivatives with a 6-amide side chain</span></div><div class="casAuthors">Nakajima, Ryo; Yamamoto, Naoshi; Hirayama, Shigeto; Iwai, Takashi; Saitoh, Akiyoshi; Nagumo, Yasuyuki; Fujii, Hideaki; Nagase, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6271-6279</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We designed and synthesized pentacyclic propellane derivs. with a 6-amide side chain to afford compds. with higher MOR/KOR ratio and lower sedative effects than nalfurafine.  The obtained etheno-bridged deriv. with a β-amide side chain, YNT-854, I, showed a higher MOR/KOR ratio than nalfurafine.  YNT-854 also exhibited a higher dose ratio between the sedative effect and the analgesic effect than obsd. with nalfurafine, which may guide the future design of useful analgesics with a weaker sedative effect than nalfurafine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou-WPvCktkO7Vg90H21EOLACvtfcHk0ljOw0g7HB0Vvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKgs7jL&md5=04f13c622c8006bb3c7a147773a0a0b7</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.08.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.08.036%26sid%3Dliteratum%253Aachs%26aulast%3DNakajima%26aufirst%3DR.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DHirayama%26aufirst%3DS.%26aulast%3DIwai%26aufirst%3DT.%26aulast%3DSaitoh%26aufirst%3DA.%26aulast%3DNagumo%26aufirst%3DY.%26aulast%3DFujii%26aufirst%3DH.%26aulast%3DNagase%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520new%2520opioid%2520derivatives%2520with%2520a%2520propellane%2520skeleton%2520and%2520their%2520pharmacologies%253A%2520Part%25205%252C%2520novel%2520pentacyclic%2520propellane%2520derivatives%2520with%2520a%25206-amide%2520side%2520chain%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D6271%26epage%3D6279%26doi%3D10.1016%2Fj.bmc.2015.08.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzgrabe, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Chen, L. Y.</span></span> <span> </span><span class="NLM_article-title">Comparison of pharmacological activities of three distinct kappa ligands (salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>312</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1124/jpet.104.073668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1124%2Fjpet.104.073668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=15383632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2005&pages=220-230&author=Y.+Wangauthor=K.+Tangauthor=S.+Inanauthor=D.+Siebertauthor=U.+Holzgrabeauthor=D.+Y.+W.+Leeauthor=P.+Huangauthor=J.+G.+Liauthor=A.+Cowanauthor=L.+Y.+Liu-Chen&title=Comparison+of+pharmacological+activities+of+three+distinct+kappa+ligands+%28salvinorin+A%2C+TRK-820+and+3FLB%29+on+kappa+opioid+receptors+in+vitro+and+their+antipruritic+and+antinociceptive+activities+in+vivo&doi=10.1124%2Fjpet.104.073668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of pharmacological activities of three distinct κ ligands (salvinorin A, TRK-820 and 3FLB) on κ opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo</span></div><div class="casAuthors">Wang, Yulin; Tang, Kang; Inan, Saadet; Siebert, Daniel; Holzgrabe, Ulrike; Lee, David Y. W.; Huang, Peng; Li, Jian-Guo; Cowan, Alan; Liu-Chen, Lee-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">220-230</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Salvinorin A, TRK-820 (17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[N-methyl-trans-3-(3-furyl) acrylamido]morphinan hydrochloride), and 3FLB (di-Et 2,4-di-[3-fluorophenyl]-3,7-dimethyl-3,7-diazabicyclo[3.3.1]nonane-9-one-1,5-dicarboxylate) are structurally distinctly different from U50,488H [(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide methanesulfonate], the prototypic selective κ agonist.  Here, we investigated their in vitro pharmacol. activities on receptors expressed in Chinese hamster ovary cells and in vivo antiscratch and antinociceptive activities in mice.  All three compds. showed high selectivity for the κ opioid receptor(KOR) over the μ opioid receptor (MOR) and the δ opioid receptor (DOR) and nociceptin or FQ receptors.  The rank order of affinity and potency for the KOR was TRK-820 >> U50,488H ∼ salvinorin A >> 3FLB.  TRK-820 acted as a partial agonist on MOR and DOR, whereas salvinorin A and 3FLB showed no activities on these receptors.  Salvinorin A, TRK-820, and 3FLB caused internalization of the human KOR in a dose-dependent manner.  Interestingly, although salvinorin A and U50,488H had similar potencies in stimulating [35S]GTPγS binding, salvinorin A was about 40-fold less potent than U50,488H in promoting internalization.  Following 4-h incubation, all three compds. induced down-regulation of the human KOR, with salvinorin A causing a lower extent of down-regulation.  Although TRK-820 was potent and efficacious against compd. 48/80-induced scratching, salvinorin A showed low and inconsistent effects, and 3FLB was inactive.  In addn., salvinorin A and 3FLB were not active in the acetic acid abdominal constriction test.  The discrepancy between in vitro and in vivo results may be due to in vivo metab. of salvinorin A and 3FLB and possibly to their effects on other pharmacol. targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiXgeaprA53bVg90H21EOLACvtfcHk0ljZaRNoZ7UAcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWmtLY%253D&md5=dbcdfc075b1ea9120f31a3c33e27a73f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.073668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.073668%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DInan%26aufirst%3DS.%26aulast%3DSiebert%26aufirst%3DD.%26aulast%3DHolzgrabe%26aufirst%3DU.%26aulast%3DLee%26aufirst%3DD.%2BY.%2BW.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DJ.%2BG.%26aulast%3DCowan%26aufirst%3DA.%26aulast%3DLiu-Chen%26aufirst%3DL.%2BY.%26atitle%3DComparison%2520of%2520pharmacological%2520activities%2520of%2520three%2520distinct%2520kappa%2520ligands%2520%2528salvinorin%2520A%252C%2520TRK-820%2520and%25203FLB%2529%2520on%2520kappa%2520opioid%2520receptors%2520in%2520vitro%2520and%2520their%2520antipruritic%2520and%2520antinociceptive%2520activities%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D312%26spage%3D220%26epage%3D230%26doi%3D10.1124%2Fjpet.104.073668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipkowski, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span> <span> </span><span class="NLM_article-title">Peptides as receptor selectivity modulators of opiate pharmacophores</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1222</span>– <span class="NLM_lpage">1225</span>, <span class="refDoi"> DOI: 10.1021/jm00157a018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00157a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaL28Xkt1ClsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1986&pages=1222-1225&author=A.+W.+Lipkowskiauthor=S.+W.+Tamauthor=P.+S.+Portoghese&title=Peptides+as+receptor+selectivity+modulators+of+opiate+pharmacophores&doi=10.1021%2Fjm00157a018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Peptides as receptor selectivity modulators of opiate pharmacophores</span></div><div class="casAuthors">Lipkowski, A. W.; Tam, S. W.; Portoghese, P. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1222-5</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Alkaloid-peptide hybrids I (R = Me, CH2CHMe2; R1 = OH, Arg-Arg-Ile-OMe) were prepd. by condensing oxymorphone (II, R = Me) or naltrexone (II, R = CH2CHMe2) with the corresponding H2NNHCO-Phe-Leu-R1.  Binding data for the μ, κ, and δ receptors indicated that the peptide portions of I can modulate the receptor selectivity of the attached alkaloid pharmacophores.  The selectivity for different opioid receptor types depends on a balance between the affinities of the message and address components.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtAn0uoT7wvLVg90H21EOLACvtfcHk0ljZaRNoZ7UAcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xkt1ClsLw%253D&md5=a790a403e7c33bbed9672f2f41da0655</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm00157a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00157a018%26sid%3Dliteratum%253Aachs%26aulast%3DLipkowski%26aufirst%3DA.%2BW.%26aulast%3DTam%26aufirst%3DS.%2BW.%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26atitle%3DPeptides%2520as%2520receptor%2520selectivity%2520modulators%2520of%2520opiate%2520pharmacophores%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1986%26volume%3D29%26spage%3D1222%26epage%3D1225%26doi%3D10.1021%2Fjm00157a018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span> <span> </span><span class="NLM_article-title">Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">230</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1016/0165-6147(89)90267-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2F0165-6147%2889%2990267-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=2549665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaL1MXkslSisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1989&pages=230-235&author=P.+S.+Portoghese&title=Bivalent+ligands+and+the+message-address+concept+in+the+design+of+selective+opioid+receptor+antagonists&doi=10.1016%2F0165-6147%2889%2990267-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists</span></div><div class="casAuthors">Portoghese, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">230-5</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    </div><div class="casAbstract">A review with 28 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-9nTE5zu1TrVg90H21EOLACvtfcHk0ljZaRNoZ7UAcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkslSisLk%253D&md5=68867543a80132745af447156d16decd</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2F0165-6147%2889%2990267-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-6147%252889%252990267-8%26sid%3Dliteratum%253Aachs%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26atitle%3DBivalent%2520ligands%2520and%2520the%2520message-address%2520concept%2520in%2520the%2520design%2520of%2520selective%2520opioid%2520receptor%2520antagonists%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1989%26volume%3D10%26spage%3D230%26epage%3D235%26doi%3D10.1016%2F0165-6147%2889%2990267-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemori, A. E.</span></span> <span> </span><span class="NLM_article-title">Design of peptidomimetic delta-opioid receptor antagonists using the message address concept</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1714</span>– <span class="NLM_lpage">1720</span>, <span class="refDoi"> DOI: 10.1021/jm00168a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00168a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaK3cXitlGlt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1990&pages=1714-1720&author=P.+S.+Portogheseauthor=M.+Sultanaauthor=A.+E.+Takemori&title=Design+of+peptidomimetic+delta-opioid+receptor+antagonists+using+the+message+address+concept&doi=10.1021%2Fjm00168a028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Design of peptidomimetic δ opioid receptor antagonists using the message-address concept</span></div><div class="casAuthors">Portoghese, P. S.; Sultana, M.; Takemori, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1714-20</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Highly selective nonpeptide ligands with potent δ opioid receptor antagonist activity have been developed using the message-address concept.  This approach envisaged the δ opioid receptor to contain two major recognition subsites; a message subsite which recognizes the pharmacophore and an address subsite that is unique for the δ receptor type and confers selectivity.  The message and address components of the δ-selective enkephalins were postulated to be Tyr1 and Phe4, resp., with Gly2-Gly3 functioning as a spacer.  The message component of the target compds. in this study was derived from naltrexone and related structures.  An indole system was fused to the C ring of naltrexone as a mimic of the address component.  The benzene moiety of indole was viewed as the δ address component, mimicking the Ph group of Phe4, and the pyrrole portion was used as a rigid spacer.  Members of the series were evaluated for opioid antagonist activity on the guinea pig ileum (GPI) and mouse vas deferens (MVD) prepns.  Naltrindole (I), was the most potent member of the series, with Ke values of ∼0.1 nM at δ receptors.  The antagonism by I was ∼200- and 350-fold greater at δ than at μ and κ opioid receptors.  The binding of I and selected members of the series to guinea pig brain membranes was qual. consistent with their pharmacol. antagonist activity profiles in the MVD and GPI, but the Ki values were not in the same rank order.  The selectivity of I arises mainly as a consequence of increased affinity at δ receptors.  Thus, the Ke and Ki values of I were 1/530 and 1/90 that of the δ antagonist enkephalin analog, ICI 174864.  In contrast to I, ICII74864 derives its selectivity through greatly decreased recognition at μ and κ receptors.  The implications of the high affinity and selectivity of I as a consequence of its conformational rigidity are discussed.  It is suggested that any attempt to model a receptor-bound conformation of an opoid peptide should consider affinity and potency at multiple receptor sites rather than selectivity alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohWBYkojIb-rVg90H21EOLACvtfcHk0lgAts44IoMtig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXitlGlt7c%253D&md5=a7324b930ba1ba211b637011d193842e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm00168a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00168a028%26sid%3Dliteratum%253Aachs%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26aulast%3DSultana%26aufirst%3DM.%26aulast%3DTakemori%26aufirst%3DA.%2BE.%26atitle%3DDesign%2520of%2520peptidomimetic%2520delta-opioid%2520receptor%2520antagonists%2520using%2520the%2520message%2520address%2520concept%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1990%26volume%3D33%26spage%3D1714%26epage%3D1720%26doi%3D10.1021%2Fjm00168a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booe, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pioszak, A. A.</span></span> <span> </span><span class="NLM_article-title">Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>763</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2015.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.ejphar.2015.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=25981303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVCmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=763&publication_year=2015&pages=196-205&author=S.+M.+Leeauthor=J.+M.+Booeauthor=A.+A.+Pioszak&title=Structural+insights+into+ligand+recognition+and+selectivity+for+classes+A%2C+B%2C+and+C+GPCRs&doi=10.1016%2Fj.ejphar.2015.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs</span></div><div class="casAuthors">Lee, Sang-Min; Booe, Jason M.; Pioszak, Augen A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">763</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">196-205</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The G protein-coupled receptor (GPCR) superfamily constitutes the largest collection of cell surface signaling proteins with approx. 800 members in the human genome.  GPCRs regulate virtually all aspects of physiol. and they are an important class of drug targets with ∼30% of drugs on the market targeting a GPCR.  Breakthroughs in GPCR structural biol. in recent years have significantly expanded our understanding of GPCR structure and function and ushered in a new era of structure-based drug design for GPCRs.  Crystal structures for nearly thirty distinct GPCRs are now available including receptors from each of the major classes, A, B, C, and F.  These structures provide a foundation for understanding the mol. basis of GPCR pharmacol.  Here, we review structural mechanisms of ligand recognition and selectivity of GPCRs with a focus on selected examples from classes A, B, and C, and we highlight major unresolved questions for future structural studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSMQ9_F1VXv7Vg90H21EOLACvtfcHk0lgAts44IoMtig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVCmsb0%253D&md5=13f6fd00a674a1020f7bfff75383b598</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BM.%26aulast%3DBooe%26aufirst%3DJ.%2BM.%26aulast%3DPioszak%26aufirst%3DA.%2BA.%26atitle%3DStructural%2520insights%2520into%2520ligand%2520recognition%2520and%2520selectivity%2520for%2520classes%2520A%252C%2520B%252C%2520and%2520C%2520GPCRs%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D763%26spage%3D196%26epage%3D205%26doi%3D10.1016%2Fj.ejphar.2015.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective agonists of delta opioid receptor by revisiting the “message-address” concept</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00423</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00423" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVWmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=391-396&author=Q.+Shenauthor=Y.+Y.+Qianauthor=X.+Q.+Huangauthor=X.+J.+Xuauthor=W.+Liauthor=J.+G.+Liuauthor=W.+Fu&title=Discovery+of+potent+and+selective+agonists+of+delta+opioid+receptor+by+revisiting+the+%E2%80%9Cmessage-address%E2%80%9D+concept&doi=10.1021%2Facsmedchemlett.5b00423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Agonists of δ Opioid Receptor by Revisiting the "Message-Address" Concept</span></div><div class="casAuthors">Shen, Qing; Qian, Yuanyuan; Huang, Xiaoqin; Xu, Xuejun; Li, Wei; Liu, Jinggen; Fu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">391-396</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The classic "message-address" concept was proposed to address the binding of endogenous peptides to the opioid receptors and was later successfully applied in the discovery of the first nonpeptide δ opioid receptor (DOR) antagonist naltrindole.  By revisiting this concept, and based on the structure of tramadol, we designed a series of novel compds. that act as highly potent and selective agonists of DOR among which (-)-6j showed the highest affinity (Ki = 2.7 nM), best agonistic activity (EC50 = 2.6 nM), and DOR selectivity (more than 1000-fold over the other two subtype opioid receptors).  Mol. docking studies suggest that the "message" part of (-)-6j interacts with residue Asp1283.32 and a neighboring water mol., and the "address" part of (-)-6j packs with hydrophobic residues Leu3007.35, Val2816.55, and Trp2846.58, rendering DOR selectivity.  The discovery of novel compd. (-)-6j, and the obtained insights into DOR-agonist binding will help us design more potent and selective DOR agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv4N8pD5ZxP7Vg90H21EOLACvtfcHk0lgAts44IoMtig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVWmt7c%253D&md5=063d1423e11044bdf5a3110fef777414</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00423%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DQian%26aufirst%3DY.%2BY.%26aulast%3DHuang%26aufirst%3DX.%2BQ.%26aulast%3DXu%26aufirst%3DX.%2BJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26aulast%3DFu%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520agonists%2520of%2520delta%2520opioid%2520receptor%2520by%2520revisiting%2520the%2520%25E2%2580%259Cmessage-address%25E2%2580%259D%2520concept%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D391%26epage%3D396%26doi%3D10.1021%2Facsmedchemlett.5b00423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, B.</span></span> <span> </span><span class="NLM_article-title">Novel analgesics and molecular rearrangements in the morphine-thebaine group. II. Alcohols derived from 6,14-endo-etheno- and 6,14-endo-ethanotetrahydrothebaine</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">3273</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1021/ja00989a031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00989a031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaF2sXksVeqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1967&pages=3273-80&author=K.+W.+Bentleyauthor=D.+G.+Hardyauthor=B.+Meek&title=Novel+analgesics+and+molecular+rearrangements+in+the+morphine-thebaine+group.+II.+Alcohols+derived+from+6%2C14-endo-etheno-+and+6%2C14-endo-ethanotetrahydrothebaine&doi=10.1021%2Fja00989a031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Novel analgesics and molecular rearrangements in the morphine-thebaine group.  II.  Alcohols derived from 6,14-endo-etheno- and 6,14-endo-ethanotetrahydrothebaine</span></div><div class="casAuthors">Bentley, Kenneth W.; Hardy, Denis G.; Meek, B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3273-80</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">cf. preceding abstr.  Series of secondary and tertiary alcs. have been prepd. by the redn. and reaction with Grignard reagents of the aldehyde I (R = H), the ketones I (R = Me, Et, Pr, and Ph), and their 6,14-ethano analogs.  The stereospecificity of the reactions is explained.  In this way analgesics of very high potency, up to 500 times that of morphine, have been obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq38eDsi98AmbVg90H21EOLACvtfcHk0li3_lkEVeY0ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXksVeqtL4%253D&md5=bee6c4d32f6a39db0540abe452dc08b0</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fja00989a031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00989a031%26sid%3Dliteratum%253Aachs%26aulast%3DBentley%26aufirst%3DK.%2BW.%26aulast%3DHardy%26aufirst%3DD.%2BG.%26aulast%3DMeek%26aufirst%3DB.%26atitle%3DNovel%2520analgesics%2520and%2520molecular%2520rearrangements%2520in%2520the%2520morphine-thebaine%2520group.%2520II.%2520Alcohols%2520derived%2520from%25206%252C14-endo-etheno-%2520and%25206%252C14-endo-ethanotetrahydrothebaine%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1967%26volume%3D89%26spage%3D3273%26epage%3D80%26doi%3D10.1021%2Fja00989a031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, D. G.</span></span> <span> </span><span class="NLM_article-title">Novel analgesics and molecular rearrangements in the morphine-thebaine group. I. Ketones derived from 6,14-endo-ethenotetrahydrothebaine</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">3267</span>– <span class="NLM_lpage">3273</span>, <span class="refDoi"> DOI: 10.1021/ja00989a030</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00989a030" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaF2sXksVeqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1967&pages=3267-3273&author=K.+W.+Bentleyauthor=D.+G.+Hardy&title=Novel+analgesics+and+molecular+rearrangements+in+the+morphine-thebaine+group.+I.+Ketones+derived+from+6%2C14-endo-ethenotetrahydrothebaine&doi=10.1021%2Fja00989a030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Novel analgesics and molecular rearrangements in the morphine-thebaine group.  I..  Ketones derived from 6,14-endo-ethenotetrahydrothebaine</span></div><div class="casAuthors">Bentley, Kenneth W.; Hardy, Denis G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3267-73</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">Several ketones (I R = COR1) derived from 6,14-endo-ethenotetrahydrothebaine have been prepd. by the Diels-Alder addn. of certain α,β-unsatd. ketones to thebaine, by the action of alkylcadmiums on the corresponding acid chloride (I, R = COCl), and, in some cases, by the action of Grignard reagents on the corresponding ester (I, R = CO2Et) which is the adduct of thebaine and ethyl acrylate.  Both 7α and 7β forms of the ketone (I, R = COMe), the ester (I, R = CO2Et), and the nitrile (I, R = CN) have been isolated.  Attempts to convert the 7α ketone (I, R = COMe) into the 7β isomer have resulted only in the formation of a ketol. (I, R = CRR1OH).  Many of the bases prepd. in this work are potent analgesics.  The reaction product obtained from thebaine methiodide and p-benzoquinone has been shown to be a charge-transfer complex and not a true Diels-Alder adduct.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcbd3y3ByDJrVg90H21EOLACvtfcHk0li3_lkEVeY0ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXksVeqt7c%253D&md5=196adf934afce85fdeb4adef562d1a03</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fja00989a030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00989a030%26sid%3Dliteratum%253Aachs%26aulast%3DBentley%26aufirst%3DK.%2BW.%26aulast%3DHardy%26aufirst%3DD.%2BG.%26atitle%3DNovel%2520analgesics%2520and%2520molecular%2520rearrangements%2520in%2520the%2520morphine-thebaine%2520group.%2520I.%2520Ketones%2520derived%2520from%25206%252C14-endo-ethenotetrahydrothebaine%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1967%26volume%3D89%26spage%3D3267%26epage%3D3273%26doi%3D10.1021%2Fja00989a030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cami-Kobeci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khroyan, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span> <span> </span><span class="NLM_article-title">Structural determinants of opioid and nop receptor activity in derivatives of buprenorphine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6531</span>– <span class="NLM_lpage">6537</span>, <span class="refDoi"> DOI: 10.1021/jm2003238</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2003238" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCgs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6531-6537&author=G.+Cami-Kobeciauthor=W.+E.+Polgarauthor=T.+V.+Khroyanauthor=L.+Tollauthor=S.+M.+Husbands&title=Structural+determinants+of+opioid+and+nop+receptor+activity+in+derivatives+of+buprenorphine&doi=10.1021%2Fjm2003238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Determinants of Opioid and NOP Receptor Activity in Derivatives of Buprenorphine</span></div><div class="casAuthors">Cami-Kobeci, Gerta; Polgar, Willma E.; Khroyan, Taline V.; Toll, Lawrence; Husbands, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6531-6537</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The unique pharmacol. profile of buprenorphine has led to its considerable success as an analgesic and as a treatment agent for drug abuse.  Activation of nociceptin/orphanin FQ peptide (NOP) receptors has been postulated to account for certain aspects of buprenorphine's behavioral profile.  In order to investigate the role of NOP activation further, a series of buprenorphine analogs has been synthesized with the aim of increasing affinity for the NOP receptor.  Binding and functional assay data on these new compds. indicate that the area around C20 in the orvinols is key to NOP receptor activity, with several compds. displaying higher affinity than buprenorphine.  One compd. was found to be a mu opioid receptor partial agonist of comparable efficacy to buprenorphine but with higher efficacy at NOP receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUcbMYUdEuarVg90H21EOLACvtfcHk0li3_lkEVeY0ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCgs7zN&md5=9e26145810991dca7f2b224326ac6d51</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm2003238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2003238%26sid%3Dliteratum%253Aachs%26aulast%3DCami-Kobeci%26aufirst%3DG.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DKhroyan%26aufirst%3DT.%2BV.%26aulast%3DToll%26aufirst%3DL.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26atitle%3DStructural%2520determinants%2520of%2520opioid%2520and%2520nop%2520receptor%2520activity%2520in%2520derivatives%2520of%2520buprenorphine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6531%26epage%3D6537%26doi%3D10.1021%2Fjm2003238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rennison, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cami-Kobeci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aceto, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Bermejo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span> <span> </span><span class="NLM_article-title">Cinnamoyl derivatives of 7 alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7 alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5176</span>– <span class="NLM_lpage">5182</span>, <span class="refDoi"> DOI: 10.1021/jm070255o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070255o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVKmsbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5176-5182&author=D.+Rennisonauthor=A.+P.+Nealauthor=G.+Cami-Kobeciauthor=M.+D.+Acetoauthor=F.+Martinez-Bermejoauthor=J.+W.+Lewisauthor=S.+M.+Husbands&title=Cinnamoyl+derivatives+of+7+alpha-aminomethyl-6%2C14-endo-ethanotetrahydrothebaine+and+7+alpha-aminomethyl-6%2C14-endo-ethanotetrahydrooripavine+and+related+opioid+ligands&doi=10.1021%2Fjm070255o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Cinnamoyl Derivatives of 7α-Aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7α-Aminomethyl-6,14-endo-ethanotetrahydrooripavine and Related Opioid Ligands</span></div><div class="casAuthors">Rennison, David; Neal, Adrian P.; Cami-Kobeci, Gerta; Aceto, Mario D.; Martinez-Bermejo, Fernando; Lewis, John W.; Husbands, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5176-5182</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of ligands (e.g. I) has been synthesized where the cinnamoyl group of the 14-cinnamoylamino morphinones has been introduced to the 7α-substituent of the 6,14-bridged oripavine series.  In vitro the compds. were mostly low efficacy partial agonists or antagonists with some selectivity for the mu opioid receptor, with evidence of mu efficacy in vivo.  The similarity in SAR between these 6,14-bridged oripavines and the 14-cinnamoylamino series suggests a similar mode of interaction with the mu opioid receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgIRwHOKf3qrVg90H21EOLACvtfcHk0li2wwE937xBkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVKmsbnP&md5=dc15fa09ae860dd3b1202a35f677f52b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm070255o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070255o%26sid%3Dliteratum%253Aachs%26aulast%3DRennison%26aufirst%3DD.%26aulast%3DNeal%26aufirst%3DA.%2BP.%26aulast%3DCami-Kobeci%26aufirst%3DG.%26aulast%3DAceto%26aufirst%3DM.%2BD.%26aulast%3DMartinez-Bermejo%26aufirst%3DF.%26aulast%3DLewis%26aufirst%3DJ.%2BW.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26atitle%3DCinnamoyl%2520derivatives%2520of%25207%2520alpha-aminomethyl-6%252C14-endo-ethanotetrahydrothebaine%2520and%25207%2520alpha-aminomethyl-6%252C14-endo-ethanotetrahydrooripavine%2520and%2520related%2520opioid%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5176%26epage%3D5182%26doi%3D10.1021%2Fjm070255o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span> <span> </span><span class="NLM_article-title">The orvinols and related opioids - high affinity ligands with diverse efficacy profiles</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.2174/1381612043453027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.2174%2F1381612043453027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=15032698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFOktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=717-732&author=J.+W.+Lewisauthor=S.+M.+Husbands&title=The+orvinols+and+related+opioids+-+high+affinity+ligands+with+diverse+efficacy+profiles&doi=10.2174%2F1381612043453027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The orvinols and related opioids - high affinity ligands with diverse efficacy profiles</span></div><div class="casAuthors">Lewis, John W.; Husbands, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">717-732</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The thevinols and orvinols derived from thebaine via the thebaine-methylvinyl ketone adduct (thevinone) were thoroughly investigated in the 1960's and 1970's by the Reckitt group.  From this work a no. of important opioids emerged.  Buprenorphine is a μ partial agonist, κ/δ-antagonist that is now used primarily in the treatment of heroin abuse and dependence though it was initially launched as an analgesic for the treatment of moderate to severe pain.  Etorphine and dihydroetorphine are very potent μ agonists that have found application in veterinary and human medicine resp.  Diprenorphine is primarily a μ antagonist though it also has some κ-partial agonist effects.  It has high affinity for all types of opioid receptors and as a "universal" opioid ligand has been much in demand as a pharmacol. tool.  It has also been converted into a [11C] version for use in Positron Emission Tomog. (PET) studies of brain function related to the opioid receptor system.  More recent medicinal chem. investigations have been concerned with gaining a greater understanding of buprenorphine's unique opioid profile.  This has involved the synthesis and evaluation of a no. of series of buprenorphine analogs in which the C20 t-Bu group has been constrained in a ring system.  These studies have suggested that the methyls in the t-Bu group inhibit the conformational changes in the κ-receptor required for generation of an agonist response.  Introduction of a 7α-cinnamoylaminomethyl group in place of the orvinol tertiary alc. function leads to selective irreversible μ antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPp0SG7a80_bVg90H21EOLACvtfcHk0li2wwE937xBkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFOktbk%253D&md5=62cd0ff1388a60a28a096692dd81c65c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2174%2F1381612043453027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612043453027%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DJ.%2BW.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26atitle%3DThe%2520orvinols%2520and%2520related%2520opioids%2520-%2520high%2520affinity%2520ligands%2520with%2520diverse%2520efficacy%2520profiles%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2004%26volume%3D10%26spage%3D717%26epage%3D732%26doi%3D10.2174%2F1381612043453027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cueva, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostovar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillhouse, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span> <span> </span><span class="NLM_article-title">C7 beta-methyl analogues of the orvinols: The discovery of kappa opioid antagonists with nociceptin/orphanin fq peptide (nop) receptor partial agonism and low, or zero, efficacy at mu opioid receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4242</span>– <span class="NLM_lpage">4249</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00130</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00130" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOgs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4242-4249&author=J.+P.+Cuevaauthor=C.+Rocheauthor=M.+Ostovarauthor=V.+Kumarauthor=M.+J.+Clarkauthor=T.+M.+Hillhouseauthor=J.+W.+Lewisauthor=J.+R.+Traynorauthor=S.+M.+Husbands&title=C7+beta-methyl+analogues+of+the+orvinols%3A+The+discovery+of+kappa+opioid+antagonists+with+nociceptin%2Forphanin+fq+peptide+%28nop%29+receptor+partial+agonism+and+low%2C+or+zero%2C+efficacy+at+mu+opioid+receptors&doi=10.1021%2Facs.jmedchem.5b00130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">C7β-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors</span></div><div class="casAuthors">Cueva, Juan Pablo; Roche, Christopher; Ostovar, Mehrnoosh; Kumar, Vinod; Clark, Mary J.; Hillhouse, Todd M.; Lewis, John W.; Traynor, John R.; Husbands, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4242-4249</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Buprenorphine is a successful analgesic and treatment for opioid abuse, with both activities relying on its partial agonist activity at mu opioid receptors.  However, there is substantial interest in its activities at the kappa opioid and nociceptin/orphanin FQ peptide receptors.  This has led to an interest in developing compds. with a buprenorphine-like pharmacol. profile but with lower efficacy at mu opioid receptors.  The present article describes aryl ring analogs of buprenorphine in which the std. C20-Me group has been moved to the C7β position, resulting in ligands with the desired profile.  In particular, moving the Me group has resulted in far more robust kappa opioid antagonist activity than seen in the std. orvinol series.  Of the compds. synthesized, a no., including 15a, have a profile of interest for the development of drug abuse relapse prevention therapies or antidepressants and others (e.g., 8c), as analgesics with a reduced side-effect profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprr8LGYf3Q2LVg90H21EOLACvtfcHk0li2wwE937xBkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOgs74%253D&md5=d9f187a092da6f0d92bfd38f8e50907a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00130%26sid%3Dliteratum%253Aachs%26aulast%3DCueva%26aufirst%3DJ.%2BP.%26aulast%3DRoche%26aufirst%3DC.%26aulast%3DOstovar%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DHillhouse%26aufirst%3DT.%2BM.%26aulast%3DLewis%26aufirst%3DJ.%2BW.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26atitle%3DC7%2520beta-methyl%2520analogues%2520of%2520the%2520orvinols%253A%2520The%2520discovery%2520of%2520kappa%2520opioid%2520antagonists%2520with%2520nociceptin%252Forphanin%2520fq%2520peptide%2520%2528nop%2529%2520receptor%2520partial%2520agonism%2520and%2520low%252C%2520or%2520zero%252C%2520efficacy%2520at%2520mu%2520opioid%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4242%26epage%3D4249%26doi%3D10.1021%2Facs.jmedchem.5b00130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridzwan, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grivas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meurice, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Gomez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogozheva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span> <span> </span><span class="NLM_article-title">Selectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4049</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1021/jm401964y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401964y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvVSqurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4049-57&author=V.+Kumarauthor=I.+E.+Ridzwanauthor=K.+Grivasauthor=J.+W.+Lewisauthor=M.+J.+Clarkauthor=C.+Meuriceauthor=C.+Jimenez-Gomezauthor=I.+Pogozhevaauthor=H.+Mosbergauthor=J.+R.+Traynorauthor=S.+M.+Husbands&title=Selectively+promiscuous+opioid+ligands%3A+discovery+of+high+affinity%2Flow+efficacy+opioid+ligands+with+substantial+nociceptin+opioid+peptide+receptor+affinity&doi=10.1021%2Fjm401964y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Selectively Promiscuous Opioid Ligands: Discovery of High Affinity/Low Efficacy Opioid Ligands with Substantial Nociceptin Opioid Peptide Receptor Affinity</span></div><div class="casAuthors">Kumar, Vinod; Ridzwan, Irna E.; Grivas, Konstantinos; Lewis, John W.; Clark, Mary J.; Meurice, Claire; Jimenez-Gomez, Corina; Pogozheva, Irina; Mosberg, Henry; Traynor, John R.; Husbands, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4049-4057</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Emerging clin. and preclin. evidence suggests that a compd. displaying high affinity for μ, κ, and δ opioid (MOP, KOP, and DOP) receptors and antagonist activity at each, coupled with moderate affinity and efficacy at nociceptin opioid peptide (NOP) receptors will have utility as a relapse prevention agent for multiple types of drug abuse.  Members of the orvinol family of opioid ligands have the desired affinity profile but have typically displayed substantial efficacy at MOP and or KOP receptors.  In this study, it is shown that a Ph ring analog I of buprenorphine displays the desired profile in vitro with high, nonselective affinity for the MOP, KOP, and DOP receptors coupled with moderate affinity for NOP receptors.  In vivo, I lacked any opioid agonist activity and was an antagonist of both the MOP receptor agonist morphine and the KOP receptor agonist ethylketocyclazocine, confirming the desired opioid receptor profile in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE3lUSsfYUTbVg90H21EOLACvtfcHk0li_3Jg4YJaPFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvVSqurc%253D&md5=7b21d7a9d02fb270941934ec78cc6211</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm401964y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401964y%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DRidzwan%26aufirst%3DI.%2BE.%26aulast%3DGrivas%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DJ.%2BW.%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DMeurice%26aufirst%3DC.%26aulast%3DJimenez-Gomez%26aufirst%3DC.%26aulast%3DPogozheva%26aufirst%3DI.%26aulast%3DMosberg%26aufirst%3DH.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26atitle%3DSelectively%2520promiscuous%2520opioid%2520ligands%253A%2520discovery%2520of%2520high%2520affinity%252Flow%2520efficacy%2520opioid%2520ligands%2520with%2520substantial%2520nociceptin%2520opioid%2520peptide%2520receptor%2520affinity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4049%26epage%3D57%26doi%3D10.1021%2Fjm401964y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greedy, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grivas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cami-Kobeci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archambeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aceto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span> <span> </span><span class="NLM_article-title">Orvinols with mixed kappa/mu opioid receptor agonist activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3207</span>– <span class="NLM_lpage">3216</span>, <span class="refDoi"> DOI: 10.1021/jm301543e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301543e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVWrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3207-3216&author=B.+M.+Greedyauthor=F.+Bradburyauthor=M.+P.+Thomasauthor=K.+Grivasauthor=G.+Cami-Kobeciauthor=A.+Archambeauauthor=K.+Bosseauthor=M.+J.+Clarkauthor=M.+Acetoauthor=J.+W.+Lewisauthor=J.+R.+Traynorauthor=S.+M.+Husbands&title=Orvinols+with+mixed+kappa%2Fmu+opioid+receptor+agonist+activity&doi=10.1021%2Fjm301543e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Orvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity</span></div><div class="casAuthors">Greedy, Benjamin M.; Bradbury, Faye; Thomas, Mark P.; Grivas, Konstantinos; Cami-Kobeci, Gerta; Archambeau, Ashley; Bosse, Kelly; Clark, Mary J.; Aceto, Mario; Lewis, John W.; Traynor, John R.; Husbands, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3207-3216</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual-acting kappa opioid receptor (KOR) agonist and mu opioid receptor (MOR) partial agonist ligands have been put forward as potential treatment agents for cocaine and other psychostimulant abuse.  Members of the orvinol series of ligands are known for their high binding affinity to both KOR and MOR, but efficacy at the individual receptors has not been thoroughly evaluated.  In this study, it is shown that a predictive model for efficacy at KOR can be derived, with efficacy being controlled by the length of the group attached to C20 and by the introduction of branching into the side chain.  In vivo evaluation of two ligands with the desired in vitro profile confirms both display KOR, and to a lesser extent MOR, activity in an analgesic assay suggesting that, in this series, in vitro measures of efficacy using the [35S]GTPγS assay are predictive of the in vivo profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJpdjCZTQt5bVg90H21EOLACvtfcHk0li_3Jg4YJaPFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVWrtbo%253D&md5=d692909a8c772cfa79f3c9697a9c64d1</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm301543e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301543e%26sid%3Dliteratum%253Aachs%26aulast%3DGreedy%26aufirst%3DB.%2BM.%26aulast%3DBradbury%26aufirst%3DF.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DGrivas%26aufirst%3DK.%26aulast%3DCami-Kobeci%26aufirst%3DG.%26aulast%3DArchambeau%26aufirst%3DA.%26aulast%3DBosse%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DAceto%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DJ.%2BW.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26atitle%3DOrvinols%2520with%2520mixed%2520kappa%252Fmu%2520opioid%2520receptor%2520agonist%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3207%26epage%3D3216%26doi%3D10.1021%2Fjm301543e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z. B.</span></span> <span> </span><span class="NLM_article-title">Molecular modeling and 3D-QSAR studies of indolomorphinan derivatives as kappa opioid antagonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">610</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.08.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.bmc.2005.08.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=16202615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSiurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=601-610&author=W.+Liauthor=Y.+Tangauthor=Y.+L.+Zhengauthor=Z.+B.+Qiu&title=Molecular+modeling+and+3D-QSAR+studies+of+indolomorphinan+derivatives+as+kappa+opioid+antagonists&doi=10.1016%2Fj.bmc.2005.08.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular modeling and 3D-QSAR studies of indolomorphinan derivatives as kappa opioid antagonists</span></div><div class="casAuthors">Li, Wei; Tang, Yun; Zheng, You-Li; Qiu, Zhui-Bai</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">601-610</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mol. modeling and 3D-QSAR studies were performed on 31 indolomorphinan derivs. to evaluate their antagonistic behaviors on κ opioid receptor and provide information for further modification of this kind of compds.  Best predictions were obtained with Co-MFA std. model (q2 = 0.693, N = 4, r2 = 0.900) and Co-MSIA combined model (q2 = 0.617, N = 4, r2 = 0.904).  Both models were further validated by an external test set of eight compds. with satisfactory predictions: r2 = 0.607 for Co-MFA and r2 = 0.701 for Co-MSIA.  In addn., the 3D structure of human κ opioid receptor was constructed based on the crystal structure of bovine rhodopsin, and the Co-MSIA contour plots were then mapped into the structural model of κ opioid receptor-GNTI complex to identify key residues, which might account for κ antagonist potency and selectivity.  The roles of nonconserved Glu297 and conserved Lys227 of human κ opioid receptor were then discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN1bM5dsQic7Vg90H21EOLACvtfcHk0li_3Jg4YJaPFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSiurjJ&md5=123c4e72e3b04c2b6c6ffa941c881d3c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.08.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.08.052%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%2BL.%26aulast%3DQiu%26aufirst%3DZ.%2BB.%26atitle%3DMolecular%2520modeling%2520and%25203D-QSAR%2520studies%2520of%2520indolomorphinan%2520derivatives%2520as%2520kappa%2520opioid%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D601%26epage%3D610%26doi%3D10.1016%2Fj.bmc.2005.08.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z. B.</span></span> <span> </span><span class="NLM_article-title">3D-QSAR studies of orvinol analogs as kappa-opioid agonists</span>. <i>J. Mol. Model.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">877</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1007/s00894-005-0084-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1007%2Fs00894-005-0084-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=16552460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFOitL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=877-884&author=W.+Liauthor=Y.+Tangauthor=Q.+Xieauthor=W.+Shengauthor=Z.+B.+Qiu&title=3D-QSAR+studies+of+orvinol+analogs+as+kappa-opioid+agonists&doi=10.1007%2Fs00894-005-0084-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">3D-QSAR studies of orvinol analogs as k-opioid agonists</span></div><div class="casAuthors">Li, Wei; Tang, Yun; Xie, Qiong; Sheng, Wei; Qiu, Zhui-Bai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">877-884</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Orvinols are potent analgesics that target opioid receptors.  However, their analgesic mechanism remains unclear and no significant preference for subtype opioid receptor has been achieved.  In order to find new orvinols that target the κ-receptor, comparative 3D-QSAR studies were performed on 26 orvinol analogs using comparative mol. field anal. (CoMFA) and comparative mol. similarity indexes anal. (CoMSIA).  The best predictions for the κ-receptor were obtained with the CoMFA std. model (q2 = 0.686, r2 = 0.947) and CoMSIA model combined steric, electrostatic, hydrophobic, and hydrogen bond donor/acceptor fields (q2 = 0.678, r2 = 0.914).  The models built were further validated by a test set made up of seven compds., leading to predictive r2 values of 0.672 for CoMFA and 0.593 for CoMSIA.  The study could be helpful for designing and prep. new category κ-agonists from orvinols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkhQlsRNUmb7Vg90H21EOLACvtfcHk0lh8dc4JeQih6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFOitL7E&md5=faedd2cf3e677636c06bb08fff098d91</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1007%2Fs00894-005-0084-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-005-0084-9%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DSheng%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DZ.%2BB.%26atitle%3D3D-QSAR%2520studies%2520of%2520orvinol%2520analogs%2520as%2520kappa-opioid%2520agonists%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2006%26volume%3D12%26spage%3D877%26epage%3D884%26doi%3D10.1007%2Fs00894-005-0084-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span> <span> </span><span class="NLM_article-title">The pharmacological heterogeneity of nepenthone analogs in conferring highly selective and potent kappa-opioid agonistic activities</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">766</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.6b00321</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00321" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFOhur7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=766-776&author=W.+Liauthor=J.+D.+Longauthor=Y.+Y.+Qianauthor=Y.+Longauthor=X.+J.+Xuauthor=Y.+J.+Wangauthor=Q.+Shenauthor=Z.+N.+Wangauthor=X.+C.+Yangauthor=L.+Xiaoauthor=H.+P.+Sunauthor=Y.+L.+Xuauthor=Y.+Y.+Chenauthor=Q.+Xieauthor=Y.+H.+Wangauthor=L.+M.+Shaoauthor=J.+G.+Liuauthor=Z.+B.+Qiuauthor=W.+Fu&title=The+pharmacological+heterogeneity+of+nepenthone+analogs+in+conferring+highly+selective+and+potent+kappa-opioid+agonistic+activities&doi=10.1021%2Facschemneuro.6b00321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The Pharmacological Heterogeneity of Nepenthone Analogs in Conferring Highly Selective and Potent κ-Opioid Agonistic Activities</span></div><div class="casAuthors">Li, Wei; Long, Jian-Dong; Qian, Yuan-Yuan; Long, Yu; Xu, Xue-Jun; Wang, Yu-Jun; Shen, Qing; Wang, Zuo-Neng; Yang, Xi-Cheng; Xiao, Li; Sun, Hong-Peng; Xu, Yu-Long; Chen, Yi-Yi; Xie, Qiong; Wang, Yong-Hui; Shao, Li-Ming; Liu, Jing-Gen; Qiu, Zhui-Bai; Fu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">766-776</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To develop novel analgesics with no or less side effects than that of traditional opioids is highly demanded to treat opioid receptors mediated pain and addiction issues.  Recently, Κ-opioid receptor (KOR) is established as an attractive target, although its selective agonists could bear heterogeneous pharmacol. activities.  In this study, the authors designed and synthesized two new series of nepenthone derivs. by inserting a spacer (carbonyl) between 6α,14α-endo-ethenyl-thebaine and the 7α-Ph substitution of the skeleton, and by substituting the 17-N-Me group with a cyclopropylmethyl group.  The authors performed in vitro tests (binding and functional assays) and mol. docking operations on the newly designed compds.  The results of wet-exptl. measures and modeled binding structures demonstrate that these new compds. are selective KOR agonists with nM level affinities.  Compd. I from these new derivs., showed highest affinity (Ki= 0.4±0.1) and the highest selectivity (μ/Κ = 339, δ/Κ = 2034) toward KOR.  The in vivo tests turned out that I is able to induce stronger (ED50=2.1 mg/kg) and much longer antinociceptive effect than that of the typical KOR agonist U50488H (ED50=4.4 mg/kg).  Therefore, I can be used as a perfect lead compd. for future design of potent analgesics acting through KOR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlKbYO9zcko7Vg90H21EOLACvtfcHk0lh8dc4JeQih6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFOhur7P&md5=6615861546def0ec4e3cf217598a0faa</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00321%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLong%26aufirst%3DJ.%2BD.%26aulast%3DQian%26aufirst%3DY.%2BY.%26aulast%3DLong%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%2BJ.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DZ.%2BN.%26aulast%3DYang%26aufirst%3DX.%2BC.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DH.%2BP.%26aulast%3DXu%26aufirst%3DY.%2BL.%26aulast%3DChen%26aufirst%3DY.%2BY.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DY.%2BH.%26aulast%3DShao%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26aulast%3DQiu%26aufirst%3DZ.%2BB.%26aulast%3DFu%26aufirst%3DW.%26atitle%3DThe%2520pharmacological%2520heterogeneity%2520of%2520nepenthone%2520analogs%2520in%2520conferring%2520highly%2520selective%2520and%2520potent%2520kappa-opioid%2520agonistic%2520activities%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D766%26epage%3D776%26doi%3D10.1021%2Facschemneuro.6b00321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span> <span> </span><span class="NLM_article-title">Highly selective and potent mu opioid ligands by unexpected substituent on morphine skeleton</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.07.119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.bmcl.2009.07.119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=19932964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=418-421&author=W.+Liauthor=Y.+M.+Taoauthor=Y.+Tangauthor=X.+J.+Xuauthor=J.+Chenauthor=W.+Fuauthor=X.+H.+Wangauthor=B.+Chaoauthor=W.+Shengauthor=Q.+Xieauthor=Z.+B.+Qiuauthor=J.+G.+Liu&title=Highly+selective+and+potent+mu+opioid+ligands+by+unexpected+substituent+on+morphine+skeleton&doi=10.1016%2Fj.bmcl.2009.07.119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Highly selective and potent μ opioid ligands by unexpected substituent on morphine skeleton</span></div><div class="casAuthors">Li, Wei; Tao, Yi-Min; Tang, Yun; Xu, Xue-Jun; Chen, Jie; Fu, Wei; Wang, Xing-Hai; Chao, Bo; Sheng, Wei; Xie, Qiong; Qiu, Zhui-Bai; Liu, Jing-Gen</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">418-421</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Unexpected substituent on the well-known morphine skeleton is described to be account for highly selective and potent μ opioid ligands, which is strongly connected to substituted arom. groups on this omitted 8α-position.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-ZI8MAPqpcrVg90H21EOLACvtfcHk0lh8dc4JeQih6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsbvK&md5=240bb32466701c8f776b878d0e031ac8</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.07.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.07.119%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DTao%26aufirst%3DY.%2BM.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%2BH.%26aulast%3DChao%26aufirst%3DB.%26aulast%3DSheng%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DQiu%26aufirst%3DZ.%2BB.%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26atitle%3DHighly%2520selective%2520and%2520potent%2520mu%2520opioid%2520ligands%2520by%2520unexpected%2520substituent%2520on%2520morphine%2520skeleton%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D418%26epage%3D421%26doi%3D10.1016%2Fj.bmcl.2009.07.119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Z.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of kappa-opioid receptor agonistic activity and antinociceptive effect of novel morphine analogues, 7 alpha-phenyl-6 alpha,14 alpha-endo-etheno-tetrahydrothebaine with substituted o-, m- and p-amino group</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1364</span>– <span class="NLM_lpage">1370</span>, <span class="refDoi"> DOI: 10.1007/s00044-010-9471-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1007%2Fs00044-010-9471-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWqtbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1364-1370&author=H.+Qiauthor=W.+Liauthor=Y.+Qiuauthor=Y.+Y.+Cuiauthor=J.+Maauthor=X.+L.+Gaoauthor=Y.+B.+Zengauthor=J.+Yangauthor=Y.+Tangauthor=X.+H.+Wangauthor=W.+Shengauthor=Q.+Xieauthor=J.+G.+Liuauthor=Z.+B.+Qiuauthor=H.+Z.+Chen&title=Synthesis+and+evaluation+of+kappa-opioid+receptor+agonistic+activity+and+antinociceptive+effect+of+novel+morphine+analogues%2C+7+alpha-phenyl-6+alpha%2C14+alpha-endo-etheno-tetrahydrothebaine+with+substituted+o-%2C+m-+and+p-amino+group&doi=10.1007%2Fs00044-010-9471-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of κ-opioid receptor agonistic activity and antinociceptive effect of novel morphine analogues, 7α-phenyl-6α,14α-endo-etheno-tetrahydrothebaine with substituted o-, m- and p-amino group</span></div><div class="casAuthors">Qi, Hong; Li, Wei; Qiu, Yu; Cui, Yong-yao; Ma, Jian; Gao, Xiao-ling; Zeng, Yi-bin; Yang, Jie; Tang, Yun; Wang, Xing-hai; Sheng, Wei; Xie, Qiong; Liu, Jing-geng; Qiu, Zhui-bai; Chen, Hong-zhuan</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1364-1370</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Boston</span>)
        </div><div class="casAbstract">7α-Phenyl-6α,14α-endo-etheno-tetrahydrothebaine I (R7 = Ph) is an analog of morphine but with much weaker affinity and efficacy to opioid receptors.  Three compds. I (R7 = C6H4-2-NH2, -3-NH2, -4-NH2) with o-, m- and p-amino substitution on its 7α-Ph group were designed and synthesized to evaluate their κ-opioid receptor agonistic activity and antinociceptive effect.  The introduction of amino group greatly increased the binding activity to κ-opioid receptor but only compd. with p-substitution showed agonistic activity with potency similar to the marketed κ agonist butorphanol.  In vivo antinociceptive test showed that compd. with p-amino substitution displayed highest antinociceptive activity while compds. with o-, m-amino substitution showed partial or little analgesia effects.  All these data indicate that p-amino substitution conferred κ agonist activity, suggesting that 7α-phenyl-6α,14α-endo-etheno-tetrahydrothebaines with a p-amino substitution may contain a novel pharmacophore component and could be considered as a leading compd. for novel antinociceptive agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWuEmPNKtEs7Vg90H21EOLACvtfcHk0lgJkPHdig39cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWqtbbN&md5=e678f3346e414c7dcd066e063d4f3ec8</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1007%2Fs00044-010-9471-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-010-9471-6%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DY.%2BY.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DX.%2BL.%26aulast%3DZeng%26aufirst%3DY.%2BB.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%2BH.%26aulast%3DSheng%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26aulast%3DQiu%26aufirst%3DZ.%2BB.%26aulast%3DChen%26aufirst%3DH.%2BZ.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520kappa-opioid%2520receptor%2520agonistic%2520activity%2520and%2520antinociceptive%2520effect%2520of%2520novel%2520morphine%2520analogues%252C%25207%2520alpha-phenyl-6%2520alpha%252C14%2520alpha-endo-etheno-tetrahydrothebaine%2520with%2520substituted%2520o-%252C%2520m-%2520and%2520p-amino%2520group%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2011%26volume%3D20%26spage%3D1364%26epage%3D1370%26doi%3D10.1007%2Fs00044-010-9471-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span> <span> </span><span class="NLM_article-title">Synthesis of the new thebaine derivatives by the Diels-Alder reaction with northebaine</span>. <i>J. Korean Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">376</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1988&pages=371-376&author=K.+Kimauthor=K.+Kim&title=Synthesis+of+the+new+thebaine+derivatives+by+the+Diels-Alder+reaction+with+northebaine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DK.%26atitle%3DSynthesis%2520of%2520the%2520new%2520thebaine%2520derivatives%2520by%2520the%2520Diels-Alder%2520reaction%2520with%2520northebaine%26jtitle%3DJ.%2520Korean%2520Chem.%2520Soc.%26date%3D1988%26volume%3D32%26spage%3D371%26epage%3D376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, D. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L. M.</span></span> <span> </span><span class="NLM_article-title">7 beta-Methyl substituent is a structural locus associated with activity cliff for nepenthone analogues</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4254</span>– <span class="NLM_lpage">4263</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.bmc.2018.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=30054192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyrtb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4254-4263&author=H.+J.+Sunauthor=Y.+H.+Wangauthor=C.+M.+Yuanauthor=L.+H.+Kongauthor=X.+J.+Xuauthor=Y.+J.+Wangauthor=H.+H.+Wuauthor=C.+Linauthor=Y.+Y.+Qianauthor=H.+M.+Huangauthor=L.+Xiaoauthor=X.+Liuauthor=Q.+Heauthor=S.+Y.+Fangauthor=D.+Q.+Xueauthor=X.+C.+Yangauthor=H.+Chenauthor=Y.+L.+Zhengauthor=L.+Zhengauthor=L.+Q.+Yuauthor=Q.+Xieauthor=W.+Fuauthor=W.+Liauthor=J.+G.+Liuauthor=Z.+B.+Qiuauthor=L.+M.+Shao&title=7+beta-Methyl+substituent+is+a+structural+locus+associated+with+activity+cliff+for+nepenthone+analogues&doi=10.1016%2Fj.bmc.2018.07.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">7β-Methyl substituent is a structural locus associated with activity cliff for nepenthone analogues</span></div><div class="casAuthors">Sun, Hui-jiao; Wang, Yu-hua; Yuan, Cong-min; Kong, Ling-hui; Xu, Xue-jun; Wang, Yu-jun; Wu, Hai-hao; Lin, Cheng; Qian, Yuan-yuan; Huang, Huo-ming; Xiao, Li; Liu, Xiao; He, Qian; Fang, Sheng-yang; Xue, Deng-qi; Yang, Xi-cheng; Chen, Hao; Zheng, Yi-lin; Zheng, Lan; Yu, Lin-qian; Xie, Qiong; Fu, Wei; Li, Wei; Liu, Jing-gen; Qiu, Zhui-bai; Shao, Li-ming</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4254-4263</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">With the purpose of identifying novel selective κ opioid receptor (KOR) antagonists as potential antidepressants from nepenthone analogs, starting from N-nor-N-cyclopropylmethyl-nepenthone (SLL-020ACP), a highly selective and potent KOR agonist, a series of 7β-methyl-nepenthone analogs was conceived, synthesized and assayed on opioid receptors based on the concept of hybridization.  According to the pharmacol. results, the functional reversal obsd. in orvinol analogs by introduction of 7β-Me substituent could not be reproduced in nepenthone analogs.  Alternatively, introduction of 7β-Me substituent was assocd. with substantial loss of both subtype selectivity and potency but not efficacy for nepenthone analogs, which was not found in 7β-Me orvinol analogs.  Surprisingly, SLL-603, a 7β-Me analog of SLL-020ACP, was identified to be a KOR full agonist.  The possible mol. mechanism for the heterogeneity in activity cliff was also investigated.  In conclusion, 7β-Me substituent was a structural locus assocd. with activity cliff and demonstrated as a pharmacol. heterogeneity between nepenthone and orvinol analogs that warrants further investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_xJC73BwHSbVg90H21EOLACvtfcHk0lgJkPHdig39cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyrtb7F&md5=13b41b5e44064960740f550d85650fe5</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%2BJ.%26aulast%3DWang%26aufirst%3DY.%2BH.%26aulast%3DYuan%26aufirst%3DC.%2BM.%26aulast%3DKong%26aufirst%3DL.%2BH.%26aulast%3DXu%26aufirst%3DX.%2BJ.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DWu%26aufirst%3DH.%2BH.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DQian%26aufirst%3DY.%2BY.%26aulast%3DHuang%26aufirst%3DH.%2BM.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DFang%26aufirst%3DS.%2BY.%26aulast%3DXue%26aufirst%3DD.%2BQ.%26aulast%3DYang%26aufirst%3DX.%2BC.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DY.%2BL.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DL.%2BQ.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26aulast%3DQiu%26aufirst%3DZ.%2BB.%26aulast%3DShao%26aufirst%3DL.%2BM.%26atitle%3D7%2520beta-Methyl%2520substituent%2520is%2520a%2520structural%2520locus%2520associated%2520with%2520activity%2520cliff%2520for%2520nepenthone%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4254%26epage%3D4263%26doi%3D10.1016%2Fj.bmc.2018.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thian, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiesen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunahara, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granier, S.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the mu-opioid receptor bound to a morphinan antagonist</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>485</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">U170</span>, <span class="refDoi"> DOI: 10.1038/nature10954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1038%2Fnature10954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=22437502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVehs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=321-U170&author=A.+Manglikauthor=A.+C.+Kruseauthor=T.+S.+Kobilkaauthor=F.+S.+Thianauthor=J.+M.+Mathiesenauthor=R.+K.+Sunaharaauthor=L.+Pardoauthor=W.+I.+Weisauthor=B.+K.+Kobilkaauthor=S.+Granier&title=Crystal+structure+of+the+mu-opioid+receptor+bound+to+a+morphinan+antagonist&doi=10.1038%2Fnature10954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the μ-opioid receptor bound to a morphinan antagonist</span></div><div class="casAuthors">Manglik, Aashish; Kruse, Andrew C.; Kobilka, Tong Sun; Thian, Foon Sun; Mathiesen, Jesper M.; Sunahara, Roger K.; Pardo, Leonardo; Weis, William I.; Kobilka, Brian K.; Granier, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7398</span>),
    <span class="NLM_cas:pages">321-326</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Opium is one of the world's oldest drugs, and its derivs. morphine and codeine are among the most used clin. drugs to relieve severe pain.  These prototypical opioids produce analgesia as well as many undesirable side effects (sedation, apnea and dependence) by binding to and activating the G-protein-coupled μ-opioid receptor (μ-OR) in the central nervous system.  Here the authors describe the 2.8 Å crystal structure of the mouse μ-OR in complex with an irreversible morphinan antagonist.  Compared to the buried binding pocket obsd. in most G-protein-coupled receptors published so far, the morphinan ligand binds deeply within a large solvent-exposed pocket.  Of particular interest, the μ-OR crystallizes as a two-fold sym. dimer through a four-helix bundle motif formed by transmembrane segments 5 and 6.  These high-resoln. insights into opioid receptor structure will enable the application of structure-based approaches to develop better drugs for the management of pain and addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2q4tys639jrVg90H21EOLACvtfcHk0lj5N1Qe1w0iPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVehs7Y%253D&md5=563d5ebda53f9a408be21d60a7e5a97d</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnature10954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10954%26sid%3Dliteratum%253Aachs%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DMathiesen%26aufirst%3DJ.%2BM.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DPardo%26aufirst%3DL.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGranier%26aufirst%3DS.%26atitle%3DCrystal%2520structure%2520of%2520the%2520mu-opioid%2520receptor%2520bound%2520to%2520a%2520morphinan%2520antagonist%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D321%26epage%3DU170%26doi%3D10.1038%2Fnature10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span> <span> </span><span class="NLM_article-title">LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>584</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2008.02.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.ejphar.2008.02.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=18353307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksVaqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=584&publication_year=2008&pages=306-11&author=Y.+M.+Taoauthor=Q.+L.+Liauthor=C.+F.+Zhangauthor=X.+J.+Xuauthor=J.+Chenauthor=Y.+W.+Juauthor=Z.+Q.+Chiauthor=Y.+Q.+Longauthor=J.+G.+Liu&title=LPK-26%2C+a+novel+kappa-opioid+receptor+agonist+with+potent+antinociceptive+effects+and+low+dependence+potential&doi=10.1016%2Fj.ejphar.2008.02.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">LPK-26, a novel κ-opioid receptor agonist with potent antinociceptive effects and low dependence potential</span></div><div class="casAuthors">Tao, Yi-Min; Li, Qing-Lin; Zhang, Cong-Fen; Xu, Xue-Jun; Chen, Jie; Ju, Ya-Wen; Chi, Zhi-Qiang; Long, Ya-Qiu; Liu, Jing-Gen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">584</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">306-311</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Analgesics such as morphine cause many side effects including addiction, but κ-opioid receptor agonist can produce antinociception without morphine-like side effects.  With the aim of developing new and potent analgesics with lower abuse potential, we studied the antinociceptive and phys. dependent properties of a derivate of ICI-199441, an analog of (-)U50,488H, named (2-(3,4-dichloro)-phenyl)-N-methyl-N-[(1S)-1-(2-isopropyl)-2-(1-(3-pyrrolinyl))ethyl] acetamides (LPK-26).  LPK-26 showed a high affinity to κ-opioid receptor with the Ki value of 0.64 nM and the low affinities to μ-opioid receptor and δ-opioid receptor with the Ki values of 1170 nM and > 10,000 nM, resp.  It stimulated [35S]GTPγS binding to G-proteins with an EC50 value of 0.0094 nM.  In vivo, LPK-26 was more potent than (-)U50,488H and morphine in analgesia, with the ED50 values of 0.049 mg/kg and 0.0084 mg/kg in hot plat and acetic acid writhing tests, resp.  Moreover, LPK-26 failed to induce phys. dependence, but it could suppress naloxone-pptd. jumping in mice when given simultaneously with morphine.  Taken together, the results show that LPK-26 is a novel selective κ-opioid receptor agonist with highly potent antinociception effects and low phys. dependence potential.  It may be valuable for the development of analgesic and drug that can be used to reduce morphine-induced phys. dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr74NJwxWVW6rVg90H21EOLACvtfcHk0lj5N1Qe1w0iPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksVaqsrs%253D&md5=0499bc1c1523a03f235681b166387301</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2008.02.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2008.02.028%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DY.%2BM.%26aulast%3DLi%26aufirst%3DQ.%2BL.%26aulast%3DZhang%26aufirst%3DC.%2BF.%26aulast%3DXu%26aufirst%3DX.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DJu%26aufirst%3DY.%2BW.%26aulast%3DChi%26aufirst%3DZ.%2BQ.%26aulast%3DLong%26aufirst%3DY.%2BQ.%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26atitle%3DLPK-26%252C%2520a%2520novel%2520kappa-opioid%2520receptor%2520agonist%2520with%2520potent%2520antinociceptive%2520effects%2520and%2520low%2520dependence%2520potential%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D584%26spage%3D306%26epage%3D11%26doi%3D10.1016%2Fj.ejphar.2008.02.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ondachi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosier, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uprety, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krumm, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strachan, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tribo, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure of the nanobody-stabilized active state of the kappa opioid receptor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.cell.2017.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=29307491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslehtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=55-67&author=T.+Cheauthor=S.+Majumdarauthor=S.+A.+Zaidiauthor=P.+Ondachiauthor=J.+D.+McCorvyauthor=S.+Wangauthor=P.+D.+Mosierauthor=R.+Upretyauthor=E.+Vardyauthor=B.+E.+Krummauthor=G.+W.+Hanauthor=M.+Y.+Leeauthor=E.+Pardonauthor=J.+Steyaertauthor=X.+P.+Huangauthor=R.+T.+Strachanauthor=A.+R.+Triboauthor=G.+W.+Pasternakauthor=F.+I.+Carrollauthor=R.+C.+Stevensauthor=V.+Cherezovauthor=V.+Katritchauthor=D.+Wackerauthor=B.+L.+Roth&title=Structure+of+the+nanobody-stabilized+active+state+of+the+kappa+opioid+receptor&doi=10.1016%2Fj.cell.2017.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the nanobody-stabilized active state of the Kappa opioid receptor</span></div><div class="casAuthors">Che, Tao; Majumdar, Susruta; Zaidi, Saheem A.; Ondachi, Pauline; McCorvy, John D.; Wang, Sheng; Mosier, Philip D.; Uprety, Rajendra; Vardy, Eyal; Krumm, Brian E.; Han, Gye Won; Lee, Ming-Yue; Pardon, Els; Steyaert, Jan; Huang, Xi-Ping; Strachan, Ryan T.; Tribo, Alexandra R.; Pasternak, Gavril W.; Carroll, F. Ivy; Stevens, Raymond C.; Cherezov, Vadim; Katritch, Vsevolod; Wacker, Daniel; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">55-67.e15</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The κ-opioid receptor (KOP) mediates the actions of opioids with hallucinogenic, dysphoric, and analgesic activities.  The design of KOP analgesics devoid of hallucinatory and dysphoric effects has been hindered by an incomplete structural and mechanistic understanding of KOP agonist actions.  Here, we provide a crystal structure of human KOP in complex with the potent epoxymorphinan opioid agonist MP1104 and an active-state-stabilizing nanobody.  Comparisons between inactive- and active-state opioid receptor structures reveal substantial conformational changes in the binding pocket and intracellular and extracellular regions.  Extensive structural anal. and exptl. validation illuminate key residues that propagate larger-scale structural rearrangements and transducer binding that, collectively, elucidate the structural determinants of KOP pharmacol., function, and biased signaling.  These mol. insights promise to accelerate the structure-guided design of safer and more effective κ-opioid receptor therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyTsV2u04FCbVg90H21EOLACvtfcHk0lj5N1Qe1w0iPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslehtg%253D%253D&md5=eb0399dc1e7e4e0cf21771243875abc9</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DChe%26aufirst%3DT.%26aulast%3DMajumdar%26aufirst%3DS.%26aulast%3DZaidi%26aufirst%3DS.%2BA.%26aulast%3DOndachi%26aufirst%3DP.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMosier%26aufirst%3DP.%2BD.%26aulast%3DUprety%26aufirst%3DR.%26aulast%3DVardy%26aufirst%3DE.%26aulast%3DKrumm%26aufirst%3DB.%2BE.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLee%26aufirst%3DM.%2BY.%26aulast%3DPardon%26aufirst%3DE.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DStrachan%26aufirst%3DR.%2BT.%26aulast%3DTribo%26aufirst%3DA.%2BR.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure%2520of%2520the%2520nanobody-stabilized%2520active%2520state%2520of%2520the%2520kappa%2520opioid%2520receptor%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D55%26epage%3D67%26doi%3D10.1016%2Fj.cell.2017.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prather, P. L.</span></span> <span> </span><span class="NLM_article-title">Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1124/mol.60.1.53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1124%2Fmol.60.1.53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=11408600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks1Crt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2001&pages=53-62&author=J.+G.+Liuauthor=P.+L.+Prather&title=Chronic+exposure+to+mu-opioid+agonists+produces+constitutive+activation+of+mu-opioid+receptors+in+direct+proportion+to+the+efficacy+of+the+agonist+used+for+pretreatment&doi=10.1124%2Fmol.60.1.53"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic exposure to μ-opioid agonists produces constitutive activation of μ-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment</span></div><div class="casAuthors">Liu, Jing-Gen; Prather, Paul L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Chronic morphine treatment has been shown to produce constitutive activation of μ-opioid receptors, and this transition might contribute to the development of tolerance and dependence.  The apparent ability of chronic morphine to increase the spontaneous, agonist-independent activation of μ-opioid receptors may be unique, due to its distinct partial-agonist properties of possessing a relatively high intrinsic activity coupled with a poor ability to produce desensitization and down-regulation.  Therefore, the present study tested the hypothesis that prolonged exposure to morphine would produce greater constitutive activity of μ-opioid receptors than exposure to the full agonist [D-Ala2,N-MePhe4,Gly-ol5]enkephalin (DAMGO).  Rat pituitary GH3MOR cells expressing μ-opioid receptors were chronically exposed to morphine, DAMGO, or no opioid under conditions known to produce maximal desensitization, down-regulation, and cAMP rebound.  After chronic treatment, the μ-opioid antagonists naloxone and β-chlornaltrexamine (β-CNA) were evaluated in two assays predictive of inverse agonist activity.  Both antagonists produced a concn.-dependent inhibition of [35S]GTPγS binding only in membranes from cells chronically exposed to opioids.  This effect was reversed by the neutral μ-opioid antagonist CTAP.  Addnl., conditions known to uncouple G protein-coupled receptors from G proteins produced a leftward shift in the competition curve of β-CNA for [3H]DAMGO binding only in membranes from chronically treated cells.  In contrast, these conditions produced no shift in the competition curve by the neutral antagonist CTAP in cells exposed to chronic DAMGO.  Therefore, prolonged exposure of GH3MOR cells to opioids produced constitutive activation of μ-opioid receptors.  Surprisingly, chronic treatment with the more effective agonist DAMGO produced greater increases in both measures of inverse agonist activity than did morphine.  These observations may lend insight into the mechanisms of opioid tolerance and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAfdltVAcsC7Vg90H21EOLACvtfcHk0ljBt3ob5vj7dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks1Crt7Y%253D&md5=43f9ff3d4c9cba9d33320c67c4a9773f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1124%2Fmol.60.1.53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.60.1.53%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26aulast%3DPrather%26aufirst%3DP.%2BL.%26atitle%3DChronic%2520exposure%2520to%2520mu-opioid%2520agonists%2520produces%2520constitutive%2520activation%2520of%2520mu-opioid%2520receptors%2520in%2520direct%2520proportion%2520to%2520the%2520efficacy%2520of%2520the%2520agonist%2520used%2520for%2520pretreatment%26jtitle%3DMol.%2520Pharmacol.%26date%3D2001%26volume%3D60%26spage%3D53%26epage%3D62%26doi%3D10.1124%2Fmol.60.1.53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumeyer, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of atpm [(−)-3-amino-thiazolo[5,4-b]-n-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>329</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1124/jpet.108.142802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1124%2Fjpet.108.142802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=19136637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVKmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2009&pages=306-313&author=Y.+J.+Wangauthor=Y.+M.+Taoauthor=F.+Y.+Liauthor=Y.+H.+Wangauthor=X.+J.+Xuauthor=J.+Chenauthor=Y.+L.+Caoauthor=Z.+Q.+Chiauthor=J.+L.+Neumeyerauthor=A.+Zhangauthor=J.+G.+Liu&title=Pharmacological+characterization+of+atpm+%5B%28%E2%88%92%29-3-amino-thiazolo%5B5%2C4-b%5D-n-cyclopropylmethylmorphinan+hydrochloride%5D%2C+a+novel+mixed+kappa-agonist+and+mu-agonist%2F-antagonist+that+attenuates+morphine+antinociceptive+tolerance+and+heroin+self-administration+behavior&doi=10.1124%2Fjpet.108.142802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of ATPM [(-)-3-amino-thiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed κ-agonist and μ-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior</span></div><div class="casAuthors">Wang, Yu-Jun; Tao, Yi-Min; Li, Fu-Ying; Wang, Yu-Hua; Xu, Xue-Jun; Chen, Jie; Cao, Ying-Lin; Chi, Zhi-Qiang; Neumeyer, John L.; Zhang, Ao; Liu, Jing-Gen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">306-313</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">ATPM [(-)-3-amino-thiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride] was found to have mixed κ- and μ-opioid activity and identified to act as a full κ-agonist and a partial μ-agonist by in vitro binding assays.  The present study was undertaken to characterize its in vivo effects on morphine antinociceptive tolerance in mice and heroin self-administration in rats.  ATPM was demonstrated to yield more potent antinociceptive effects than (-)U50,488H (trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] benzeneacetamide).  It was further found that the antinociceptive effects of ATPM were mediated by κ- and μ-, but not δ-opioid, receptors.  In addn. to its agonist profile on the μ-receptor, ATPM also acted as a μ-antagonist, as measured by its inhibition of morphine-induced antinociception.  It is more important that ATPM had a greater ratio of the ED50 value of sedation to that of antinociception than (-)U50,488 (11.8 vs. 3.7), indicative of a less sedative effect than (-)U50,488H.  In addn., ATPM showed less potential to develop antinociceptive tolerance relative to (-)U50,488H and morphine.  Moreover, it dose-dependently inhibited morphine-induced antinociceptive tolerance.  Furthermore, it was found that chronic treatment of rats for 8 consecutive days with ATPM (0.5 mg/kg s.c.) produced sustained decreases in heroin self-administration.  (-)U50,488H (2 mg/kg s.c.) also produced similar inhibitory effect.  Taken together, our findings demonstrated that ATPM, a novel mixed κ-agonist and μ-agonist/-antagonist, could inhibit morphine-induced antinociceptive tolerance, with less potential to develop tolerance and reduce heroin self-administration with less sedative effect.  κ-Agonists with some μ-activity appear to offer some advantages over selective κ-agonists for the treatment of heroin abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU8tFFGb2tBrVg90H21EOLACvtfcHk0ljBt3ob5vj7dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVKmsrw%253D&md5=985fb6c56a87dd9283c12df05ef47576</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.142802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.142802%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DTao%26aufirst%3DY.%2BM.%26aulast%3DLi%26aufirst%3DF.%2BY.%26aulast%3DWang%26aufirst%3DY.%2BH.%26aulast%3DXu%26aufirst%3DX.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DY.%2BL.%26aulast%3DChi%26aufirst%3DZ.%2BQ.%26aulast%3DNeumeyer%26aufirst%3DJ.%2BL.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26atitle%3DPharmacological%2520characterization%2520of%2520atpm%2520%255B%2528%25E2%2588%2592%2529-3-amino-thiazolo%255B5%252C4-b%255D-n-cyclopropylmethylmorphinan%2520hydrochloride%255D%252C%2520a%2520novel%2520mixed%2520kappa-agonist%2520and%2520mu-agonist%252F-antagonist%2520that%2520attenuates%2520morphine%2520antinociceptive%2520tolerance%2520and%2520heroin%2520self-administration%2520behavior%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D329%26spage%3D306%26epage%3D313%26doi%3D10.1124%2Fjpet.108.142802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiao Liu, Shuang Jiang, Linghui Kong, Rongrong Ye, Li Xiao, Xuejun Xu, Qian He, Yuanyuan Wei, Zixiang Li, Huijiao Sun, Qiong Xie, Xu Xu, Yan Lu, Yujun Wang, Wei Li, Wei Fu, Zhuibai Qiu, Jinggen Liu, <span class="NLM_string-name hlFld-ContribAuthor">Liming Shao</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of the SAR Connection between Morphinan- and Arylacetamide-Based κ Opioid Receptor (κOR) Agonists Using the Strategy of Bridging. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2021,</strong> <em>12 </em>
                                    (6)
                                     , 1018-1030. <a href="https://doi.org/10.1021/acschemneuro.1c00034" title="DOI URL">https://doi.org/10.1021/acschemneuro.1c00034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.1c00034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.1c00034%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DExploration%252Bof%252Bthe%252BSAR%252BConnection%252Bbetween%252BMorphinan-%252Band%252BArylacetamide-Based%252B%2525CE%2525BA%252BOpioid%252BReceptor%252B%252528%2525CE%2525BAOR%252529%252BAgonists%252BUsing%252Bthe%252BStrategy%252Bof%252BBridging%26aulast%3DLiu%26aufirst%3DXiao%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D18012021%26date%3D23022021%26date%3D02032021%26volume%3D12%26issue%3D6%26spage%3D1018%26epage%3D1030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anastasija O.  Finke</span>, <span class="hlFld-ContribAuthor ">Marina Y.  Ravaeva</span>, <span class="hlFld-ContribAuthor ">Vyacheslav I.  Krasnov</span>, <span class="hlFld-ContribAuthor ">Igor V.  Cheretaev</span>, <span class="hlFld-ContribAuthor ">Elena N.  Chuyan</span>, <span class="hlFld-ContribAuthor ">Dmitry S.  Baev</span>, <span class="hlFld-ContribAuthor ">Elvira E.  Shults</span>. </span><span class="cited-content_cbyCitation_article-title">Cross‐Coupling‐Cyclocondensation Reaction Sequence to Access a Library of Ring‐C Bridged Pyrimidino‐tetrahydrothebaines and Pyrimidinotetrahydrooripavines. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (29)
                                     , 7391-7397. <a href="https://doi.org/10.1002/slct.202101790" title="DOI URL">https://doi.org/10.1002/slct.202101790</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202101790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202101790%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DCross%2525E2%252580%252590Coupling%2525E2%252580%252590Cyclocondensation%252BReaction%252BSequence%252Bto%252BAccess%252Ba%252BLibrary%252Bof%252BRing%2525E2%252580%252590C%252BBridged%252BPyrimidino%2525E2%252580%252590tetrahydrothebaines%252Band%252BPyrimidinotetrahydrooripavines%26aulast%3DFinke%26aufirst%3DAnastasija%2BO.%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D29%26spage%3D7391%26epage%3D7397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bangyi  Zhao</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Lijie  Sun</span>, <span class="hlFld-ContribAuthor ">Wei  Fu</span>. </span><span class="cited-content_cbyCitation_article-title">The Use of Computational Approaches in the Discovery and Mechanism Study of Opioid Analgesics. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fchem.2020.00335" title="DOI URL">https://doi.org/10.3389/fchem.2020.00335</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2020.00335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2020.00335%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DThe%252BUse%252Bof%252BComputational%252BApproaches%252Bin%252Bthe%252BDiscovery%252Band%252BMechanism%252BStudy%252Bof%252BOpioid%252BAnalgesics%26aulast%3DZhao%26aufirst%3DBangyi%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huoming  Huang</span>, <span class="hlFld-ContribAuthor ">Wenli  Wang</span>, <span class="hlFld-ContribAuthor ">Xuejun  Xu</span>, <span class="hlFld-ContribAuthor ">Chen  Zhu</span>, <span class="hlFld-ContribAuthor ">Yujun  Wang</span>, <span class="hlFld-ContribAuthor ">Jinggen  Liu</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Fu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>189 </em>, 112070. <a href="https://doi.org/10.1016/j.ejmech.2020.112070" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112070</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112070%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B3-%252528%252528dimethylamino%252529methyl%252529-4-hydroxy-4-%2525283-methoxyphenyl%252529-N-phenylpiperidine-1-carboxamide%252Bas%252Bnovel%252Bpotent%252Banalgesic%26aulast%3DHuang%26aufirst%3DHuoming%26date%3D2020%26volume%3D189%26spage%3D112070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of typical κ opioid agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Examples of compounds derived from the Diels–Alder adducts of thebaine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Design Rationale for Novel 4,5-Epoxymorphinan Derivatives as Potential κ Opioid Receptor Ligands Based on the Message–Address Concept</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>N</i>-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DIAD, HCl and CH<sub>3</sub>CN; (b) cyclopropylmethyl bromide, Na<sub>2</sub>CO<sub>3</sub> and DMF at rt; (c) 4-nitrostyrene and xylene under reflux; (d) Pd/C and H<sub>2</sub> at 65 psi and 25 °C; (e) DIPEA, Cbz-Cl, and DCM at 35 °C, followed by LiAlH<sub>4</sub> and THF at 0 °C; (f) haloalkanes, Na<sub>2</sub>CO<sub>3</sub>, and DMF at rt; (g) dibromoalkanes, Na<sub>2</sub>CO<sub>3</sub>, and CH<sub>3</sub>CN at 110 °C under microwave; (h) haloalkanes or acyl chlorides, Et<sub>3</sub>N, and DCM at rt; (i) NaNO<sub>2</sub>, HCl, and H<sub>2</sub>O at −5 to 0 °C; phenol, NaOH, and H<sub>2</sub>O at −5 to 0 °C.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Putative binding mode of SLL-039 (in green) in the μ opioid receptor binding site and (b) overlays with compounds <b>8</b> (in magenta), <b>11b</b> (in yellow), and <b>11c</b> (in cyan). All these models were developed based on the crystal structure of the μ opioid receptor (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DKL">4DKL</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Putative binding mode of SLL-039 (in green) in the κ opioid receptor binding site. (b) Overlays with compounds <b>8</b> (in magenta) and <b>11b</b> (in yellow). (c) Overlays with nalfurafine (in indigo) and SLL-020ACP (in orange). (d) Electrostatic potential surfaces generated by residues around SLL-039. All these models were developed based on the crystal structure of κ opioid receptor (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B73">6B73</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Time course for the antinociceptive effects of compound SLL-039 in the hot plate test. Mice were injected with SLL-039 (0.8 mg/kg) intraperitoneally. At varying times, antinociception was measured in the hot plate test. Data are the mean ± SEM from 8 to 10 mice/data point.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. The κ opioid receptor mediated SLL-039-induced antinociception. Mice were pretreated with the κ-opioid receptor antagonist nor-BNI (10 mg/kg, sc, −24 h) or μ-opioid receptor antagonist β-FNA (20 mg/kg, sc, −24 h). Then the antinociceptive effects of the compound SLL-039 (0.2 mg/kg, sc) were assessed 2 h after administration in the abdominal constriction test. Data are presented as the mean ± SEM from 8 mice/data point: ***<i>p</i> < 0.001 compared with SLL-039 alone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effects of U50,488H and SLL-039 on novelty-induced locomotor activity. Mice were treated with U50,488H (5 mg/kg) for 30 min or various doses of SLL-039 (0.3, 0.9, or 2.7 mg/kg) for 2 h, Then the total locomotor activities were monitored for 30 min. Data are presented as the mean ± SEM from 8 mice/data point: *<i>p</i> < 0.05 compared with the saline group by one-way ANOVA followed by Bonferroni test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/medium/jm9b00857_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (a) Residue triad in the κ opioid receptor involved in binding with SLL-039 (in green) and the corresponding residues in the μ and δ receptors. (b) Top view of overlays from the modeled structure of the SLL-039 (in green)−κ opioid receptor complex based on the crystal structure of the κ opioid receptor (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B73">6B73</a>) and the crystal structure of the naltrindole (in white)−δ opioid receptor complex (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EJ4">4EJ4</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00857/20191219/images/large/jm9b00857_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00857&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85606" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85606" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 68 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dinakar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillman, A. M.</span></span> <span> </span><span class="NLM_article-title">Pathogenesis of pain</span>. <i>Semin Pediatr Neurol</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/j.spen.2016.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.spen.2016.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=27989327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FlvFequg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=201-208&author=P.+Dinakarauthor=A.+M.+Stillman&title=Pathogenesis+of+pain&doi=10.1016%2Fj.spen.2016.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis of Pain</span></div><div class="casAuthors">Dinakar Pradeep; Stillman Alexandra Marion</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in pediatric neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">201-208</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The pathogenesis of pain sensation includes mechanisms that result in acute or chronic pain.  Pain itself is described as an unpleasant sensory and emotional experience beginning with a peripheral stimulus that undergoes a physiological process ultimately resulting in the sensation of pain.  Biologists recognize pain to be a common sign of potential tissue damage.  Hence, pain sensation is protective in function.  However, pathologic states of pain exist secondary to disruption of the nociceptive process both peripherally and centrally or secondary to psychological conditions.  It is essential to identify these aberrant states of pain and distinguish them from situations of potential tissue damage.  Chronic pain is defined as pain that exceeds 3 or 6 months duration.  This article is an overview of the essential neuroanatomy and neurophysiology of normal pain nociception, its clinical implications, and the development of persistent and pathological pain conditions following improperly or poorly treated pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAFoyTiUN_4WhHGZei4OW9fW6udTcc2eaEKQvyMuSEM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FlvFequg%253D%253D&md5=e119e44f0ca474ae0de47125abfcf903</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.spen.2016.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.spen.2016.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DDinakar%26aufirst%3DP.%26aulast%3DStillman%26aufirst%3DA.%2BM.%26atitle%3DPathogenesis%2520of%2520pain%26jtitle%3DSemin%2520Pediatr%2520Neurol%26date%3D2016%26volume%3D23%26spage%3D201%26epage%3D208%26doi%3D10.1016%2Fj.spen.2016.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raffaeli, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnaudo, E.</span></span> <span> </span><span class="NLM_article-title">Pain as a disease: an overview</span>. <i>J. Pain Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2003</span>– <span class="NLM_lpage">2008</span>, <span class="refDoi"> DOI: 10.2147/JPR.S138864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.2147%2FJPR.S138864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=28860855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADC%252BC1cbjs1Wrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=2003-2008&author=W.+Raffaeliauthor=E.+Arnaudo&title=Pain+as+a+disease%3A+an+overview&doi=10.2147%2FJPR.S138864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Pain as a disease: an overview</span></div><div class="casAuthors">Raffaeli William; Arnaudo Elisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pain research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2003-2008</span>
        ISSN:<span class="NLM_cas:issn">1178-7090</span>.
    </div><div class="casAbstract">The acknowledgment of pain as a pathologic entity in its own right remains debated.  Notwithstanding the data showing the burden of pain as a disease, an ultimate recognition of the pathologic nature of this condition is lacking.  In this study, we analyze the notion of pain as a disease through an historical overview of its several conceptualizations and report the main evidence supporting this notion.  We believe that a clear definition of pain as a disease is necessary, especially considering the enormous global burden of this condition.  Indeed, the recognition of pain as a definite pathologic state is crucial to raise awareness about this neglected global health problem and to promote the exploration of new specific therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbiAT6YvtYabesJRIHUP1ofW6udTcc2eaEKQvyMuSEM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbjs1Wrsg%253D%253D&md5=223877b7200e08efd88b0726870326fd</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2147%2FJPR.S138864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FJPR.S138864%26sid%3Dliteratum%253Aachs%26aulast%3DRaffaeli%26aufirst%3DW.%26aulast%3DArnaudo%26aufirst%3DE.%26atitle%3DPain%2520as%2520a%2520disease%253A%2520an%2520overview%26jtitle%3DJ.%2520Pain%2520Res.%26date%3D2017%26volume%3D10%26spage%3D2003%26epage%3D2008%26doi%3D10.2147%2FJPR.S138864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rice, A. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blyth, F. M.</span></span> <span> </span><span class="NLM_article-title">Pain and the global burden of disease</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">796</span>, <span class="refDoi"> DOI: 10.1097/j.pain.0000000000000454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1097%2Fj.pain.0000000000000454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=26670465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADC%252BC28vpvFynsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2016&pages=791-796&author=A.+S.+C.+Riceauthor=B.+H.+Smithauthor=F.+M.+Blyth&title=Pain+and+the+global+burden+of+disease&doi=10.1097%2Fj.pain.0000000000000454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Pain and the global burden of disease</span></div><div class="casAuthors">Rice Andrew S C; Smith Blair H; Blyth Fiona M</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">791-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKHO5fBRG3WE2yPDyEFiigfW6udTcc2eZP4EfMPUzFL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vpvFynsQ%253D%253D&md5=4b920f9d391385db51b43bea65d9dec7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1097%2Fj.pain.0000000000000454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fj.pain.0000000000000454%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DA.%2BS.%2BC.%26aulast%3DSmith%26aufirst%3DB.%2BH.%26aulast%3DBlyth%26aufirst%3DF.%2BM.%26atitle%3DPain%2520and%2520the%2520global%2520burden%2520of%2520disease%26jtitle%3DPain%26date%3D2016%26volume%3D157%26spage%3D791%26epage%3D796%26doi%3D10.1097%2Fj.pain.0000000000000454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benyamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trescot, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buenaventura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adlaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehgal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallejo, R.</span></span> <span> </span><span class="NLM_article-title">Opioid complications and side effects</span>. <i>Pain Physician</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">S105</span>– <span class="NLM_lpage">S120</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=18443635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADC%252BD1czosVSjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=S105-S120&author=R.+Benyaminauthor=A.+M.+Trescotauthor=S.+Dattaauthor=R.+Buenaventuraauthor=R.+Adlakaauthor=N.+Sehgalauthor=S.+E.+Glaserauthor=R.+Vallejo&title=Opioid+complications+and+side+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid complications and side effects</span></div><div class="casAuthors">Benyamin Ramsin; Trescot Andrea M; Datta Sukdeb; Buenaventura Ricardo; Adlaka Rajive; Sehgal Nalini; Glaser Scott E; Vallejo Ricardo</div><div class="citationInfo"><span class="NLM_cas:title">Pain physician</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2 Suppl</span>),
    <span class="NLM_cas:pages">S105-20</span>
        ISSN:<span class="NLM_cas:issn">1533-3159</span>.
    </div><div class="casAbstract">Medications which bind to opioid receptors are increasingly being prescribed for the treatment of multiple and diverse chronic painful conditions.  Their use for acute pain or terminal pain is well accepted.  Their role in the long-term treatment of chronic noncancer pain is, however, controversial for many reasons.  One of the primary reasons is the well-known phenomenon of psychological addiction that can occur with the use of these medications.  Abuse and diversion of these medications is a growing problem as the availability of these medications increases and this public health issue confounds their clinical utility.  Also, the extent of their efficacy in the treatment of pain when utilized on a chronic basis has not been definitively proven.  Lastly, the role of opioids in the treatment of chronic pain is also influenced by the fact that these potent analgesics are associated with a significant number of side effects and complications.  It is these phenomena that are the focus of this review.  Common side effects of opioid administration include sedation, dizziness, nausea, vomiting, constipation, physical dependence, tolerance, and respiratory depression.  Physical dependence and addiction are clinical concerns that may prevent proper prescribing and in turn inadequate pain management.  Less common side effects may include delayed gastric emptying, hyperalgesia, immunologic and hormonal dysfunction, muscle rigidity, and myoclonus.  The most common side effects of opioid usage are constipation (which has a very high incidence) and nausea.  These 2 side effects can be difficult to manage and frequently tolerance to them does not develop; this is especially true for constipation.  They may be severe enough to require opioid discontinuation, and contribute to under-dosing and inadequate analgesia.  Several clinical trials are underway to identify adjunct therapies that may mitigate these side effects.  Switching opioids and/or routes of administration may also provide benefits for patients.  Proper patient screening, education, and preemptive treatment of potential side effects may aid in maximizing effectiveness while reducing the severity of side effects and adverse events.  Opioids can be considered broad spectrum analgesic agents, affecting a wide number of organ systems and influencing a large number of body functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRS-eBn7Ppy6vx2phytoz6_fW6udTcc2eZP4EfMPUzFL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czosVSjsQ%253D%253D&md5=26196f3cc302b1cad86e32477bb52e18</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBenyamin%26aufirst%3DR.%26aulast%3DTrescot%26aufirst%3DA.%2BM.%26aulast%3DDatta%26aufirst%3DS.%26aulast%3DBuenaventura%26aufirst%3DR.%26aulast%3DAdlaka%26aufirst%3DR.%26aulast%3DSehgal%26aufirst%3DN.%26aulast%3DGlaser%26aufirst%3DS.%2BE.%26aulast%3DVallejo%26aufirst%3DR.%26atitle%3DOpioid%2520complications%2520and%2520side%2520effects%26jtitle%3DPain%2520Physician%26date%3D2008%26volume%3D11%26spage%3DS105%26epage%3DS120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kata, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novitch, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anyama, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helander, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, A. D.</span></span> <span> </span><span class="NLM_article-title">Opioid addiction, diversion, and abuse in chronic and cancer pain</span>. <i>Curr. Opin Support Pa</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">124</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1097/SPC.0000000000000333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1097%2FSPC.0000000000000333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=29465470" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=124-130&author=V.+Kataauthor=M.+B.+Novitchauthor=M.+R.+Jonesauthor=B.+O.+Anyamaauthor=E.+M.+Helanderauthor=A.+D.+Kaye&title=Opioid+addiction%2C+diversion%2C+and+abuse+in+chronic+and+cancer+pain&doi=10.1097%2FSPC.0000000000000333"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2FSPC.0000000000000333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FSPC.0000000000000333%26sid%3Dliteratum%253Aachs%26aulast%3DKata%26aufirst%3DV.%26aulast%3DNovitch%26aufirst%3DM.%2BB.%26aulast%3DJones%26aufirst%3DM.%2BR.%26aulast%3DAnyama%26aufirst%3DB.%2BO.%26aulast%3DHelander%26aufirst%3DE.%2BM.%26aulast%3DKaye%26aufirst%3DA.%2BD.%26atitle%3DOpioid%2520addiction%252C%2520diversion%252C%2520and%2520abuse%2520in%2520chronic%2520and%2520cancer%2520pain%26jtitle%3DCurr.%2520Opin%2520Support%2520Pa%26date%3D2018%26volume%3D12%26spage%3D124%26epage%3D130%26doi%3D10.1097%2FSPC.0000000000000333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuczynska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzonkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kacprzak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawilska, J. B.</span></span> <span> </span><span class="NLM_article-title">Abuse of fentanyl: An emerging problem to face</span>. <i>Forensic Sci. Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/j.forsciint.2018.05.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.forsciint.2018.05.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=29902699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFSgtrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2018&pages=207-214&author=K.+Kuczynskaauthor=P.+Grzonkowskiauthor=L.+Kacprzakauthor=J.+B.+Zawilska&title=Abuse+of+fentanyl%3A+An+emerging+problem+to+face&doi=10.1016%2Fj.forsciint.2018.05.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Abuse of fentanyl: An emerging problem to face</span></div><div class="casAuthors">Kuczynska, Katarzyna; Grzonkowski, Piotr; Kacprzak, Lukasz; Zawilska, Jolanta B.</div><div class="citationInfo"><span class="NLM_cas:title">Forensic Science International</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207-214</span>CODEN:
                <span class="NLM_cas:coden">FSINDR</span>;
        ISSN:<span class="NLM_cas:issn">0379-0738</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Fentanyl is a potent synthetic opioid used as a narcotic analgesic supplement in general and regional anesthesia as well as in management of persistent, severe chronic pain.  Alarming epidemiol. and forensic medicine reports, accumulated mainly during the last two decades, point to a growing increase in illicit use of fentanyl, mainly in North America and Europe.  Toxicol. data indicates that fentanyl use is inextricably linked with polydrug use.  There are two main sources of fentanyl on the "recreational" drug market.  First, the most common, combines illicitly manufd. fentanyl from clandestine sources.  The drug is often mixed up with heroin ("fake heroin") to increase its potency at a little cost, or included in cocaine products.  It can also be mixed into and sold as oxycodone-, hydrocodone- or alprazolam-contg. tablets.  The other way to gain fentanyl is through the diversion of fentanyl-contg. medicines, esp. transdermal patches (FTPs).  Fentanyl extd. from FTP can be administered i.v., insufflated or inhaled after volatilization.  The drug can also be delivered by oral or transmucosal application of the whole patch, or by rectal insertion.  The most common overdose symptoms are coma, lethargy, respiratory depression and arrest.  Although naloxone, an opioid receptor antagonist, is the std. drug for fentanyl overdose rescue, attempts to revive patients with naloxone could be unsuccessful, due to the rapid onset of fentanyl's action.  As the fentanyl problem is constantly growing, there is an urgent need for new, effective harm-redn. strategies and technologies, as well as overdose maintenance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobGFPK9MCq1bVg90H21EOLACvtfcHk0ljklVnFP_1Efw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFSgtrjO&md5=94abe4ec9777382050539428405e01dd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.forsciint.2018.05.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.forsciint.2018.05.042%26sid%3Dliteratum%253Aachs%26aulast%3DKuczynska%26aufirst%3DK.%26aulast%3DGrzonkowski%26aufirst%3DP.%26aulast%3DKacprzak%26aufirst%3DL.%26aulast%3DZawilska%26aufirst%3DJ.%2BB.%26atitle%3DAbuse%2520of%2520fentanyl%253A%2520An%2520emerging%2520problem%2520to%2520face%26jtitle%3DForensic%2520Sci.%2520Int.%26date%3D2018%26volume%3D289%26spage%3D207%26epage%3D214%26doi%3D10.1016%2Fj.forsciint.2018.05.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volkow, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, A. T.</span></span> <span> </span><span class="NLM_article-title">Opioid abuse in chronic pain - misconceptions and mitigation strategies</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1253</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1507771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1056%2FNEJMra1507771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=27028915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1253-1263&author=N.+D.+Volkowauthor=A.+T.+McLellan&title=Opioid+abuse+in+chronic+pain+-+misconceptions+and+mitigation+strategies&doi=10.1056%2FNEJMra1507771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid abuse in chronic pain - misconceptions and mitigation strategies</span></div><div class="casAuthors">Volkow, Nora D.; McLellan, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1253-1263</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Chronic pain not caused by cancer is among the most prevalent and debilitating medical conditions but also among the most controversial and complex to manage.  The urgency of patients' needs, the demonstrated effectiveness of opioid analgesics for the management of acute pain, and the limited therapeutic alternatives for chronic pain have combined to produce an overreliance on opioid medications in the United States, with assocd. alarming increases in diversion, overdose, and addiction.  Given the lack of clin. consensus and research-supported guidance, physicians understandably have questions about whether, when, and how to prescribe opioid analgesics for chronic pain without increasing public health risks.  Here, we draw on recent research to address common misconceptions regarding the abuse-related risks of opioid analgesics and highlight strategies to minimize those risks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyMM2U8jPbvbVg90H21EOLACvtfcHk0lgs269mtCty4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurrM&md5=9e32c0adcd78ab163267bc7735efb514</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1507771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1507771%26sid%3Dliteratum%253Aachs%26aulast%3DVolkow%26aufirst%3DN.%2BD.%26aulast%3DMcLellan%26aufirst%3DA.%2BT.%26atitle%3DOpioid%2520abuse%2520in%2520chronic%2520pain%2520-%2520misconceptions%2520and%2520mitigation%2520strategies%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1253%26epage%3D1263%26doi%3D10.1056%2FNEJMra1507771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y. X.</span></span> <span> </span><span class="NLM_article-title">Mu opioids and their receptors: evolution of a concept</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1257</span>– <span class="NLM_lpage">1317</span>, <span class="refDoi"> DOI: 10.1124/pr.112.007138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1124%2Fpr.112.007138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=24076545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1257-1317&author=G.+W.+Pasternakauthor=Y.+X.+Pan&title=Mu+opioids+and+their+receptors%3A+evolution+of+a+concept&doi=10.1124%2Fpr.112.007138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mu opioids and their receptors: evolution of a concept</span></div><div class="casAuthors">Pasternak, Gavril W.; Pan, Ying-Xian</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1257-1317</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Opiates arc among the oldest medications available to manage a no. of medical problems.  Although pain is the current focus, early use initially focused upon the treatment of dysentery.  Opium contains high concns. of both morphine and codeine, along with thebaine, which is used in the synthesis of a no. of semisynthetic opioid analgesics.  Thus, it is not surprising that new agents were initially based upon the morphine scaffold.  The concept of multiple opioid receptors was first suggested almost 50 years ago, opening the possibility of new classes of drugs, but the morphine-like agents have remained the mainstay in the medical management of pain.  Termed mu, our understanding of these morphine-like agents and their receptors has undergone an evolution in thinking over the past 35 years.  Early pharmacol. studies identified three major classes of receptors, helped by the discovery of endogenous opioid peptides and receptor subtypes-primarily through the synthesis of novel agents.  These chem. biol. approaches were then eclipsed by the mol. biol. revolution, which now reveals a complexity of the morphine-like agents and their receptors that had not been previously appreciated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodv3eFyO841LVg90H21EOLACvtfcHk0lgs269mtCty4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLzJ&md5=49f6dc7f031f9302b72710d42f2a00ea</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1124%2Fpr.112.007138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.112.007138%26sid%3Dliteratum%253Aachs%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26aulast%3DPan%26aufirst%3DY.%2BX.%26atitle%3DMu%2520opioids%2520and%2520their%2520receptors%253A%2520evolution%2520of%2520a%2520concept%26jtitle%3DPharmacol.%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D1257%26epage%3D1317%26doi%3D10.1124%2Fpr.112.007138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhawan, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesselin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghubir, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, M.</span></span> <span> </span><span class="NLM_article-title">International union of pharmacology. XII. Classification of opioid receptors</span>. <i>Pharmacol Rev.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">592</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=8981566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaK2sXlsVGgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1996&pages=567-592&author=B.+N.+Dhawanauthor=F.+Cesselinauthor=R.+Raghubirauthor=T.+Reisineauthor=P.+B.+Bradleyauthor=P.+S.+Portogheseauthor=M.+Hamon&title=International+union+of+pharmacology.+XII.+Classification+of+opioid+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">International union of Pharmacology. XII. Classification of opioid receptors</span></div><div class="casAuthors">Dhawan, B. N.; Cesselin, R. Raghubir; Reisine, T.; Bradley, P. B.; Portoghese, P. S.; Hamon, M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">567-592</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review, with >300 refs.  Topics discussed include: characterization and distribution of opioid receptors, mol. biol. of opioid receptors and transduction mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0spM3ygvAyrVg90H21EOLACvtfcHk0lgs269mtCty4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlsVGgtQ%253D%253D&md5=faf0720d736a8cff4fb432755543d705</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDhawan%26aufirst%3DB.%2BN.%26aulast%3DCesselin%26aufirst%3DF.%26aulast%3DRaghubir%26aufirst%3DR.%26aulast%3DReisine%26aufirst%3DT.%26aulast%3DBradley%26aufirst%3DP.%2BB.%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26aulast%3DHamon%26aufirst%3DM.%26atitle%3DInternational%2520union%2520of%2520pharmacology.%2520XII.%2520Classification%2520of%2520opioid%2520receptors%26jtitle%3DPharmacol%2520Rev.%26date%3D1996%26volume%3D48%26spage%3D567%26epage%3D592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janecka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janecki, T.</span></span> <span> </span><span class="NLM_article-title">Opioid receptors and their ligands</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.2174/1568026043451618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.2174%2F1568026043451618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=14754373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitlCgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1-17&author=A.+Janeckaauthor=J.+Fichnaauthor=T.+Janecki&title=Opioid+receptors+and+their+ligands&doi=10.2174%2F1568026043451618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid receptors and their ligands</span></div><div class="casAuthors">Janecka, Anna; Fichna, Jakub; Janecki, Tomasz</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-17</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review which gives an historical perspective, summarizing ∼25 yr of research on opioids.  The typical opioid peptides produced in the brain, atypical opioids encrypted in milk protein or Hb sequences, and extremely potent and selective opioids of amphibian origin are described.  The main focus is on the structure-activity relationship studies of peptide ligands for 3 main opioid receptor types (μ, δ, κ), their selectivities and pharmacol. activities in vitro.  Chem. modifications that led to obtaining potent and selective agonists and antagonists for these receptors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxFiGL3DSyLbVg90H21EOLACvtfcHk0ljwS7GvhqCaKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitlCgtg%253D%253D&md5=dddd8e79e184730707b8fa926295dcc2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F1568026043451618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026043451618%26sid%3Dliteratum%253Aachs%26aulast%3DJanecka%26aufirst%3DA.%26aulast%3DFichna%26aufirst%3DJ.%26aulast%3DJanecki%26aufirst%3DT.%26atitle%3DOpioid%2520receptors%2520and%2520their%2520ligands%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D1%26epage%3D17%26doi%3D10.2174%2F1568026043451618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldhoer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whistler, J. L.</span></span> <span> </span><span class="NLM_article-title">Opioid receptors</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">990</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.73.011303.073940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1146%2Fannurev.biochem.73.011303.073940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=15189164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslagsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2004&pages=953-990&author=M.+Waldhoerauthor=S.+E.+Bartlettauthor=J.+L.+Whistler&title=Opioid+receptors&doi=10.1146%2Fannurev.biochem.73.011303.073940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid receptors</span></div><div class="casAuthors">Waldhoer, Maria; Bartlett, Selena E.; Whistler, Jennifer L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">953-990</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Opioid receptors belong to the large superfamily of 7 transmembrane-spanning (7TM) G protein-coupled receptors (GPCRs).  As a class, GPCRs are of fundamental physiol. importance mediating the actions of the majority of known neurotransmitters and hormones.  Opioid receptors are particularly intriguing members of this receptor family.  They are activated both by endogenously produced opioid peptides and by exogenously administered opiate compds., some of which are not only among the most effective analgesics known but also highly addictive drugs of abuse.  A fundamental question in addiction biol. is why exogenous opioid drugs, such as morphine and heroin, have a high liability for inducing tolerance, dependence, and addiction.  This review focuses on many aspects of opioid receptors with the aim of gaining a greater insight into mechanisms of opioid tolerance and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSV3Nl3WDHrVg90H21EOLACvtfcHk0ljwS7GvhqCaKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslagsbs%253D&md5=9f865544116a6dac76c80432587180a3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.73.011303.073940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.73.011303.073940%26sid%3Dliteratum%253Aachs%26aulast%3DWaldhoer%26aufirst%3DM.%26aulast%3DBartlett%26aufirst%3DS.%2BE.%26aulast%3DWhistler%26aufirst%3DJ.%2BL.%26atitle%3DOpioid%2520receptors%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2004%26volume%3D73%26spage%3D953%26epage%3D990%26doi%3D10.1146%2Fannurev.biochem.73.011303.073940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Assana, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fogel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frelka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottfried, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kujawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lautz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ries, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schauer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strandberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strandberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, C.</span></span> <span> </span><span class="NLM_article-title">Kappa opioid receptor-based treatments for pain</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">LB88</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=LB88&author=C.+Assanaauthor=C.+Fellerauthor=M.+Fogelauthor=A.+Frelkaauthor=S.+Gottfriedauthor=R.+Jaberauthor=M.+Keyesauthor=M.+Koehlerauthor=K.+Kujawaauthor=N.+Lautzauthor=S.+Olsonauthor=J.+Penaauthor=L.+Riesauthor=L.+Schauerauthor=C.+Scherrerauthor=C.+Strandbergauthor=S.+Strandbergauthor=C.+Cunningham&title=Kappa+opioid+receptor-based+treatments+for+pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAssana%26aufirst%3DC.%26aulast%3DFeller%26aufirst%3DC.%26aulast%3DFogel%26aufirst%3DM.%26aulast%3DFrelka%26aufirst%3DA.%26aulast%3DGottfried%26aufirst%3DS.%26aulast%3DJaber%26aufirst%3DR.%26aulast%3DKeyes%26aufirst%3DM.%26aulast%3DKoehler%26aufirst%3DM.%26aulast%3DKujawa%26aufirst%3DK.%26aulast%3DLautz%26aufirst%3DN.%26aulast%3DOlson%26aufirst%3DS.%26aulast%3DPena%26aufirst%3DJ.%26aulast%3DRies%26aufirst%3DL.%26aulast%3DSchauer%26aufirst%3DL.%26aulast%3DScherrer%26aufirst%3DC.%26aulast%3DStrandberg%26aufirst%3DC.%26aulast%3DStrandberg%26aufirst%3DS.%26aulast%3DCunningham%26aufirst%3DC.%26atitle%3DKappa%2520opioid%2520receptor-based%2520treatments%2520for%2520pain%26jtitle%3DFASEB%2520J.%26date%3D2014%26volume%3D28%26spage%3DLB88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grechko, O. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spasov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shtareva, D. M.</span></span> <span> </span><span class="NLM_article-title">Opioid kappa receptors as a molecular target for the creation of a new generation of analgesic drugs</span>. <i>Pharm. Chem. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1007/s11094-016-1388-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1007%2Fs11094-016-1388-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsV2lurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2016&pages=1-9&author=O.+Y.+Grechkoauthor=A.+A.+Spasovauthor=D.+M.+Shtareva&title=Opioid+kappa+receptors+as+a+molecular+target+for+the+creation+of+a+new+generation+of+analgesic+drugs&doi=10.1007%2Fs11094-016-1388-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid κ Receptors as a Molecular Target for the Creation of a New Generation of Analgesic Drugs</span></div><div class="casAuthors">Grechko, O. Yu.; Spasov, A. A.; Shtareva, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Chemistry Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">PCJOAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-150X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  This review provides a brief description of the main structural and functional features of the κ opioid receptor, along with the properties of its agonists and the potential for using these in medicine.  Of all the opioid receptor subtypes, κ receptors are the most attractive in terms of creating new drugs with a min. of side effects.  The opioid κ receptor is a member of the superfamily of metabotropic G-protein-coupled receptors.  Opioid κ receptors are widely distributed in the CNS and at the periphery.  They are involved in numerous physiol. processes, including analgesia, regulation of neuroendocrine secretion, water balance, drinking and feeding behavior, autonomic functions, and the mechanisms of learning and memory.  Data have been reported on the existence of three subtypes of κ opioid receptor, though the mol. properties of only subtype 1 (e  1) have been studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBuNcDBDCKWLVg90H21EOLACvtfcHk0lgcsBZG0qikBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsV2lurk%253D&md5=1501d222bcc5ec998330a3ecad4968a1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs11094-016-1388-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11094-016-1388-z%26sid%3Dliteratum%253Aachs%26aulast%3DGrechko%26aufirst%3DO.%2BY.%26aulast%3DSpasov%26aufirst%3DA.%2BA.%26aulast%3DShtareva%26aufirst%3DD.%2BM.%26atitle%3DOpioid%2520kappa%2520receptors%2520as%2520a%2520molecular%2520target%2520for%2520the%2520creation%2520of%2520a%2520new%2520generation%2520of%2520analgesic%2520drugs%26jtitle%3DPharm.%2520Chem.%2520J.%26date%3D2016%26volume%3D50%26spage%3D1%26epage%3D9%26doi%3D10.1007%2Fs11094-016-1388-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanderah, T. W.</span></span> <span> </span><span class="NLM_article-title">Delta and kappa opioid receptors as suitable drug targets for pain</span>. <i>Clin J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">S10</span>– <span class="NLM_lpage">S15</span>, <span class="refDoi"> DOI: 10.1097/AJP.0b013e3181c49e3a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1097%2FAJP.0b013e3181c49e3a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=20026960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FjtV2lsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2010&pages=S10-S15&author=T.+W.+Vanderah&title=Delta+and+kappa+opioid+receptors+as+suitable+drug+targets+for+pain&doi=10.1097%2FAJP.0b013e3181c49e3a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Delta and kappa opioid receptors as suitable drug targets for pain</span></div><div class="casAuthors">Vanderah Todd W</div><div class="citationInfo"><span class="NLM_cas:title">The Clinical journal of pain</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">26 Suppl 10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">S10-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Similar to mu opioid receptors, kappa and delta opioid receptors reside in the periphery, the dorsal root ganglion, the spinal cord, and in supraspinal regions associated with pain modulation.  Both delta and kappa opioid agonists have been shown to activate pain inhibitory pathways in the central nervous system.  Yet, currently there are only a few pharmacologic agents that target kappa receptors, and none that target delta receptors.  Spurred by the need for an efficacious analgesic without the unwanted side effects associated with the typical clinical profile of mu opioid agonists, new research has provided insight into why the development of effective kappa and delta opioid receptor agonists has remained elusive thus far, and importantly, how these obstacles may be overcome.  For example, for delta opioid agonists to be effective, a state of inflammation may be required as this induces delta opioid receptors to migrate to the surface of neuronal cells and thereby become accessible to delta opioid agonists.  Studies have shown that delta opioid agonists can provide relief of inflammatory pain and malignant bone pain.  Meanwhile, peripherally restricted kappa opioid agonists have been developed to target kappa opioid receptors located on visceral and somatic afferent nerves for relief of inflammatory, visceral, and neuropathic chronic pain.  The recently shown efficacy of these analgesics combined with a possible lower abuse potential and side effect burden than mu opioid receptor agonists makes delta and peripherally restricted kappa opioid receptor agonists promising targets for treating pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwsScs20wGhFZoq0fPSOTvfW6udTcc2eaOmYgxC799lLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FjtV2lsQ%253D%253D&md5=bdde085a4b229f4a12c5b6034e5a1b20</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1097%2FAJP.0b013e3181c49e3a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FAJP.0b013e3181c49e3a%26sid%3Dliteratum%253Aachs%26aulast%3DVanderah%26aufirst%3DT.%2BW.%26atitle%3DDelta%2520and%2520kappa%2520opioid%2520receptors%2520as%2520suitable%2520drug%2520targets%2520for%2520pain%26jtitle%3DClin%2520J.%2520Pain%26date%3D2010%26volume%3D26%26spage%3DS10%26epage%3DS15%26doi%3D10.1097%2FAJP.0b013e3181c49e3a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaitseva, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galan, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlova, L. A.</span></span> <span> </span><span class="NLM_article-title">Prospects of a search for kappa-opioid receptor agonists with analgesic activity (review)</span>. <i>Pharm. Chem. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1007/s11094-018-1703-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1007%2Fs11094-018-1703-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&pages=843-851&author=N.+I.+Zaitsevaauthor=S.+E.+Galanauthor=L.+A.+Pavlova&title=Prospects+of+a+search+for+kappa-opioid+receptor+agonists+with+analgesic+activity+%28review%29&doi=10.1007%2Fs11094-018-1703-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects of a Search for Kappa-Opioid Receptor Agonists with Analgesic Activity (Review)</span></div><div class="casAuthors">Zaitseva, N. I.; Galan, S. E.; Pavlova, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Chemistry Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">843-851</span>CODEN:
                <span class="NLM_cas:coden">PCJOAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-150X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Current approaches to the search for new kappa-opioid receptor (κ-OR) agonists with potential analgesic activity are reviewed.  Agents with peripheral activity and biased agonists are most promising for development.  Signal events initiated by κ-OR activation are considered.  Chem. structures of presently known κ-OR agonists are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMeghxEJcAUbVg90H21EOLACvtfcHk0ljnwY2ppHkd-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKltr0%253D&md5=e76be1dd8fbe48432b2997724aeb863b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs11094-018-1703-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11094-018-1703-y%26sid%3Dliteratum%253Aachs%26aulast%3DZaitseva%26aufirst%3DN.%2BI.%26aulast%3DGalan%26aufirst%3DS.%2BE.%26aulast%3DPavlova%26aufirst%3DL.%2BA.%26atitle%3DProspects%2520of%2520a%2520search%2520for%2520kappa-opioid%2520receptor%2520agonists%2520with%2520analgesic%2520activity%2520%2528review%2529%26jtitle%3DPharm.%2520Chem.%2520J.%26date%3D2018%26volume%3D51%26spage%3D843%26epage%3D851%26doi%3D10.1007%2Fs11094-018-1703-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charleson, S.</span></span> <span> </span><span class="NLM_article-title">High-affinity [h-3]-labeled ethylketazocine binding - evidence for specific kappa-receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1016/0028-3908(82)90190-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2F0028-3908%2882%2990190-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=6122185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaL38XksV2hsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1982&pages=215-219&author=P.+L.+Woodauthor=S.+Charleson&title=High-affinity+%5Bh-3%5D-labeled+ethylketazocine+binding+-+evidence+for+specific+kappa-receptors&doi=10.1016%2F0028-3908%2882%2990190-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">High affinity tritium-labeled ethylketazocine binding:  evidence for specific κ receptors</span></div><div class="casAuthors">Wood, P. L.; Charleson, S.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-19</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    </div><div class="casAbstract">κ Opiate receptors (3H-labeled ethylketazocine  [36292-66-7] binding) in rat brain membrane prepns. were resistant to low concns. of N-ethylmaleimide  [128-53-0], whereas μ (3H-labeled dihydromorphine binding) and δ [3H-labeled 2-D-alanine-5-D-leucine-enkephalin (I)] opiate receptors were not.  The κ site was selectively protected from inactivation with 5mM N-ethylmaleimide by the κ agonists, ethylketazocine and (-)-α-(1R,5R,9R)-5,9-dimethyl-2-(L-tetrahydrofurfuryl)-2'-hydroxy-6,7-benzomorphan, but not by morphine or I.  Hence, a unique κ receptor may be present in the rat CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Rc8yuIlGWrVg90H21EOLACvtfcHk0ljnwY2ppHkd-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XksV2hsLw%253D&md5=9e851db138d0a7f32c9d23fd7c54cacb</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2F0028-3908%2882%2990190-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0028-3908%252882%252990190-3%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DP.%2BL.%26aulast%3DCharleson%26aufirst%3DS.%26atitle%3DHigh-affinity%2520%255Bh-3%255D-labeled%2520ethylketazocine%2520binding%2520-%2520evidence%2520for%2520specific%2520kappa-receptors%26jtitle%3DNeuropharmacology%26date%3D1982%26volume%3D21%26spage%3D215%26epage%3D219%26doi%3D10.1016%2F0028-3908%2882%2990190-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dortch-Carnes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, D. E.</span></span> <span> </span><span class="NLM_article-title">Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2005.tb00270.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1111%2Fj.1527-3458.2005.tb00270.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=16007240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVOlsbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=195-212&author=J.+Dortch-Carnesauthor=D.+E.+Potter&title=Bremazocine%3A+a+kappa-opioid+agonist+with+potent+analgesic+and+other+pharmacologic+properties&doi=10.1111%2Fj.1527-3458.2005.tb00270.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Bremazocine: A κ-opioid agonist with potent analgesic and other pharmacologic properties</span></div><div class="casAuthors">Dortch-Carnes, Juanita; Potter, David E.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-212</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review.  Bremazocine is a κ-opioid receptor agonist with potent analgesic and diuretic activities.  As an analgesic it is three- to four-times more potent than morphine, as detd. in both hot plate and tail flick tests.  Bremazocine and other benzomorphan analogs were synthesized in an effort to produce opiates with greater κ-opioid receptor selectivity and with minimal morphine-like side effects.  Unlike morphine bremazocine is devoid of phys. and psychol. dependence liability in animal models and produces little or no respiratory depression.  While bremazocine does not produce the characteristic euphoria assocd. with morphine and its abuse, it has been shown to induce dysphoria, a property that limits its clin. usefulness.  Similarly to morphine, repeated administration of bremazocine leads to tolerance to its analgesic effect.  It has been demonstrated that the marked diuretic effect of bremazocine is mediated primarily by the central nervous system.  Because of its psychotomimetic side effects (disturbance in the perception of space and time, abnormal visual experience, disturbance in body image perception, de-personalization, de-realization and loss of self control) bremazocine has limited potential as a clin. analgesic.  However, its possible utility for the therapy of alc. and drug addiction warrants further consideration because of its ability to decrease ethanol and cocaine self-administration in non-human primates.  In addn., the ability of bremazocine-like drugs to lower intraocular pressure and to minimize ischemic damage in animal models suggests their possible use in the therapy of glaucoma and cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6rq4x2jCP0bVg90H21EOLACvtfcHk0ljnwY2ppHkd-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVOlsbfM&md5=6ecfd3bdfc3d5969ed4ed5e7afd54d83</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2005.tb00270.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2005.tb00270.x%26sid%3Dliteratum%253Aachs%26aulast%3DDortch-Carnes%26aufirst%3DJ.%26aulast%3DPotter%26aufirst%3DD.%2BE.%26atitle%3DBremazocine%253A%2520a%2520kappa-opioid%2520agonist%2520with%2520potent%2520analgesic%2520and%2520other%2520pharmacologic%2520properties%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2005%26volume%3D11%26spage%3D195%26epage%3D212%26doi%3D10.1111%2Fj.1527-3458.2005.tb00270.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahti, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonvoigtlander, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsuhn, C.</span></span> <span> </span><span class="NLM_article-title">Properties of a selective kappa agonist, u-50,488h</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2257</span>– <span class="NLM_lpage">2260</span>, <span class="refDoi"> DOI: 10.1016/0024-3205(82)90132-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2F0024-3205%2882%2990132-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=6131357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaL3sXhtFemtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1982&pages=2257-2260&author=R.+A.+Lahtiauthor=P.+F.+Vonvoigtlanderauthor=C.+Barsuhn&title=Properties+of+a+selective+kappa+agonist%2C+u-50%2C488h&doi=10.1016%2F0024-3205%2882%2990132-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Properties of a selective kappa agonist, U-50,488H</span></div><div class="casAuthors">Lahti, R. A.; VonVoigtlander, P. F.; Barsuhn, C.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">20-21</span>),
    <span class="NLM_cas:pages">2257-60</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    </div><div class="casAbstract">U-50488H (I)  [83913-06-8] was shown to be a naloxone-antagonizable analgesic in rodents.  However, the dose of naloxone needed for antagonism was higher than it was for morphine.  I did not produce phys. dependence; however it did produce tolerance upon chronic administration.  I was cross tolerant with bremazocine but not with morphine.  Monkeys trained to discriminate ethylketocyclazocine (EKC) from saline showed a complete generalization to I but not to morphine.  The evaluation of I in 3H-EKC site-selective binding indicated that it has a high affinity for the κ receptor and a low affinity for the μ receptor.  I appears to be a selective inhibitor of opioid κ receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTQYm0oFnQYLVg90H21EOLACvtfcHk0liRZwwx1uuEWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhtFemtw%253D%253D&md5=ea19b1ba054b4b74f8e9f53579666eed</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2882%2990132-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252882%252990132-1%26sid%3Dliteratum%253Aachs%26aulast%3DLahti%26aufirst%3DR.%2BA.%26aulast%3DVonvoigtlander%26aufirst%3DP.%2BF.%26aulast%3DBarsuhn%26aufirst%3DC.%26atitle%3DProperties%2520of%2520a%2520selective%2520kappa%2520agonist%252C%2520u-50%252C488h%26jtitle%3DLife%2520Sci.%26date%3D1982%26volume%3D31%26spage%3D2257%26epage%3D2260%26doi%3D10.1016%2F0024-3205%2882%2990132-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vonvoigtlander, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahti, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludens, J. H.</span></span> <span> </span><span class="NLM_article-title">U-50,488: a selective and structurally novel non-mu-(kappa) opioid agonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>224</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=6129321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaL3sXhtF2ms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=224&publication_year=1983&pages=7-12&author=P.+F.+Vonvoigtlanderauthor=R.+A.+Lahtiauthor=J.+H.+Ludens&title=U-50%2C488%3A+a+selective+and+structurally+novel+non-mu-%28kappa%29+opioid+agonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">U-50,488: a selective and structurally novel non-mu (kappa) opioid agonist</span></div><div class="casAuthors">Vonvoigtlander, P. F.; Lahti, R. A.; Ludens, J. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">224</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-12</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">U-50,488 (I)  [67198-13-4] displays analgesic actions in a variety (thermal, pressure and irritant) of assays in mice and rats.  Naloxone and MR-2266 block this analgesic effect; thus it is mediated by opioid receptors.  However, when compared to morphine analgesia, the naloxone and MR-2266 pA2 values for U-50,488 analgesia were much lower and higher, resp.  Likewise, although tolerance occurs to both morphine and U-50,488 analgesia, there was no cross-tolerance between these drugs, and U-50,488 does not cause morphine-type phys. dependence.  Apparently, different opioid receptors mediate the analgesic effects of morphine and U-50,488.  The effects of U-50,488 appear to be mediated by the so-called κ opioid receptor.  In contrast to U-50,488, other reputed κ opioid agonists displayed varying degrees of μ agonist (ketazocine and ethylketocyclazocine) and narcotic antagonist (bremazocine) activities.  Thus, U-50,488 is a more selective κ agonist.  This conclusion is further supported by binding studies; of all compds. tested, U-50,488 displacement of [3H]ethyllketocyclazocine binding was uniquely not blocked by high concns. of dihydromorphine.  In addn. to analgesia, this selective κ agonist also causes opioid receptor-mediated sedation, diuresis and corticosteroid elevations.  U-50,488 is a useful tool for studying contrasting κ and μ opioid receptor-mediated effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB4gIGB1gYe7Vg90H21EOLACvtfcHk0liRZwwx1uuEWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhtF2ms7k%253D&md5=b54070c6b374dd8a938ff3dccbfda564</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVonvoigtlander%26aufirst%3DP.%2BF.%26aulast%3DLahti%26aufirst%3DR.%2BA.%26aulast%3DLudens%26aufirst%3DJ.%2BH.%26atitle%3DU-50%252C488%253A%2520a%2520selective%2520and%2520structurally%2520novel%2520non-mu-%2528kappa%2529%2520opioid%2520agonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1983%26volume%3D224%26spage%3D7%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pande, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyke, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wideman, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, M. W.</span></span> <span> </span><span class="NLM_article-title">Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain</span>. <i>Clin. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1097/00002826-199619050-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1097%2F00002826-199619050-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=8889289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaK28Xmtlynu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1996&pages=451-456&author=A.+C.+Pandeauthor=R.+E.+Pykeauthor=M.+Greinerauthor=G.+L.+Widemanauthor=R.+Benjaminauthor=M.+W.+Pierce&title=Analgesic+efficacy+of+enadoline+versus+placebo+or+morphine+in+postsurgical+pain&doi=10.1097%2F00002826-199619050-00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain</span></div><div class="casAuthors">Pande, Atul C.; Pyke, Robert E.; Greiner, Martha; Wideman, Gilder L.; Benjamin, Ronald; Pierce, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Neuropharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">451-456</span>CODEN:
                <span class="NLM_cas:coden">CLNEDB</span>;
        ISSN:<span class="NLM_cas:issn">0362-5664</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">Enadoline, a selective agonist of the κ-opioid receptor, was studied for its analgesic efficacy in patients with pain after obstetric or gynecol. surgery.  An initial study involving a comparison of enadoline (2, 5, 15μg), an acetaminophen-codeine (ACET/COD) combination, and placebo showed all treatments to be ineffective analgesics.  Therefore, a second study with the same design but using higher doses of enadoline (15 and 25μg) and replacing ACET/COD with morphine 10 mg i.m. was conducted.  Enadoline 25μg produced similar pain relief to that of morphine, although of shorter duration, and better than enadoline 15μg or placebo.  However, enadoline was assocd. with dose-limiting neuropsychiatric adverse events, which led to early termination of the study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkWntz_uJvzLVg90H21EOLACvtfcHk0lg4puCQa_ieHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xmtlynu74%253D&md5=111db0a878ebfed0fdec77f0e936aaf7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1097%2F00002826-199619050-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00002826-199619050-00009%26sid%3Dliteratum%253Aachs%26aulast%3DPande%26aufirst%3DA.%2BC.%26aulast%3DPyke%26aufirst%3DR.%2BE.%26aulast%3DGreiner%26aufirst%3DM.%26aulast%3DWideman%26aufirst%3DG.%2BL.%26aulast%3DBenjamin%26aufirst%3DR.%26aulast%3DPierce%26aufirst%3DM.%2BW.%26atitle%3DAnalgesic%2520efficacy%2520of%2520enadoline%2520versus%2520placebo%2520or%2520morphine%2520in%2520postsurgical%2520pain%26jtitle%3DClin.%2520Neuropharmacol.%26date%3D1996%26volume%3D19%26spage%3D451%26epage%3D456%26doi%3D10.1097%2F00002826-199619050-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strain, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abreu, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigelow, G. E.</span></span> <span> </span><span class="NLM_article-title">Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1007/s002130100788</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1007%2Fs002130100788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=11594439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3MXns1Clt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2001&pages=151-162&author=S.+L.+Walshauthor=E.+C.+Strainauthor=M.+E.+Abreuauthor=G.+E.+Bigelow&title=Enadoline%2C+a+selective+kappa+opioid+agonist%3A+comparison+with+butorphanol+and+hydromorphone+in+humans&doi=10.1007%2Fs002130100788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans</span></div><div class="casAuthors">Walsh, Sharon L.; Strain, Eric C.; Abreu, Mary E.; Bigelow, George E.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-162</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">The availability of the highly selective and specific kappa opioid agonist enadoline provides an opportunity to explore the function of kappa receptors in humans and their potential utility as a target for substance abuse pharmacotherapy development.  The pharmacodynamic effects of enadoline, a selective kappa agonist, were characterized and butorphanol, a mixed mu/kappa agonist, and hydromorphone, a mu agonist, were compared with it in humans.  Pilot evaluation served to establish i.m. doses of enadoline (20, 40, 80, and 160 μg/70 kg), butorphanol (1.5, 3, 6, and 12 mg/70 kg), and hydromorphone (1.5, 3, and 6 mg/70 kg) of comparable activity.  These acute doses were examd. under double-blind, placebo-controlled and constrained randomized conditions with a min. of 72 h between tests in volunteers with polysubstance abuse histories.  Physiol. and subject- and observer-rated measures were collected 30 min before and for 4 h after administration.  Enadoline significantly increased measures of sedation, confusion and dizziness, produced visual distortions and feelings of depersonalization, and increased urinary output.  The highest dose (160 μg/70 kg) was not tolerated and led to psychotomimetic effects.  Hydromorphone produced prototypic mu opioid effects including respiratory depression, miosis, and euphoria.  Butorphanol was most similar to hydromorphone and shared few effects with enadoline.  These results are discussed with respect to the potential use and safety of kappa agonists for clin. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUXIJ-OK2aL7Vg90H21EOLACvtfcHk0lg4puCQa_ieHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXns1Clt7w%253D&md5=2eec6fc4a78e9fabf79a0508babe5d4e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs002130100788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002130100788%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DS.%2BL.%26aulast%3DStrain%26aufirst%3DE.%2BC.%26aulast%3DAbreu%26aufirst%3DM.%2BE.%26aulast%3DBigelow%26aufirst%3DG.%2BE.%26atitle%3DEnadoline%252C%2520a%2520selective%2520kappa%2520opioid%2520agonist%253A%2520comparison%2520with%2520butorphanol%2520and%2520hydromorphone%2520in%2520humans%26jtitle%3DPsychopharmacology%26date%3D2001%26volume%3D157%26spage%3D151%26epage%3D162%26doi%3D10.1007%2Fs002130100788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wadenberg, M. L. G.</span></span> <span> </span><span class="NLM_article-title">A review of the properties of spiradoline: A potent and selective kappa-opioid receptor agonist</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2003.tb00248.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1111%2Fj.1527-3458.2003.tb00248.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=12847558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsl2qt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=187-198&author=M.+L.+G.+Wadenberg&title=A+review+of+the+properties+of+spiradoline%3A+A+potent+and+selective+kappa-opioid+receptor+agonist&doi=10.1111%2Fj.1527-3458.2003.tb00248.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A review of the properties of spiradoline: a potent and selective .vkappa.-opioid receptor agonist</span></div><div class="casAuthors">Wadenberg, M.-L. G.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-198</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review.  The selective .vkappa.-opioid receptor agonist spiradoline mesylate (U62,066E), an arylacetamide, was synthesized with the intention of creating an analgesic that, while still retaining its analgesic properties, would be devoid of the, mainly μ receptor mediated, side effects such as phys. dependence and respiratory depression assocd. with morphine.  Spiradoline is highly selective for the .vkappa. receptor with Ki of 8.6 nM in guinea pig.  Examn. of the enantiomers of spiradoline, showed the (-)enantiomer to be responsible for the .vkappa. agonist properties.  Spiradoline easily penetrates the blood brain barrier, and does not seem to have any significant active metabolites.  In preclin. studies, spiradoline has a short duration of action with a peak at around 30 min after administration.  The analgesic properties of spiradoline are well documented in mice and rats.  Antitussive properties have also been reported in rats.  Furthermore, spiradoline was reported to display effects suggestive of neuroprotective properties in animal models of ischemia.  In humans, spiradoline is a potent diuretic.  It also produces significant sedation presumably due to its antihistamine properties.  Preclin. studies have shown that spiradoline reduces blood pressure and heart rate, and has possible antiarrhythmic properties.  Clin. studies did not confirm these findings.  .vkappa. Receptors inhibit dopaminergic neurotransmission.  Spiradoline, given systematically to rats, produces a significant and long lasting decrease in dopamine release, and in locomotor activity.  It has also antipsychotic-like effect in animal behavioral tests.  At low doses spiradoline was reported to decrease tics in patients with Tourette's syndrome.  Although spiradoline had promising effects in animal tests of analgesia, and a reasonably good safety profile in preliminary studies, it did not replace morphine as an analgesic.  The available clin. data suggest that spiradoline produces disturbing adverse effects such as diuresis, sedation, and dysphoria at doses lower than those needed for analgesic effects.  Thus, future development of spiradoline-like analgesic compds. should preferably focus on redn. of unwanted effects on the central nervous system.  Spiradoline, which currently is com. available for preclin. research, might prove useful in some psychiatric conditions and possibly as a neuroprotective agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvNIeGyLqL87Vg90H21EOLACvtfcHk0lg4puCQa_ieHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsl2qt7s%253D&md5=11de5c95875bd8a8f1db5304a1cd2889</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2003.tb00248.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2003.tb00248.x%26sid%3Dliteratum%253Aachs%26aulast%3DWadenberg%26aufirst%3DM.%2BL.%2BG.%26atitle%3DA%2520review%2520of%2520the%2520properties%2520of%2520spiradoline%253A%2520A%2520potent%2520and%2520selective%2520kappa-opioid%2520receptor%2520agonist%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2003%26volume%3D9%26spage%3D187%26epage%3D198%26doi%3D10.1111%2Fj.1527-3458.2003.tb00248.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butelman, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreek, M. J.</span></span> <span> </span><span class="NLM_article-title">Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">190</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.3389%2Ffphar.2015.00190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=26441647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADC%252BC283ps1Sgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=190&author=E.+R.+Butelmanauthor=M.+J.+Kreek&title=Salvinorin+A%2C+a+kappa-opioid+receptor+agonist+hallucinogen%3A+pharmacology+and+potential+template+for+novel+pharmacotherapeutic+agents+in+neuropsychiatric+disorders&doi=10.3389%2Ffphar.2015.00190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders</span></div><div class="casAuthors">Butelman Eduardo R; Kreek Mary Jeanne</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">190</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Salvinorin A is a potent hallucinogen, isolated from the ethnomedical plant Salvia divinorum.  Salvinorin A is a selective high efficacy kappa-opioid receptor (KOPr) agonist, and thus implicates the KOPr system and its endogenous agonist ligands (the dynorphins) in higher functions, including cognition and perceptual effects.  Salvinorin A is the only selective KOPr ligand to be widely available outside research or medical settings, and salvinorin A-containing products have undergone frequent non-medical use.  KOPr/dynorphin systems in the brain are known to be powerful counter-modulatory mechanisms to dopaminergic function, which is important in mood and reward engendered by natural and chemical reinforcers (including drugs of abuse).  KOPr activation (including by salvinorin A) can thus cause aversion and anhedonia in preclinical models.  Salvinorin A is also a completely new scaffold for medicinal chemistry approaches, since it is a non-nitrogenous neoclerodane, unlike other known opioid ligands.  Ongoing efforts have the goal of discovering novel semi-synthetic salvinorin analogs with potential KOPr-mediated pharmacotherapeutic effects (including partial agonist or biased agonist effects), with a reduced burden of undesirable effects associated with salvinorin A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTsuodK6iLMsve_zCu79I8fW6udTcc2ea2OXwYaxz8Xbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ps1Sgsw%253D%253D&md5=5e7d64ca553f082d43c77510a0e14970</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00190%26sid%3Dliteratum%253Aachs%26aulast%3DButelman%26aufirst%3DE.%2BR.%26aulast%3DKreek%26aufirst%3DM.%2BJ.%26atitle%3DSalvinorin%2520A%252C%2520a%2520kappa-opioid%2520receptor%2520agonist%2520hallucinogen%253A%2520pharmacology%2520and%2520potential%2520template%2520for%2520novel%2520pharmacotherapeutic%2520agents%2520in%2520neuropsychiatric%2520disorders%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D190%26doi%3D10.3389%2Ffphar.2015.00190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hameroff, S. R.</span></span> <span> </span><span class="NLM_article-title">Opiate receptor pharmacology: mixed agonist/antagonist narcotics</span>. <i>Contemp. Anesth. Pract</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">43</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=6136392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADyaL3s3os1Kjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1983&pages=27-43&author=S.+R.+Hameroff&title=Opiate+receptor+pharmacology%3A+mixed+agonist%2Fantagonist+narcotics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Opiate receptor pharmacology: mixed agonist/antagonist narcotics</span></div><div class="casAuthors">Hameroff S R</div><div class="citationInfo"><span class="NLM_cas:title">Contemporary anesthesia practice</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-43</span>
        ISSN:<span class="NLM_cas:issn">0191-247X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAAtttRn0ZGNFxYDaSSP8XfW6udTcc2ea2OXwYaxz8Xbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s3os1Kjtg%253D%253D&md5=405d24054d313803505f5c79c404642d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHameroff%26aufirst%3DS.%2BR.%26atitle%3DOpiate%2520receptor%2520pharmacology%253A%2520mixed%2520agonist%252Fantagonist%2520narcotics%26jtitle%3DContemp.%2520Anesth.%2520Pract%26date%3D1983%26volume%3D7%26spage%3D27%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Souza, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhar, M. J.</span></span> <span> </span><span class="NLM_article-title">Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>244</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">402</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=2826773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaL1cXosl2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=1988&pages=391-402&author=E.+B.+De%0ASouzaauthor=W.+K.+Schmidtauthor=M.+J.+Kuhar&title=Nalbuphine%3A+an+autoradiographic+opioid+receptor+binding+profile+in+the+central+nervous+system+of+an+agonist%2Fantagonist+analgesic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Nalbuphine:  an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic</span></div><div class="casAuthors">De Souza, Errol B.; Schmidt, William K.; Kuhar, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">391-402</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The sites of nalbuphine binding to μ, δ, and κ opioid receptors in the central nervous system (CNS) were localized by use of in vitro labeling light-microscopic autoradiog.  Mu, delta and kappa opioid receptors were labeled selectively by [3H]dihydromorphine, D-[3H]Ala2-D-Leu5-enkephalin and (-)-[3H]ethylketocyclazocine, resp.  In displacement studies in rat brain homogenates, nalbuphine had the highest affinity for μ receptors (0.5 nM) with progressively lower affinities for κ (29 nM) and δ (60 nM) opioid receptors.  In autoradiog. studies in slide-mounted sections of guinea pig brain and monkey spinal cord, nalbuphine (300 nM) displaced completely the binding at μ and κ receptors without significantly altering the binding at δ receptors.  The binding of [3H]nalbuphine in slide-mounted sections of guinea pig forebrain was saturable and showed a curvilinear profile, indicating the presence of 2 binding sites with apparent dissocn. const. values of 0.5 and 12 nM.  Morphine and U-50,488H, which have high affinities for μ and κ opioid receptors, resp., inhibited [3H]nalbuphine binding with IC50 values of 0.9 and 10 nM, resp.  In satn. studies, morphine (50 nM) and U-50,488H (100 nM) selectively blocked the high- and low-affinity components of [3H]nalbuphine binding, resp.  The autoradiog. distribution of [3H]nalbuphine binding sites in the CNS corresponds well to the distribution of μ and κ opioid receptors.  In addn., CNS areas (deep layers of the cerebral cortex, laminae I and II of the spinal cord, substantia gelatinosa of the trigeminal nerve, periaqueductal gray and thalamic nuclei) that mediate analgesia contain high concns. of [3H]nalbuphine binding sites.  These data demonstrate that nalbuphine acts on μ and κ opioid receptors and identify anatomical loci in the CNS in which nalbuphine may produce its actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmheQFujG0trVg90H21EOLACvtfcHk0lgVT4hDMomUTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXosl2ruw%253D%253D&md5=3e081fc8a7bd54a10a3c83d38b62a18d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSouza%26aufirst%3DE.%2BB.%26aulast%3DSchmidt%26aufirst%3DW.%2BK.%26aulast%3DKuhar%26aufirst%3DM.%2BJ.%26atitle%3DNalbuphine%253A%2520an%2520autoradiographic%2520opioid%2520receptor%2520binding%2520profile%2520in%2520the%2520central%2520nervous%2520system%2520of%2520an%2520agonist%252Fantagonist%2520analgesic%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1988%26volume%3D244%26spage%3D391%26epage%3D402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosow, C. E.</span></span> <span> </span><span class="NLM_article-title">Butorphanol in perspective</span>. <i>Acute Care</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">Suppl. 1</span>),  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">7</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=2830756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADyaL1c7kslehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1988&pages=2-7&issue=Suppl.+1&author=C.+E.+Rosow&title=Butorphanol+in+perspective"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Butorphanol in perspective</span></div><div class="casAuthors">Rosow C E</div><div class="citationInfo"><span class="NLM_cas:title">Acute care</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">12 Suppl 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2-7</span>
        ISSN:<span class="NLM_cas:issn">0254-0819</span>.
    </div><div class="casAbstract">Butorphanol tartrate is a highly effective opioid agonist-antagonist analgesic with qualitative as well as quantitative differences from the pure agonists.  These differences are thought to be due to interaction with a distinct subset of opioid receptors.  Although it relieves severe pain, the drug does not usually elevate mood, and it may occasionally cause dysphoria.  Counterbalancing its disadvantages is a wealth of clinical experience with the drug showing an impressive record of safety.  Butorphanol produces limited respiratory depression and smooth muscle spasm, and both effects are reversible with naloxone.  The most prominent side effect is sedation, a property that is generally quite useful in the perioperative period.  Butorphanol is a weak morphine antagonist, so it may interact with agonists like morphine or fentanyl.  The chief advantages of this agent are its low toxicity and very low potential for abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6VtwAdAXrBhpyrDyM_m9cfW6udTcc2ebKkJ2k2JN0Zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c7kslehug%253D%253D&md5=084e280ae238036875c8f14d66c393c8</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosow%26aufirst%3DC.%2BE.%26atitle%3DButorphanol%2520in%2520perspective%26jtitle%3DAcute%2520Care%26date%3D1988%26volume%3D12%26issue%3DSuppl.%25201%26spage%3D2%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brogden, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speight, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, G. S.</span></span> <span> </span><span class="NLM_article-title">Pentazocine: a review of its pharmacological properties, therapeutic efficacy and dependence liability</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.2165/00003495-197305010-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.2165%2F00003495-197305010-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=4578369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaE3sXktlygt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1973&pages=6-91&author=R.+N.+Brogdenauthor=T.+M.+Speightauthor=G.+S.+Avery&title=Pentazocine%3A+a+review+of+its+pharmacological+properties%2C+therapeutic+efficacy+and+dependence+liability&doi=10.2165%2F00003495-197305010-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pentazocine.  Review of its pharmacological properties, therapeutic efficacy, and dependence liability</span></div><div class="casAuthors">Brogden, R. N.; Speight, T. M.; Avery, G. S.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-91</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    </div><div class="casAbstract">A review with 121 refs.  The analgesic and side effects of pentazocine (I) [359-83-1] are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnJ3bri5VkZ7Vg90H21EOLACvtfcHk0lgVT4hDMomUTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXktlygt78%253D&md5=b7a86c1a0dfc4c122c3d916d5f895b6b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2165%2F00003495-197305010-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-197305010-00002%26sid%3Dliteratum%253Aachs%26aulast%3DBrogden%26aufirst%3DR.%2BN.%26aulast%3DSpeight%26aufirst%3DT.%2BM.%26aulast%3DAvery%26aufirst%3DG.%2BS.%26atitle%3DPentazocine%253A%2520a%2520review%2520of%2520its%2520pharmacological%2520properties%252C%2520therapeutic%2520efficacy%2520and%2520dependence%2520liability%26jtitle%3DDrugs%26date%3D1973%26volume%3D5%26spage%3D6%26epage%3D91%26doi%3D10.2165%2F00003495-197305010-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span> <span> </span><span class="NLM_article-title">Pentazocine-Induced Biphasic Analgesia in Mice</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1827</span>– <span class="NLM_lpage">1835</span>, <span class="refDoi"> DOI: 10.1016/0024-3205(91)90238-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2F0024-3205%2891%2990238-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1645834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaK3MXit1Whtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1991&pages=1827-1835&author=T.+Suzukiauthor=M.+Naritaauthor=M.+Misawaauthor=H.+Nagase&title=Pentazocine-Induced+Biphasic+Analgesia+in+Mice&doi=10.1016%2F0024-3205%2891%2990238-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pentazocine-induced biphasic analgesia in mice</span></div><div class="casAuthors">Suzuki, Tsutomu; Narita, Minoru; Misawa, Miwa; Nagase, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1827-35</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    </div><div class="casAbstract">Pentazocine (PZ) is well known to act as an opioid mixed agonist-antagonist analgesic.  In the present study, mouse warm plate test condition of 51° was selected instead of 55° to det. the analgesic action of PZ.  PZ (intracerebroventricular, i.c.v.) produced a biphasic antinociceptive response, while U-50,488H (U-50) and morphine (MRP) produced a monophasic response.  Pretreatment with i.c.v. β-FNA (μ antagonist) antagonized the initial response, whereas the delayed response was antagonized by pretreatment with nor-BNI (κ antagonist).  In addn., pretreatment with NTI (δ antagonist) significantly attenuated the initial response but not the delayed response.  These results suggest that the initial and delayed responses may be mediated mainly by μ/δ and κ receptors, resp.  With regards to the interaction between MRP and PZ, a low dose of PZ antagonized the analgesic action of MRP, while a high dose PZ plus MRP showed the additive effect.  Furthermore, tolerance developed almost equally to both initial and delayed responses, indicating that tolerance to both the κ and the μ components of action of PZ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrpC7oURoIobVg90H21EOLACvtfcHk0lh48c-FylCRVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXit1Whtb8%253D&md5=39f108f607d3e736b286b2881d098b2d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2891%2990238-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252891%252990238-7%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DNarita%26aufirst%3DM.%26aulast%3DMisawa%26aufirst%3DM.%26aulast%3DNagase%26aufirst%3DH.%26atitle%3DPentazocine-Induced%2520Biphasic%2520Analgesia%2520in%2520Mice%26jtitle%3DLife%2520Sci.%26date%3D1991%26volume%3D48%26spage%3D1827%26epage%3D1835%26doi%3D10.1016%2F0024-3205%2891%2990238-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Endoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumimoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span> <span> </span><span class="NLM_article-title">TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys</span>. <i>Jpn. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1254/jjp.85.282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1254%2Fjjp.85.282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=11325021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitlSlsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2001&pages=282-290&author=T.+Endohauthor=A.+Tajimaauthor=N.+Izumimotoauthor=T.+Suzukiauthor=A.+Saitohauthor=T.+Suzukiauthor=M.+Naritaauthor=J.+Kameiauthor=L.+F.+Tsengauthor=H.+Mizoguchiauthor=H.+Nagase&title=TRK-820%2C+a+selective+kappa-opioid+agonist%2C+produces+potent+antinociception+in+cynomolgus+monkeys&doi=10.1254%2Fjjp.85.282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">TRK-820, a selective κ-opioid agonist, produces potent antinociception in cynomolgus monkeys</span></div><div class="casAuthors">Endoh, Takashi; Tajima, Atsushi; Izumimoto, Naoki; Suzuki, Tomohiko; Saitoh, Akiyoshi; Suzuki, Tsutomu; Narita, Minoru; Kamei, Junzo; Tseng, Leon F.; Mizoguchi, Hirokazu; Nagase, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">282-290</span>CODEN:
                <span class="NLM_cas:coden">JJPAAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-5198</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">TRK-820 ((-)-17-cyclopropylmethyl-3,14b-dihydroxy-4,5a-epoxy-6b-[N-methyl-trans-3-(3-furyl)acrylamide]morphinan hydrochloride) has been shown to be a potent opioid κ-receptor agonist with pharmacol. properties different from those produced by κ1-opioid receptor agonists in rodents.  To ascertain whether or not these properties of TRK-820 would be extended to primates, the antinociceptive effect of TRK-820 was evaluated in cynomolgus monkeys by the hot-water tail-withdrawal procedure.  TRK-820 given i.m. produced a potent antinociceptive effect that was 295- and 495-fold more potent than morphine with the 50 and 55 hot-water tests, resp., and 40-fold more potent than U-50,488H and 1,000-fold more potent than pentazocine in the 50 hot-water test.  The duration of antinociceptive effects of TRK-820 treatment (0.01 and 0.03 mg/kg, i.m.) lasted more than 6 h, which was much longer than those of U-50,488H.  The antinociception produced by the higher dose (0.03 mg/kg, i.m.) of TRK-820 was not inhibited by nor-binaltorphimine (3.2 and 10 mg/kg, s.c.) or by naloxone (0.1 mg/kg, s.c.), although the antinociception induced by a lower dose of TRK-820 (0.01 mg/kg, i.m.) was inhibited by nor-binaltorphimine (10 mg/kg, s.c.).  The same doses of nor-binaltorphimine and naloxone effectively inhibited the antinociception induced by the higher doses of U-50,488H (1.0 mg/kg, i.m.) and morphine (10 mg/kg, i.m.), resp.  These results indicate that the antinociception induced by TRK-820 is less sensitive to nor-binaltorphimine and suggest that it is mediated by the stimulation of a subtype of κ-opioid receptor different from the κ1-opioid receptor in cynomolgus monkeys.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF6dqs9rxXi7Vg90H21EOLACvtfcHk0lh48c-FylCRVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitlSlsL4%253D&md5=f0218796bbb4cab1693fec812c6c5b85</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1254%2Fjjp.85.282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjjp.85.282%26sid%3Dliteratum%253Aachs%26aulast%3DEndoh%26aufirst%3DT.%26aulast%3DTajima%26aufirst%3DA.%26aulast%3DIzumimoto%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DSaitoh%26aufirst%3DA.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DNarita%26aufirst%3DM.%26aulast%3DKamei%26aufirst%3DJ.%26aulast%3DTseng%26aufirst%3DL.%2BF.%26aulast%3DMizoguchi%26aufirst%3DH.%26aulast%3DNagase%26aufirst%3DH.%26atitle%3DTRK-820%252C%2520a%2520selective%2520kappa-opioid%2520agonist%252C%2520produces%2520potent%2520antinociception%2520in%2520cynomolgus%2520monkeys%26jtitle%3DJpn.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D85%26spage%3D282%26epage%3D290%26doi%3D10.1254%2Fjjp.85.282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorbera, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. A.</span></span> <span> </span><span class="NLM_article-title">Nalfurafine hydrochloride. Antipruritic, analgesic, kappa opioid agonist</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1358/dof.2003.028.03.723584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1358%2Fdof.2003.028.03.723584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvVCju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=237-242&author=L.+A.+Sorberaauthor=J.+Castanerauthor=P.+A.+Leeson&title=Nalfurafine+hydrochloride.+Antipruritic%2C+analgesic%2C+kappa+opioid+agonist&doi=10.1358%2Fdof.2003.028.03.723584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Nalfurafine hydrochloride</span></div><div class="casAuthors">Sorbera, L. A.; Castaner, J.; Leeson, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">237-242</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Pruritus is a common symptom seen in 25-90% of uremic patients, esp. those with chronic renal failure requiring hemodialysis.  The cause and mechanism of induction of pruritus are not known.  However, studies comparing hemodialysis patients with healthy subjects provided evidence that an imbalance in the endogenous opioid system may be responsible for pruritus with particular involvement of the kappa opioid system.  Although existing kappa opioid receptor agonists lack morphine-like adverse effects, they are assocd. with dysphoria and psychotomimetic alterations.  Thus, research efforts continue to focus on new kappa opioid agonists with novel structures to circumvent unwanted adverse effects.  Nalfurafine hydrochloride is a novel kappa opioid receptor agonist that emerged using procedures incorporating a modification of the message-address concept.  Nalfurafine was shown to be highly selective for the kappa opioid receptor in vitro and has displayed potent antipruritic activity in vivo.  Moreover, a single dose of an oral formulation was shown to alleviate itch in hemodialysis patients suffering from severe pruritus.  Nalfurafine has also shown potent antinociceptive activity both in vitro and in vivo in various animal models of pain and was also selected for further development as an analgesic for moderate and severe pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooH3rw2_KPFLVg90H21EOLACvtfcHk0ljzr0cxzsT0ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvVCju7w%253D&md5=c49ca8c50d9a670f443f604b39b9753e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1358%2Fdof.2003.028.03.723584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2003.028.03.723584%26sid%3Dliteratum%253Aachs%26aulast%3DSorbera%26aufirst%3DL.%2BA.%26aulast%3DCastaner%26aufirst%3DJ.%26aulast%3DLeeson%26aufirst%3DP.%2BA.%26atitle%3DNalfurafine%2520hydrochloride.%2520Antipruritic%252C%2520analgesic%252C%2520kappa%2520opioid%2520agonist%26jtitle%3DDrugs%2520Future%26date%3D2003%26volume%3D28%26spage%3D237%26epage%3D242%26doi%3D10.1358%2Fdof.2003.028.03.723584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumimoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takezawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endoh, T.</span></span> <span> </span><span class="NLM_article-title">Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>995</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2003.09.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.brainres.2003.09.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=14672806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1Gktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=995&publication_year=2004&pages=167-175&author=T.+Suzukiauthor=N.+Izumimotoauthor=Y.+Takezawaauthor=M.+Fujimuraauthor=Y.+Togashiauthor=H.+Nagaseauthor=T.+Tanakaauthor=T.+Endoh&title=Effect+of+repeated+administration+of+TRK-820%2C+a+kappa-opioid+receptor+agonist%2C+on+tolerance+to+its+antinociceptive+and+sedative+actions&doi=10.1016%2Fj.brainres.2003.09.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of repeated administration of TRK-820, a κ-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions</span></div><div class="casAuthors">Suzuki, Tomohiko; Izumimoto, Naoki; Takezawa, Yuko; Fujimura, Morihiro; Togashi, Yuko; Nagase, Hiroshi; Tanaka, Toshiaki; Endoh, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">995</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-175</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Repeated administration of μ-opioid receptor agonist, morphine induces tolerance not only to the antinociceptive effect but also to other pharmacol. effects, resulting in shortened working duration and decreased efficacy.  But less is known about κ-opioid agonist-induced tolerance.  The tolerance-development potency of κ-opioid receptor agonists with a focus on TRK-820 was characterized.  After five administrations of κ-opioid receptor agonists, TRK-820 (0.1 - 0.8 mg/kg), U-50488H (10 - 80 mg/kg) and ICI-199441 (0.025 - 0.2 mg/kg) s.c. over 3 days, tolerance to the antinociceptive effects, assessed by an acetic acid-induced abdominal constriction test, developed in a repeated dose-dependent manner.  The tolerance-development potency of TRK-820 was the least among these κ-opioid receptor agonists.  Similarly, TRK-820 and U-50488H induced tolerance to their sedative effects as judged by a wheel-running test in mice.  Greater tolerance was developed to the sedative effect than to the antinociceptive effect in both compds.  After repeated administration, the no. of κ-opioid receptors in the mouse brain was reduced by U-50488H (80 mg/kg) but not by TRK-820 (0.4 mg/kg).  There was no change of the affinity by the treatment with both compds.  These results demonstrated that the κ-opioid receptor agonists developed tolerance both to the antinociceptive and the sedative effects, though the tolerance to the sedative effect developed more readily than tolerance to the antinociceptive effect.  The difference in the potency for down-regulating the κ-opioid receptors in the brain may account for the tolerance-development potency of the compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvzd730_cPurVg90H21EOLACvtfcHk0ljzr0cxzsT0ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1Gktrc%253D&md5=7c0c3e01e44ca51bb2ac4972e1b10786</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2003.09.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2003.09.057%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DIzumimoto%26aufirst%3DN.%26aulast%3DTakezawa%26aufirst%3DY.%26aulast%3DFujimura%26aufirst%3DM.%26aulast%3DTogashi%26aufirst%3DY.%26aulast%3DNagase%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DEndoh%26aufirst%3DT.%26atitle%3DEffect%2520of%2520repeated%2520administration%2520of%2520TRK-820%252C%2520a%2520kappa-opioid%2520receptor%2520agonist%252C%2520on%2520tolerance%2520to%2520its%2520antinociceptive%2520and%2520sedative%2520actions%26jtitle%3DBrain%2520Res.%26date%3D2004%26volume%3D995%26spage%3D167%26epage%3D175%26doi%3D10.1016%2Fj.brainres.2003.09.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozono, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshitani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, R.</span></span> <span> </span><span class="NLM_article-title">Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch (R) capsules 2.5 mu g) in 3,762 hemodialysis patients with intractable pruritus</span>. <i>Int. J. Nephrol. Renovasc. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.2147/IJNRD.S145720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.2147%2FIJNRD.S145720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=29391822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Crtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=9-24&author=H.+Kozonoauthor=H.+Yoshitaniauthor=R.+Nakano&title=Post-marketing+surveillance+study+of+the+safety+and+efficacy+of+nalfurafine+hydrochloride+%28Remitch+%28R%29+capsules+2.5+mu+g%29+in+3%2C762+hemodialysis+patients+with+intractable+pruritus&doi=10.2147%2FIJNRD.S145720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch capsules 2.5 μg) in 3,762 hemodialysis patients with intractable pruritus</span></div><div class="casAuthors">Kozono, Hideki; Yoshitani, Hiroshi; Nakano, Ryoko</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nephrology and Renovascular Disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-24</span>CODEN:
                <span class="NLM_cas:coden">IJNRBW</span>;
        ISSN:<span class="NLM_cas:issn">1178-7058</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Intractable pruritus in hemodialysis patients can significantly decrease their quality of life and is also assocd. with poor vital prognosis.  Although combined multiple causes of intractable pruritus in these patients have been identified, no existing treatments are proven to be sufficiently effective.  We conducted a post-marketing surveillance to follow-up and assess the safety and efficacy of nalfurafine, a selective-opioid receptor agonist, for the treatment of intractable pruritus in patients undergoing hemodialysis.  Patients and methods: Hemodialysis patients with intractable pruritus from institutions in Japan who received oral nalfurafine hydrochloride between Jan. 2010 and Dec. 2013 were enrolled in the surveillance.  Surveillance was completed in July 2015.  Safety data during 1 yr after nalfurafine treatment onset, and efficacy data of nalfurafine evaluating the first 12-wk treatment period and the following period until 1 yr after the initial dose of nalfurafine (using global assessment of the itch improvement by the physician, Visual Analog Scale, and the Shiratori's severity scores) were collected and analyzed.  Results: In total, 3,762 patients were analyzed for safety.  Adverse drug reactions were experienced by 402/3,762 (10.69%) patients.  The most frequent adverse drug reactions were insomnia (127/3,762 [3.38%] patients), constipation (34 [0.90%]), somnolence (32 [0.85%]), dizziness (23 [0.61%]), nausea (13 [0.35%]), and malaise (9 [0.24%]).  No patients developed dependence on nalfurafine.  Nalfurafine was effective in 82.50% (2,880/3,491) of patients during the first 12 wk and in 84.95% (2,167/2,551) on treatment during the subsequent period until 1 yr after nalfurafine treatment initiation.  Statistically significant decreases were reported in the Visual Analog Scale and the Shiratori's severity scores (p = 0.001).  Conclusion: Oral nalfurafine hydrochloride (from 2.5 μg/day to a max. of 5.0 μg/day) continues to be safe and effective for the treatment of intractable pruritus in hemodialysis patients in real-world clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpk-a0x0gULrVg90H21EOLACvtfcHk0lgUnksy3y2rag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Crtb%252FJ&md5=720d3fae7de92bad56e3bc991ee8f473</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2147%2FIJNRD.S145720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJNRD.S145720%26sid%3Dliteratum%253Aachs%26aulast%3DKozono%26aufirst%3DH.%26aulast%3DYoshitani%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DR.%26atitle%3DPost-marketing%2520surveillance%2520study%2520of%2520the%2520safety%2520and%2520efficacy%2520of%2520nalfurafine%2520hydrochloride%2520%2528Remitch%2520%2528R%2529%2520capsules%25202.5%2520mu%2520g%2529%2520in%25203%252C762%2520hemodialysis%2520patients%2520with%2520intractable%2520pruritus%26jtitle%3DInt.%2520J.%2520Nephrol.%2520Renovasc.%2520Dis.%26date%3D2018%26volume%3D11%26spage%3D9%26epage%3D24%26doi%3D10.2147%2FIJNRD.S145720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumagai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients</span>. <i>Am. J. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1159/000341268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1159%2F000341268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=22868684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KmsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=175-183&author=H.+Kumagaiauthor=T.+Ebataauthor=K.+Takamoriauthor=K.+Miyasatoauthor=T.+Muramatsuauthor=H.+Nakamotoauthor=M.+Kuriharaauthor=T.+Yanagitaauthor=H.+Suzuki&title=Efficacy+and+safety+of+a+novel+k-agonist+for+managing+intractable+pruritus+in+dialysis+patients&doi=10.1159%2F000341268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of a Novel κ-Agonist for Managing Intractable Pruritus in Dialysis Patients</span></div><div class="casAuthors">Kumagai, Hiroo; Ebata, Toshiya; Takamori, Kenji; Miyasato, Katsumasa; Muramatsu, Taro; Nakamoto, Hidetomo; Kurihara, Masanao; Yanagita, Tomoji; Suzuki, Hiromichi</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Nephrology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-183</span>CODEN:
                <span class="NLM_cas:coden">AJNED9</span>;
        ISSN:<span class="NLM_cas:issn">0250-8095</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Our previous placebo-controlled, prospective, double-blind study demonstrated that a new opioid κ-receptor agonist, nalfurafine hydrochloride, effectively reduced treatment-resistant pruritus in 337 hemodialysis patients.  Thus, we designed this study to evaluate prospectively the efficacy, safety, addiction liability, and pharmacokinetics of nalfurafine given orally for 1 yr.  Methods: This open-label study examd. the effects and adverse drug reactions (ADRs) of 52-wk oral administration of nalfurafine hydrochloride (5 μg/day) in 211 hemodialysis patients with a treatment-resistant itch.  Results: Of 211 patients, 145 completed the study as scheduled.  The mean pruritus value assessed by the visual analog scale was 75.2 mm during the pre-observation period, which decreased significantly to 50.9 and 30.9 mm in week 2 and 52, resp., indicating a long-lasting efficacy.  ADRs occurred in 103 patients (48.8%).  Frequent ADRs were insomnia (sleep disturbance, 19.4%), constipation (7.1%) and increased blood prolactin (3.3%), similar to previous reports.  Regarding addiction liability, it appeared unlikely that nalfurafine hydrochloride was abused.  After the start of treatment, plasma drug levels reached a steady state in week 2 with no apparent tendency of systemic accumulation.  Conclusions: Nalfurafine hydrochloride, orally administered at 5 μg/day for 52 wk to hemodialysis patients, produced a long-term suppression of pruritus without significant safety problems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0PURKsHap9LVg90H21EOLACvtfcHk0lgUnksy3y2rag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KmsbvM&md5=7ecde41d3b88711f9130b167fb350c85</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1159%2F000341268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000341268%26sid%3Dliteratum%253Aachs%26aulast%3DKumagai%26aufirst%3DH.%26aulast%3DEbata%26aufirst%3DT.%26aulast%3DTakamori%26aufirst%3DK.%26aulast%3DMiyasato%26aufirst%3DK.%26aulast%3DMuramatsu%26aufirst%3DT.%26aulast%3DNakamoto%26aufirst%3DH.%26aulast%3DKurihara%26aufirst%3DM.%26aulast%3DYanagita%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DH.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520a%2520novel%2520k-agonist%2520for%2520managing%2520intractable%2520pruritus%2520in%2520dialysis%2520patients%26jtitle%3DAm.%2520J.%2520Nephrol.%26date%3D2012%26volume%3D36%26spage%3D175%26epage%3D183%26doi%3D10.1159%2F000341268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrom, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gellert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladefoged, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ide, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span> <span> </span><span class="NLM_article-title">Kappa-opioid system in uremic pruritus: Multicenter, randomized, double-blind, placebo-controlled clinical studies</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3742</span>– <span class="NLM_lpage">3747</span>, <span class="refDoi"> DOI: 10.1681/ASN.2005020152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1681%2FASN.2005020152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=16251241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A280%3ADC%252BD2MnjtlCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=3742-3747&author=B.+Wikstromauthor=R.+Gellertauthor=S.+D.+Ladefogedauthor=Y.+Dandaauthor=M.+Akaiauthor=K.+Ideauthor=M.+Ogasawaraauthor=Y.+Kawashimaauthor=K.+Uenoauthor=A.+Moriauthor=Y.+Ueno&title=Kappa-opioid+system+in+uremic+pruritus%3A+Multicenter%2C+randomized%2C+double-blind%2C+placebo-controlled+clinical+studies&doi=10.1681%2FASN.2005020152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies</span></div><div class="casAuthors">Wikstrom Bjorn; Gellert Ryszard; Ladefoged Soren D; Danda Yasuaki; Akai Masahiko; Ide Kaoru; Ogasawara Midori; Kawashima Yoshiharu; Ueno Koki; Mori Akio; Ueno Yuji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology : JASN</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3742-7</span>
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    </div><div class="casAbstract">Uremic pruritus is a very common and frustrating condition for both patients and clinicians because no treatment has been demonstrated to be effective in relieving the itch.  In this report, nalfurafine, a new kappa-opioid receptor agonist, was used to treat uremic pruritus in patients who were undergoing routine hemodialysis.  Two multicenter, randomized, double-blind, placebo-controlled studies enrolled 144 patients with uremic pruritus to postdialysis intravenous treatment with either nalfurafine or placebo for 2 to 4 wk.  A meta-analysis approach was used to assess the efficacy of nalfurafine.  Statistically significant reductions in worst itching (P = 0.0212), itching intensity (P = 0.0410), and sleep disturbances (P = 0.0003) were noted in the nalfurafine group as compared with placebo.  Improvements in itching (P = 0.0025) and excoriations (P = 0.0060) were noted for the nalfurafine-treated patients.  Nalfurafine showed similar types and incidences of drug-related adverse events as did placebo.  Nalfurafine was shown to be an effective and safe compound for use in this severely ill patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8PRRh3zI6BxLDWw4HIq2sfW6udTcc2eZKf7Ys5s5WYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnjtlCjtQ%253D%253D&md5=e4360617b3c4477bed75b44de0aed872</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1681%2FASN.2005020152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2005020152%26sid%3Dliteratum%253Aachs%26aulast%3DWikstrom%26aufirst%3DB.%26aulast%3DGellert%26aufirst%3DR.%26aulast%3DLadefoged%26aufirst%3DS.%2BD.%26aulast%3DDanda%26aufirst%3DY.%26aulast%3DAkai%26aufirst%3DM.%26aulast%3DIde%26aufirst%3DK.%26aulast%3DOgasawara%26aufirst%3DM.%26aulast%3DKawashima%26aufirst%3DY.%26aulast%3DUeno%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DUeno%26aufirst%3DY.%26atitle%3DKappa-opioid%2520system%2520in%2520uremic%2520pruritus%253A%2520Multicenter%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520clinical%2520studies%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2005%26volume%3D16%26spage%3D3742%26epage%3D3747%26doi%3D10.1681%2FASN.2005020152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schattauer, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhar, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavkin, C.</span></span> <span> </span><span class="NLM_article-title">Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2017.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.cellsig.2017.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=28088389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=59-65&author=S.+S.+Schattauerauthor=J.+R.+Kuharauthor=A.+Songauthor=C.+Chavkin&title=Nalfurafine+is+a+G-protein+biased+agonist+having+significantly+greater+bias+at+the+human+than+rodent+form+of+the+kappa+opioid+receptor&doi=10.1016%2Fj.cellsig.2017.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor</span></div><div class="casAuthors">Schattauer, Selena S.; Kuhar, Jamie R.; Song, Allisa; Chavkin, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-65</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Nalfurafine is a moderately selective kappa opioid receptor (KOR) analgesic with low incidence of dysphoric side effects in clin. development for the treatment of uremic pruritis.  The basis for its reduced dysphoric effect compared to other KOR agonists is not clear, but prior studies suggest that the aversive properties of KOR agonists require p38α MAPK activation through an arrestin-dependent mechanism.  To det. whether nalfurafine is a functionally selective KOR agonist, we measured its potency to activate the G protein-dependent early phase of Extracellular Signal-Regulated Kinase (ERK1/2) phosphorylation and the arrestin-dependent late phase of p38 MAPK signaling.  Nalfurafine was approx. 250 fold more potent for ERK1/2 activation as compared to p38 MAPK activation in human KOR (hKOR) expressing HEK293 cells, and approx. 20 fold more potent for ERK1/2 activation than p38 activation in rodent KOR (rKOR) expressing HEK293 cells.  The 10-fold greater G-bias at the hKOR than rKOR was unexpected, however the G protein biased effect of nalfurafine is consistent with its reduced dysphoric effects in human and rodent models.  Although nalfurafine is reported to have low receptor selectivity in radioligand binding assays, its antinociceptive effect was blocked by the selective KOR antagonist norbinaltorphimine.  Nalfurafine pretreatment also resulted in a KOR-dependent and mu opioid receptor-independent redn. in scratching induced by 5'-GNTI.  These findings suggest that nalfurafine is a functionally selective KOR agonist and that KOR agonists able to selectively activate G protein signaling without activating p38α MAPK may have therapeutic potential as non-dysphoric antipruritic analgesics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqJR2Iu_bivbVg90H21EOLACvtfcHk0liFSxdGca799A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCrtL8%253D&md5=13799707352aa7133e92eff7e6f32b71</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2017.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2017.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DSchattauer%26aufirst%3DS.%2BS.%26aulast%3DKuhar%26aufirst%3DJ.%2BR.%26aulast%3DSong%26aufirst%3DA.%26aulast%3DChavkin%26aufirst%3DC.%26atitle%3DNalfurafine%2520is%2520a%2520G-protein%2520biased%2520agonist%2520having%2520significantly%2520greater%2520bias%2520at%2520the%2520human%2520than%2520rodent%2520form%2520of%2520the%2520kappa%2520opioid%2520receptor%26jtitle%3DCell.%2520Signalling%26date%3D2017%26volume%3D32%26spage%3D59%26epage%3D65%26doi%3D10.1016%2Fj.cellsig.2017.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehrich, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messinger, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knakal, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhar, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schattauer, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchas, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweifel, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, P. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavkin, C.</span></span> <span> </span><span class="NLM_article-title">Kappa opioid receptor-induced aversion requires p38 mapk activation in vta dopamine neurons</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">12917</span>– <span class="NLM_lpage">12931</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.2444-15.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1523%2FJNEUROSCI.2444-15.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=26377476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1yjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=12917-12931&author=J.+M.+Ehrichauthor=D.+I.+Messingerauthor=C.+R.+Knakalauthor=J.+R.+Kuharauthor=S.+S.+Schattauerauthor=M.+R.+Bruchasauthor=L.+S.+Zweifelauthor=B.+L.+Kiefferauthor=P.+E.+M.+Phillipsauthor=C.+Chavkin&title=Kappa+opioid+receptor-induced+aversion+requires+p38+mapk+activation+in+vta+dopamine+neurons&doi=10.1523%2FJNEUROSCI.2444-15.2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Kappa opioid receptor-induced aversion requires p38 MAPK activation in VTA dopamine neurons</span></div><div class="casAuthors">Ehrich, Jonathan M.; Messinger, Daniel I.; Knakal, Cerise R.; Kuhar, Jamie R.; Schattauer, Selena S.; Bruchas, Michael R.; Zweifel, Larry S.; Kieffer, Brigitte L.; Phillips, Paul E. M.; Chavkin, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">12917-12931</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The endogenous dynorphin-κ opioid receptor (KOR) system encodes the dysphoric component of the stress response and controls the risk of depression-like and addiction behaviors; however, the mol. and neural circuit mechanisms are not understood.  In this study, we report that KOR activation of p38α MAPK in ventral tegmental (VTA) dopaminergic neurons was required for conditioned place aversion (CPA) in mice.  Conditional genetic deletion of floxed KOR or floxed p38α MAPK by Cre recombinase expression in dopaminergic neurons blocked place aversion to the KOR agonist U50,488.  Selective viral rescue by wild-type KOR expression in dopaminergic neurons of KOR-/- mice restored U50,488-CPA, whereas expression of a mutated form of KOR that could not initiate p38α MAPK activation did not.  Surprisingly, while p38α MAPK inactivation blocked U50,488-CPA, p38α MAPK was not required for KOR inhibition of evoked dopamine release measured by fast scan cyclic voltammetry in the nucleus accumbens.  In contrast, KOR activation acutely inhibited VTA dopaminergic neuron firing, and repeated exposure attenuated the opioid response.  This adaptation to repeated exposure was blocked by conditional deletion of p38α MAPK, which also blocked KOR-induced tyrosine phosphorylation of the inwardly rectifying potassium channel (GIRK) subunit Kir3.1 in VTA dopaminergic neurons.  Consistent with the reduced response, GIRK phosphorylation at this amino terminal tyrosine residue (Y12) enhances channel deactivation.  Thus, contrary to prevailing expectations, these results suggest that κ opioid-induced aversion requires regulation of VTA dopaminergic neuron somatic excitability through a p38α MAPK effect on GIRK deactivation kinetics rather than by presynaptically inhibiting dopamine release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfHJ_3hcX-grVg90H21EOLACvtfcHk0liFSxdGca799A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1yjs7c%253D&md5=2df9bcde190fbec2d09aa964de4cd17e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2444-15.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2444-15.2015%26sid%3Dliteratum%253Aachs%26aulast%3DEhrich%26aufirst%3DJ.%2BM.%26aulast%3DMessinger%26aufirst%3DD.%2BI.%26aulast%3DKnakal%26aufirst%3DC.%2BR.%26aulast%3DKuhar%26aufirst%3DJ.%2BR.%26aulast%3DSchattauer%26aufirst%3DS.%2BS.%26aulast%3DBruchas%26aufirst%3DM.%2BR.%26aulast%3DZweifel%26aufirst%3DL.%2BS.%26aulast%3DKieffer%26aufirst%3DB.%2BL.%26aulast%3DPhillips%26aufirst%3DP.%2BE.%2BM.%26aulast%3DChavkin%26aufirst%3DC.%26atitle%3DKappa%2520opioid%2520receptor-induced%2520aversion%2520requires%2520p38%2520mapk%2520activation%2520in%2520vta%2520dopamine%2520neurons%26jtitle%3DJ.%2520Neurosci.%26date%3D2015%26volume%3D35%26spage%3D12917%26epage%3D12931%26doi%3D10.1523%2FJNEUROSCI.2444-15.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brust, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenweck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarry, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aube, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">ra117</span>, <span class="refDoi"> DOI: 10.1126/scisignal.aai8441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1126%2Fscisignal.aai8441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=27899527" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=ra117&author=T.+F.+Brustauthor=J.+Morgenweckauthor=S.+A.+Kimauthor=J.+H.+Roseauthor=J.+L.+Lockeauthor=C.+L.+Schmidauthor=L.+Zhouauthor=E.+L.+Stahlauthor=M.+D.+Cameronauthor=S.+M.+Scarryauthor=J.+Aubeauthor=S.+R.+Jonesauthor=T.+J.+Martinauthor=L.+M.+Bohn&title=Biased+agonists+of+the+kappa+opioid+receptor+suppress+pain+and+itch+without+causing+sedation+or+dysphoria&doi=10.1126%2Fscisignal.aai8441"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aai8441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aai8441%26sid%3Dliteratum%253Aachs%26aulast%3DBrust%26aufirst%3DT.%2BF.%26aulast%3DMorgenweck%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BA.%26aulast%3DRose%26aufirst%3DJ.%2BH.%26aulast%3DLocke%26aufirst%3DJ.%2BL.%26aulast%3DSchmid%26aufirst%3DC.%2BL.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DScarry%26aufirst%3DS.%2BM.%26aulast%3DAube%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DS.%2BR.%26aulast%3DMartin%26aufirst%3DT.%2BJ.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DBiased%2520agonists%2520of%2520the%2520kappa%2520opioid%2520receptor%2520suppress%2520pain%2520and%2520itch%2520without%2520causing%2520sedation%2520or%2520dysphoria%26jtitle%3DSci.%2520Signaling%26date%3D2016%26volume%3D9%26spage%3Dra117%26doi%3D10.1126%2Fscisignal.aai8441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiBerto, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polepally, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zjawiony, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malanga, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">The G protein-biased kappa-opioid receptor agonist rb-64 is analgesic with a unique spectrum of activities in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.216820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1124%2Fjpet.114.216820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=25320048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOlu7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=98-109&author=K.+L.+Whiteauthor=J.+E.+Robinsonauthor=H.+Zhuauthor=J.+F.+DiBertoauthor=P.+R.+Polepallyauthor=J.+K.+Zjawionyauthor=D.+E.+Nicholsauthor=C.+J.+Malangaauthor=B.+L.+Roth&title=The+G+protein-biased+kappa-opioid+receptor+agonist+rb-64+is+analgesic+with+a+unique+spectrum+of+activities+in+vivo&doi=10.1124%2Fjpet.114.216820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo</span></div><div class="casAuthors">White, Kate L.; Robinson, J. Elliott; Zhu, Hu; DiBerto, Jeffrey F.; Polepally, Prabhakar R.; Zjawiony, Jordan K.; Nichols, David E.; Malanga, C. J.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">98-109, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The hypothesis that functionally selective G protein-coupled receptor (GPCR) agonists may have enhanced therapeutic benefits has revitalized interest for many GPCR targets.  In particular, although κ-opioid receptor (KOR) agonists are analgesic with a low risk of dependence and abuse, their use is limited by a propensity to induce sedation, motor incoordination, hallucinations, and dysphoria-like states.  Several labs. have produced a body of work suggesting that G protein-biased KOR agonists might be analgesic with fewer side effects.  Although that has been an intriguing hypothesis, suitable KOR-selective and G protein-biased agonists have not been available to test this idea.  Here we provide data using a G protein-biased agonist, RB-64 (22-thiocyanatosalvinorin A), which suggests that KOR-mediated G protein signaling induces analgesia and aversion, whereas β-arrestin-2 signaling may be assocd. with motor incoordination.  Addnl., unlike unbiased KOR agonists, the G protein-biased ligand RB-64 does not induce sedation and does not have anhedonia-like actions, suggesting that a mechanism other than G protein signaling mediates these effects.  Our findings provide the first evidence for a highly selective and G protein-biased tool compd. for which many, but not all, of the neg. side effects of KOR agonists can be minimized by creating G protein-biased KOR agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGporsYw3knd37Vg90H21EOLACvtfcHk0lh_uetYbbmq-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOlu7bM&md5=686b5b718e2919aaf08e34855cc39ebf</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.216820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.216820%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DRobinson%26aufirst%3DJ.%2BE.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DDiBerto%26aufirst%3DJ.%2BF.%26aulast%3DPolepally%26aufirst%3DP.%2BR.%26aulast%3DZjawiony%26aufirst%3DJ.%2BK.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DMalanga%26aufirst%3DC.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DThe%2520G%2520protein-biased%2520kappa-opioid%2520receptor%2520agonist%2520rb-64%2520is%2520analgesic%2520with%2520a%2520unique%2520spectrum%2520of%2520activities%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D98%26epage%3D109%26doi%3D10.1124%2Fjpet.114.216820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazenka, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moerke, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span> <span> </span><span class="NLM_article-title">Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>235</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1007/s00213-017-4758-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1007%2Fs00213-017-4758-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=29063139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslShs73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2018&pages=203-213&author=M.+L.+Lazenkaauthor=M.+J.+Moerkeauthor=E.+A.+Townsendauthor=K.+B.+Freemanauthor=F.+I.+Carrollauthor=S.+S.+Negus&title=Dissociable+effects+of+the+kappa+opioid+receptor+agonist+nalfurafine+on+pain%2Fitch-stimulated+and+pain%2Fitch-depressed+behaviors+in+male+rats&doi=10.1007%2Fs00213-017-4758-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats</span></div><div class="casAuthors">Lazenka, Matthew L.; Moerke, Megan J.; Townsend, E. Andrew; Freeman, Kevin B.; Carroll, F. Ivy; Negus, S. Stevens</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">203-213</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Nalfurafine is a G protein signaling-biased kappa opioid receptor (KOR) agonist approved in Japan for second-line treatment of uremic pruritus.  Neither nalfurafine nor any other KOR agonist is currently approved anywhere for treatment of pain, but recent evidence suggests that G protein signaling-biased KOR agonists may have promise as candidate analgesics/antipruritics with reduced side effects compared to nonbiased or ss-arrestin-signaling-biased KOR agonists.  Objectives: This study compared nalfurafine effects in rats using assays of pain-stimulated and pain-depressed behavior used previously to evaluate other candidate analgesics.  Nalfurafine effects were also examd. in complementary assays of itch-stimulated and itch-depressed behavior.  Methods: I.p. lactic acid (IP acid) and intradermal serotonin (ID 5HT) served as noxious and pruritic stimuli, resp., in male Sprague Dawley rats to stimulate stretching (IP acid) or scratching (ID 5HT) or to depress pos. reinforced operant responding in an assay of intracranial self-stimulation (ICSS; both stimuli).  Results: Nalfurafine was equipotent to decrease IP acid-stimulated stretching and ID 5HT-stimulated scratching; however, doses of nalfurafine that decreased these pain/itch-stimulated behaviors also decreased control ICSS performance.  Moreover, nalfurafine failed to alleviate either IP acid- or ID 5HT-induced depression of ICSS.  Conclusions: These results suggest that nalfurafine-induced decreases in pain/itch-stimulated behaviors may reflect nonselective decreases in motivated behavior rather than analgesia or antipruritus against the noxious and pruritic stimuli used here.  This conclusion agrees with the absence of clin. data for nalfurafine analgesia and the weak clin. data for nalfurafine antipruritus.  Nalfurafine bias for G protein signaling may not be sufficient for clin. safe and reliable analgesia or antipruritus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEkm4nAMagerVg90H21EOLACvtfcHk0lgwWDgl_LHXBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslShs73K&md5=13f9d2d5f4340b136971eb1bc2bbfc5e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs00213-017-4758-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-017-4758-7%26sid%3Dliteratum%253Aachs%26aulast%3DLazenka%26aufirst%3DM.%2BL.%26aulast%3DMoerke%26aufirst%3DM.%2BJ.%26aulast%3DTownsend%26aufirst%3DE.%2BA.%26aulast%3DFreeman%26aufirst%3DK.%2BB.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DNegus%26aufirst%3DS.%2BS.%26atitle%3DDissociable%2520effects%2520of%2520the%2520kappa%2520opioid%2520receptor%2520agonist%2520nalfurafine%2520on%2520pain%252Fitch-stimulated%2520and%2520pain%252Fitch-depressed%2520behaviors%2520in%2520male%2520rats%26jtitle%3DPsychopharmacology%26date%3D2018%26volume%3D235%26spage%3D203%26epage%3D213%26doi%3D10.1007%2Fs00213-017-4758-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Machelska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celik, M. O.</span></span> <span> </span><span class="NLM_article-title">Advances in achieving opioid analgesia without side effects</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1388</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.3389%2Ffphar.2018.01388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=30555325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGmurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1388&author=H.+Machelskaauthor=M.+O.+Celik&title=Advances+in+achieving+opioid+analgesia+without+side+effects&doi=10.3389%2Ffphar.2018.01388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in achieving opioid analgesia without side effects</span></div><div class="casAuthors">Machelska, Halina; Celik, Melih O.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1388</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Opioids are the most effective drugs for the treatment of severe pain, but they also cause addiction and overdose deaths, which have led to a worldwide opioid crisis.  Therefore, the development of safer opioids is urgently needed.  In this article, we provide a crit. overview of emerging opioid-based strategies aimed at effective pain relief and improved side effect profiles.  These approaches comprise biased agonism, the targeting of (i) opioid receptors in peripheral inflamed tissue (by reducing agonist access to the brain, the use of nanocarriers, or low pH-sensitive agonists); (ii) heteromers or multiple receptors (by monovalent, bivalent, and multifunctional ligands); (iii) receptor splice variants; and (iv) endogenous opioid peptides (by preventing their degrdn. or enhancing their prodn. by gene transfer).  Substantial advancements are underscored by pharmaceutical development of new opioids such as peripheral κ-receptor agonists, and by treatments augmenting the action of endogenous opioids, which have entered clin. trials.  Addnl., there are several promising novel opioids comprehensively examd. in preclin. studies, but also strategies such as biased agonism, which might require careful rethinking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfgv-LX7fUPbVg90H21EOLACvtfcHk0lgwWDgl_LHXBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGmurjM&md5=fa4937fcdbc17a3590623c4368fded38</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01388%26sid%3Dliteratum%253Aachs%26aulast%3DMachelska%26aufirst%3DH.%26aulast%3DCelik%26aufirst%3DM.%2BO.%26atitle%3DAdvances%2520in%2520achieving%2520opioid%2520analgesia%2520without%2520side%2520effects%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1388%26doi%3D10.3389%2Ffphar.2018.01388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMattio, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muschamp, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Chen, L. Y.</span></span> <span> </span><span class="NLM_article-title">Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in kappa opioid aversion</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1038/s41386-018-0155-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1038%2Fs41386-018-0155-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=30082888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGrs7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=939-949&author=J.+J.+Liuauthor=Y.+T.+Chiuauthor=K.+M.+DiMattioauthor=C.+Chenauthor=P.+Huangauthor=T.+A.+Gentileauthor=J.+W.+Muschampauthor=A.+Cowanauthor=M.+Mannauthor=L.+Y.+Liu-Chen&title=Phosphoproteomic+approach+for+agonist-specific+signaling+in+mouse+brains%3A+mTOR+pathway+is+involved+in+kappa+opioid+aversion&doi=10.1038%2Fs41386-018-0155-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion</span></div><div class="casAuthors">Liu, Jeffrey J.; Chiu, Yi-Ting; DiMattio, Kelly M.; Chen, Chongguang; Huang, Peng; Gentile, Taylor A.; Muschamp, John W.; Cowan, Alan; Mann, Matthias; Liu-Chen, Lee-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">939-949</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Kappa opioid receptor (KOR) agonists produce analgesic and anti-pruritic effects, but their clin. application was limited by dysphoria and hallucinations.  Nalfurafine, a clin. used KOR agonist, does not cause dysphoria or hallucinations at therapeutic doses in humans.  We found that in CD-1 mice nalfurafine produced analgesic and anti-scratch effects dose-dependently, like the prototypic KOR agonist U50,488H.  In contrast, unlike U50,488H, nalfurafine caused no aversion, anhedonia, or sedation or and a low level of motor incoordination at the effective analgesia and anti-scratch doses.  Thus, we established a mouse model that recapitulated important aspects of the clin. observations.  We then employed a phosphoproteomics approach to investigate mechanisms underlying differential KOR-mediated effects.  A large-scale mass spectrometry (MS)-based anal. on brains revealed that nalfurafine perturbed phosphoproteomes differently from U50,488H in a brain-region specific manner after 30-min treatment.  In particular, U50,488H and nalfurafine imparted phosphorylation changes to proteins found in different cellular components or signaling pathways in different brain regions.  Notably, we obsd. that U50,488H, but not nalfurafine, activated the mammalian target of rapamycin (mTOR) pathway in the striatum and cortex.  Inhibition of the mTOR pathway by rapamycin abolished U50,488H-induced aversion, without affecting analgesic, anti-scratch, and sedative effects and motor incoordination.  The results indicate that the mTOR pathway is involved in KOR agonist-induced aversion.  This is the first demonstration that phosphoproteomics can be applied to agonist-specific signaling of G protein-coupled receptors (GPCRs) in mouse brains to unravel pharmacol. important pathways.  Furthermore, this is one of the first two reports that the mTOR pathway mediates aversion caused by KOR activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWThicLA_aOLVg90H21EOLACvtfcHk0liU4moZPtzWnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGrs7fJ&md5=1321e5b38ad0626c6f47291c69eb887d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fs41386-018-0155-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41386-018-0155-0%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DChiu%26aufirst%3DY.%2BT.%26aulast%3DDiMattio%26aufirst%3DK.%2BM.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DGentile%26aufirst%3DT.%2BA.%26aulast%3DMuschamp%26aufirst%3DJ.%2BW.%26aulast%3DCowan%26aufirst%3DA.%26aulast%3DMann%26aufirst%3DM.%26aulast%3DLiu-Chen%26aufirst%3DL.%2BY.%26atitle%3DPhosphoproteomic%2520approach%2520for%2520agonist-specific%2520signaling%2520in%2520mouse%2520brains%253A%2520mTOR%2520pathway%2520is%2520involved%2520in%2520kappa%2520opioid%2520aversion%26jtitle%3DNeuropsychopharmacology%26date%3D2019%26volume%3D44%26spage%3D939%26epage%3D949%26doi%3D10.1038%2Fs41386-018-0155-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagumo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of new opioid derivatives with a propellane skeleton and their pharmacologies: Part 5, novel pentacyclic propellane derivatives with a 6-amide side chain</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6271</span>– <span class="NLM_lpage">6279</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.08.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.bmc.2015.08.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=26346669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKgs7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=6271-6279&author=R.+Nakajimaauthor=N.+Yamamotoauthor=S.+Hirayamaauthor=T.+Iwaiauthor=A.+Saitohauthor=Y.+Nagumoauthor=H.+Fujiiauthor=H.+Nagase&title=Synthesis+of+new+opioid+derivatives+with+a+propellane+skeleton+and+their+pharmacologies%3A+Part+5%2C+novel+pentacyclic+propellane+derivatives+with+a+6-amide+side+chain&doi=10.1016%2Fj.bmc.2015.08.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of new opioid derivatives with a propellane skeleton and their pharmacologies: Part 5, novel pentacyclic propellane derivatives with a 6-amide side chain</span></div><div class="casAuthors">Nakajima, Ryo; Yamamoto, Naoshi; Hirayama, Shigeto; Iwai, Takashi; Saitoh, Akiyoshi; Nagumo, Yasuyuki; Fujii, Hideaki; Nagase, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6271-6279</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We designed and synthesized pentacyclic propellane derivs. with a 6-amide side chain to afford compds. with higher MOR/KOR ratio and lower sedative effects than nalfurafine.  The obtained etheno-bridged deriv. with a β-amide side chain, YNT-854, I, showed a higher MOR/KOR ratio than nalfurafine.  YNT-854 also exhibited a higher dose ratio between the sedative effect and the analgesic effect than obsd. with nalfurafine, which may guide the future design of useful analgesics with a weaker sedative effect than nalfurafine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou-WPvCktkO7Vg90H21EOLACvtfcHk0liU4moZPtzWnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKgs7jL&md5=04f13c622c8006bb3c7a147773a0a0b7</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.08.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.08.036%26sid%3Dliteratum%253Aachs%26aulast%3DNakajima%26aufirst%3DR.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DHirayama%26aufirst%3DS.%26aulast%3DIwai%26aufirst%3DT.%26aulast%3DSaitoh%26aufirst%3DA.%26aulast%3DNagumo%26aufirst%3DY.%26aulast%3DFujii%26aufirst%3DH.%26aulast%3DNagase%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520new%2520opioid%2520derivatives%2520with%2520a%2520propellane%2520skeleton%2520and%2520their%2520pharmacologies%253A%2520Part%25205%252C%2520novel%2520pentacyclic%2520propellane%2520derivatives%2520with%2520a%25206-amide%2520side%2520chain%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D6271%26epage%3D6279%26doi%3D10.1016%2Fj.bmc.2015.08.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzgrabe, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Chen, L. Y.</span></span> <span> </span><span class="NLM_article-title">Comparison of pharmacological activities of three distinct kappa ligands (salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>312</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1124/jpet.104.073668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1124%2Fjpet.104.073668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=15383632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2005&pages=220-230&author=Y.+Wangauthor=K.+Tangauthor=S.+Inanauthor=D.+Siebertauthor=U.+Holzgrabeauthor=D.+Y.+W.+Leeauthor=P.+Huangauthor=J.+G.+Liauthor=A.+Cowanauthor=L.+Y.+Liu-Chen&title=Comparison+of+pharmacological+activities+of+three+distinct+kappa+ligands+%28salvinorin+A%2C+TRK-820+and+3FLB%29+on+kappa+opioid+receptors+in+vitro+and+their+antipruritic+and+antinociceptive+activities+in+vivo&doi=10.1124%2Fjpet.104.073668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of pharmacological activities of three distinct κ ligands (salvinorin A, TRK-820 and 3FLB) on κ opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo</span></div><div class="casAuthors">Wang, Yulin; Tang, Kang; Inan, Saadet; Siebert, Daniel; Holzgrabe, Ulrike; Lee, David Y. W.; Huang, Peng; Li, Jian-Guo; Cowan, Alan; Liu-Chen, Lee-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">220-230</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Salvinorin A, TRK-820 (17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[N-methyl-trans-3-(3-furyl) acrylamido]morphinan hydrochloride), and 3FLB (di-Et 2,4-di-[3-fluorophenyl]-3,7-dimethyl-3,7-diazabicyclo[3.3.1]nonane-9-one-1,5-dicarboxylate) are structurally distinctly different from U50,488H [(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide methanesulfonate], the prototypic selective κ agonist.  Here, we investigated their in vitro pharmacol. activities on receptors expressed in Chinese hamster ovary cells and in vivo antiscratch and antinociceptive activities in mice.  All three compds. showed high selectivity for the κ opioid receptor(KOR) over the μ opioid receptor (MOR) and the δ opioid receptor (DOR) and nociceptin or FQ receptors.  The rank order of affinity and potency for the KOR was TRK-820 >> U50,488H ∼ salvinorin A >> 3FLB.  TRK-820 acted as a partial agonist on MOR and DOR, whereas salvinorin A and 3FLB showed no activities on these receptors.  Salvinorin A, TRK-820, and 3FLB caused internalization of the human KOR in a dose-dependent manner.  Interestingly, although salvinorin A and U50,488H had similar potencies in stimulating [35S]GTPγS binding, salvinorin A was about 40-fold less potent than U50,488H in promoting internalization.  Following 4-h incubation, all three compds. induced down-regulation of the human KOR, with salvinorin A causing a lower extent of down-regulation.  Although TRK-820 was potent and efficacious against compd. 48/80-induced scratching, salvinorin A showed low and inconsistent effects, and 3FLB was inactive.  In addn., salvinorin A and 3FLB were not active in the acetic acid abdominal constriction test.  The discrepancy between in vitro and in vivo results may be due to in vivo metab. of salvinorin A and 3FLB and possibly to their effects on other pharmacol. targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiXgeaprA53bVg90H21EOLACvtfcHk0li7eHDgXmaGdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWmtLY%253D&md5=dbcdfc075b1ea9120f31a3c33e27a73f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.073668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.073668%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DInan%26aufirst%3DS.%26aulast%3DSiebert%26aufirst%3DD.%26aulast%3DHolzgrabe%26aufirst%3DU.%26aulast%3DLee%26aufirst%3DD.%2BY.%2BW.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DJ.%2BG.%26aulast%3DCowan%26aufirst%3DA.%26aulast%3DLiu-Chen%26aufirst%3DL.%2BY.%26atitle%3DComparison%2520of%2520pharmacological%2520activities%2520of%2520three%2520distinct%2520kappa%2520ligands%2520%2528salvinorin%2520A%252C%2520TRK-820%2520and%25203FLB%2529%2520on%2520kappa%2520opioid%2520receptors%2520in%2520vitro%2520and%2520their%2520antipruritic%2520and%2520antinociceptive%2520activities%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D312%26spage%3D220%26epage%3D230%26doi%3D10.1124%2Fjpet.104.073668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipkowski, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span> <span> </span><span class="NLM_article-title">Peptides as receptor selectivity modulators of opiate pharmacophores</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1222</span>– <span class="NLM_lpage">1225</span>, <span class="refDoi"> DOI: 10.1021/jm00157a018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00157a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaL28Xkt1ClsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1986&pages=1222-1225&author=A.+W.+Lipkowskiauthor=S.+W.+Tamauthor=P.+S.+Portoghese&title=Peptides+as+receptor+selectivity+modulators+of+opiate+pharmacophores&doi=10.1021%2Fjm00157a018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Peptides as receptor selectivity modulators of opiate pharmacophores</span></div><div class="casAuthors">Lipkowski, A. W.; Tam, S. W.; Portoghese, P. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1222-5</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Alkaloid-peptide hybrids I (R = Me, CH2CHMe2; R1 = OH, Arg-Arg-Ile-OMe) were prepd. by condensing oxymorphone (II, R = Me) or naltrexone (II, R = CH2CHMe2) with the corresponding H2NNHCO-Phe-Leu-R1.  Binding data for the μ, κ, and δ receptors indicated that the peptide portions of I can modulate the receptor selectivity of the attached alkaloid pharmacophores.  The selectivity for different opioid receptor types depends on a balance between the affinities of the message and address components.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtAn0uoT7wvLVg90H21EOLACvtfcHk0li7eHDgXmaGdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xkt1ClsLw%253D&md5=a790a403e7c33bbed9672f2f41da0655</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm00157a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00157a018%26sid%3Dliteratum%253Aachs%26aulast%3DLipkowski%26aufirst%3DA.%2BW.%26aulast%3DTam%26aufirst%3DS.%2BW.%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26atitle%3DPeptides%2520as%2520receptor%2520selectivity%2520modulators%2520of%2520opiate%2520pharmacophores%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1986%26volume%3D29%26spage%3D1222%26epage%3D1225%26doi%3D10.1021%2Fjm00157a018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span> <span> </span><span class="NLM_article-title">Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">230</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1016/0165-6147(89)90267-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2F0165-6147%2889%2990267-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=2549665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaL1MXkslSisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1989&pages=230-235&author=P.+S.+Portoghese&title=Bivalent+ligands+and+the+message-address+concept+in+the+design+of+selective+opioid+receptor+antagonists&doi=10.1016%2F0165-6147%2889%2990267-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists</span></div><div class="casAuthors">Portoghese, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">230-5</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    </div><div class="casAbstract">A review with 28 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-9nTE5zu1TrVg90H21EOLACvtfcHk0lg1R1LWHgDWbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkslSisLk%253D&md5=68867543a80132745af447156d16decd</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2F0165-6147%2889%2990267-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-6147%252889%252990267-8%26sid%3Dliteratum%253Aachs%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26atitle%3DBivalent%2520ligands%2520and%2520the%2520message-address%2520concept%2520in%2520the%2520design%2520of%2520selective%2520opioid%2520receptor%2520antagonists%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1989%26volume%3D10%26spage%3D230%26epage%3D235%26doi%3D10.1016%2F0165-6147%2889%2990267-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemori, A. E.</span></span> <span> </span><span class="NLM_article-title">Design of peptidomimetic delta-opioid receptor antagonists using the message address concept</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1714</span>– <span class="NLM_lpage">1720</span>, <span class="refDoi"> DOI: 10.1021/jm00168a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00168a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaK3cXitlGlt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1990&pages=1714-1720&author=P.+S.+Portogheseauthor=M.+Sultanaauthor=A.+E.+Takemori&title=Design+of+peptidomimetic+delta-opioid+receptor+antagonists+using+the+message+address+concept&doi=10.1021%2Fjm00168a028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Design of peptidomimetic δ opioid receptor antagonists using the message-address concept</span></div><div class="casAuthors">Portoghese, P. S.; Sultana, M.; Takemori, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1714-20</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Highly selective nonpeptide ligands with potent δ opioid receptor antagonist activity have been developed using the message-address concept.  This approach envisaged the δ opioid receptor to contain two major recognition subsites; a message subsite which recognizes the pharmacophore and an address subsite that is unique for the δ receptor type and confers selectivity.  The message and address components of the δ-selective enkephalins were postulated to be Tyr1 and Phe4, resp., with Gly2-Gly3 functioning as a spacer.  The message component of the target compds. in this study was derived from naltrexone and related structures.  An indole system was fused to the C ring of naltrexone as a mimic of the address component.  The benzene moiety of indole was viewed as the δ address component, mimicking the Ph group of Phe4, and the pyrrole portion was used as a rigid spacer.  Members of the series were evaluated for opioid antagonist activity on the guinea pig ileum (GPI) and mouse vas deferens (MVD) prepns.  Naltrindole (I), was the most potent member of the series, with Ke values of ∼0.1 nM at δ receptors.  The antagonism by I was ∼200- and 350-fold greater at δ than at μ and κ opioid receptors.  The binding of I and selected members of the series to guinea pig brain membranes was qual. consistent with their pharmacol. antagonist activity profiles in the MVD and GPI, but the Ki values were not in the same rank order.  The selectivity of I arises mainly as a consequence of increased affinity at δ receptors.  Thus, the Ke and Ki values of I were 1/530 and 1/90 that of the δ antagonist enkephalin analog, ICI 174864.  In contrast to I, ICII74864 derives its selectivity through greatly decreased recognition at μ and κ receptors.  The implications of the high affinity and selectivity of I as a consequence of its conformational rigidity are discussed.  It is suggested that any attempt to model a receptor-bound conformation of an opoid peptide should consider affinity and potency at multiple receptor sites rather than selectivity alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohWBYkojIb-rVg90H21EOLACvtfcHk0lg1R1LWHgDWbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXitlGlt7c%253D&md5=a7324b930ba1ba211b637011d193842e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm00168a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00168a028%26sid%3Dliteratum%253Aachs%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26aulast%3DSultana%26aufirst%3DM.%26aulast%3DTakemori%26aufirst%3DA.%2BE.%26atitle%3DDesign%2520of%2520peptidomimetic%2520delta-opioid%2520receptor%2520antagonists%2520using%2520the%2520message%2520address%2520concept%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1990%26volume%3D33%26spage%3D1714%26epage%3D1720%26doi%3D10.1021%2Fjm00168a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booe, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pioszak, A. A.</span></span> <span> </span><span class="NLM_article-title">Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>763</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2015.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.ejphar.2015.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=25981303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVCmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=763&publication_year=2015&pages=196-205&author=S.+M.+Leeauthor=J.+M.+Booeauthor=A.+A.+Pioszak&title=Structural+insights+into+ligand+recognition+and+selectivity+for+classes+A%2C+B%2C+and+C+GPCRs&doi=10.1016%2Fj.ejphar.2015.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs</span></div><div class="casAuthors">Lee, Sang-Min; Booe, Jason M.; Pioszak, Augen A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">763</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">196-205</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The G protein-coupled receptor (GPCR) superfamily constitutes the largest collection of cell surface signaling proteins with approx. 800 members in the human genome.  GPCRs regulate virtually all aspects of physiol. and they are an important class of drug targets with ∼30% of drugs on the market targeting a GPCR.  Breakthroughs in GPCR structural biol. in recent years have significantly expanded our understanding of GPCR structure and function and ushered in a new era of structure-based drug design for GPCRs.  Crystal structures for nearly thirty distinct GPCRs are now available including receptors from each of the major classes, A, B, C, and F.  These structures provide a foundation for understanding the mol. basis of GPCR pharmacol.  Here, we review structural mechanisms of ligand recognition and selectivity of GPCRs with a focus on selected examples from classes A, B, and C, and we highlight major unresolved questions for future structural studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSMQ9_F1VXv7Vg90H21EOLACvtfcHk0lg1R1LWHgDWbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVCmsb0%253D&md5=13f6fd00a674a1020f7bfff75383b598</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BM.%26aulast%3DBooe%26aufirst%3DJ.%2BM.%26aulast%3DPioszak%26aufirst%3DA.%2BA.%26atitle%3DStructural%2520insights%2520into%2520ligand%2520recognition%2520and%2520selectivity%2520for%2520classes%2520A%252C%2520B%252C%2520and%2520C%2520GPCRs%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D763%26spage%3D196%26epage%3D205%26doi%3D10.1016%2Fj.ejphar.2015.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective agonists of delta opioid receptor by revisiting the “message-address” concept</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00423</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00423" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVWmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=391-396&author=Q.+Shenauthor=Y.+Y.+Qianauthor=X.+Q.+Huangauthor=X.+J.+Xuauthor=W.+Liauthor=J.+G.+Liuauthor=W.+Fu&title=Discovery+of+potent+and+selective+agonists+of+delta+opioid+receptor+by+revisiting+the+%E2%80%9Cmessage-address%E2%80%9D+concept&doi=10.1021%2Facsmedchemlett.5b00423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Agonists of δ Opioid Receptor by Revisiting the "Message-Address" Concept</span></div><div class="casAuthors">Shen, Qing; Qian, Yuanyuan; Huang, Xiaoqin; Xu, Xuejun; Li, Wei; Liu, Jinggen; Fu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">391-396</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The classic "message-address" concept was proposed to address the binding of endogenous peptides to the opioid receptors and was later successfully applied in the discovery of the first nonpeptide δ opioid receptor (DOR) antagonist naltrindole.  By revisiting this concept, and based on the structure of tramadol, we designed a series of novel compds. that act as highly potent and selective agonists of DOR among which (-)-6j showed the highest affinity (Ki = 2.7 nM), best agonistic activity (EC50 = 2.6 nM), and DOR selectivity (more than 1000-fold over the other two subtype opioid receptors).  Mol. docking studies suggest that the "message" part of (-)-6j interacts with residue Asp1283.32 and a neighboring water mol., and the "address" part of (-)-6j packs with hydrophobic residues Leu3007.35, Val2816.55, and Trp2846.58, rendering DOR selectivity.  The discovery of novel compd. (-)-6j, and the obtained insights into DOR-agonist binding will help us design more potent and selective DOR agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv4N8pD5ZxP7Vg90H21EOLACvtfcHk0lgx01keFR-tGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVWmt7c%253D&md5=063d1423e11044bdf5a3110fef777414</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00423%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DQian%26aufirst%3DY.%2BY.%26aulast%3DHuang%26aufirst%3DX.%2BQ.%26aulast%3DXu%26aufirst%3DX.%2BJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26aulast%3DFu%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520agonists%2520of%2520delta%2520opioid%2520receptor%2520by%2520revisiting%2520the%2520%25E2%2580%259Cmessage-address%25E2%2580%259D%2520concept%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D391%26epage%3D396%26doi%3D10.1021%2Facsmedchemlett.5b00423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, B.</span></span> <span> </span><span class="NLM_article-title">Novel analgesics and molecular rearrangements in the morphine-thebaine group. II. Alcohols derived from 6,14-endo-etheno- and 6,14-endo-ethanotetrahydrothebaine</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">3273</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1021/ja00989a031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00989a031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaF2sXksVeqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1967&pages=3273-80&author=K.+W.+Bentleyauthor=D.+G.+Hardyauthor=B.+Meek&title=Novel+analgesics+and+molecular+rearrangements+in+the+morphine-thebaine+group.+II.+Alcohols+derived+from+6%2C14-endo-etheno-+and+6%2C14-endo-ethanotetrahydrothebaine&doi=10.1021%2Fja00989a031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Novel analgesics and molecular rearrangements in the morphine-thebaine group.  II.  Alcohols derived from 6,14-endo-etheno- and 6,14-endo-ethanotetrahydrothebaine</span></div><div class="casAuthors">Bentley, Kenneth W.; Hardy, Denis G.; Meek, B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3273-80</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">cf. preceding abstr.  Series of secondary and tertiary alcs. have been prepd. by the redn. and reaction with Grignard reagents of the aldehyde I (R = H), the ketones I (R = Me, Et, Pr, and Ph), and their 6,14-ethano analogs.  The stereospecificity of the reactions is explained.  In this way analgesics of very high potency, up to 500 times that of morphine, have been obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq38eDsi98AmbVg90H21EOLACvtfcHk0lgx01keFR-tGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXksVeqtL4%253D&md5=bee6c4d32f6a39db0540abe452dc08b0</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fja00989a031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00989a031%26sid%3Dliteratum%253Aachs%26aulast%3DBentley%26aufirst%3DK.%2BW.%26aulast%3DHardy%26aufirst%3DD.%2BG.%26aulast%3DMeek%26aufirst%3DB.%26atitle%3DNovel%2520analgesics%2520and%2520molecular%2520rearrangements%2520in%2520the%2520morphine-thebaine%2520group.%2520II.%2520Alcohols%2520derived%2520from%25206%252C14-endo-etheno-%2520and%25206%252C14-endo-ethanotetrahydrothebaine%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1967%26volume%3D89%26spage%3D3273%26epage%3D80%26doi%3D10.1021%2Fja00989a031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, D. G.</span></span> <span> </span><span class="NLM_article-title">Novel analgesics and molecular rearrangements in the morphine-thebaine group. I. Ketones derived from 6,14-endo-ethenotetrahydrothebaine</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">3267</span>– <span class="NLM_lpage">3273</span>, <span class="refDoi"> DOI: 10.1021/ja00989a030</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00989a030" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADyaF2sXksVeqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1967&pages=3267-3273&author=K.+W.+Bentleyauthor=D.+G.+Hardy&title=Novel+analgesics+and+molecular+rearrangements+in+the+morphine-thebaine+group.+I.+Ketones+derived+from+6%2C14-endo-ethenotetrahydrothebaine&doi=10.1021%2Fja00989a030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Novel analgesics and molecular rearrangements in the morphine-thebaine group.  I..  Ketones derived from 6,14-endo-ethenotetrahydrothebaine</span></div><div class="casAuthors">Bentley, Kenneth W.; Hardy, Denis G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3267-73</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">Several ketones (I R = COR1) derived from 6,14-endo-ethenotetrahydrothebaine have been prepd. by the Diels-Alder addn. of certain α,β-unsatd. ketones to thebaine, by the action of alkylcadmiums on the corresponding acid chloride (I, R = COCl), and, in some cases, by the action of Grignard reagents on the corresponding ester (I, R = CO2Et) which is the adduct of thebaine and ethyl acrylate.  Both 7α and 7β forms of the ketone (I, R = COMe), the ester (I, R = CO2Et), and the nitrile (I, R = CN) have been isolated.  Attempts to convert the 7α ketone (I, R = COMe) into the 7β isomer have resulted only in the formation of a ketol. (I, R = CRR1OH).  Many of the bases prepd. in this work are potent analgesics.  The reaction product obtained from thebaine methiodide and p-benzoquinone has been shown to be a charge-transfer complex and not a true Diels-Alder adduct.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcbd3y3ByDJrVg90H21EOLACvtfcHk0liOqzkFepJZGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXksVeqt7c%253D&md5=196adf934afce85fdeb4adef562d1a03</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fja00989a030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00989a030%26sid%3Dliteratum%253Aachs%26aulast%3DBentley%26aufirst%3DK.%2BW.%26aulast%3DHardy%26aufirst%3DD.%2BG.%26atitle%3DNovel%2520analgesics%2520and%2520molecular%2520rearrangements%2520in%2520the%2520morphine-thebaine%2520group.%2520I.%2520Ketones%2520derived%2520from%25206%252C14-endo-ethenotetrahydrothebaine%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1967%26volume%3D89%26spage%3D3267%26epage%3D3273%26doi%3D10.1021%2Fja00989a030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cami-Kobeci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khroyan, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span> <span> </span><span class="NLM_article-title">Structural determinants of opioid and nop receptor activity in derivatives of buprenorphine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6531</span>– <span class="NLM_lpage">6537</span>, <span class="refDoi"> DOI: 10.1021/jm2003238</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2003238" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCgs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6531-6537&author=G.+Cami-Kobeciauthor=W.+E.+Polgarauthor=T.+V.+Khroyanauthor=L.+Tollauthor=S.+M.+Husbands&title=Structural+determinants+of+opioid+and+nop+receptor+activity+in+derivatives+of+buprenorphine&doi=10.1021%2Fjm2003238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Determinants of Opioid and NOP Receptor Activity in Derivatives of Buprenorphine</span></div><div class="casAuthors">Cami-Kobeci, Gerta; Polgar, Willma E.; Khroyan, Taline V.; Toll, Lawrence; Husbands, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6531-6537</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The unique pharmacol. profile of buprenorphine has led to its considerable success as an analgesic and as a treatment agent for drug abuse.  Activation of nociceptin/orphanin FQ peptide (NOP) receptors has been postulated to account for certain aspects of buprenorphine's behavioral profile.  In order to investigate the role of NOP activation further, a series of buprenorphine analogs has been synthesized with the aim of increasing affinity for the NOP receptor.  Binding and functional assay data on these new compds. indicate that the area around C20 in the orvinols is key to NOP receptor activity, with several compds. displaying higher affinity than buprenorphine.  One compd. was found to be a mu opioid receptor partial agonist of comparable efficacy to buprenorphine but with higher efficacy at NOP receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUcbMYUdEuarVg90H21EOLACvtfcHk0liOqzkFepJZGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCgs7zN&md5=9e26145810991dca7f2b224326ac6d51</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm2003238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2003238%26sid%3Dliteratum%253Aachs%26aulast%3DCami-Kobeci%26aufirst%3DG.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DKhroyan%26aufirst%3DT.%2BV.%26aulast%3DToll%26aufirst%3DL.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26atitle%3DStructural%2520determinants%2520of%2520opioid%2520and%2520nop%2520receptor%2520activity%2520in%2520derivatives%2520of%2520buprenorphine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6531%26epage%3D6537%26doi%3D10.1021%2Fjm2003238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rennison, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cami-Kobeci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aceto, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Bermejo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span> <span> </span><span class="NLM_article-title">Cinnamoyl derivatives of 7 alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7 alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5176</span>– <span class="NLM_lpage">5182</span>, <span class="refDoi"> DOI: 10.1021/jm070255o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070255o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVKmsbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5176-5182&author=D.+Rennisonauthor=A.+P.+Nealauthor=G.+Cami-Kobeciauthor=M.+D.+Acetoauthor=F.+Martinez-Bermejoauthor=J.+W.+Lewisauthor=S.+M.+Husbands&title=Cinnamoyl+derivatives+of+7+alpha-aminomethyl-6%2C14-endo-ethanotetrahydrothebaine+and+7+alpha-aminomethyl-6%2C14-endo-ethanotetrahydrooripavine+and+related+opioid+ligands&doi=10.1021%2Fjm070255o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Cinnamoyl Derivatives of 7α-Aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7α-Aminomethyl-6,14-endo-ethanotetrahydrooripavine and Related Opioid Ligands</span></div><div class="casAuthors">Rennison, David; Neal, Adrian P.; Cami-Kobeci, Gerta; Aceto, Mario D.; Martinez-Bermejo, Fernando; Lewis, John W.; Husbands, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5176-5182</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of ligands (e.g. I) has been synthesized where the cinnamoyl group of the 14-cinnamoylamino morphinones has been introduced to the 7α-substituent of the 6,14-bridged oripavine series.  In vitro the compds. were mostly low efficacy partial agonists or antagonists with some selectivity for the mu opioid receptor, with evidence of mu efficacy in vivo.  The similarity in SAR between these 6,14-bridged oripavines and the 14-cinnamoylamino series suggests a similar mode of interaction with the mu opioid receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgIRwHOKf3qrVg90H21EOLACvtfcHk0lgWBHbMpW6BIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVKmsbnP&md5=dc15fa09ae860dd3b1202a35f677f52b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm070255o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070255o%26sid%3Dliteratum%253Aachs%26aulast%3DRennison%26aufirst%3DD.%26aulast%3DNeal%26aufirst%3DA.%2BP.%26aulast%3DCami-Kobeci%26aufirst%3DG.%26aulast%3DAceto%26aufirst%3DM.%2BD.%26aulast%3DMartinez-Bermejo%26aufirst%3DF.%26aulast%3DLewis%26aufirst%3DJ.%2BW.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26atitle%3DCinnamoyl%2520derivatives%2520of%25207%2520alpha-aminomethyl-6%252C14-endo-ethanotetrahydrothebaine%2520and%25207%2520alpha-aminomethyl-6%252C14-endo-ethanotetrahydrooripavine%2520and%2520related%2520opioid%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5176%26epage%3D5182%26doi%3D10.1021%2Fjm070255o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span> <span> </span><span class="NLM_article-title">The orvinols and related opioids - high affinity ligands with diverse efficacy profiles</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.2174/1381612043453027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.2174%2F1381612043453027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=15032698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFOktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=717-732&author=J.+W.+Lewisauthor=S.+M.+Husbands&title=The+orvinols+and+related+opioids+-+high+affinity+ligands+with+diverse+efficacy+profiles&doi=10.2174%2F1381612043453027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The orvinols and related opioids - high affinity ligands with diverse efficacy profiles</span></div><div class="casAuthors">Lewis, John W.; Husbands, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">717-732</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The thevinols and orvinols derived from thebaine via the thebaine-methylvinyl ketone adduct (thevinone) were thoroughly investigated in the 1960's and 1970's by the Reckitt group.  From this work a no. of important opioids emerged.  Buprenorphine is a μ partial agonist, κ/δ-antagonist that is now used primarily in the treatment of heroin abuse and dependence though it was initially launched as an analgesic for the treatment of moderate to severe pain.  Etorphine and dihydroetorphine are very potent μ agonists that have found application in veterinary and human medicine resp.  Diprenorphine is primarily a μ antagonist though it also has some κ-partial agonist effects.  It has high affinity for all types of opioid receptors and as a "universal" opioid ligand has been much in demand as a pharmacol. tool.  It has also been converted into a [11C] version for use in Positron Emission Tomog. (PET) studies of brain function related to the opioid receptor system.  More recent medicinal chem. investigations have been concerned with gaining a greater understanding of buprenorphine's unique opioid profile.  This has involved the synthesis and evaluation of a no. of series of buprenorphine analogs in which the C20 t-Bu group has been constrained in a ring system.  These studies have suggested that the methyls in the t-Bu group inhibit the conformational changes in the κ-receptor required for generation of an agonist response.  Introduction of a 7α-cinnamoylaminomethyl group in place of the orvinol tertiary alc. function leads to selective irreversible μ antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPp0SG7a80_bVg90H21EOLACvtfcHk0lgWBHbMpW6BIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFOktbk%253D&md5=62cd0ff1388a60a28a096692dd81c65c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2174%2F1381612043453027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612043453027%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DJ.%2BW.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26atitle%3DThe%2520orvinols%2520and%2520related%2520opioids%2520-%2520high%2520affinity%2520ligands%2520with%2520diverse%2520efficacy%2520profiles%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2004%26volume%3D10%26spage%3D717%26epage%3D732%26doi%3D10.2174%2F1381612043453027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cueva, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostovar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillhouse, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span> <span> </span><span class="NLM_article-title">C7 beta-methyl analogues of the orvinols: The discovery of kappa opioid antagonists with nociceptin/orphanin fq peptide (nop) receptor partial agonism and low, or zero, efficacy at mu opioid receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4242</span>– <span class="NLM_lpage">4249</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00130</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00130" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOgs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4242-4249&author=J.+P.+Cuevaauthor=C.+Rocheauthor=M.+Ostovarauthor=V.+Kumarauthor=M.+J.+Clarkauthor=T.+M.+Hillhouseauthor=J.+W.+Lewisauthor=J.+R.+Traynorauthor=S.+M.+Husbands&title=C7+beta-methyl+analogues+of+the+orvinols%3A+The+discovery+of+kappa+opioid+antagonists+with+nociceptin%2Forphanin+fq+peptide+%28nop%29+receptor+partial+agonism+and+low%2C+or+zero%2C+efficacy+at+mu+opioid+receptors&doi=10.1021%2Facs.jmedchem.5b00130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">C7β-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors</span></div><div class="casAuthors">Cueva, Juan Pablo; Roche, Christopher; Ostovar, Mehrnoosh; Kumar, Vinod; Clark, Mary J.; Hillhouse, Todd M.; Lewis, John W.; Traynor, John R.; Husbands, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4242-4249</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Buprenorphine is a successful analgesic and treatment for opioid abuse, with both activities relying on its partial agonist activity at mu opioid receptors.  However, there is substantial interest in its activities at the kappa opioid and nociceptin/orphanin FQ peptide receptors.  This has led to an interest in developing compds. with a buprenorphine-like pharmacol. profile but with lower efficacy at mu opioid receptors.  The present article describes aryl ring analogs of buprenorphine in which the std. C20-Me group has been moved to the C7β position, resulting in ligands with the desired profile.  In particular, moving the Me group has resulted in far more robust kappa opioid antagonist activity than seen in the std. orvinol series.  Of the compds. synthesized, a no., including 15a, have a profile of interest for the development of drug abuse relapse prevention therapies or antidepressants and others (e.g., 8c), as analgesics with a reduced side-effect profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprr8LGYf3Q2LVg90H21EOLACvtfcHk0lgWBHbMpW6BIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOgs74%253D&md5=d9f187a092da6f0d92bfd38f8e50907a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00130%26sid%3Dliteratum%253Aachs%26aulast%3DCueva%26aufirst%3DJ.%2BP.%26aulast%3DRoche%26aufirst%3DC.%26aulast%3DOstovar%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DHillhouse%26aufirst%3DT.%2BM.%26aulast%3DLewis%26aufirst%3DJ.%2BW.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26atitle%3DC7%2520beta-methyl%2520analogues%2520of%2520the%2520orvinols%253A%2520The%2520discovery%2520of%2520kappa%2520opioid%2520antagonists%2520with%2520nociceptin%252Forphanin%2520fq%2520peptide%2520%2528nop%2529%2520receptor%2520partial%2520agonism%2520and%2520low%252C%2520or%2520zero%252C%2520efficacy%2520at%2520mu%2520opioid%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4242%26epage%3D4249%26doi%3D10.1021%2Facs.jmedchem.5b00130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridzwan, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grivas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meurice, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Gomez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogozheva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span> <span> </span><span class="NLM_article-title">Selectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4049</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1021/jm401964y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401964y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvVSqurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4049-57&author=V.+Kumarauthor=I.+E.+Ridzwanauthor=K.+Grivasauthor=J.+W.+Lewisauthor=M.+J.+Clarkauthor=C.+Meuriceauthor=C.+Jimenez-Gomezauthor=I.+Pogozhevaauthor=H.+Mosbergauthor=J.+R.+Traynorauthor=S.+M.+Husbands&title=Selectively+promiscuous+opioid+ligands%3A+discovery+of+high+affinity%2Flow+efficacy+opioid+ligands+with+substantial+nociceptin+opioid+peptide+receptor+affinity&doi=10.1021%2Fjm401964y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Selectively Promiscuous Opioid Ligands: Discovery of High Affinity/Low Efficacy Opioid Ligands with Substantial Nociceptin Opioid Peptide Receptor Affinity</span></div><div class="casAuthors">Kumar, Vinod; Ridzwan, Irna E.; Grivas, Konstantinos; Lewis, John W.; Clark, Mary J.; Meurice, Claire; Jimenez-Gomez, Corina; Pogozheva, Irina; Mosberg, Henry; Traynor, John R.; Husbands, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4049-4057</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Emerging clin. and preclin. evidence suggests that a compd. displaying high affinity for μ, κ, and δ opioid (MOP, KOP, and DOP) receptors and antagonist activity at each, coupled with moderate affinity and efficacy at nociceptin opioid peptide (NOP) receptors will have utility as a relapse prevention agent for multiple types of drug abuse.  Members of the orvinol family of opioid ligands have the desired affinity profile but have typically displayed substantial efficacy at MOP and or KOP receptors.  In this study, it is shown that a Ph ring analog I of buprenorphine displays the desired profile in vitro with high, nonselective affinity for the MOP, KOP, and DOP receptors coupled with moderate affinity for NOP receptors.  In vivo, I lacked any opioid agonist activity and was an antagonist of both the MOP receptor agonist morphine and the KOP receptor agonist ethylketocyclazocine, confirming the desired opioid receptor profile in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE3lUSsfYUTbVg90H21EOLACvtfcHk0lgAdkqszrjpWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvVSqurc%253D&md5=7b21d7a9d02fb270941934ec78cc6211</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm401964y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401964y%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DRidzwan%26aufirst%3DI.%2BE.%26aulast%3DGrivas%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DJ.%2BW.%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DMeurice%26aufirst%3DC.%26aulast%3DJimenez-Gomez%26aufirst%3DC.%26aulast%3DPogozheva%26aufirst%3DI.%26aulast%3DMosberg%26aufirst%3DH.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26atitle%3DSelectively%2520promiscuous%2520opioid%2520ligands%253A%2520discovery%2520of%2520high%2520affinity%252Flow%2520efficacy%2520opioid%2520ligands%2520with%2520substantial%2520nociceptin%2520opioid%2520peptide%2520receptor%2520affinity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4049%26epage%3D57%26doi%3D10.1021%2Fjm401964y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greedy, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grivas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cami-Kobeci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archambeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aceto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span> <span> </span><span class="NLM_article-title">Orvinols with mixed kappa/mu opioid receptor agonist activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3207</span>– <span class="NLM_lpage">3216</span>, <span class="refDoi"> DOI: 10.1021/jm301543e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301543e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVWrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3207-3216&author=B.+M.+Greedyauthor=F.+Bradburyauthor=M.+P.+Thomasauthor=K.+Grivasauthor=G.+Cami-Kobeciauthor=A.+Archambeauauthor=K.+Bosseauthor=M.+J.+Clarkauthor=M.+Acetoauthor=J.+W.+Lewisauthor=J.+R.+Traynorauthor=S.+M.+Husbands&title=Orvinols+with+mixed+kappa%2Fmu+opioid+receptor+agonist+activity&doi=10.1021%2Fjm301543e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Orvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity</span></div><div class="casAuthors">Greedy, Benjamin M.; Bradbury, Faye; Thomas, Mark P.; Grivas, Konstantinos; Cami-Kobeci, Gerta; Archambeau, Ashley; Bosse, Kelly; Clark, Mary J.; Aceto, Mario; Lewis, John W.; Traynor, John R.; Husbands, Stephen M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3207-3216</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual-acting kappa opioid receptor (KOR) agonist and mu opioid receptor (MOR) partial agonist ligands have been put forward as potential treatment agents for cocaine and other psychostimulant abuse.  Members of the orvinol series of ligands are known for their high binding affinity to both KOR and MOR, but efficacy at the individual receptors has not been thoroughly evaluated.  In this study, it is shown that a predictive model for efficacy at KOR can be derived, with efficacy being controlled by the length of the group attached to C20 and by the introduction of branching into the side chain.  In vivo evaluation of two ligands with the desired in vitro profile confirms both display KOR, and to a lesser extent MOR, activity in an analgesic assay suggesting that, in this series, in vitro measures of efficacy using the [35S]GTPγS assay are predictive of the in vivo profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJpdjCZTQt5bVg90H21EOLACvtfcHk0ljdJ6AGj2imMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVWrtbo%253D&md5=d692909a8c772cfa79f3c9697a9c64d1</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm301543e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301543e%26sid%3Dliteratum%253Aachs%26aulast%3DGreedy%26aufirst%3DB.%2BM.%26aulast%3DBradbury%26aufirst%3DF.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DGrivas%26aufirst%3DK.%26aulast%3DCami-Kobeci%26aufirst%3DG.%26aulast%3DArchambeau%26aufirst%3DA.%26aulast%3DBosse%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DAceto%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DJ.%2BW.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26atitle%3DOrvinols%2520with%2520mixed%2520kappa%252Fmu%2520opioid%2520receptor%2520agonist%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3207%26epage%3D3216%26doi%3D10.1021%2Fjm301543e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z. B.</span></span> <span> </span><span class="NLM_article-title">Molecular modeling and 3D-QSAR studies of indolomorphinan derivatives as kappa opioid antagonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">610</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.08.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.bmc.2005.08.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=16202615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSiurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=601-610&author=W.+Liauthor=Y.+Tangauthor=Y.+L.+Zhengauthor=Z.+B.+Qiu&title=Molecular+modeling+and+3D-QSAR+studies+of+indolomorphinan+derivatives+as+kappa+opioid+antagonists&doi=10.1016%2Fj.bmc.2005.08.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular modeling and 3D-QSAR studies of indolomorphinan derivatives as kappa opioid antagonists</span></div><div class="casAuthors">Li, Wei; Tang, Yun; Zheng, You-Li; Qiu, Zhui-Bai</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">601-610</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mol. modeling and 3D-QSAR studies were performed on 31 indolomorphinan derivs. to evaluate their antagonistic behaviors on κ opioid receptor and provide information for further modification of this kind of compds.  Best predictions were obtained with Co-MFA std. model (q2 = 0.693, N = 4, r2 = 0.900) and Co-MSIA combined model (q2 = 0.617, N = 4, r2 = 0.904).  Both models were further validated by an external test set of eight compds. with satisfactory predictions: r2 = 0.607 for Co-MFA and r2 = 0.701 for Co-MSIA.  In addn., the 3D structure of human κ opioid receptor was constructed based on the crystal structure of bovine rhodopsin, and the Co-MSIA contour plots were then mapped into the structural model of κ opioid receptor-GNTI complex to identify key residues, which might account for κ antagonist potency and selectivity.  The roles of nonconserved Glu297 and conserved Lys227 of human κ opioid receptor were then discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN1bM5dsQic7Vg90H21EOLACvtfcHk0ljdJ6AGj2imMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSiurjJ&md5=123c4e72e3b04c2b6c6ffa941c881d3c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.08.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.08.052%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%2BL.%26aulast%3DQiu%26aufirst%3DZ.%2BB.%26atitle%3DMolecular%2520modeling%2520and%25203D-QSAR%2520studies%2520of%2520indolomorphinan%2520derivatives%2520as%2520kappa%2520opioid%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D601%26epage%3D610%26doi%3D10.1016%2Fj.bmc.2005.08.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z. B.</span></span> <span> </span><span class="NLM_article-title">3D-QSAR studies of orvinol analogs as kappa-opioid agonists</span>. <i>J. Mol. Model.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">877</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1007/s00894-005-0084-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1007%2Fs00894-005-0084-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=16552460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFOitL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=877-884&author=W.+Liauthor=Y.+Tangauthor=Q.+Xieauthor=W.+Shengauthor=Z.+B.+Qiu&title=3D-QSAR+studies+of+orvinol+analogs+as+kappa-opioid+agonists&doi=10.1007%2Fs00894-005-0084-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">3D-QSAR studies of orvinol analogs as k-opioid agonists</span></div><div class="casAuthors">Li, Wei; Tang, Yun; Xie, Qiong; Sheng, Wei; Qiu, Zhui-Bai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">877-884</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Orvinols are potent analgesics that target opioid receptors.  However, their analgesic mechanism remains unclear and no significant preference for subtype opioid receptor has been achieved.  In order to find new orvinols that target the κ-receptor, comparative 3D-QSAR studies were performed on 26 orvinol analogs using comparative mol. field anal. (CoMFA) and comparative mol. similarity indexes anal. (CoMSIA).  The best predictions for the κ-receptor were obtained with the CoMFA std. model (q2 = 0.686, r2 = 0.947) and CoMSIA model combined steric, electrostatic, hydrophobic, and hydrogen bond donor/acceptor fields (q2 = 0.678, r2 = 0.914).  The models built were further validated by a test set made up of seven compds., leading to predictive r2 values of 0.672 for CoMFA and 0.593 for CoMSIA.  The study could be helpful for designing and prep. new category κ-agonists from orvinols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkhQlsRNUmb7Vg90H21EOLACvtfcHk0ljdJ6AGj2imMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFOitL7E&md5=faedd2cf3e677636c06bb08fff098d91</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1007%2Fs00894-005-0084-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-005-0084-9%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DSheng%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DZ.%2BB.%26atitle%3D3D-QSAR%2520studies%2520of%2520orvinol%2520analogs%2520as%2520kappa-opioid%2520agonists%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2006%26volume%3D12%26spage%3D877%26epage%3D884%26doi%3D10.1007%2Fs00894-005-0084-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span> <span> </span><span class="NLM_article-title">The pharmacological heterogeneity of nepenthone analogs in conferring highly selective and potent kappa-opioid agonistic activities</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">766</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.6b00321</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00321" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFOhur7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=766-776&author=W.+Liauthor=J.+D.+Longauthor=Y.+Y.+Qianauthor=Y.+Longauthor=X.+J.+Xuauthor=Y.+J.+Wangauthor=Q.+Shenauthor=Z.+N.+Wangauthor=X.+C.+Yangauthor=L.+Xiaoauthor=H.+P.+Sunauthor=Y.+L.+Xuauthor=Y.+Y.+Chenauthor=Q.+Xieauthor=Y.+H.+Wangauthor=L.+M.+Shaoauthor=J.+G.+Liuauthor=Z.+B.+Qiuauthor=W.+Fu&title=The+pharmacological+heterogeneity+of+nepenthone+analogs+in+conferring+highly+selective+and+potent+kappa-opioid+agonistic+activities&doi=10.1021%2Facschemneuro.6b00321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The Pharmacological Heterogeneity of Nepenthone Analogs in Conferring Highly Selective and Potent κ-Opioid Agonistic Activities</span></div><div class="casAuthors">Li, Wei; Long, Jian-Dong; Qian, Yuan-Yuan; Long, Yu; Xu, Xue-Jun; Wang, Yu-Jun; Shen, Qing; Wang, Zuo-Neng; Yang, Xi-Cheng; Xiao, Li; Sun, Hong-Peng; Xu, Yu-Long; Chen, Yi-Yi; Xie, Qiong; Wang, Yong-Hui; Shao, Li-Ming; Liu, Jing-Gen; Qiu, Zhui-Bai; Fu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">766-776</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To develop novel analgesics with no or less side effects than that of traditional opioids is highly demanded to treat opioid receptors mediated pain and addiction issues.  Recently, Κ-opioid receptor (KOR) is established as an attractive target, although its selective agonists could bear heterogeneous pharmacol. activities.  In this study, the authors designed and synthesized two new series of nepenthone derivs. by inserting a spacer (carbonyl) between 6α,14α-endo-ethenyl-thebaine and the 7α-Ph substitution of the skeleton, and by substituting the 17-N-Me group with a cyclopropylmethyl group.  The authors performed in vitro tests (binding and functional assays) and mol. docking operations on the newly designed compds.  The results of wet-exptl. measures and modeled binding structures demonstrate that these new compds. are selective KOR agonists with nM level affinities.  Compd. I from these new derivs., showed highest affinity (Ki= 0.4±0.1) and the highest selectivity (μ/Κ = 339, δ/Κ = 2034) toward KOR.  The in vivo tests turned out that I is able to induce stronger (ED50=2.1 mg/kg) and much longer antinociceptive effect than that of the typical KOR agonist U50488H (ED50=4.4 mg/kg).  Therefore, I can be used as a perfect lead compd. for future design of potent analgesics acting through KOR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlKbYO9zcko7Vg90H21EOLACvtfcHk0lhFjC0s7QK5kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFOhur7P&md5=6615861546def0ec4e3cf217598a0faa</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00321%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLong%26aufirst%3DJ.%2BD.%26aulast%3DQian%26aufirst%3DY.%2BY.%26aulast%3DLong%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%2BJ.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DZ.%2BN.%26aulast%3DYang%26aufirst%3DX.%2BC.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DH.%2BP.%26aulast%3DXu%26aufirst%3DY.%2BL.%26aulast%3DChen%26aufirst%3DY.%2BY.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DY.%2BH.%26aulast%3DShao%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26aulast%3DQiu%26aufirst%3DZ.%2BB.%26aulast%3DFu%26aufirst%3DW.%26atitle%3DThe%2520pharmacological%2520heterogeneity%2520of%2520nepenthone%2520analogs%2520in%2520conferring%2520highly%2520selective%2520and%2520potent%2520kappa-opioid%2520agonistic%2520activities%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D766%26epage%3D776%26doi%3D10.1021%2Facschemneuro.6b00321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span> <span> </span><span class="NLM_article-title">Highly selective and potent mu opioid ligands by unexpected substituent on morphine skeleton</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.07.119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.bmcl.2009.07.119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=19932964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=418-421&author=W.+Liauthor=Y.+M.+Taoauthor=Y.+Tangauthor=X.+J.+Xuauthor=J.+Chenauthor=W.+Fuauthor=X.+H.+Wangauthor=B.+Chaoauthor=W.+Shengauthor=Q.+Xieauthor=Z.+B.+Qiuauthor=J.+G.+Liu&title=Highly+selective+and+potent+mu+opioid+ligands+by+unexpected+substituent+on+morphine+skeleton&doi=10.1016%2Fj.bmcl.2009.07.119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Highly selective and potent μ opioid ligands by unexpected substituent on morphine skeleton</span></div><div class="casAuthors">Li, Wei; Tao, Yi-Min; Tang, Yun; Xu, Xue-Jun; Chen, Jie; Fu, Wei; Wang, Xing-Hai; Chao, Bo; Sheng, Wei; Xie, Qiong; Qiu, Zhui-Bai; Liu, Jing-Gen</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">418-421</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Unexpected substituent on the well-known morphine skeleton is described to be account for highly selective and potent μ opioid ligands, which is strongly connected to substituted arom. groups on this omitted 8α-position.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-ZI8MAPqpcrVg90H21EOLACvtfcHk0lhFjC0s7QK5kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsbvK&md5=240bb32466701c8f776b878d0e031ac8</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.07.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.07.119%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DTao%26aufirst%3DY.%2BM.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%2BH.%26aulast%3DChao%26aufirst%3DB.%26aulast%3DSheng%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DQiu%26aufirst%3DZ.%2BB.%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26atitle%3DHighly%2520selective%2520and%2520potent%2520mu%2520opioid%2520ligands%2520by%2520unexpected%2520substituent%2520on%2520morphine%2520skeleton%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D418%26epage%3D421%26doi%3D10.1016%2Fj.bmcl.2009.07.119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Z.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of kappa-opioid receptor agonistic activity and antinociceptive effect of novel morphine analogues, 7 alpha-phenyl-6 alpha,14 alpha-endo-etheno-tetrahydrothebaine with substituted o-, m- and p-amino group</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1364</span>– <span class="NLM_lpage">1370</span>, <span class="refDoi"> DOI: 10.1007/s00044-010-9471-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1007%2Fs00044-010-9471-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWqtbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=1364-1370&author=H.+Qiauthor=W.+Liauthor=Y.+Qiuauthor=Y.+Y.+Cuiauthor=J.+Maauthor=X.+L.+Gaoauthor=Y.+B.+Zengauthor=J.+Yangauthor=Y.+Tangauthor=X.+H.+Wangauthor=W.+Shengauthor=Q.+Xieauthor=J.+G.+Liuauthor=Z.+B.+Qiuauthor=H.+Z.+Chen&title=Synthesis+and+evaluation+of+kappa-opioid+receptor+agonistic+activity+and+antinociceptive+effect+of+novel+morphine+analogues%2C+7+alpha-phenyl-6+alpha%2C14+alpha-endo-etheno-tetrahydrothebaine+with+substituted+o-%2C+m-+and+p-amino+group&doi=10.1007%2Fs00044-010-9471-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of κ-opioid receptor agonistic activity and antinociceptive effect of novel morphine analogues, 7α-phenyl-6α,14α-endo-etheno-tetrahydrothebaine with substituted o-, m- and p-amino group</span></div><div class="casAuthors">Qi, Hong; Li, Wei; Qiu, Yu; Cui, Yong-yao; Ma, Jian; Gao, Xiao-ling; Zeng, Yi-bin; Yang, Jie; Tang, Yun; Wang, Xing-hai; Sheng, Wei; Xie, Qiong; Liu, Jing-geng; Qiu, Zhui-bai; Chen, Hong-zhuan</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1364-1370</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Boston</span>)
        </div><div class="casAbstract">7α-Phenyl-6α,14α-endo-etheno-tetrahydrothebaine I (R7 = Ph) is an analog of morphine but with much weaker affinity and efficacy to opioid receptors.  Three compds. I (R7 = C6H4-2-NH2, -3-NH2, -4-NH2) with o-, m- and p-amino substitution on its 7α-Ph group were designed and synthesized to evaluate their κ-opioid receptor agonistic activity and antinociceptive effect.  The introduction of amino group greatly increased the binding activity to κ-opioid receptor but only compd. with p-substitution showed agonistic activity with potency similar to the marketed κ agonist butorphanol.  In vivo antinociceptive test showed that compd. with p-amino substitution displayed highest antinociceptive activity while compds. with o-, m-amino substitution showed partial or little analgesia effects.  All these data indicate that p-amino substitution conferred κ agonist activity, suggesting that 7α-phenyl-6α,14α-endo-etheno-tetrahydrothebaines with a p-amino substitution may contain a novel pharmacophore component and could be considered as a leading compd. for novel antinociceptive agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWuEmPNKtEs7Vg90H21EOLACvtfcHk0ljbSy83IoW8Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWqtbbN&md5=e678f3346e414c7dcd066e063d4f3ec8</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1007%2Fs00044-010-9471-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-010-9471-6%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DY.%2BY.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DX.%2BL.%26aulast%3DZeng%26aufirst%3DY.%2BB.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%2BH.%26aulast%3DSheng%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26aulast%3DQiu%26aufirst%3DZ.%2BB.%26aulast%3DChen%26aufirst%3DH.%2BZ.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520kappa-opioid%2520receptor%2520agonistic%2520activity%2520and%2520antinociceptive%2520effect%2520of%2520novel%2520morphine%2520analogues%252C%25207%2520alpha-phenyl-6%2520alpha%252C14%2520alpha-endo-etheno-tetrahydrothebaine%2520with%2520substituted%2520o-%252C%2520m-%2520and%2520p-amino%2520group%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2011%26volume%3D20%26spage%3D1364%26epage%3D1370%26doi%3D10.1007%2Fs00044-010-9471-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span> <span> </span><span class="NLM_article-title">Synthesis of the new thebaine derivatives by the Diels-Alder reaction with northebaine</span>. <i>J. Korean Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">376</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1988&pages=371-376&author=K.+Kimauthor=K.+Kim&title=Synthesis+of+the+new+thebaine+derivatives+by+the+Diels-Alder+reaction+with+northebaine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DK.%26atitle%3DSynthesis%2520of%2520the%2520new%2520thebaine%2520derivatives%2520by%2520the%2520Diels-Alder%2520reaction%2520with%2520northebaine%26jtitle%3DJ.%2520Korean%2520Chem.%2520Soc.%26date%3D1988%26volume%3D32%26spage%3D371%26epage%3D376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, D. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L. M.</span></span> <span> </span><span class="NLM_article-title">7 beta-Methyl substituent is a structural locus associated with activity cliff for nepenthone analogues</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4254</span>– <span class="NLM_lpage">4263</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.bmc.2018.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=30054192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyrtb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4254-4263&author=H.+J.+Sunauthor=Y.+H.+Wangauthor=C.+M.+Yuanauthor=L.+H.+Kongauthor=X.+J.+Xuauthor=Y.+J.+Wangauthor=H.+H.+Wuauthor=C.+Linauthor=Y.+Y.+Qianauthor=H.+M.+Huangauthor=L.+Xiaoauthor=X.+Liuauthor=Q.+Heauthor=S.+Y.+Fangauthor=D.+Q.+Xueauthor=X.+C.+Yangauthor=H.+Chenauthor=Y.+L.+Zhengauthor=L.+Zhengauthor=L.+Q.+Yuauthor=Q.+Xieauthor=W.+Fuauthor=W.+Liauthor=J.+G.+Liuauthor=Z.+B.+Qiuauthor=L.+M.+Shao&title=7+beta-Methyl+substituent+is+a+structural+locus+associated+with+activity+cliff+for+nepenthone+analogues&doi=10.1016%2Fj.bmc.2018.07.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">7β-Methyl substituent is a structural locus associated with activity cliff for nepenthone analogues</span></div><div class="casAuthors">Sun, Hui-jiao; Wang, Yu-hua; Yuan, Cong-min; Kong, Ling-hui; Xu, Xue-jun; Wang, Yu-jun; Wu, Hai-hao; Lin, Cheng; Qian, Yuan-yuan; Huang, Huo-ming; Xiao, Li; Liu, Xiao; He, Qian; Fang, Sheng-yang; Xue, Deng-qi; Yang, Xi-cheng; Chen, Hao; Zheng, Yi-lin; Zheng, Lan; Yu, Lin-qian; Xie, Qiong; Fu, Wei; Li, Wei; Liu, Jing-gen; Qiu, Zhui-bai; Shao, Li-ming</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4254-4263</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">With the purpose of identifying novel selective κ opioid receptor (KOR) antagonists as potential antidepressants from nepenthone analogs, starting from N-nor-N-cyclopropylmethyl-nepenthone (SLL-020ACP), a highly selective and potent KOR agonist, a series of 7β-methyl-nepenthone analogs was conceived, synthesized and assayed on opioid receptors based on the concept of hybridization.  According to the pharmacol. results, the functional reversal obsd. in orvinol analogs by introduction of 7β-Me substituent could not be reproduced in nepenthone analogs.  Alternatively, introduction of 7β-Me substituent was assocd. with substantial loss of both subtype selectivity and potency but not efficacy for nepenthone analogs, which was not found in 7β-Me orvinol analogs.  Surprisingly, SLL-603, a 7β-Me analog of SLL-020ACP, was identified to be a KOR full agonist.  The possible mol. mechanism for the heterogeneity in activity cliff was also investigated.  In conclusion, 7β-Me substituent was a structural locus assocd. with activity cliff and demonstrated as a pharmacol. heterogeneity between nepenthone and orvinol analogs that warrants further investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_xJC73BwHSbVg90H21EOLACvtfcHk0lig7Rgup-lYvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyrtb7F&md5=13b41b5e44064960740f550d85650fe5</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%2BJ.%26aulast%3DWang%26aufirst%3DY.%2BH.%26aulast%3DYuan%26aufirst%3DC.%2BM.%26aulast%3DKong%26aufirst%3DL.%2BH.%26aulast%3DXu%26aufirst%3DX.%2BJ.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DWu%26aufirst%3DH.%2BH.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DQian%26aufirst%3DY.%2BY.%26aulast%3DHuang%26aufirst%3DH.%2BM.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DFang%26aufirst%3DS.%2BY.%26aulast%3DXue%26aufirst%3DD.%2BQ.%26aulast%3DYang%26aufirst%3DX.%2BC.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DY.%2BL.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DL.%2BQ.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26aulast%3DQiu%26aufirst%3DZ.%2BB.%26aulast%3DShao%26aufirst%3DL.%2BM.%26atitle%3D7%2520beta-Methyl%2520substituent%2520is%2520a%2520structural%2520locus%2520associated%2520with%2520activity%2520cliff%2520for%2520nepenthone%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4254%26epage%3D4263%26doi%3D10.1016%2Fj.bmc.2018.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thian, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiesen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunahara, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granier, S.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the mu-opioid receptor bound to a morphinan antagonist</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>485</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">U170</span>, <span class="refDoi"> DOI: 10.1038/nature10954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1038%2Fnature10954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=22437502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVehs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=321-U170&author=A.+Manglikauthor=A.+C.+Kruseauthor=T.+S.+Kobilkaauthor=F.+S.+Thianauthor=J.+M.+Mathiesenauthor=R.+K.+Sunaharaauthor=L.+Pardoauthor=W.+I.+Weisauthor=B.+K.+Kobilkaauthor=S.+Granier&title=Crystal+structure+of+the+mu-opioid+receptor+bound+to+a+morphinan+antagonist&doi=10.1038%2Fnature10954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the μ-opioid receptor bound to a morphinan antagonist</span></div><div class="casAuthors">Manglik, Aashish; Kruse, Andrew C.; Kobilka, Tong Sun; Thian, Foon Sun; Mathiesen, Jesper M.; Sunahara, Roger K.; Pardo, Leonardo; Weis, William I.; Kobilka, Brian K.; Granier, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7398</span>),
    <span class="NLM_cas:pages">321-326</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Opium is one of the world's oldest drugs, and its derivs. morphine and codeine are among the most used clin. drugs to relieve severe pain.  These prototypical opioids produce analgesia as well as many undesirable side effects (sedation, apnea and dependence) by binding to and activating the G-protein-coupled μ-opioid receptor (μ-OR) in the central nervous system.  Here the authors describe the 2.8 Å crystal structure of the mouse μ-OR in complex with an irreversible morphinan antagonist.  Compared to the buried binding pocket obsd. in most G-protein-coupled receptors published so far, the morphinan ligand binds deeply within a large solvent-exposed pocket.  Of particular interest, the μ-OR crystallizes as a two-fold sym. dimer through a four-helix bundle motif formed by transmembrane segments 5 and 6.  These high-resoln. insights into opioid receptor structure will enable the application of structure-based approaches to develop better drugs for the management of pain and addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2q4tys639jrVg90H21EOLACvtfcHk0lig7Rgup-lYvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVehs7Y%253D&md5=563d5ebda53f9a408be21d60a7e5a97d</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnature10954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10954%26sid%3Dliteratum%253Aachs%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DMathiesen%26aufirst%3DJ.%2BM.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DPardo%26aufirst%3DL.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGranier%26aufirst%3DS.%26atitle%3DCrystal%2520structure%2520of%2520the%2520mu-opioid%2520receptor%2520bound%2520to%2520a%2520morphinan%2520antagonist%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D321%26epage%3DU170%26doi%3D10.1038%2Fnature10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span> <span> </span><span class="NLM_article-title">LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>584</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2008.02.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.ejphar.2008.02.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=18353307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksVaqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=584&publication_year=2008&pages=306-11&author=Y.+M.+Taoauthor=Q.+L.+Liauthor=C.+F.+Zhangauthor=X.+J.+Xuauthor=J.+Chenauthor=Y.+W.+Juauthor=Z.+Q.+Chiauthor=Y.+Q.+Longauthor=J.+G.+Liu&title=LPK-26%2C+a+novel+kappa-opioid+receptor+agonist+with+potent+antinociceptive+effects+and+low+dependence+potential&doi=10.1016%2Fj.ejphar.2008.02.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">LPK-26, a novel κ-opioid receptor agonist with potent antinociceptive effects and low dependence potential</span></div><div class="casAuthors">Tao, Yi-Min; Li, Qing-Lin; Zhang, Cong-Fen; Xu, Xue-Jun; Chen, Jie; Ju, Ya-Wen; Chi, Zhi-Qiang; Long, Ya-Qiu; Liu, Jing-Gen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">584</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">306-311</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Analgesics such as morphine cause many side effects including addiction, but κ-opioid receptor agonist can produce antinociception without morphine-like side effects.  With the aim of developing new and potent analgesics with lower abuse potential, we studied the antinociceptive and phys. dependent properties of a derivate of ICI-199441, an analog of (-)U50,488H, named (2-(3,4-dichloro)-phenyl)-N-methyl-N-[(1S)-1-(2-isopropyl)-2-(1-(3-pyrrolinyl))ethyl] acetamides (LPK-26).  LPK-26 showed a high affinity to κ-opioid receptor with the Ki value of 0.64 nM and the low affinities to μ-opioid receptor and δ-opioid receptor with the Ki values of 1170 nM and > 10,000 nM, resp.  It stimulated [35S]GTPγS binding to G-proteins with an EC50 value of 0.0094 nM.  In vivo, LPK-26 was more potent than (-)U50,488H and morphine in analgesia, with the ED50 values of 0.049 mg/kg and 0.0084 mg/kg in hot plat and acetic acid writhing tests, resp.  Moreover, LPK-26 failed to induce phys. dependence, but it could suppress naloxone-pptd. jumping in mice when given simultaneously with morphine.  Taken together, the results show that LPK-26 is a novel selective κ-opioid receptor agonist with highly potent antinociception effects and low phys. dependence potential.  It may be valuable for the development of analgesic and drug that can be used to reduce morphine-induced phys. dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr74NJwxWVW6rVg90H21EOLACvtfcHk0lgb9MLvGEyU-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksVaqsrs%253D&md5=0499bc1c1523a03f235681b166387301</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2008.02.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2008.02.028%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DY.%2BM.%26aulast%3DLi%26aufirst%3DQ.%2BL.%26aulast%3DZhang%26aufirst%3DC.%2BF.%26aulast%3DXu%26aufirst%3DX.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DJu%26aufirst%3DY.%2BW.%26aulast%3DChi%26aufirst%3DZ.%2BQ.%26aulast%3DLong%26aufirst%3DY.%2BQ.%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26atitle%3DLPK-26%252C%2520a%2520novel%2520kappa-opioid%2520receptor%2520agonist%2520with%2520potent%2520antinociceptive%2520effects%2520and%2520low%2520dependence%2520potential%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D584%26spage%3D306%26epage%3D11%26doi%3D10.1016%2Fj.ejphar.2008.02.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ondachi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosier, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uprety, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vardy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krumm, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strachan, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tribo, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure of the nanobody-stabilized active state of the kappa opioid receptor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1016%2Fj.cell.2017.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=29307491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslehtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=55-67&author=T.+Cheauthor=S.+Majumdarauthor=S.+A.+Zaidiauthor=P.+Ondachiauthor=J.+D.+McCorvyauthor=S.+Wangauthor=P.+D.+Mosierauthor=R.+Upretyauthor=E.+Vardyauthor=B.+E.+Krummauthor=G.+W.+Hanauthor=M.+Y.+Leeauthor=E.+Pardonauthor=J.+Steyaertauthor=X.+P.+Huangauthor=R.+T.+Strachanauthor=A.+R.+Triboauthor=G.+W.+Pasternakauthor=F.+I.+Carrollauthor=R.+C.+Stevensauthor=V.+Cherezovauthor=V.+Katritchauthor=D.+Wackerauthor=B.+L.+Roth&title=Structure+of+the+nanobody-stabilized+active+state+of+the+kappa+opioid+receptor&doi=10.1016%2Fj.cell.2017.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the nanobody-stabilized active state of the Kappa opioid receptor</span></div><div class="casAuthors">Che, Tao; Majumdar, Susruta; Zaidi, Saheem A.; Ondachi, Pauline; McCorvy, John D.; Wang, Sheng; Mosier, Philip D.; Uprety, Rajendra; Vardy, Eyal; Krumm, Brian E.; Han, Gye Won; Lee, Ming-Yue; Pardon, Els; Steyaert, Jan; Huang, Xi-Ping; Strachan, Ryan T.; Tribo, Alexandra R.; Pasternak, Gavril W.; Carroll, F. Ivy; Stevens, Raymond C.; Cherezov, Vadim; Katritch, Vsevolod; Wacker, Daniel; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">55-67.e15</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The κ-opioid receptor (KOP) mediates the actions of opioids with hallucinogenic, dysphoric, and analgesic activities.  The design of KOP analgesics devoid of hallucinatory and dysphoric effects has been hindered by an incomplete structural and mechanistic understanding of KOP agonist actions.  Here, we provide a crystal structure of human KOP in complex with the potent epoxymorphinan opioid agonist MP1104 and an active-state-stabilizing nanobody.  Comparisons between inactive- and active-state opioid receptor structures reveal substantial conformational changes in the binding pocket and intracellular and extracellular regions.  Extensive structural anal. and exptl. validation illuminate key residues that propagate larger-scale structural rearrangements and transducer binding that, collectively, elucidate the structural determinants of KOP pharmacol., function, and biased signaling.  These mol. insights promise to accelerate the structure-guided design of safer and more effective κ-opioid receptor therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyTsV2u04FCbVg90H21EOLACvtfcHk0lgb9MLvGEyU-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslehtg%253D%253D&md5=eb0399dc1e7e4e0cf21771243875abc9</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DChe%26aufirst%3DT.%26aulast%3DMajumdar%26aufirst%3DS.%26aulast%3DZaidi%26aufirst%3DS.%2BA.%26aulast%3DOndachi%26aufirst%3DP.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMosier%26aufirst%3DP.%2BD.%26aulast%3DUprety%26aufirst%3DR.%26aulast%3DVardy%26aufirst%3DE.%26aulast%3DKrumm%26aufirst%3DB.%2BE.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLee%26aufirst%3DM.%2BY.%26aulast%3DPardon%26aufirst%3DE.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DStrachan%26aufirst%3DR.%2BT.%26aulast%3DTribo%26aufirst%3DA.%2BR.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26aulast%3DCarroll%26aufirst%3DF.%2BI.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure%2520of%2520the%2520nanobody-stabilized%2520active%2520state%2520of%2520the%2520kappa%2520opioid%2520receptor%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D55%26epage%3D67%26doi%3D10.1016%2Fj.cell.2017.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prather, P. L.</span></span> <span> </span><span class="NLM_article-title">Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1124/mol.60.1.53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1124%2Fmol.60.1.53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=11408600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks1Crt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2001&pages=53-62&author=J.+G.+Liuauthor=P.+L.+Prather&title=Chronic+exposure+to+mu-opioid+agonists+produces+constitutive+activation+of+mu-opioid+receptors+in+direct+proportion+to+the+efficacy+of+the+agonist+used+for+pretreatment&doi=10.1124%2Fmol.60.1.53"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic exposure to μ-opioid agonists produces constitutive activation of μ-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment</span></div><div class="casAuthors">Liu, Jing-Gen; Prather, Paul L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Chronic morphine treatment has been shown to produce constitutive activation of μ-opioid receptors, and this transition might contribute to the development of tolerance and dependence.  The apparent ability of chronic morphine to increase the spontaneous, agonist-independent activation of μ-opioid receptors may be unique, due to its distinct partial-agonist properties of possessing a relatively high intrinsic activity coupled with a poor ability to produce desensitization and down-regulation.  Therefore, the present study tested the hypothesis that prolonged exposure to morphine would produce greater constitutive activity of μ-opioid receptors than exposure to the full agonist [D-Ala2,N-MePhe4,Gly-ol5]enkephalin (DAMGO).  Rat pituitary GH3MOR cells expressing μ-opioid receptors were chronically exposed to morphine, DAMGO, or no opioid under conditions known to produce maximal desensitization, down-regulation, and cAMP rebound.  After chronic treatment, the μ-opioid antagonists naloxone and β-chlornaltrexamine (β-CNA) were evaluated in two assays predictive of inverse agonist activity.  Both antagonists produced a concn.-dependent inhibition of [35S]GTPγS binding only in membranes from cells chronically exposed to opioids.  This effect was reversed by the neutral μ-opioid antagonist CTAP.  Addnl., conditions known to uncouple G protein-coupled receptors from G proteins produced a leftward shift in the competition curve of β-CNA for [3H]DAMGO binding only in membranes from chronically treated cells.  In contrast, these conditions produced no shift in the competition curve by the neutral antagonist CTAP in cells exposed to chronic DAMGO.  Therefore, prolonged exposure of GH3MOR cells to opioids produced constitutive activation of μ-opioid receptors.  Surprisingly, chronic treatment with the more effective agonist DAMGO produced greater increases in both measures of inverse agonist activity than did morphine.  These observations may lend insight into the mechanisms of opioid tolerance and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAfdltVAcsC7Vg90H21EOLACvtfcHk0lgf2FSZoXzMLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks1Crt7Y%253D&md5=43f9ff3d4c9cba9d33320c67c4a9773f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1124%2Fmol.60.1.53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.60.1.53%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26aulast%3DPrather%26aufirst%3DP.%2BL.%26atitle%3DChronic%2520exposure%2520to%2520mu-opioid%2520agonists%2520produces%2520constitutive%2520activation%2520of%2520mu-opioid%2520receptors%2520in%2520direct%2520proportion%2520to%2520the%2520efficacy%2520of%2520the%2520agonist%2520used%2520for%2520pretreatment%26jtitle%3DMol.%2520Pharmacol.%26date%3D2001%26volume%3D60%26spage%3D53%26epage%3D62%26doi%3D10.1124%2Fmol.60.1.53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumeyer, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. G.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of atpm [(−)-3-amino-thiazolo[5,4-b]-n-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>329</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1124/jpet.108.142802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=10.1124%2Fjpet.108.142802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=19136637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVKmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2009&pages=306-313&author=Y.+J.+Wangauthor=Y.+M.+Taoauthor=F.+Y.+Liauthor=Y.+H.+Wangauthor=X.+J.+Xuauthor=J.+Chenauthor=Y.+L.+Caoauthor=Z.+Q.+Chiauthor=J.+L.+Neumeyerauthor=A.+Zhangauthor=J.+G.+Liu&title=Pharmacological+characterization+of+atpm+%5B%28%E2%88%92%29-3-amino-thiazolo%5B5%2C4-b%5D-n-cyclopropylmethylmorphinan+hydrochloride%5D%2C+a+novel+mixed+kappa-agonist+and+mu-agonist%2F-antagonist+that+attenuates+morphine+antinociceptive+tolerance+and+heroin+self-administration+behavior&doi=10.1124%2Fjpet.108.142802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of ATPM [(-)-3-amino-thiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed κ-agonist and μ-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior</span></div><div class="casAuthors">Wang, Yu-Jun; Tao, Yi-Min; Li, Fu-Ying; Wang, Yu-Hua; Xu, Xue-Jun; Chen, Jie; Cao, Ying-Lin; Chi, Zhi-Qiang; Neumeyer, John L.; Zhang, Ao; Liu, Jing-Gen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">306-313</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">ATPM [(-)-3-amino-thiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride] was found to have mixed κ- and μ-opioid activity and identified to act as a full κ-agonist and a partial μ-agonist by in vitro binding assays.  The present study was undertaken to characterize its in vivo effects on morphine antinociceptive tolerance in mice and heroin self-administration in rats.  ATPM was demonstrated to yield more potent antinociceptive effects than (-)U50,488H (trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] benzeneacetamide).  It was further found that the antinociceptive effects of ATPM were mediated by κ- and μ-, but not δ-opioid, receptors.  In addn. to its agonist profile on the μ-receptor, ATPM also acted as a μ-antagonist, as measured by its inhibition of morphine-induced antinociception.  It is more important that ATPM had a greater ratio of the ED50 value of sedation to that of antinociception than (-)U50,488 (11.8 vs. 3.7), indicative of a less sedative effect than (-)U50,488H.  In addn., ATPM showed less potential to develop antinociceptive tolerance relative to (-)U50,488H and morphine.  Moreover, it dose-dependently inhibited morphine-induced antinociceptive tolerance.  Furthermore, it was found that chronic treatment of rats for 8 consecutive days with ATPM (0.5 mg/kg s.c.) produced sustained decreases in heroin self-administration.  (-)U50,488H (2 mg/kg s.c.) also produced similar inhibitory effect.  Taken together, our findings demonstrated that ATPM, a novel mixed κ-agonist and μ-agonist/-antagonist, could inhibit morphine-induced antinociceptive tolerance, with less potential to develop tolerance and reduce heroin self-administration with less sedative effect.  κ-Agonists with some μ-activity appear to offer some advantages over selective κ-agonists for the treatment of heroin abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU8tFFGb2tBrVg90H21EOLACvtfcHk0lgf2FSZoXzMLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVKmsrw%253D&md5=985fb6c56a87dd9283c12df05ef47576</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.142802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.142802%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DTao%26aufirst%3DY.%2BM.%26aulast%3DLi%26aufirst%3DF.%2BY.%26aulast%3DWang%26aufirst%3DY.%2BH.%26aulast%3DXu%26aufirst%3DX.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DY.%2BL.%26aulast%3DChi%26aufirst%3DZ.%2BQ.%26aulast%3DNeumeyer%26aufirst%3DJ.%2BL.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DJ.%2BG.%26atitle%3DPharmacological%2520characterization%2520of%2520atpm%2520%255B%2528%25E2%2588%2592%2529-3-amino-thiazolo%255B5%252C4-b%255D-n-cyclopropylmethylmorphinan%2520hydrochloride%255D%252C%2520a%2520novel%2520mixed%2520kappa-agonist%2520and%2520mu-agonist%252F-antagonist%2520that%2520attenuates%2520morphine%2520antinociceptive%2520tolerance%2520and%2520heroin%2520self-administration%2520behavior%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D329%26spage%3D306%26epage%3D313%26doi%3D10.1124%2Fjpet.108.142802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DKL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DKL','PDB','4DKL'); return false;">PDB: 4DKL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B73" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B73','PDB','6B73'); return false;">PDB: 6B73</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EJ4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EJ4','PDB','4EJ4'); return false;">PDB: 4EJ4</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i51"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00857">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_27204"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b00857?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00857</a>. <ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Activity of compound <b>4</b>, <sup>1</sup>H and <sup>13</sup>C NMR spectra for all final compounds, and and HPLC spectra for compound <b>4</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00857/suppl_file/jm9b00857_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00857/suppl_file/jm9b00857_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00857/suppl_file/jm9b00857_si_001.pdf">jm9b00857_si_001.pdf (3.65 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00857/suppl_file/jm9b00857_si_002.csv">jm9b00857_si_002.csv (2.4 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00857&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-24%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00857" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00857" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679913d89caad1af","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
